
<html lang="en"     class="pb-page"  data-request-id="9a74c5b8-cfd2-4cca-b5d7-8762d2898ca4"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;issue:issue:10.1021/jmcmar.2019.62.issue-14;website:website:acspubs;article:article:10.1021/acs.jmedchem.9b00706;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Structure-Guided Design, Synthesis, and Biological Evaluation of (2-(1H-Indol-3-yl)-1H-imidazol-4-yl)(3,4,5-trimethoxyphenyl) Methanone (ABI-231) Analogues Targeting the Colchicine Binding Site in Tubulin" /></meta><meta name="dc.Creator" content="Qinghui  Wang" /></meta><meta name="dc.Creator" content="Kinsie E.  Arnst" /></meta><meta name="dc.Creator" content="Yuxi  Wang" /></meta><meta name="dc.Creator" content="Gyanendra  Kumar" /></meta><meta name="dc.Creator" content="Dejian  Ma" /></meta><meta name="dc.Creator" content="Stephen W.  White" /></meta><meta name="dc.Creator" content="Duane D.  Miller" /></meta><meta name="dc.Creator" content="Weimin  Li" /></meta><meta name="dc.Creator" content="Wei  Li" /></meta><meta name="dc.Description" content="ABI-231 is a potent, orally bioavailable tubulin inhibitor that interacts with the colchicine binding site and is currently undergoing clinical trials for prostate cancer. Guided by the crystal str..." /></meta><meta name="Description" content="ABI-231 is a potent, orally bioavailable tubulin inhibitor that interacts with the colchicine binding site and is currently undergoing clinical trials for prostate cancer. Guided by the crystal str..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="June 28, 2019" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.9b00706" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright © 2019 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.9b00706" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.9b00706" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.9b00706" /></link>
        
    
    

<title>Structure-Guided Design, Synthesis, and Biological Evaluation of (2-(1H-Indol-3-yl)-1H-imidazol-4-yl)(3,4,5-trimethoxyphenyl) Methanone (ABI-231) Analogues Targeting the Colchicine Binding Site in Tubulin | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.9b00706" /></meta><meta property="og:title" content="Structure-Guided Design, Synthesis, and Biological Evaluation of (2-(1H-Indol-3-yl)-1H-imidazol-4-yl)(3,4,5-trimethoxyphenyl) Methanone (ABI-231) Analogues Targeting the Colchicine Binding Site in Tubulin" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00706/20190719/images/large/jm-2019-00706x_0011.jpeg" /></meta><meta property="og:description" content="ABI-231 is a potent, orally bioavailable tubulin inhibitor that interacts with the colchicine binding site and is currently undergoing clinical trials for prostate cancer. Guided by the crystal structure of ABI-231 in complex with tubulin, we performed structure–activity relationship studies around the 3-indole moiety that led to the discovery of several potent ABI-231 analogues, most notably 10ab and 10bb. The crystal structures of 10ab and 10bb in complex with tubulin confirmed their improved molecular interactions to the colchicine site. In vitro, biological studies showed that new ABI-231 analogues disrupt tubulin polymerization, promote microtubule fragmentation, and inhibit cancer cell migration. In vivo, analogue 10bb not only significantly inhibits primary tumor growth and decreases tumor metastasis in melanoma xenograft models but also shows a significant ability to overcome paclitaxel resistance in a taxane-resistant PC-3/TxR model. In addition, pharmacological screening suggested that 10bb has a low risk of potential off-target function." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.9b00706"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b00706">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.9b00706&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.9b00706&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.9b00706&amp;href=/doi/10.1021/acs.jmedchem.9b00706" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2019</span><span class="cit-fg-volume">, 62</span><span class="cit-fg-issue">, 14</span><span class="cit-fg-pageRange">, 6734-6750</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/62/14" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.9b00662" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.9b00711" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Structure-Guided Design, Synthesis, and Biological Evaluation of (2-(1<i>H</i>-Indol-3-yl)-1<i>H</i>-imidazol-4-yl)(3,4,5-trimethoxyphenyl) Methanone (ABI-231) Analogues Targeting the Colchicine Binding Site in Tubulin</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Qinghui Wang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Qinghui Wang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Pharmaceutical Sciences, College of Pharmacy, University of Tennessee Health Science Center, Memphis, Tennessee 38163, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Qinghui++Wang">Qinghui Wang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Kinsie E. Arnst</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Kinsie E. Arnst</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Pharmaceutical Sciences, College of Pharmacy, University of Tennessee Health Science Center, Memphis, Tennessee 38163, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Kinsie+E.++Arnst">Kinsie E. Arnst</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Yuxi Wang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yuxi Wang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Respiratory and Critical Care Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yuxi++Wang">Yuxi Wang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Gyanendra Kumar</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Gyanendra Kumar</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Structural Biology, St. Jude Children’s Research Hospital, Memphis, Tennessee 38105, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Gyanendra++Kumar">Gyanendra Kumar</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Dejian Ma</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Dejian Ma</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Pharmaceutical Sciences, College of Pharmacy, University of Tennessee Health Science Center, Memphis, Tennessee 38163, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Dejian++Ma">Dejian Ma</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Stephen W. White</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Stephen W. White</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Structural Biology, St. Jude Children’s Research Hospital, Memphis, Tennessee 38105, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Stephen+W.++White">Stephen W. White</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Duane D. Miller</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Duane D. Miller</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Pharmaceutical Sciences, College of Pharmacy, University of Tennessee Health Science Center, Memphis, Tennessee 38163, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Duane+D.++Miller">Duane D. Miller</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-6093-0985" title="Orcid link">http://orcid.org/0000-0002-6093-0985</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Weimin Li</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Weimin Li</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Respiratory and Critical Care Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#fa8d9f939793cacac9ba89998fd49f9e8fd49994"><span class="__cf_email__" data-cfemail="2f584a4642461f1f1c6f5c4c5a014a4b5a014c41">[email protected]</span></a> (Weimin Li).</span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Weimin++Li">Weimin Li</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Wei Li</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Wei Li</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Pharmaceutical Sciences, College of Pharmacy, University of Tennessee Health Science Center, Memphis, Tennessee 38163, United States</div></div><span class="conrtib-corresp"><strong>*</strong>E-mail: Email: <a href="/cdn-cgi/l/email-protection#36415a5f7643425e455518535243"><span class="__cf_email__" data-cfemail="cdbaa1a48db8b9a5beaee3a8a9b8">[email protected]</span></a>. Phone: 901-448-7532. Fax: 901-448-6828 (Wei Li).</span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Wei++Li">Wei Li</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-9522-4474" title="Orcid link">http://orcid.org/0000-0002-9522-4474</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.9b00706&amp;href=/doi/10.1021%2Facs.jmedchem.9b00706" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2019</span></span><span class="cit-volume">, 62</span><span class="cit-issue">, 14</span><span class="cit-pageRange">, 6734–6750</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">June 28, 2019</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>30 April 2019</li><li><span class="item_label"><b>Published</b> online</span>28 June 2019</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 25 July 2019</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.9b00706" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b00706</a></div><div class="article_header-article-copyright"><strong>Copyright © 2019 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D6734%26pageCount%3D17%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DQinghui%2BWang%252C%2BKinsie%2BE.%2BArnst%252C%2BYuxi%2BWang%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D62%26issueNum%3D14%26contentID%3Dacs.jmedchem.9b00706%26title%3DStructure-Guided%2BDesign%252C%2BSynthesis%252C%2Band%2BBiological%2BEvaluation%2Bof%2B%25282-%25281H-Indol-3-yl%2529-1H-imidazol-4-yl%2529%25283%252C4%252C5-trimethoxyphenyl%2529%2BMethanone%2B%2528ABI-231%2529%2BAnalogues%2BTargeting%2Bthe%2BColchicine%2BBinding%2BSite%2Bin%2BTubulin%26numPages%3D17%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D6750%26publicationDate%3DJuly%2B2019">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.9b00706"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">1862</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">20</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.9b00706" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Structure-Guided Design, Synthesis, and Biological Evaluation of (2-(1H-Indol-3-yl)-1H-imidazol-4-yl)(3,4,5-trimethoxyphenyl) Methanone (ABI-231) Analogues Targeting the Colchicine Binding Site in Tubulin&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Qinghui&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Kinsie&quot;,&quot;last_name&quot;:&quot;E. Arnst&quot;},{&quot;first_name&quot;:&quot;Yuxi&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Gyanendra&quot;,&quot;last_name&quot;:&quot;Kumar&quot;},{&quot;first_name&quot;:&quot;Dejian&quot;,&quot;last_name&quot;:&quot;Ma&quot;},{&quot;first_name&quot;:&quot;Stephen&quot;,&quot;last_name&quot;:&quot;W. White&quot;},{&quot;first_name&quot;:&quot;Duane&quot;,&quot;last_name&quot;:&quot;D. Miller&quot;},{&quot;first_name&quot;:&quot;Weimin&quot;,&quot;last_name&quot;:&quot;Li&quot;},{&quot;first_name&quot;:&quot;Wei&quot;,&quot;last_name&quot;:&quot;Li&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2019&quot;,&quot;month&quot;:&quot;06&quot;,&quot;day&quot;:&quot;28&quot;,&quot;issue&quot;:&quot;14&quot;,&quot;volume&quot;:&quot;62&quot;,&quot;pages&quot;:&quot;6734-6750&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.9b00706&quot;},&quot;abstract&quot;:&quot;ABI-231 is a potent, orally bioavailable tubulin inhibitor that interacts with the colchicine binding site and is currently undergoing clinical trials for prostate cancer. Guided by the crystal structure of ABI-231 in complex with tubulin, we performed structure–activity relationship studies around the 3-indole moiety that led to the discovery of several potent ABI-231 analogues, most notably 10ab and 10bb. The crystal structures of 10ab and 10bb in complex with tubulin confirmed their improved molecular interactions to the colchicine site. In vitro, biological studies showed that new ABI-231 analogues disrupt tubulin polymerization, promote microtubule fragmentation, and inhibit cancer cell migration. In vivo, analogue 10bb not only significantly inhibits primary tumor growth and decreases tumor metastasis in melanoma xenograft models but also shows a significant ability to overcome paclitaxel resistance in a taxane-resistant PC-3/TxR model. In addition, pharmacological screening suggested that 10bb has a lo&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b00706&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b00706" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b00706&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b00706" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b00706&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b00706" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.9b00706&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b00706&amp;href=/doi/10.1021/acs.jmedchem.9b00706" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.9b00706" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.9b00706" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (8 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b00706&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.9b00706%26sid%3Dliteratum%253Aachs%26pmid%3D31251599%26genre%3Darticle%26aulast%3DWang%26date%3D2019%26atitle%3DStructure-Guided%2BDesign%252C%2BSynthesis%252C%2Band%2BBiological%2BEvaluation%2Bof%2B%25282-%25281H-Indol-3-yl%2529-1H-imidazol-4-yl%2529%25283%252C4%252C5-trimethoxyphenyl%2529%2BMethanone%2B%2528ABI-231%2529%2BAnalogues%2BTargeting%2Bthe%2BColchicine%2BBinding%2BSite%2Bin%2BTubulin%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D62%26issue%3D14%26spage%3D6734%26epage%3D6750%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292258" title="Cancer">Cancer</a>,</li><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=290896" title="Cells">Cells</a>,</li><li><a href="/action/doSearch?ConceptID=290768" title="Antineoplastic agents">Antineoplastic agents</a>,</li><li><a href="/action/doSearch?ConceptID=292153" title="Tumors">Tumors</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/62/14" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/jmcmar.2019.62.issue-14/20190725/jmcmar.2019.62.issue-14.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00706/20190719/images/medium/jm-2019-00706x_0011.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00706/20190719/images/large/jm-2019-00706x_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00706&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">ABI-231 is a potent, orally bioavailable tubulin inhibitor that interacts with the colchicine binding site and is currently undergoing clinical trials for prostate cancer. Guided by the crystal structure of ABI-231 in complex with tubulin, we performed structure–activity relationship studies around the 3-indole moiety that led to the discovery of several potent ABI-231 analogues, most notably <b>10ab</b> and <b>10bb</b>. The crystal structures of <b>10ab</b> and <b>10bb</b> in complex with tubulin confirmed their improved molecular interactions to the colchicine site. In vitro, biological studies showed that new ABI-231 analogues disrupt tubulin polymerization, promote microtubule fragmentation, and inhibit cancer cell migration. In vivo, analogue <b>10bb</b> not only significantly inhibits primary tumor growth and decreases tumor metastasis in melanoma xenograft models but also shows a significant ability to overcome paclitaxel resistance in a taxane-resistant PC-3/TxR model. In addition, pharmacological screening suggested that <b>10bb</b> has a low risk of potential off-target function.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_43708" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_43708" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Microtubules are cylindrical polymers that are of great importance for many cellular functions such as cell division and the formation of the mitotic spindle, cell shape maintenance, and cell motility. Microtubules also play a critical role in the proliferation of cancer cells,<a onclick="showRef(event, 'ref1 ref2 ref3'); return false;" href="javascript:void(0);" class="ref ref1 ref2 ref3">(1−3)</a> and microtubule dynamics is therefore one of the most productive therapeutic targets for cancer treatment.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> Microtubule-targeting agents (MTAs) can interfere with functions of microtubules to disrupt the formation of the mitotic spindle, eventually leading to mitotic arrest at the metaphase/anaphase transition. A large number of MTAs have now been discovered and many have been approved by the FDA for the treatment of different cancer types, such as prostate cancer, breast cancer, lung cancer, and ovarian cancer.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> Based on their effects on microtubule dynamics, MTAs are generally classified into two categories: microtubule-stabilizing and microtubule-destabilizing agents. Microtubule-stabilizing agents such as epothilone, ixabepilone, paclitaxel, docetaxel, and cabazitaxel bind to polymerized tubulin proteins and enhance microtubule polymerization. On the contrary, microtubule-destabilizing agents such as colchicine and vinca alkaloids inhibit the polymerization of microtubules.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a></div><div class="NLM_p">The MTAs have achieved great success in cancer treatment for many types of cancers. However, drug resistance is acquired over the course of treatment and becomes a significant clinical limitation. It is estimated that more than 1.7 million new cancer cases will be diagnosed in United States in 2019, and developing new anticancer agents to treat resistant phenotypes is therefore urgently needed.<a onclick="showRef(event, 'ref6 ref7'); return false;" href="javascript:void(0);" class="ref ref6 ref7">(6,7)</a> Mechanisms that mediate drug resistance against MTAs include but are not limited to the overexpression of membrane-bound drug efflux proteins, such as P-glycoprotein (P-gp); the overexpression of certain β-tubulin isotypes; and tubulin protein mutations.<a onclick="showRef(event, 'ref8 ref9'); return false;" href="javascript:void(0);" class="ref ref8 ref9">(8,9)</a> Taxanes and vinca alkaloids are especially susceptible to efflux by ATP-binding cassette (ABC) transporters and are less effective against cells overexpressing the tubulin β-III isotype.<a onclick="showRef(event, 'ref10 ref11 ref12'); return false;" href="javascript:void(0);" class="ref ref10 ref11 ref12">(10−12)</a></div><div class="NLM_p">The colchicine binding site is one of the well-documented binding sites in tubulin and located at the interface between α and β-tubulin heterodimers.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> Colchicine binding site inhibitors (CBSIs, examples are listed in <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>) mechanistically decrease cellular motility, alter cell morphology, impair protein assembly, and arrest mitosis.<a onclick="showRef(event, 'ref14 ref15'); return false;" href="javascript:void(0);" class="ref ref14 ref15">(14,15)</a> Colchicine (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>) is a secondary metabolite isolated from natural sources and has wide-scope mechanisms of action. Unfortunately, it induces systemic toxicities and multiorgan dysfunction in a clinical trial for cancer treatment<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> and thus is not currently approved by the FDA for cancer treatment. Other than colchicine and its derivatives, a number of other CBSIs have also been reported in the past decades; some examples are listed in <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>. Encouragingly, extensive preclinical studies have strongly suggested that CBSIs are effective in suppressing the overexpression of tubulin isotypes and surmount drug resistance mediated by P-gp, MRP1, and MRP2.<a onclick="showRef(event, 'ref16 ref17 ref18'); return false;" href="javascript:void(0);" class="ref ref16 ref17 ref18">(16−18)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00706/20190719/images/medium/jm-2019-00706x_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00706/20190719/images/large/jm-2019-00706x_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Examples of microtubule inhibitors that target colchicine binding sites in tubulin.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00706/20190719/images/large/jm-2019-00706x_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00706&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">In our prior reports, we have described the discovery of several scaffolds of potent tubulin inhibitors, including SMARTs, RABIs, ABIs, and IBIs.<a onclick="showRef(event, 'ref19 ref20 ref21 ref22 ref23 ref24'); return false;" href="javascript:void(0);" class="ref ref19 ref20 ref21 ref22 ref23 ref24">(19−24)</a> The SMART structure is our initially discovered scaffold that exhibited nanomolar range antiproliferative activities against a panel of cancer cell lines and showed promising in vivo activities in both melanoma and prostate xenograft models.<a onclick="showRef(event, 'ref19 ref25 ref26 ref27'); return false;" href="javascript:void(0);" class="ref ref19 ref25 ref26 ref27">(19,25−27)</a> Subsequent structural modification of the SMART scaffold by replacing the central thiazole ring with a more metabolically stable imidazole ring resulted in the discovery of 2-aryl-4-benzoyl-imidazole (ABI-I/II) pharmacophores. ABI-I/IIs not only showed more potent activities but also improved bioavailability in comparison with SMARTs.<a onclick="showRef(event, 'ref19 ref20'); return false;" href="javascript:void(0);" class="ref ref19 ref20">(19,20)</a> The ABI-III’s pharmacophore differed from ABI-I/IIs in having bicyclic heterocycles,<a onclick="showRef(event, 'ref21 ref22'); return false;" href="javascript:void(0);" class="ref ref21 ref22">(21,22)</a> which are versatile moieties in medicinal chemistry.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> ABI-III exhibited more potent antiproliferative activity (IC<sub>50</sub> values are in low single-digit nanomolar range) than ABI-I/IIs. Rotation of the imidazole ring in ABI-I/IIs led to the establishment of reverse ABIs (RABIs) which maintain comparable antiproliferative potency.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> Substituting the central imidazole ring and carbonyl linker in ABI-IIIs with bicyclic heterocycles provided the IBIs, which displayed potency similar to that of ABI-IIIs.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> SMARTs, ABIs, RABIs, and IBIs share the same mechanism of action: binding to the colchicine binding site in tubulin and inhibiting tubulin polymerization. Interestingly, they are all effective against multidrug-resistant cell lines and can circumvent P-gp-mediated drug resistance.<a onclick="showRef(event, 'ref20 ref21 ref22'); return false;" href="javascript:void(0);" class="ref ref20 ref21 ref22">(20−22)</a> Amongst all of the scaffolds, ABI-231, a member of the ABI-III class, displays optimum activity and has an average IC<sub>50</sub> value of 5.2 nM against a large panel of cancer cell lines.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> Additionally, it was revealed that ABI-231 inhibits the expression of tubulin βIII and βIV over other isotypes via restoring the expression of miR-200c in a panel of pancreatic cancer cell lines, which supports the ability of ABI-231 to surmount drug resistance to existing tubulin inhibitors.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> Recently, we described a focused structure–activity relationship (SAR) investigation of the trimethoxyphenyl (TMP) moiety in ABI-231 that lead to a unique 3-methoxybenzo[4,5]-dioxene analogue, which showed more potent antiproliferative activity than ABI-231.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> In this work, we describe an efficient synthesis of ABI-231 that facilitated an SAR evaluation of the indole moiety, provide the molecular interactions and rationales between tubulin proteins and ABI-231 or its two potent derivatives using X-ray crystallography, investigate the mechanism of action of the new analogues, and determine their biological activities.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Chemistry</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_40740" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_40740" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">To rapidly generate ABI-231 analogues modifying the indole moiety, we designed an efficient synthetic strategy illustrated in <a href="/doi/suppl/10.1021/acs.jmedchem.9b00706/suppl_file/jm9b00706_si_001.pdf" class="ext-link">Scheme S1</a>. Creation of the ABI-231 scaffold uses imidazoline cyclization, which requires a diamine intermediate and indolyl-3-carboxyaldehyde according to a reported methodology.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> In this method, it is crucial to accumulate a large quantity of the diamine intermediate, the synthesis of which was furnished in six steps and described in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>. Commercially available 3,4,5-trimethoxybenzaldehyde was treated with Grignard reagent vinylmagnesium bromide to generate the racemic mixture 1,<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> which was subsequently treated with <i>tert</i>-butyldimethylsilyl chloride in the presence of imidazole to give <b>2</b>. <b>2</b> then underwent the Upjohn reaction in the presence of a catalytic equivalent of osmium tetroxide to obtain a mixture of diastereoisomers <b>3</b> in 79% yield over three steps. Diazide <b>5</b> was produced in two steps from <b>3</b> by following reported procedures:<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> mesylation of the diol <b>3</b> in the presence of methanesulfonyl chloride and triethylamine yielded dimesylate <b>4</b> in 86% yield; <b>4</b> was then refluxed with sodium azide in dimethylformamide to give diazide <b>5</b> in 67% yield. Hydrogenation of diazide <b>5</b> in the presence of 10% Pd/C provided diamine <b>6</b> in 53% yield.</div><figure id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00706/20190719/images/medium/jm-2019-00706x_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00706/20190719/images/large/jm-2019-00706x_0008.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Diamine Intermediate <b>6</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00706/20190719/images/large/jm-2019-00706x_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00706&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">With <b>6</b> in hand, syntheses of ABI-231 and its analogues were pursued as outlined in <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a> and furnished in 19% yield over four steps. Treatment of indole-3-carboxyaldehyde with di<i>tert</i>-butyl dicarbonate gave <b>7</b>. In the presence of <i>N</i>-bromosuccinimide, <b>7</b> then reacted with diamine <b>6</b> at ice temperature to form imidazoline <b>8</b>, which was subjected to the deprotection of TBS in the presence of TBAF and deprotection of Boc in the presence of trifluoroacetic acid (TFA) to provide <b>9</b> in two steps. ABI-231 was accomplished through simultaneous oxidation of the imidazoline to imidazole and the secondary alcohol to carbonyl in <b>9</b> in the presence of 3.0–5.0 equiv of 2-iodoxybenzoic acid (IBX).<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> By following <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>, we furnished 26 new ABI-231 analogues (<b>10aa–10av</b> and <b>10ba–10be</b>) in 10–20% yield over four steps. Hydrogenation of <b>10ak</b> and <b>10ao</b> afforded <b>10au</b> and <b>10av</b>.</div><figure id="sch2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00706/20190719/images/medium/jm-2019-00706x_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00706/20190719/images/large/jm-2019-00706x_0009.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of ABI-231 Analogues Modifying the Indole Moiety</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00706/20190719/images/large/jm-2019-00706x_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00706&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i6">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_76813" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_76813" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec3_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i7" class="anchor-spacer"></div><h3 class="article-section__title" id="_i7"> SAR Investigation</h3><div class="NLM_p">To compare to the antiproliferative potency of ABI-231 that was reported previously, the cytotoxicity of all new ABI-231 analogues was evaluated in human melanoma cell lines A375, WM164, and M14. Colchicine was used as a positive control, and ABI-231 was used as a prototype for comparison. The antiproliferative activities of the compounds were evaluated in the cell viability MTS assay. IC<sub>50</sub> values are reported in nM and were calculated from at least three independent experiments, each performed in quadruplicates using 96-well plates. Results from these in vitro assays are shown in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>. ABI-231 has an IC<sub>50</sub> value ranging from 5.6 to 8.1 nM and is comparable to our previously reported data.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a></div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. In Vitro Growth Inhibitory Effects of ABI-231 Analogues Modifying the Indole Moiety (nM)</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00706/20190719/images/medium/jm-2019-00706x_0010.gif" alt="" id="gr10" /></img><div></div></div><div class="NLM_p">Twenty-two new analogues (<b>10aa</b> to <b>10at</b>) were synthesized to inspect substituent effects to the 3-indolyls. Compared to the prototype ABI-231, analogue <b>10aa</b> with a bulky phenyl group on the 2-position of indole moiety showed essentially a total loss of activity with IC<sub>50</sub> values larger than 1 μM. This indicated that bulky substituents on the indole are not tolerated. Five analogues were synthesized in the 4-position substituted series, including <b>10ab–10af</b> and <b>10au</b>. The best inhibitory effect was observed in 4-methyl analogue <b>10ab</b>, which has IC<sub>50</sub> values ranging from 1.7 to 3.2 nM, which is ∼3-fold more potent than ABI-231. Analogue <b>10ac</b> has a small substituent (4-F) and displays nearly equipotent antiproliferative activity to that of ABI-231 with its IC<sub>50</sub> values ranging from 7.2 to 8.2 nM. In contrast, <b>10ad</b>, an analogue with a large-size halogen 4-bromo, has IC<sub>50</sub> values ranging from 10.4 to 67.1 nM and is twofold less potent than ABI-231. For analogues <b>10ae</b> with a 4-methoxy group and <b>10af</b> with a 4-benzoxy group, remarkable reductions of activities were observed; their IC<sub>50</sub> values are more than 1 μM. In general, 5-position-substituted analogues show substantially decreased antiproliferative activities in comparison with their corresponding 4-position-substituted counterparts. For example, the 5-fluoro analogue <b>10ah</b> and the 5-bromo analogue <b>10aj</b> are 2-fold and 10-fold less potent than <b>10ac</b> and <b>10ad</b>, respectively. The 5-methyl analogue <b>10ag</b> has approximately 100-fold decreased antiproliferative activity compared to <b>10ab</b>. In this series, the best activity was observed in the 5-fluoro analogue <b>10ah</b>, which has IC<sub>50</sub> values ranging from 18.0 to 80.9 nM. It is surprising to find that hydrogenation of the bulky 5-benzyloxy analogue (<b>10ak</b>) to 5-hydroxy analogue (<b>10au</b>) does not lead to any improvement of the antiproliferative activity. For the 6-position-substituted analogues, similarly, bulky functional groups such as analogues <b>10ao</b>, <b>10ap</b>, and <b>10aq</b> lost activities (all have IC<sub>50</sub> values of more than 1 μM), whereas small substituent benefited the cytotoxicity, for example, 6-fluoro analogue <b>10am</b>. The best activity in this series was observed in 10am, having IC<sub>50</sub> values ranging from 5.8 to 17.5 nM. Hydrogenation of the bulky benzyloxy to hydroxy on the 6-position did not provide any significant improvement of activity (<b>10av</b>) neither. Among the 7-position-substituted 3-indolyl analogues, <b>10ar</b> with a methyl substitution possesses the most potent inhibitory effect (IC<sub>50</sub> values range from 10.8 to 61.3 nM). Interestingly, <b>10at</b> with a 7-methoxy substituent showed significantly stronger activity (IC<sub>50</sub> ranges from 34.1 to 115.4 nM) than its other position substituted counterparts (<b>10ae</b> and <b>10ap</b>). Taken together, these SAR data revealed that small substituents (e.g., fluoro and methyl) are strongly preferred over bulky functional groups on the 3-indolyl moiety, and modification at the 4-position generates the most potent analogue (<b>10ab</b> in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>).</div><div class="NLM_p last">In addition, we previously reported a series of indolyl-imidazopyridines as CBSIs in 2015.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> SAR studies in those compounds revealed that indolyl rotation significantly affects antiproliferative activities. We hypothesized that this may also apply to ABI-231, considering its overall structural similarity to the indolyl-imidazopyridines. To test this hypothesis, four ABI-231 analogues <b>10bb–10be</b> were synthesized (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>) and their in vitro growth inhibitory effects are also shown in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>. In this series, 5- and 6-indolyl analogues <b>10bc</b> and <b>10bd</b> showed comparable antiproliferative activities to that of ABI-231 and have IC<sub>50</sub> values ranging from 6.1 to 18.5 and 3.8 to 8.0 nM, respectively. The 7-indolyl analogue <b>10be</b> was significantly less potent than ABI-231, having IC<sub>50</sub> values more than 100 nM. <b>10bb</b>, the 4-indolyl analogue, showed approximately twofold improvement of activity compared to ABI-231 and has IC<sub>50</sub> values ranging from 1.6 to 3.7 nM. Collectively, these data suggest that the antiproliferative activity of the ABI-231 scaffold is very sensitive to the position in the indole moiety connecting to the central imidazole ring (e.g., 3-indole and 4-indole are the best) and position/size in this indole ring (e.g., a small, hydrophobic substitution at the 3- or 4-position are strongly preferred).</div></div><div id="sec3_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9"> X-ray Structures of ABI-231, <b>10ab</b>, and <b>10bb</b> in Complex with Tubulin</h3><div class="NLM_p">To understand the molecular interactions between ABI-231 and tubulin protein, and the structural basis of the SAR observed above, we first determined the crystal structure of the T2R-TTL (consisting of two α/β-tubulin dimers, the stathmin-like protein RB3, and tubulin tyrosine ligase) in complex with ABI-231 at a resolution of 2.6 Å (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6O61">6O61</a>). The crystallographic data and refinement statistics are shown in <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. X-ray Data Collection and Refinement Statistics</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center">ABI-231 (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6O61">6O61</a>)</th><th class="colsep0 rowsep0" align="center">compound <b>10ab</b> (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6O5N">6O5N</a>)</th><th class="colsep0 rowsep0" align="center">compound <b>10bb</b> (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6O5M">6O5M</a>)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="4" align="center"><b>Data Collection</b></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">space group</td><td class="colsep0 rowsep0" align="left"><i>P</i>2<sub>1</sub>2<sub>1</sub>2<sub>1</sub></td><td class="colsep0 rowsep0" align="left"><i>P</i>2<sub>1</sub>2<sub>1</sub>2<sub>1</sub></td><td class="colsep0 rowsep0" align="left"><i>P</i>2<sub>1</sub>2<sub>1</sub>2<sub>1</sub></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="4" align="center"><b>Cell Dimensions</b></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>a</i>, <i>b</i>, <i>c</i> (Å)</td><td class="colsep0 rowsep0" align="left">105.26, 157.09, 184.04</td><td class="colsep0 rowsep0" align="left">105.30, 157.76, 182.08</td><td class="colsep0 rowsep0" align="left">104.97, 157.72, 181.61</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">α, β, γ (°)</td><td class="colsep0 rowsep0" align="left">90, 90, 90</td><td class="colsep0 rowsep0" align="left">90, 90, 90</td><td class="colsep0 rowsep0" align="left">90, 90, 90</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">resolution (Å)</td><td class="colsep0 rowsep0" align="left">50–2.60 (2.69–2.60)<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">50–3.00 (3.11–3.00)</td><td class="colsep0 rowsep0" align="left">50–2.3 (2.37–2.3)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>R</i><sub>meas</sub></td><td class="colsep0 rowsep0" align="left">0.116 (0.965)</td><td class="colsep0 rowsep0" align="left">0.150 (1.00)</td><td class="colsep0 rowsep0" align="left">0.113 (1.00)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>I</i>/σ(<i>I</i>)</td><td class="colsep0 rowsep0" align="left">16.25 (2.0)</td><td class="colsep0 rowsep0" align="left">12.25 (2.0)</td><td class="colsep0 rowsep0" align="left">22.6 (3.0)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">completeness (%)</td><td class="colsep0 rowsep0" align="left">99.2 (99.5)</td><td class="colsep0 rowsep0" align="left">99.9 (100)</td><td class="colsep0 rowsep0" align="left">99.9 (99.8)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">redundancy</td><td class="colsep0 rowsep0" align="left">6.8 (6.9)</td><td class="colsep0 rowsep0" align="left">6.7 (6.8)</td><td class="colsep0 rowsep0" align="left">13.0 (13.1)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="4" align="center"><b>Refinement</b></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">resolution (Å)</td><td class="colsep0 rowsep0" align="left">39.83–2.60 (2.69–2.60)</td><td class="colsep0 rowsep0" align="left">41.78–3.00 (3.11–3.00)</td><td class="colsep0 rowsep0" align="left">49.76–2.3 (2.37–2.3)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">no. reflections</td><td class="colsep0 rowsep0" align="left">92 647 (8453)</td><td class="colsep0 rowsep0" align="left">58 910 (4504)</td><td class="colsep0 rowsep0" align="left">135 160 (12 695)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>R</i><sub>work</sub>/<i>R</i><sub>free</sub></td><td class="colsep0 rowsep0" align="left">0.2049/0.2452</td><td class="colsep0 rowsep0" align="left">0.2024/0.2452</td><td class="colsep0 rowsep0" align="left">0.1899/0.2233</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">no. atoms</td><td class="colsep0 rowsep0" align="left">17 165</td><td class="colsep0 rowsep0" align="left">17 476</td><td class="colsep0 rowsep0" align="left">17 881</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">protein</td><td class="colsep0 rowsep0" align="left">16 695</td><td class="colsep0 rowsep0" align="left">17 228</td><td class="colsep0 rowsep0" align="left">16 860</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ligand/ion</td><td class="colsep0 rowsep0" align="left">236</td><td class="colsep0 rowsep0" align="left">207</td><td class="colsep0 rowsep0" align="left">253</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">water</td><td class="colsep0 rowsep0" align="left">234</td><td class="colsep0 rowsep0" align="left">41</td><td class="colsep0 rowsep0" align="left">768</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="4" align="center"><i>B factors</i></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">protein</td><td class="colsep0 rowsep0" align="left">55.27</td><td class="colsep0 rowsep0" align="left">65.25</td><td class="colsep0 rowsep0" align="left">43.65</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ligand/ion</td><td class="colsep0 rowsep0" align="left">55.85</td><td class="colsep0 rowsep0" align="left">48.52</td><td class="colsep0 rowsep0" align="left">42.35</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">water</td><td class="colsep0 rowsep0" align="left">40.72</td><td class="colsep0 rowsep0" align="left">47.30</td><td class="colsep0 rowsep0" align="left">41.74</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="4" align="center"><i>rms deviations</i></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">bond lengths (Å)</td><td class="colsep0 rowsep0" align="left">0.005</td><td class="colsep0 rowsep0" align="left">0.004</td><td class="colsep0 rowsep0" align="left">0.004</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">bond angles (deg)</td><td class="colsep0 rowsep0" align="left">1.14</td><td class="colsep0 rowsep0" align="left">1.03</td><td class="colsep0 rowsep0" align="left">1.05</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="4" align="center"><i>Ramachandra plot</i></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">favored (%)</td><td class="colsep0 rowsep0" align="left">97.99</td><td class="colsep0 rowsep0" align="left">96.10</td><td class="colsep0 rowsep0" align="left">98.18</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">allowed (%)</td><td class="colsep0 rowsep0" align="left">1.92</td><td class="colsep0 rowsep0" align="left">3.71</td><td class="colsep0 rowsep0" align="left">1.77</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">outliers (%)</td><td class="colsep0 rowsep0" align="left">0.09</td><td class="colsep0 rowsep0" align="left">0.19</td><td class="colsep0 rowsep0" align="left">0.05</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">Values in parentheses are for highest-resolution shell.</p></div></div></div><div class="NLM_p">The structure was clearly resolved (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>A) and revealed that ABI-231 is bound at the colchicine binding site at the interface of α and β-tubulin opposite to the GTP that also binds at this interface (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>B,C). It is positioned to make three hydrogen bonds with tubulin; the carbonyl with the main chain NH of β-Asp249, the imidazole NH with the main chain C═O of α-Thr179, and the indole NH with the main chain C═O of β-Asn347 and α-Thr178 through a water “bridge”. The TMP moiety of ABI-231 occupies a deep pocket lined by β-Tyr200, β-Val236, β-Cys239, and β-Leu253. The imidazole ring is sandwiched between the side chains of β-Leu246 on one side and β-Ly252 and β-Asn256 on the other side. The indole ring occupies a pocket lined by β-Asn256, β-Met257, β-Ala314, β-Lys350, β-Lys350, and α-Val181. Note that ABI-231 mostly interacts with the β-tubulin, but it also makes two interactions with the α-tubulin (α-Thr179 and α-Thr178) across the interface. Thus, the compound acts like glue to increase the α- and β-interaction. ABI-231 shares a binding pose similar to that of colchicine (<a href="/doi/suppl/10.1021/acs.jmedchem.9b00706/suppl_file/jm9b00706_si_001.pdf" class="ext-link">Figure S1A</a>), indicating that the two compounds share a similar mode of inhibition.</div><figure id="fig2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00706/20190719/images/medium/jm-2019-00706x_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00706/20190719/images/large/jm-2019-00706x_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Complex structures of ABI-231 (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6O61">6O61</a>) and the new analogues <b>10ab</b> (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6O5N">6O5N</a>) and <b>10bb</b> (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6O5M">6O5M</a>) with tubulin protein. (A,D,G) Overall crystal structure of the three compounds in complex with tubulin proteins. (B,E,H) Detailed interactions between ABI-231, <b>10ab</b>, and <b>10bb</b> and tubulin (ABI-231 is in yellow stick representation, <b>10ab</b> is in green stick representation, and <b>10bb</b> is in orange stick representation). (C,F,I) 90° counterclockwise rotation view of the corresponding structures along the <i>x</i> axis.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00706/20190719/images/large/jm-2019-00706x_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00706&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">To investigate the prominent potencies of <b>10ab</b> and <b>10bb</b>, we also solved the crystal structures of these compounds in complexes with tubulin protein (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6O5N">6O5N</a> for <b>10ab</b>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6O5M">6O5M</a> for <b>10bb</b>). The crystallographic data and structure refinement statistics for <b>10ab</b> and <b>10bb</b> in complex with tubulin are also shown in <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>, and the electron density maps are shown in <a href="/doi/suppl/10.1021/acs.jmedchem.9b00706/suppl_file/jm9b00706_si_001.pdf" class="ext-link">Figure S2B,C</a>, along with the electron density map for ABI-231 (<a href="/doi/suppl/10.1021/acs.jmedchem.9b00706/suppl_file/jm9b00706_si_001.pdf" class="ext-link">Figure S2A</a>). Similar to ABI-231, <b>10ab</b> and <b>10bb</b> both bound to the colchicine binding site of tubulin and overlapped well with colchicine (<a href="/doi/suppl/10.1021/acs.jmedchem.9b00706/suppl_file/jm9b00706_si_001.pdf" class="ext-link">Figure S1B,C</a>). <b>10ab</b> shows hydrogen bonding interactions similar to those of ABI-231, and its increased activity can be attributed to the additional van der Waal interactions afforded by the extra 4-methyl group that fills a small cavity in the ABI-231 complex bounded by β-Leu253, β-Met257, and β-Ala314 (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>D–F). <b>10bb</b> as a 4-indole compound shares the main chain ABI-231 hydrogen bonding interactions with α-Thr179 and β-Asp249. Although the hydrogen bonding to β-Asp249 is weakened compared with that in ABI-231 or <b>10ab</b>, the rotated indole now allows a direct hydrogen bond between the indole NH and main chain C═O of β-Asn347 rather than the water-mediated hydrogen bond seen in ABI-231 (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>B,C). This direct hydrogen bonding interaction also pull the <b>10bb</b> slightly up from the pocket where the TMP moiety occupies, allowing a separate water-bridged hydrogen bonding network between the middle methoxy oxygen to the backbone NH in β-Cys239 and CO in β-Gly235. This water molecule has also been seen in a number of previously reported high-resolution crystal structures with another scaffold of CBSIs.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> Collectively, the direct hydrogen bond from the 4-indole moiety, added water-bridged hydrogen bond at the TMP pocket, and ability of the rotated indole to still occupy its binding pocket are likely to explain its increased activity. Both ABI-231 and its new analogue binding are not compatible with the original straight conformation of tubulin protein. Specifically, the curve-to-straight transition of tubulin is hindered by steric clashes between ABI-231/<b>10ab</b>/<b>10bb</b> and the surrounding secondary elements (<a href="/doi/suppl/10.1021/acs.jmedchem.9b00706/suppl_file/jm9b00706_si_001.pdf" class="ext-link">Figure S3</a>), which is consistent with previous reports.<a onclick="showRef(event, 'ref13 ref38'); return false;" href="javascript:void(0);" class="ref ref13 ref38">(13,38)</a></div></div><div id="sec3_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11"> New ABI-231 Analogues Showed Potent Activities against NCI-60 Panel Cell Lines</h3><div class="NLM_p last">Besides their excellent antiproliferative activities observed in melanoma cell lines as tested in our laboratory, <b>10ab</b>, <b>10bb</b>, and <b>10bd</b> were also tested against NCI-60 cell lines in both one-dose and full five-dose assays. The compounds effectively inhibited cancer cell growth in a variety of cancer types and were particularly active against leukemia, colon, and prostate cancer (<a href="/doi/suppl/10.1021/acs.jmedchem.9b00706/suppl_file/jm9b00706_si_001.pdf" class="ext-link">Figure S4A</a>). They also produced IC<sub>50</sub> values in the low nanomolar range against the vast majority of the NCI-60 cell lines (<a href="/doi/suppl/10.1021/acs.jmedchem.9b00706/suppl_file/jm9b00706_si_001.pdf" class="ext-link">Figure S4B</a>). It is clear that the new ABI-231 analogues <b>10ab</b>, <b>10bb</b>, and <b>10bd</b> all exhibit strong inhibitory effects against a wide range of cancers.</div></div><div id="sec3_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12"> Inhibition of Tubulin Polymerization</h3><div class="NLM_p">We next determined the effects of the most potent new analogues (<b>10ab</b> and <b>10bb</b>) for their ability to inhibit tubulin polymerization, the primary mechanisms of action of ABI-231. In a cell-free purified tubulin polymerization assay, 10 μM concentrations of <b>10ab</b> and <b>10bb</b> were evaluated against vehicle control and docetaxel, a well-documented inducer of tubulin polymerization. <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>A clearly shows that compounds <b>10ab</b> and <b>10bb</b> potently inhibited tubulin polymerization, whereas the vehicle experienced an initial and rapid increase in polymerization and docetaxel strongly and consistently promoted polymerization. The effects on microtubule networks were then observed by immunofluorescence via confocal microscopy. The microtubule morphology in WM164 cells was visualized after 18 h of treatment of with 100 nM of <b>10ab</b>, <b>10bb</b>, docetaxel, or untreated control cells. As shown in <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>B, <b>10ab</b> and <b>10bb</b> dramatically disrupt microtubules, resulting in fragmentation and disassembly. Docetaxel works in the opposite manner, causing hyperpolymerization and the formation of dense, aggregated bundles of microtubules. These mechanistic studies confirm a mode of action by which these compounds induce depolymerization of tubulin and disturb microtubule networks by interacting with the colchicine binding site.</div><figure id="fig3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00706/20190719/images/medium/jm-2019-00706x_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00706/20190719/images/large/jm-2019-00706x_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. New ABI-231 analogues inhibit tubulin polymerization. (A) Polymerization of purified tubulin in a cell-free assay. Tubulin (3.33 mg/mL) was exposed to vehicle control or 10 μM of the compounds (<i>n</i> = 2). Absorbance at 340 nm was monitored at 37 °C every minute for 30 min. (B) Effect on microtubules of WM164 cells following 18 h exposure to 100 nM of <b>10ab</b>, <b>10bb</b>, docetaxel, or vehicle control. Confocal microscopy was utilized to visualize the microtubules following immunofluorescent staining. Microtubules are shown in red and DNA is shown in blue. Scale bar = 20 μm.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00706/20190719/images/large/jm-2019-00706x_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00706&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13"> In Vitro Inhibition of Cancer Growth and Migration</h3><div class="NLM_p">The long-term inhibitory growth effects of <b>10ab</b> and <b>10bb</b> were tested in A375 cells in an anchorage-dependent colony formation assay. The visual result and quantitative data are shown in <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>A,B. While the vehicle control-treated cells averaged 199.3 ± 10.7 colonies after 12 days, both <b>10ab</b> and <b>10bb</b> significantly inhibited colony number, with an average of 81.7 ± 7.8 and 128.3 ± 9.1 colonies, respectively. This represents a 59.0 and 35.6% decrease, respectively, from the control. These compounds out-performed colchicine, which averaged 150.0 ± 5.3 colonies, corresponding to a 24.7% decrease in the colony number. Tubulin and microtubule function are also implicated in cell migration and motility. Therefore, we assessed the effect of <b>10ab</b> and <b>10bb</b> in a wound healing assay. After removing a confluent monolayer of adherent A375 or RPMI7951 melanoma cells, the remaining cells were treated for 18–22 h with 5 or 25 nM of <b>10ab</b>, <b>10bb</b>, or colchicine and compared against untreated control cells. The total closure was calculated as a percentage of the total wound area after treatment compared to the total area of removed cells immediately prior to treatment. In A375 and RPMI7951 cell lines, the control cells were able to efficiently migrate into the wound channel apprehended, recovering 60.7 ± 3.5 and 71.8 ± 1.8% of the area, respectively (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>C,D). Following 5 nM treatment, A375 cells only migrated into 48.5 ± 1.6, 38.5 ± 2.2, and 46.0 ± 1.4% of the wound area for <b>10ab</b>, <b>10bb</b>, and colchicine, respectively (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>C,D). At higher concentrations of 25 nM, greater inhibition was observed, where <b>10ab</b>-treated cells recovered 25.9 ± 1.6%, <b>10bb</b> recovered 38.5 ± 2.2%, and colchicine-treated cells recovered 20.7 ± 2.2% (<i>P</i> < 0.0001). A significant difference was also observed in RPMI7951 cells treated at 25 nM of <b>10ab</b>, <b>10bb</b>, or colchicine, leading to wound closure averaging 35.6 ± 6.6, 35.0 ± 7.8, and 42.8 ± 5.8%, respectively (<i>P</i> = 0.0004) (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>C,D). Normalized to the control cell lines, the average inhibition of cell migration for the treated cells was 53.5% for <b>10ab</b>, 52.8% for <b>10bb</b>, and 32.8% for colchicine. Taken together, these results demonstrate that <b>10ab</b> and <b>10bb</b> potently inhibit proliferation and migration of cancer cells in vitro at low nM concentrations.</div><figure id="fig4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00706/20190719/images/medium/jm-2019-00706x_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00706/20190719/images/large/jm-2019-00706x_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. <b>10ab</b> and <b>10bb</b> inhibit colony growth and cancer cell migration. (A) Representative images of A375 colony formation for control or treated cells. (B) Quantification of colony numbers (<i>n</i> = 3). Statistical analysis was performed by ANOVA (<i>P</i> < 0.0001) followed by Dunnett’s multiple comparison test. (C) Representative images of wound area in a scratch assay. Images were obtained after 18–22 h for A375 (top) or RPMI7951 (bottom) cells after treatment with 5 or 25 nM concentrations of <b>10ab</b>, <b>10bb</b>, colchicine, or untreated control. (D) Percentage of the wound closed for A375 cells (top) or RPMI7951 cells (bottom) (<i>n</i> = 3). Area of the wound channel was calculated using ImageJ software. Statistical analysis was performed by ANOVA (<i>P</i> < 0.0001 for A375, <i>P</i> = 0.0004 for RPMI7951) followed by the Dunnett’s multiple comparison test.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00706/20190719/images/large/jm-2019-00706x_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00706&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14"> In Vitro Microsomal Stability</h3><div class="NLM_p">To determine the most suitable candidates for in vivo efficacy studies, we examined the in vitro metabolic stabilities of the most potent analogues by measuring their half-life upon incubation with mouse, rat, and human liver microsomes in the presence of an NADPH regeneration system. The results are summarized in <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>. Overall, all three new ABI-231 analogues exhibited very good liver microsomal stabilities in three different species. <b>10bb</b>, which showed overall best in vitro potency and stability, was then selected for subsequent in vivo studies.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Microsomal Stability Study of Tested Compounds in Liver Microsome of Different Species</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="±" /></col><col align="char" char="." /></col><col align="char" char="±" /></col><col align="char" char="." /></col><col align="char" char="±" /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center" char="±">metabolic stability (mouse)</th><th class="rowsep1 colsep0" colspan="2" align="center" char="±">metabolic stability (rat)</th><th class="rowsep1 colsep0" colspan="2" align="center" char="±">metabolic stability (human)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compounds</th><th class="colsep0 rowsep0" align="center" char="±"><i>t</i><sub>1/2</sub> (h)</th><th class="colsep0 rowsep0" align="center" char=".">Cl<sub>int</sub> (mL/min/kg)</th><th class="colsep0 rowsep0" align="center" char="±"><i>t</i><sub>1/2</sub> (h)</th><th class="colsep0 rowsep0" align="center" char=".">Cl<sub>int</sub> (mL/min/kg)</th><th class="colsep0 rowsep0" align="center" char="±"><i>t</i><sub>1/2</sub> (h)</th><th class="colsep0 rowsep0" align="center" char=".">Cl<sub>int</sub> (mL/min/kg)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Verapamil</td><td class="colsep0 rowsep0" align="char" char="±">0.94 ± 0.06</td><td class="colsep0 rowsep0" align="char" char=".">60.66</td><td class="colsep0 rowsep0" align="char" char="±">1.29 ± 0.09</td><td class="colsep0 rowsep0" align="char" char=".">36.18</td><td class="colsep0 rowsep0" align="char" char="±">1.68 ± 0.16</td><td class="colsep0 rowsep0" align="char" char=".">12.41</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ABI-231</td><td class="colsep0 rowsep0" align="char" char="±">3.76 ± 0.24</td><td class="colsep0 rowsep0" align="char" char=".">15.20</td><td class="colsep0 rowsep0" align="char" char="±">6.74 ± 0.59</td><td class="colsep0 rowsep0" align="char" char=".">6.94</td><td class="colsep0 rowsep0" align="char" char="±">5.13 ± 0.26</td><td class="colsep0 rowsep0" align="char" char=".">4.05</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>10ab</b></td><td class="colsep0 rowsep0" align="char" char="±">2.42 ± 0.15</td><td class="colsep0 rowsep0" align="char" char=".">23.60</td><td class="colsep0 rowsep0" align="char" char="±">1.80 ± 0.09</td><td class="colsep0 rowsep0" align="char" char=".">25.98</td><td class="colsep0 rowsep0" align="char" char="±">6.70 ± 0.82</td><td class="colsep0 rowsep0" align="char" char=".">3.10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>10bb</b></td><td class="colsep0 rowsep0" align="char" char="±">5.04 ± 0.30</td><td class="colsep0 rowsep0" align="char" char=".">11.34</td><td class="colsep0 rowsep0" align="char" char="±">5.26 ± 0.35</td><td class="colsep0 rowsep0" align="char" char=".">8.90</td><td class="colsep0 rowsep0" align="char" char="±">6.72 ± 0.74</td><td class="colsep0 rowsep0" align="char" char=".">3.10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>10bd</b></td><td class="colsep0 rowsep0" align="char" char="±">5.56 ± 0.35</td><td class="colsep0 rowsep0" align="char" char=".">10.28</td><td class="colsep0 rowsep0" align="char" char="±">15.19 ± 2.09</td><td class="colsep0 rowsep0" align="char" char=".">3.10</td><td class="colsep0 rowsep0" align="char" char="±">7.61 ± 0.91</td><td class="colsep0 rowsep0" align="char" char=".">2.73</td></tr></tbody></table></div></div></div><div id="sec3_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> <b>10bb</b> Inhibits Melanoma Tumor Growth and Metastasis in Vivo</h3><div class="NLM_p">The anticancer efficacy of <b>10bb</b> was evaluated in vivo in two melanoma mouse models. All animal experiments performed in this report were conducted in compliance with the NIH and institutional guidelines, using approved animal protocols from the University of Tennessee Health Science Center. First, a xenograft model of nude mice challenged with A375 melanoma subcutaneously was treated every other day via i.p. injection with 15 or 30 mg/kg doses of <b>10bb</b>, paclitaxel, or a vehicle solution only. After 20 days, the group receiving 15 mg/kg treatments of <b>10bb</b> achieved an average tumor growth inhibition (TGI) of 82.3% and the group receiving the higher dose of 30 mg/kg achieved a TGI of 90.6% (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>A). Both treatment groups were more effective against the xenograft tumors than the paclitaxel group, which had an average TGI of 68.6%. The one-way ANOVA analysis (<i>P</i> = 0.0014) followed by Dunnett’s multiple comparison test also revealed that there was a significant decrease compared to the control for both concentrations of <b>10bb</b>-treated groups (<i>P</i> < 0.01) and the paclitaxel treatment group (<i>P</i> < 0.05). Additionally, the final tumor weights of the <b>10bb</b> 15 and 30 mg/kg-treated groups were 67.3 and 70.1% less than the average final tumor weight for the control group, respectively (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>B). One-way ANOVA (<i>P</i> = 0.0024) followed by the Dunnett’s multiple comparison test confirmed the statistical significance between average tumor weights of the <b>10bb</b> treatment groups and the control (<i>P</i> < 0.01). To investigate the ability of <b>10bb</b> to impede cancer metastasis, it was also tested in a lung metastasis mouse model at 30 mg/kg doses in C57BL mice (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>C). After inoculation with melanoma cells via the lateral tail vein, mice were treated for 2 weeks at the same dosing schedule as before. The average tumor index based on the lung metastasis nodule size and number was 13.6 ± 2.9 for the control group and 2.6 ± 0.6 for the <b>10bb</b> treatment group. This was significantly less than the control based on an unpaired Student’s <i>t</i>-test (<i>P</i> = 0.0013) and represents an 80.9% decrease in metastasis. Mouse weight and activity were monitored for both the xenograft model and lung metastasis model (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>D,E). The pathohistological analysis was performed on the major organs collected from both in vivo studies, including heart, liver, kidneys, lungs, and spleen, to assess for acute toxicities. Sections stained with hematoxylin and eosin revealed no apparent drug-related injury or morphological abnormalities in the cellular structure of the various tissues in both the xenograft mouse model (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>A) and experimental lung metastasis mouse model (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>B). Additionally, in vitro pharmacological profiling was utilized to identify undesirable off-target effects and assess the safety profile. <b>10bb</b> was evaluated at 1 μM (300–500× of its IC<sub>50</sub> values against cancer cells as determined in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>) in the Safety47 Panel which includes the assessment of the functional response of 47 major physiologically important targets across 78 assays (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>C). Only a value higher than |70%| response is considered significant. <b>10bb</b> only showed hit responses in only 2 of the 78 assays, which were norepinephrine transporter (NET) and serotonin receptor 2B (HTR2B) antagonism. These findings support a good safety profile for <b>10bb</b> based on the in vitro and in vivo data.</div><figure id="fig5" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00706/20190719/images/medium/jm-2019-00706x_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00706/20190719/images/large/jm-2019-00706x_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. <b>10bb</b> inhibits melanoma tumor growth and metastasis in vivo. (A) Tumor volumes in an A375 xenograft model in nude mice (<i>n</i> = 10). Statistical significance for final tumor volume was determined by ANOVA (<i>P</i> = 0.0014) followed by Dunnett’s multiple comparison test. (B) Individual tumor weights. Error bars represent 95% CIs. Statistical significance was determined by ANOVA (<i>P</i> = 0.0024) analysis followed by Dunnett’s multiple comparison test. (C) B16F10 lung metastasis in C57BL/6 mice. The graph represents the tumor index for mice (<i>n</i> = 10) and error bars represent 95% CIs. An unpaired Student’s <i>t</i>-test was performed to show statistical significance between the groups (<i>P</i> = 0.0013). Mouse body weights in the xenograft model (D) and lung metastasis model (E). Graph represents percent change in body weight compared to the starting weight.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00706/20190719/images/large/jm-2019-00706x_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00706&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig6" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00706/20190719/images/medium/jm-2019-00706x_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00706/20190719/images/large/jm-2019-00706x_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. <b>10bb</b> does not cause apparent toxicities to major organs. Pathological sections of major tissues (heart, kidney, liver, lung, and spleen) were obtained from the (A) A375 xenograft and (B) B16F10 lung metastasis studies. Organs were stained with hematoxylin and eosin (H&E) and representative images were captured. (C) In vitro pharmacological profiling of <b>10bb</b> to assess potential off-target effects to major targets at 1 μM concentrations using the Safety47 Panel (<i>n</i> = 2). Graph represents mean percent response ± range. Values in between −70 and +70% (indicated with dashed lines) are considered insignificant.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00706/20190719/images/large/jm-2019-00706x_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00706&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> <b>10bb</b> Can Circumvent Paclitaxel Resistance in Vitro and Vivo</h3><div class="NLM_p">We next investigated the potential for this scaffold of tubulin inhibitor in overcoming resistance mechanisms to which taxanes are susceptible. We initially determined their activity against PC-3, DU-145, and their corresponding paclitaxel resistant PC-3/TxR and DU-145/TxR cell lines in vitro. The resistance index was determined by dividing the average IC<sub>50</sub> for the resistance cells by their parental cell lines. We found that paclitaxel had a resistant index of 103.5 and >869 for PC-3/TxR and DU-145/TxR, respectively. Remarkably, <b>10bb</b> demonstrated greater potency against the resistant cells, showing a resistance index of 0.7 and 2.2 (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>). Therefore, we wanted to confirm the ability of <b>10bb</b> to escape paclitaxel resistance in vivo. First, we confirmed the efficacy of paclitaxel against tumors that had not developed resistance. Nude mice bearing PC-3 xenograft tumors were dosed with 15 mg/kg paclitaxel or the vehicle solution every other day for 3 weeks. As expected, paclitaxel was effective in inhibiting tumor growth tumor growth, resulting in TGI of 101.2% (<i>P</i> = 0.003) (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>A). Paclitaxel also caused an average reduction in tumor weight by 79.3% which was significantly less than the vehicle-treated group (<i>P</i> = 0.0003) (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>B). We next tested our compound <b>10bb</b> against a taxane-resistant PC-3 (PC-3/TxR) model that was developed previously by others.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> At the same dosing concentrations and frequency as the previous model, paclitaxel showed a marked decline in anticancer capabilities, yielding a TGI of only 37.8% (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>D) and a modest reduction in tumor weight of 34.5% (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>E). In contrast, 30 mg/kg treatments of <b>10bb</b> produced a significant reduction in tumor growth by 83.8% and also decreased the average tumor weight by 62.8%. The ANOVA analysis (<i>P</i> < 0.0001) followed by Dunnet’s multiple comparison test confirmed a significant decrease in the final tumor volume and weight (<i>P</i> < 0.0001) for the <b>10bb</b>-treated groups. Animal activity and body weights were monitored and recorded throughout the experiment, and major deviations in body weight were not observed (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>C,F).</div><figure id="fig7" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00706/20190719/images/medium/jm-2019-00706x_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00706/20190719/images/large/jm-2019-00706x_0007.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. <b>10bb</b> is effective in vivo at inhibiting Taxol resistant tumor growth. Two models were investigated in nude mice, one with parental PC-3 xenograft tumors and another with Taxol resistant PC-3/TxR tumors. (A) Tumor volumes for the PC-3 xenograft model (<i>n</i> = 7). Statistical analysis was performed by an unpaired <i>t</i>-test, showing a significant difference for the final volumes of the paclitaxel-treated group compared to the control group (<i>P</i> = 0.003). (B) Final tumor weights for the PC-3 xenograft model. Error bars represent 95% CIs. An unpaired <i>t</i>-test showed a significant difference between the paclitaxel- and vehicle-treated groups (<i>P</i> = 0.0003). (C) Mouse body weights expressed as percent change compared to the starting weight in the PC-3 model. (D) Tumor volumes for the PC-3/TxR xenograft model (<i>n</i> = 8). Statistical analysis was performed by ANOVA (<i>P</i> < 0.0001) followed by Dunnett’s multiple comparisons test for the final tumor volumes. (E) Final tumor weights for PC-3/TxR mice. Error bars represent 95% CIs. Statistical analysis was performed by ANOVA (<i>P</i> = 0.0001) followed by Dunnet’s multiple comparisons test (F) Body weights for PC-3/TxR mouse model. Graph represents mean body weight change as a percentage compared to initial weight.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00706/20190719/images/large/jm-2019-00706x_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00706&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. In Vitro Cytotoxicity of <b>10ab</b> and <b>10bb</b> in Taxol-Resistant Cancer Cell Lines</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col /></col><col /></col><col /></col><col /></col><col /></col><col /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="5" align="center">IC<sub>50</sub> ± SEM (nM)</th></tr><tr valign="top" class="colsep0"><th class="rowsep1 colsep0" align="center">cell lines</th><th class="rowsep1 colsep0" align="center"><b>10ab</b></th><th class="rowsep1 colsep0" align="center"><b>10bb</b></th><th class="rowsep1 colsep0" align="center">colchicine</th><th class="rowsep1 colsep0" align="center">paclitaxel</th><th class="rowsep1 colsep0" align="center">docetaxel</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0">PC-3</td><td class="colsep0 rowsep0">5.2 ± 0.4</td><td class="colsep0 rowsep0">89.9 ± 6.3</td><td class="colsep0 rowsep0">10.4 ± 0.5</td><td class="colsep0 rowsep0">1.1 ± 0.2</td><td class="colsep0 rowsep0">0.5 ± 0.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0">PC-3/TxR</td><td class="colsep0 rowsep0">3.9 ± 0.3</td><td class="colsep0 rowsep0">66.9 ± 4.4</td><td class="colsep0 rowsep0">37.4 ± 2.2</td><td class="colsep0 rowsep0">113.9 ± 4.3</td><td class="colsep0 rowsep0">27.9 ± 1.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0"><a class="ref internalNav" href="#t4fn1" aria-label="a">a</a>RI</td><td class="colsep0 rowsep0">0.8</td><td class="colsep0 rowsep0">0.7</td><td class="colsep0 rowsep0">3.6</td><td class="colsep0 rowsep0">103.5</td><td class="colsep0 rowsep0">55.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0">DU-145</td><td class="colsep0 rowsep0">13.8 ± 1.0</td><td class="colsep0 rowsep0">169.1 ± 4.4</td><td class="colsep0 rowsep0">35.5 ± 3.5</td><td class="colsep0 rowsep0">1.15 ± 0.2</td><td class="colsep0 rowsep0">0.10 ± 0.01</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0">DU-145/TxR</td><td class="colsep0 rowsep0">25.2 ± 2.0</td><td class="colsep0 rowsep0">379.1 ± 80.0</td><td class="colsep0 rowsep0">>1000</td><td class="colsep0 rowsep0">>1000</td><td class="colsep0 rowsep0">352.3 ± 118.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0"><a class="ref internalNav" href="#t4fn1" aria-label="a">a</a>RI</td><td class="colsep0 rowsep0">1.8</td><td class="colsep0 rowsep0">2.2</td><td class="colsep0 rowsep0">>28</td><td class="colsep0 rowsep0">>869</td><td class="colsep0 rowsep0">>3523</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup><sup>a</sup></sup><p class="last">RI: resistance index is calculated by dividing the IC<sub>50</sub> value of compound in resistant cell lines by the IC<sub>50</sub> in the corresponding parental cell lines.</p></div></div></div></div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i19">Conclusion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_41502" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_41502" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">In this report, a SAR investigation of ABI-231 focusing on the modification of the indole moiety is reported, revealing that <b>10ab</b> and <b>10bb</b> are more potent derivatives than the ABI-231 prototype. The X-ray crystal structures of ABI-231, <b>10ab</b>, and <b>10bb</b> in complex with tubulin were obtained, which confirmed that they directly bind to the colchicine site in tubulin, and revealed their molecular mechanisms responsible for their improved interactions to tubulin proteins and the resulted increased antiproliferative activities. We also demonstrated the abilities of the new analogues to block tubulin polymerization and to inhibit cancer cell motility and migration. In vivo, <b>10bb</b> effectively inhibited tumor growth and lung metastasis in melanoma xenograft and lung metastasis models without showing signs of acute toxicity. More interestingly, <b>10bb</b> was highly potent in the inhibiting tumor growth of PC-3/TxR prostate xenograft tumors. This suggests, along with the in vitro cell viability results, that <b>10bb</b> may circumvent certain types of MDR that taxanes cannot escape. Taken together, these new ABI-231 analogues represent promising candidates for further development as a new generation of tubulin inhibitors for cancer treatment.</div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i20">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_07724" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_07724" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> General Chemistry</h3><div class="NLM_p last">Tetrahydrofuran was distilled from sodium-benzophenone. All other solvents and chemical reagents were obtained from commercial sources and directly used without further purification. Glassware was oven-dried before use. All reactions were performed under an argon atmosphere. TLC was performed on silica gel 60 GF254 and monitored under UV light or visualized using a phosphomolybdic acid reagent. Flash chromatography was performed on 230–400 mesh silica gel (Fisher Scientific). Melting points were recorded on a MPA100 Automated Melting Point Apparatus. NMR spectra were obtained on a Bruker Ascend 400 (Billerica, MA) spectrometer or Varian Inova-500 spectrometer (Agilent Technologies, Santa Clara, CA). HR-MS were obtained on Waters Acquity UPLC linked to a Waters Acquity Photodiode Array Detector and Waters qTof mass detector. All compounds reported herein with biological data had purities ≥ 95% as determined by HPLC. The purity of associated compounds was verified by the HPLC study performed on a BEH C18 (2.1 × 50 mm, 1.7 μm) column using a mixture of solvent acetonitrile/water (with 0.1% formic acid) at a flow rate of 0.3 mL/min and monitoring by UV absorption at the appropriate wavelength. Chemical shifts are given in ppm. Tetramethylsilane is used as an internal reference for NMR spectra taken in chloroform-<i>d</i>. All coupling constants (<i>J</i>) are given in hertz.</div></div><div id="sec5_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> Synthesis of <i>tert</i>-Butyldimethyl(1-(3,4,5-trimethoxyphenyl)allyl)oxysilane (<b>2</b>)</h3><div class="NLM_p last">To a solution of 3,4,5-trimethoxybenzaldehyde (30 g, 0.153 mol) in anhydrous tetrahydrofuran (THF; 100 mL) at 0 °C under argon was added vinylmagnesium bromide solution (168 mL, 0.168 mol, 1.0 M in THF) dropwise; the resulting mixture was stirred for 1 h. On completion, the reaction was quenched with saturated NH<sub>4</sub>Cl. The mixture was then extracted with ethyl acetate, washed with brine, and dried with anhydrous Na<sub>2</sub>SO<sub>4</sub>. The combined extracts were evaporated under vacuum to give <b>1</b> as crude oil which was used directly for next step without purification.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> Imidazole (15.6 g, 0.229 mol) and <i>tert</i>-butyldimethylsilyl chloride (34.4 g, 0.229 mol) were sequentially added to a solution of the above crude oil in dichloromethane (150 mL) in a round-bottom flask with stirring under argon. The resulting suspension was stirred for 2 h. Water was then added, and the mixture was extracted with dichloromethane, washed with brine, and dried with anhydrous Na<sub>2</sub>SO<sub>4</sub>. The combined extracts were evaporated to give a crude oil mixture which was directly used for next step without purification.</div></div><div id="sec5_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> Synthesis of 3-((<i>tert</i>-Butyldimethylsilyl)oxy)-3-(3,4,5-trimethoxyphenyl)propane-1,2-diol (<b>3</b>)</h3><div class="NLM_p last">To a solution of the compound <b>2</b> (44.0 g, 0.13 mol) in acetone (150 mL) was added <i>N</i>-methylmorpholine <i>N</i>-oxide (22.9 g, 0.195 mol) and osmium tetroxide (40 mg, 0.157 mmol) in <i>tert-</i>butanol (5 mL) at room temperature under stirring. After 48 h, acetone was removed under vacuum, water and ethyl acetate were then added, and the organic phase was separated, washed with brine, and dried with Na<sub>2</sub>SO<sub>4</sub>. Evaporation under vacuum gave the oily residue that was purified with flash chromatography on silica. Elution with hexane/ethyl acetate (2:1–1:1) gave diol <b>3</b> as colorless oil (45.1 g, 79% for three steps). <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>): δ 6.55 (d, <i>J</i> = 3.9 Hz, 2H), 4.65 (dd, <i>J</i> = 35.9, 6.1 Hz, 1H), 3.84 (t, <i>J</i> = 1.9 Hz, 9H), 3.77–3.40 (m, 3H), 2.87–1.97 (m, 2H), 0.91 (d, <i>J</i> = 0.7 Hz, 9H), 0.08 (d, <i>J</i> = 9.9 Hz, 3H), −0.07 to −0.19 (m, 3H).</div></div><div id="sec5_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> Synthesis of 3-((<i>tert</i>-Butyldimethylsilyl)oxy)-3-(3,4,5-trimethoxyphenyl)propane-1,2-diyl Dimethanesulfonate (<b>4</b>)</h3><div class="NLM_p last">To a solution of compound <b>3</b> (45.0 g, 0.12 mol) and methanesulfonyl chloride (23.4 mL, 0.30 mol) in anhydrous dichloromethane (100 mL) in a round-bottom flask at 0 °C under argon, trimethylamine (36.9 mL, 0.26 mol) was added dropwise under vigorous stirring. The resulting mixture was stirred overnight, water was then added, and the reaction mixture was extracted with dichloromethane, washed with brine, and dried with anhydrous Na<sub>2</sub>SO<sub>4</sub>. The combined extracts were evaporated under vacuum to give the oily crude, which was directly used for next step without purification.</div></div><div id="sec5_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> Synthesis of <i>tert</i>-Butyl(2,3-diazido-1-(3,4,5-trimethoxyphenyl)propoxy)dimethylsilane (<b>5</b>)</h3><div class="NLM_p last">To a solution of mesylate <b>4</b> (45.0 g, 0.085 mol) in anhydrous <i>N</i>,<i>N</i>-dimethylformamide (100 mL) in a round-bottom flask under argon, sodium azide (30 g, 0.46 mol) was added in portions under stirring. The resulting mixture was refluxed overnight. The precipitate was filtered off and washed with dichloromethane. The combined filtration was evaporated under vacuum to give the oily crude which was directly used for the next step without purification.</div></div><div id="sec5_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> Synthesis of 3-((<i>tert</i>-Butyldimethylsilyl)oxy)-3-(3,4,5-trimethoxyphenyl)propane-1,2-diamine (<b>6</b>)</h3><div class="NLM_p last">A suspension of azide <b>5</b> (20.0 g, 0.047 mol) and 10% Pd/C (0.2 g) in ethyl acetate–methanol (1:1, 50 mL) was charged with hydrogen and stirred overnight, and the reaction mixture was filtered off and washed with dichloromethane/methanol (1:1). The combined filtration was evaporated under vacuum to give the oily crude, which was purified with flash chromatography on silica. Pure diamine <b>7</b> was eluted out with dichloromethane/methanol (15:0–15:1) as slightly yellowish oil (10.6 g, 61%). <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>): δ 6.51 (d, <i>J</i> = 13.4 Hz, 2H), 4.45 (dd, <i>J</i> = 34.5, 5.1 Hz, 1H), 3.83 (d, <i>J</i> = 1.2 Hz, 9H), 2.97–2.46 (m, 3H), 0.90 (d, <i>J</i> = 10.8 Hz, 9H), −0.17 (d, <i>J</i> = 8.5 Hz, 3H).</div></div><div id="sec5_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> General Procedure for Boc Protection of Indolecarboxyaldehydes <b>7aa–7at</b> and <b>7ba–7be</b></h3><div class="NLM_p last">To a solution of the indoles (1.34 mmol) and 4-dimethylaminopyridine (65 mg, 0.54 mol) in anhydrous dichloromethane (5 mL) under argon was added di<i>tert-</i>butyl dicarbonate (351 mg, 1.61 mmol) under stirring. After 1 h, water was then added, and the reaction mixture was extracted with dichloromethane, washed with brine, and dried with Na<sub>2</sub>SO<sub>4</sub>. Evaporation under vacuum gave the crude solid residue <b>7aa–7at</b> and <b>7ba–7be</b> as white to yellowish solids that were used directly for next step without purification.</div></div><div id="sec5_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> General Procedure for Cyclization To Form Imidazoline <b>8aa–8at</b> and <b>8ba–8be</b></h3><div class="NLM_p last">A solution of compound <b>6</b> (370 mg, 1.0 mmol) and boc-protected indole (1.1 mmol) in anhydrous dichloromethane (10 mL) was stirred for 1 h under argon, then <i>N</i>-bromosuccinimide (151 mg, 0.85 mmol) was added at ice temperature, and the reaction was warmed to room temperature. After 4 h, the reaction was quenched with saturated sodium thiosulfate solution and extracted with dichloromethane three times, washed with brine, and dried with Na<sub>2</sub>SO<sub>4</sub>. The combined extracts were evaporated to give crude oil <b>8aa–8at</b> and <b>8ba–8be</b>, which were used directly for the next step without purification.</div></div><div id="sec5_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29"> General Procedure for Removal of the TBS Protecting Group</h3><div class="NLM_p last">To a stirred solution of compound <b>8aa-8at</b> (0.5 mmol) in THF (5.0 mL) was added tetra-<i>n</i>-butylammonium fluoride (1.0 M in THF, 1.0 mL, 1.0 mmol) under argon. On completion, the reaction was quenched with water, extracted with ethyl acetate three times, washed with brine, and dried with Na<sub>2</sub>SO<sub>4</sub>. The combined extracts were evaporated to give crude oil <b>9aa–9at</b> and <b>9ba–9be</b>, which were used directly for next step without purification.</div></div><div id="sec5_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30"> General Procedure for Synthesis of <b>10ab–10at</b> and <b>10ba–10be</b></h3><div class="NLM_p last">To a stirred solution of compound <b>9</b> (0.1 mmol) in anhydrous dichloromethane (1.0 mL) was added TFA (1.0 mL) under argon at room temperature. After 1 h, the solvent was removed under reduced pressure to give crude solid that was directly used for next step without purification. To a stirred solution of the above crude in anhydrous dimethyl sulfoxide (2.0 mL) under argon was added IBX (84 mg, 0.3 mmol) at room temperature. The reaction mixture was stirred overnight, extracted with ethyl acetate three times, washed with brine, and dried with Na<sub>2</sub>SO<sub>4</sub>. The combined extracts were evaporated to give crude solid, which was purified with flash chromatography on silica. Elution with hexane/ethyl acetate (4:1–1:1) gave pure compound <b>10ba–10be</b>.</div></div><div id="sec5_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31"> General Procedure for Synthesis of <b>10au</b> and <b>10av</b></h3><div class="NLM_p">To a stirred solution of compound <b>10ak</b> or <b>10ao</b> (0.05 mmol) in EtOAc-MeOH (3 mL, 1:1) was added a catalytic equivalent of 10% Pd/C (0.0025 mmol) under argon at room temperature. The reaction was then charged with hydrogen, stirred, and monitored by TLC. Upon the disappearance of the starting material, the reaction mixture was filtered through Celite and was with EtOAc. The combined solvents were evaporated to give crude solid, which was purified with flash chromatography on silica. Elution with hexanes/ethyl acetate (1:1–1:4) gave pure compound <b>10au</b> or <b>10av</b>.</div><div id="sec5_11_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i32" class="anchor-spacer"></div><h4 class="article-section__title" id="_i32"> (2-(2-Phenyl-1<i>H</i>-indol-3-yl)-1<i>H</i>-imidazol-4-yl)(3,4,5-trimethoxyphenyl)methanone (<b>10aa</b>)</h4><div class="NLM_p last"><b>10aa</b> was obtained as a yellowish solid (25.4 mg, 56.3% from <b>9aa</b>). <sup>1</sup>H NMR (400 MHz, methylene chloride-<i>d</i><sub>2</sub>/methanol-<i>d</i><sub>4</sub> = 10:1): δ 8.15–8.06 (m, 1H), 7.79 (s, 1H), 7.59–7.53 (m, 2H), 7.47–7.41 (m, 4H), 7.22 (dddd, <i>J</i> = 20.6, 8.1, 7.1, 1.2 Hz, 3H), 3.89 (s, 6H), 3.87 (s, 3H). <sup>13</sup>C NMR (101 MHz, methylene chloride-<i>d</i><sub>2</sub>/methanol-<i>d</i><sub>4</sub> = 10:1): δ 183.58, 153.73, 142.58, 138.59, 136.68, 133.65, 132.38, 129.72, 129.63, 129.13, 128.11, 123.63, 121.59, 121.06, 111.94, 111.89, 107.17, 61.19, 56.78. HRMS: calcd for C<sub>27</sub>H<sub>24</sub>N<sub>3</sub>O<sub>4</sub> [M + H]<sup>+</sup>, 454.1767; found, 454.1759. Purity: 95.0% by HPLC (<i>R</i><sub>t</sub> = 2.36 min).</div></div><div id="sec5_11_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33"> (2-(4-Methyl-1<i>H</i>-indol-3-yl)-1<i>H</i>-imidazol-4-yl)(3,4,5-trimethoxyphenyl)methanone (<b>10ab</b>)</h4><div class="NLM_p last"><b>10ab</b> was obtained as a yellowish solid (23.2 mg, 59.2% from <b>9ab</b>). <sup>1</sup>H NMR (400 MHz, methylene chloride-<i>d</i><sub>2</sub>/methanol-<i>d</i><sub>4</sub> = 10:1): δ 7.78 (s, 1H), 7.36 (s, 1H), 7.22 (d, <i>J</i> = 16.4 Hz, 3H), 7.08 (t, <i>J</i> = 7.6 Hz, 1H), 6.93–6.84 (m, 1H), 3.88 (d, <i>J</i> = 2.0 Hz, 9H), 2.50 (s, 3H). <sup>13</sup>C NMR (101 MHz, methylene chloride-<i>d</i><sub>2</sub>/methanol-<i>d</i><sub>4</sub> = 10/1): δ 184.41, 153.78, 148.55, 142.68, 137.13, 136.97, 135.76, 133.67, 133.22, 131.08, 127.41, 127.24, 125.09, 125.06, 123.30, 122.79, 110.14, 110.09, 107.17, 106.73, 106.69, 61.21, 56.82, 21.07. HRMS: calcd for C<sub>22</sub>H<sub>22</sub>N<sub>3</sub>O<sub>4</sub> [M + H]<sup>+</sup>, 392.1610; found, 392.1613. Purity: 99.2% by HPLC (<i>R</i><sub>t</sub> = 1.83 min).</div></div><div id="sec5_11_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> (2-(4-Fluoro-1<i>H</i>-indol-3-yl)-1<i>H</i>-imidazol-4-yl)(3,4,5-trimethoxyphenyl)methanone (<b>10ac</b>)</h4><div class="NLM_p last"><b>10ac</b> was obtained as a yellowish solid (18.4 mg, 46.5% from <b>9ac</b>). <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>): δ 8.04 (s, 1H), 7.71 (s, 1H), 7.24 (d, <i>J</i> = 8.1 Hz, 1H), 7.19 (s, 2H), 7.14 (td, <i>J</i> = 8.0, 5.2 Hz, 1H), 6.91 (dd, <i>J</i> = 12.7, 7.8 Hz, 1H), 3.90 (d, <i>J</i> = 1.1 Hz, 9H). <sup>13</sup>C NMR (101 MHz, chloroform-<i>d</i>): δ 182.71, 154.61, 153.21, 146.69, 142.09, 139.45, 139.35, 132.94, 127.76, 123.83, 123.75, 112.42, 112.23, 108.90, 106.73, 106.51, 106.31, 104.39, 61.02, 56.32. HRMS: calcd for C<sub>21</sub>H<sub>19</sub>FN<sub>3</sub>O<sub>4</sub> [M + H]<sup>+</sup>, 396.1360; found, 396.1370. Purity: 97.4% by HPLC (<i>R</i><sub>t</sub> = 2.52 min).</div></div><div id="sec5_11_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35"> (2-(4-Bromo-1<i>H</i>-indol-3-yl)-1<i>H</i>-imidazol-4-yl)(3,4,5-trimethoxyphenyl)methanone (<b>10ad</b>)</h4><div class="NLM_p last"><b>10ad</b> was obtained as a yellowish solid (28.9 mg, 63.4% from <b>9ad</b>). <sup>1</sup>H NMR (400 MHz, methylene chloride-<i>d</i><sub>2</sub>/methanol-<i>d</i><sub>4</sub> = 10:1): δ 7.77 (s, 1H), 7.68 (s, 1H), 7.42 (d, <i>J</i> = 8.1 Hz, 1H), 7.34 (d, <i>J</i> = 7.6 Hz, 1H), 7.26 (s, 2H), 7.06 (t, <i>J</i> = 7.9 Hz, 1H), 3.91 (s, 6H), 3.87 (s, 3H). <sup>13</sup>C NMR (101 MHz, methylene chloride-<i>d</i><sub>2</sub>/methanol-<i>d</i><sub>4</sub> = 10:1): δ 184.36, 153.80, 146.48, 142.67, 138.16, 133.68, 129.87, 125.75, 124.76, 123.88, 113.25, 112.31, 112.25, 107.15, 106.35, 61.20, 56.84. HRMS: calcd for C<sub>21</sub>H<sub>19</sub>BrN<sub>3</sub>O<sub>4</sub> [M + H]<sup>+</sup>, 456.0559; found, 456.0556. Purity: 98.6% by HPLC (<i>R</i><sub>t</sub> = 1.89 min).</div></div><div id="sec5_11_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i36" class="anchor-spacer"></div><h4 class="article-section__title" id="_i36"> (2-(4-Methoxy-1<i>H</i>-indol-3-yl)-1<i>H</i>-imidazol-4-yl)(3,4,5-trimethoxyphenyl)methanone (<b>10ae</b>)</h4><div class="NLM_p last"><b>10ae</b> was obtained as a yellowish solid (17.6 mg, 43.1% from <b>9ae</b>). <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>/methanol-<i>d</i><sub>4</sub> = 10:1): δ 9.91 (s, 1H), 8.75 (s, 1H), 7.90 (s, 1H), 7.41 (d, <i>J</i> = 8.4 Hz, 1H), 7.30 (s, 2H), 7.26 (s, 2H), 6.70 (d, <i>J</i> = 8.4 Hz, 1H), 4.26 (s, 3H), 4.01 (s, 3H), 4.00 (s, 6H). <sup>13</sup>C NMR (101 MHz, chloroform-<i>d</i>): δ 181.65, 153.51, 151.42, 145.59, 143.17, 138.93, 131.25, 130.44, 128.59, 127.66, 124.71, 113.49, 107.27, 106.23, 102.57, 99.65, 61.05, 56.41, 56.09. HRMS: calcd for C<sub>22</sub>H<sub>22</sub>N<sub>3</sub>O<sub>5</sub> [M + H]<sup>+</sup>, 408.1559; found, 408.1540. Purity: 96.9% by HPLC (<i>R</i><sub>t</sub> = 2.00 min).</div></div><div id="sec5_11_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37"> (2-(4-(Benzyloxy)-1<i>H</i>-indol-3-yl)-1<i>H</i>-imidazol-4-yl)(3,4,5-trimethoxyphenyl)methanone (<b>10af</b>)</h4><div class="NLM_p last"><b>10af</b> was obtained as a yellowish solid (32.9 mg, 70.0% from <b>9af</b>). <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>): δ 9.79 (s, 1H), 8.14 (d, <i>J</i> = 2.6 Hz, 1H), 7.60 (s, 1H), 7.55–7.50 (m, 2H), 7.38 (t, <i>J</i> = 7.4 Hz, 2H), 7.33 (d, <i>J</i> = 7.1 Hz, 1H), 7.29 (s, 2H), 7.18–7.07 (m, 2H), 6.75 (d, <i>J</i> = 7.2 Hz, 1H), 5.52 (s, 2H), 3.96 (s, 3H), 3.94 (s, 6H). <sup>13</sup>C NMR (101 MHz, methylene chloride-<i>d</i><sub>2</sub>): δ 183.51, 153.73, 151.84, 142.38, 139.56, 136.73, 134.10, 129.41, 129.04, 128.66, 126.85, 124.00, 114.88, 107.16, 107.09, 103.65, 71.70, 61.15, 56.78. HRMS: calcd for C<sub>28</sub>H<sub>26</sub>N<sub>3</sub>O<sub>5</sub> [M + H]<sup>+</sup>, 484.1872; found, 484.1871. Purity: 98.7% by HPLC (<i>R</i><sub>t</sub> = 2.42 min).</div></div><div id="sec5_11_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i38" class="anchor-spacer"></div><h4 class="article-section__title" id="_i38"> (2-(5-Methyl-1<i>H</i>-indol-3-yl)-1<i>H</i>-imidazol-4-yl)(3,4,5-trimethoxyphenyl)methanone (<b>10ag</b>)</h4><div class="NLM_p last"><b>10ag</b> was obtained as a yellowish solid (23.8 mg, 60.7% from <b>9ag</b>). <sup>1</sup>H NMR (400 MHz, methylene chloride-<i>d</i><sub>2</sub>/methanol-<i>d</i><sub>4</sub> = 10:1): δ 8.03 (s, 1H), 7.88 (d, <i>J</i> = 1.6 Hz, 1H), 7.79 (s, 1H), 7.36 (dd, <i>J</i> = 8.4, 1.5 Hz, 1H), 7.27 (s, 2H), 7.09 (d, <i>J</i> = 8.4 Hz, 1H), 3.92 (d, <i>J</i> = 1.6 Hz, 6H), 3.88 (d, <i>J</i> = 1.6 Hz, 3H), 2.62–2.40 (m, 3H). <sup>13</sup>C NMR (101 MHz, methylene chloride-<i>d</i><sub>2</sub>/methanol-<i>d</i><sub>4</sub> = 10:1): δ 184.33, 153.77, 149.36, 142.51, 135.52, 134.01, 131.13, 126.56, 125.50, 125.01, 120.34, 112.08, 107.14, 106.03, 61.22, 56.79, 21.80. HRMS: calcd for C<sub>22</sub>H<sub>22</sub>N<sub>3</sub>O<sub>4</sub> [M + H]<sup>+</sup>, 392.1610; found, 392.1608. Purity: 100.0% by HPLC (<i>R</i><sub>t</sub> = 1.96 min).</div></div><div id="sec5_11_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> (2-(5-Fluoro-1<i>H</i>-indol-3-yl)-1<i>H</i>-imidazol-4-yl)(3,4,5-trimethoxyphenyl)methanone (<b>10ah</b>)</h4><div class="NLM_p last"><b>10ah</b> was obtained as a yellowish solid (17.7 mg, 44.7% from <b>9ah</b>). <sup>1</sup>H NMR (400 MHz, methylene chloride-<i>d</i><sub>2</sub>/methanol-<i>d</i><sub>4</sub> = 10:1): δ 8.00–7.91 (m, 2H), 7.80 (s, 1H), 7.41 (dd, <i>J</i> = 8.9, 4.5 Hz, 1H), 7.30 (s, 2H), 7.01 (td, <i>J</i> = 9.0, 2.5 Hz, 1H), 3.92 (s, 6H), 3.88 (s, 3H). <sup>13</sup>C NMR (101 MHz, methylene chloride-<i>d</i><sub>2</sub>/methanol-<i>d</i><sub>4</sub> = 10:1): δ 184.61, 160.45, 158.11, 153.75, 142.54, 134.00, 133.81, 127.77, 125.96, 125.85, 113.26, 113.17, 111.74, 111.48, 107.28, 106.92, 106.88, 106.21, 105.96, 61.22, 56.79. HRMS: calcd for C<sub>21</sub>H<sub>19</sub>FN<sub>3</sub>O<sub>4</sub> [M + H]<sup>+</sup>, 396.1360; found, 396.1371. Purity: 99.0% by HPLC (<i>R</i><sub>t</sub> = 1.94 min).</div></div><div id="sec5_11_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40"> (2-(5-Chloro-1<i>H</i>-indol-3-yl)-1<i>H</i>-imidazol-4-yl)(3,4,5-trimethoxyphenyl)methanone (<b>10ai</b>)</h4><div class="NLM_p last"><b>10ai</b> was obtained as a yellowish solid (28.5 mg, 69.2% from <b>9ai</b>). <sup>1</sup>H NMR (400 MHz, acetone-<i>d</i><sub>6</sub>): δ 10.93 (s, 1H), 8.64 (d, <i>J</i> = 2.2 Hz, 1H), 8.29 (s, 1H), 7.92 (s, 1H), 7.54 (d, <i>J</i> = 8.7 Hz, 2H), 7.23 (dd, <i>J</i> = 8.7, 2.1 Hz, 1H), 3.97 (s, 6H), 3.85 (s, 3H). <sup>13</sup>C NMR (101 MHz, acetone-<i>d</i><sub>6</sub>): δ 154.15, 142.94, 136.18, 134.44, 127.60, 126.71, 123.53, 121.78, 114.04, 114.00, 107.57, 60.71, 56.67. HRMS: calcd for C<sub>21</sub>H<sub>19</sub>ClN<sub>3</sub>O<sub>4</sub> [M + H]<sup>+</sup>, 412.1064; found, 412.1057. Purity: 99.1% by HPLC (<i>R</i><sub>t</sub> = 2.12 min).</div></div><div id="sec5_11_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i41" class="anchor-spacer"></div><h4 class="article-section__title" id="_i41"> (2-(5-Bromo-1<i>H</i>-indol-3-yl)-1<i>H</i>-imidazol-4-yl)(3,4,5-trimethoxyphenyl)methanone (<b>10aj</b>)</h4><div class="NLM_p last"><b>10aj</b> was obtained as a yellowish solid (26.9 mg, 58.9% from <b>9aj</b>). <sup>1</sup>H NMR (400 MHz, methylene chloride-<i>d</i><sub>2</sub>/methanol-<i>d</i><sub>4</sub> = 10:1): δ 8.44 (dd, <i>J</i> = 1.9, 0.8 Hz, 1H), 7.90 (s, 1H), 7.80 (s, 1H), 7.39–7.26 (m, 4H), 3.93 (s, 6H), 3.88 (s, 3H). <sup>13</sup>C NMR (101 MHz, methylene chloride-<i>d</i><sub>2</sub>/methanol-<i>d</i><sub>4</sub> = 10:1): δ 184.63, 153.78, 148.24, 142.61, 135.92, 133.91, 127.33, 127.10, 126.19, 123.58, 114.77, 113.96, 107.29, 106.30, 61.23, 56.84. HRMS: calcd for C<sub>21</sub>H<sub>19</sub>BrN<sub>3</sub>O<sub>4</sub> [M + H]<sup>+</sup>, 456.0559; found, 456.0570. Purity: 100.0% by HPLC (<i>R</i><sub>t</sub> = 2.18 min).</div></div><div id="sec5_11_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i42" class="anchor-spacer"></div><h4 class="article-section__title" id="_i42"> (2-(5-(Benzyloxy)-1<i>H</i>-indol-3-yl)-1<i>H</i>-imidazol-4-yl)(3,4,5-trimethoxyphenyl)methanone (<b>10ak</b>)</h4><div class="NLM_p last"><b>10ak</b> was obtained as a yellowish solid (29.1 mg, 60.1% from <b>9ak</b>). <sup>1</sup>H NMR (400 MHz, acetone-<i>d</i><sub>6</sub>): δ 10.69 (s, 1H), 8.24 (dd, <i>J</i> = 9.5, 2.5 Hz, 2H), 7.93 (s, 1H), 7.59–7.46 (m, 4H), 7.46–7.35 (m, 3H), 7.35–7.28 (m, 1H), 6.98 (dd, <i>J</i> = 8.8, 2.5 Hz, 1H), 5.16 (s, 2H), 3.95 (s, 6H), 3.82 (s, 3H). <sup>13</sup>C NMR (101 MHz, acetone-<i>d</i><sub>6</sub>): δ 183.75, 155.14, 154.15, 142.92, 138.97, 134.58, 133.03, 132.88, 129.20, 128.58, 128.47, 127.12, 126.57, 126.40, 114.10, 113.23, 113.18, 107.92, 107.32, 105.98, 71.25, 60.71, 60.54, 56.69. HRMS: calcd for C<sub>28</sub>H<sub>26</sub>N<sub>3</sub>O<sub>5</sub> [M + H]<sup>+</sup>, 484.1872; found, 484.1896. Purity: 99.4% by HPLC (<i>R</i><sub>t</sub> = 2.34 min).</div></div><div id="sec5_11_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i43" class="anchor-spacer"></div><h4 class="article-section__title" id="_i43"> (2-(6-Methyl-1<i>H</i>-indol-3-yl)-1<i>H</i>-imidazol-4-yl)(3,4,5-trimethoxyphenyl)methanone (<b>10al</b>)</h4><div class="NLM_p last"><b>10al</b> was obtained as a yellowish solid (17.3 mg, 44.1% from <b>9al</b>). <sup>1</sup>H NMR (400 MHz, methylene chloride-<i>d</i><sub>2</sub>): δ 8.06 (d, <i>J</i> = 8.2 Hz, 1H), 7.88 (s, 1H), 7.83 (s, 1H), 7.25 (s, 2H), 7.21 (s, 1H), 7.05 (d, <i>J</i> = 8.0 Hz, 1H), 3.87 (d, <i>J</i> = 3.0 Hz, 9H), 2.41 (s, 3H). <sup>13</sup>C NMR (101 MHz, methylene chloride-<i>d</i><sub>2</sub>): δ 183.51, 153.86, 148.33, 142.82, 137.43, 133.85, 133.46, 132.01, 125.84, 123.74, 123.03, 120.50, 112.28, 107.08, 106.16, 61.20, 56.83, 21.90. HRMS: calcd for C<sub>22</sub>H<sub>22</sub>N<sub>3</sub>O<sub>4</sub> [M + H]<sup>+</sup>, 392.1610; found, 392.1612. Purity: 98.4% by HPLC (<i>R</i><sub>t</sub> = 1.92 min).</div></div><div id="sec5_11_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i44" class="anchor-spacer"></div><h4 class="article-section__title" id="_i44"> (2-(6-Fluoro-1<i>H</i>-indol-3-yl)-1<i>H</i>-imidazol-4-yl)(3,4,5-trimethoxyphenyl)methanone (<b>10am</b>)</h4><div class="NLM_p last"><b>10am</b> was obtained as a yellowish solid (19.5 mg, 49.2% from <b>9am</b>). <sup>1</sup>H NMR (400 MHz, methylene chloride-<i>d</i><sub>2</sub>/methanol-<i>d</i><sub>4</sub> = 10:1): δ 8.27–8.17 (m, 1H), 7.88 (d, <i>J</i> = 2.1 Hz, 1H), 7.79 (d, <i>J</i> = 2.5 Hz, 1H), 7.30 (d, <i>J</i> = 2.1 Hz, 2H), 7.15 (dt, <i>J</i> = 9.6, 2.4 Hz, 1H), 6.98 (ddd, <i>J</i> = 9.6, 8.8, 2.4 Hz, 1H), 3.91 (d, <i>J</i> = 2.2 Hz, 6H), 3.87 (s, 3H). <sup>13</sup>C NMR (101 MHz, methylene chloride-<i>d</i><sub>2</sub>/methanol-<i>d</i><sub>4</sub> = 10:1): δ 184.67, 161.98, 159.62, 153.76, 148.67, 142.55, 137.37, 137.25, 134.00, 126.67, 126.64, 122.14, 122.10, 122.00, 110.09, 109.85, 107.27, 106.71, 98.65, 98.40, 61.23, 56.77. HRMS: calcd for C<sub>21</sub>H<sub>19</sub>FN<sub>3</sub>O<sub>4</sub> [M + H]<sup>+</sup>, 396.1360; found, 396.1360. Purity: 98.4% by HPLC (<i>R</i><sub>t</sub> = 1.96 min).</div></div><div id="sec5_11_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i45" class="anchor-spacer"></div><h4 class="article-section__title" id="_i45"> (2-(6-Bromo-1<i>H</i>-indol-3-yl)-1<i>H</i>-imidazol-4-yl)(3,4,5-trimethoxyphenyl)methanone (<b>10an</b>)</h4><div class="NLM_p last"><b>10an</b> was obtained as a yellowish solid (26.3 mg, 57.6% from <b>9an</b>). <sup>1</sup>H NMR (400 MHz, methylene chloride-<i>d</i><sub>2</sub>/methanol-<i>d</i><sub>4</sub> = 10:1): δ 8.17 (d, <i>J</i> = 8.5 Hz, 1H), 7.87 (s, 1H), 7.80 (s, 1H), 7.59 (d, <i>J</i> = 1.9 Hz, 1H), 7.30 (d, <i>J</i> = 10.4 Hz, 3H), 3.90 (s, 6H), 3.88 (s, 3H). <sup>13</sup>C NMR (101 MHz, methylene chloride-<i>d</i><sub>2</sub>/methanol-<i>d</i><sub>4</sub> = 10:1): δ 184.48, 153.73, 148.37, 142.54, 137.94, 133.90, 126.73, 124.56, 124.45, 124.42, 122.51, 116.67, 115.32, 115.27, 107.20, 106.91, 61.21, 56.77. HRMS: calcd for C<sub>21</sub>H<sub>19</sub>BrN<sub>3</sub>O<sub>4</sub> [M + H]<sup>+</sup>, 456.0559; found, 456.0560. Purity: 99.1% by HPLC (<i>R</i><sub>t</sub> = 2.14 min).</div></div><div id="sec5_11_15" class="NLM_sec NLM_sec_level_3"><div id="ac_i46" class="anchor-spacer"></div><h4 class="article-section__title" id="_i46"> (2-(6-(Benzyloxy)-1<i>H</i>-indol-3-yl)-1<i>H</i>-imidazol-4-yl)(3,4,5-trimethoxyphenyl)methanone (<b>10ao</b>)</h4><div class="NLM_p last"><b>10ao</b> was obtained as a yellowish solid (21.8 mg, 44.2% from <b>9ao</b>). <sup>1</sup>H NMR (400 MHz, methylene chloride-<i>d</i><sub>2</sub>): δ 9.54 (s, 1H), 8.21 (d, <i>J</i> = 8.6 Hz, 1H), 7.83 (d, <i>J</i> = 7.0 Hz, 2H), 7.49–7.20 (m, 7H), 7.00–6.84 (m, 2H), 4.98 (s, 2H), 3.86 (s, 3H), 3.84 (s, 6H). <sup>13</sup>C NMR (101 MHz, methylene chloride-<i>d</i><sub>2</sub>): δ 156.66, 153.75, 142.52, 137.89, 137.81, 133.88, 129.02, 128.41, 128.12, 124.92, 122.11, 120.08, 112.30, 107.17, 96.74, 70.92, 61.17, 56.75. HRMS: calcd for C<sub>28</sub>H<sub>26</sub>N<sub>3</sub>O<sub>5</sub> [M + H]<sup>+</sup>, 484.1872; found, 484.1880. Purity: 98.4% by HPLC (<i>R</i><sub>t</sub> = 2.34 min).</div></div><div id="sec5_11_16" class="NLM_sec NLM_sec_level_3"><div id="ac_i47" class="anchor-spacer"></div><h4 class="article-section__title" id="_i47"> (2-(6-Methoxy-1<i>H</i>-indol-3-yl)-1<i>H</i>-imidazol-4-yl)(3,4,5-trimethoxyphenyl)methanone (<b>10ap</b>)</h4><div class="NLM_p last"><b>10ap</b> was obtained as a yellowish solid (19.8 mg, 48.3% from <b>9ap</b>). <sup>1</sup>H NMR (400 MHz, methylene chloride-<i>d</i><sub>2</sub>/methanol-<i>d</i><sub>4</sub> = 10:1): δ 8.12 (dd, <i>J</i> = 8.7, 0.6 Hz, 1H), 7.79 (d, <i>J</i> = 5.8 Hz, 2H), 7.27 (s, 2H), 6.94 (d, <i>J</i> = 2.2 Hz, 1H), 6.88 (dd, <i>J</i> = 8.8, 2.3 Hz, 1H), 3.91 (s, 6H), 3.87 (s, 3H), 3.83 (s, 3H). <sup>13</sup>C NMR (101 MHz, methylene chloride-<i>d</i><sub>2</sub>/methanol-<i>d</i><sub>4</sub> = 10:1): δ 184.25, 157.54, 153.75, 149.09, 142.51, 137.98, 133.96, 125.15, 121.60, 119.63, 111.53, 107.14, 106.61, 95.58, 95.52, 61.20, 56.78, 56.06. HRMS: calcd for C<sub>22</sub>H<sub>22</sub>N<sub>3</sub>O<sub>5</sub> [M + H]<sup>+</sup>, 408.1559; found, 408.1567. Purity: 95.0% by HPLC (<i>R</i><sub>t</sub> = 1.89 min).</div></div><div id="sec5_11_17" class="NLM_sec NLM_sec_level_3"><div id="ac_i48" class="anchor-spacer"></div><h4 class="article-section__title" id="_i48"> Methyl 3-(4-(3,4,5-Trimethoxybenzoyl)-1<i>H</i>-imidazole-2-yl)-1<i>H</i>-indole-6-carboxylate (<b>10aq</b>)</h4><div class="NLM_p last"><b>10aq</b> was obtained as a yellowish solid (22.0 mg, 50.5% from <b>9aq</b>). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 13.21 (s, 1H), 11.98 (s, 1H), 8.52 (d, <i>J</i> = 8.4 Hz, 1H), 8.45 (s, 1H), 8.15 (s, 1H), 8.00 (s, 1H), 7.77 (d, <i>J</i> = 8.4 Hz, 1H), 7.49 (s, 2H), 3.91 (s, 6H), 3.88 (s, 3H), 3.79 (s, 3H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>): δ 182.97, 166.98, 152.62, 141.15, 135.65, 133.24, 129.07, 128.45, 127.98, 127.74, 127.50, 123.27, 120.91, 120.60, 117.93, 113.86, 106.82, 106.36, 60.14, 55.98, 51.84. HRMS: calcd for C<sub>23</sub>H<sub>22</sub>N<sub>3</sub>O<sub>6</sub> [M + H]<sup>+</sup>, 436.1509; found, 436.1508. Purity: 99.7% by HPLC (<i>R</i><sub>t</sub> = 1.98 min).</div></div><div id="sec5_11_18" class="NLM_sec NLM_sec_level_3"><div id="ac_i49" class="anchor-spacer"></div><h4 class="article-section__title" id="_i49"> (2-(7-Methyl-1<i>H</i>-indol-3-yl)-1<i>H</i>-imidazol-4-yl)(3,4,5-trimethoxyphenyl)methanone (<b>10ar</b>)</h4><div class="NLM_p last"><b>10ar</b> was obtained as a yellowish solid (18.7 mg, 47.7% from <b>9ar</b>). <sup>1</sup>H NMR (400 MHz, methylene chloride-<i>d</i><sub>2</sub>/methanol-<i>d</i><sub>4</sub> = 10:1): δ 8.09 (dt, <i>J</i> = 7.7, 0.9 Hz, 1H), 7.92 (s, 1H), 7.81 (s, 1H), 7.28 (s, 2H), 7.14 (dd, <i>J</i> = 8.1, 7.1 Hz, 1H), 7.05 (dt, <i>J</i> = 7.2, 1.0 Hz, 1H), 3.90 (s, 6H), 3.88 (s, 3H), 2.51 (s, 3H). <sup>13</sup>C NMR (101 MHz, methylene chloride-<i>d</i><sub>2</sub>/methanol-<i>d</i><sub>4</sub> = 10:1): δ 184.19, 153.74, 149.12, 142.49, 136.79, 136.65, 133.95, 126.24, 126.08, 124.99, 124.96, 123.86, 121.99, 121.95, 121.75, 118.53, 107.15, 107.08, 107.03, 61.18, 56.76, 16.91. HRMS: calcd for C<sub>22</sub>H<sub>22</sub>N<sub>3</sub>O<sub>4</sub> [M + H]<sup>+</sup>, 392.1610; found, 392.1619. Purity: 99.4% by HPLC (<i>R</i><sub>t</sub> = 1.92 min).</div></div><div id="sec5_11_19" class="NLM_sec NLM_sec_level_3"><div id="ac_i50" class="anchor-spacer"></div><h4 class="article-section__title" id="_i50"> (2-(7-(Benzyloxy)-1<i>H</i>-indol-3-yl)-1<i>H</i>-imidazol-4-yl)(3,4,5-trimethoxyphenyl)methanone (<b>10as</b>)</h4><div class="NLM_p last"><b>10as</b> was obtained as a yellowish solid (24.6 mg, 50.8% from <b>9as</b>). <sup>1</sup>H NMR (400 MHz, methylene chloride-<i>d</i><sub>2</sub>): δ 9.29 (s, 1H), 7.95 (d, <i>J</i> = 2.9 Hz, 1H), 7.90 (d, <i>J</i> = 8.1 Hz, 1H), 7.84 (s, 1H), 7.54–7.47 (m, 2H), 7.44–7.33 (m, 3H), 7.30 (s, 2H), 7.15 (t, <i>J</i> = 7.9 Hz, 1H), 6.82 (dd, <i>J</i> = 7.8, 0.7 Hz, 1H), 5.24 (s, 2H), 3.90 (s, 6H), 3.87 (s, 3H). <sup>13</sup>C NMR (101 MHz, methylene chloride-<i>d</i><sub>2</sub>): δ 183.55, 153.81, 146.12, 142.59, 137.54, 133.81, 129.15, 128.74, 128.43, 127.78, 126.94, 125.29, 122.36, 114.16, 107.82, 107.07, 104.86, 70.93, 61.17, 56.81. HRMS: calcd for C<sub>28</sub>H<sub>26</sub>N<sub>3</sub>O<sub>5</sub> [M + H]<sup>+</sup>, 484.1872; found, 484.1882. Purity: 99.6% by HPLC (<i>R</i><sub>t</sub> = 2.37 min).</div></div><div id="sec5_11_20" class="NLM_sec NLM_sec_level_3"><div id="ac_i51" class="anchor-spacer"></div><h4 class="article-section__title" id="_i51"> (2-(7-Methoxy-1<i>H</i>-indol-3-yl)-1<i>H</i>-imidazol-4-yl)(3,4,5-trimethoxyphenyl)methanone (<b>10at</b>)</h4><div class="NLM_p last"><b>10at</b> was obtained as a yellowish solid (16.9 mg, 41.1% from <b>9at</b>). <sup>1</sup>H NMR (400 MHz, methylene chloride-<i>d</i><sub>2</sub>/methanol-<i>d</i><sub>4</sub> = 10:1): δ 7.88 (s, 1H), 7.85–7.77 (m, 2H), 7.28 (s, 2H), 7.17 (t, <i>J</i> = 7.9 Hz, 1H), 6.74 (dd, <i>J</i> = 7.9, 0.8 Hz, 1H), 3.98 (s, 3H), 3.91 (s, 6H), 3.88 (s, 3H). <sup>13</sup>C NMR (101 MHz, methylene chloride-<i>d</i><sub>2</sub>/methanol-<i>d</i><sub>4</sub> = 10:1): δ 184.15, 153.77, 147.11, 142.55, 133.91, 127.59, 126.64, 125.67, 122.28, 113.43, 107.26, 107.12, 103.42, 61.20, 56.79, 56.01. HRMS: calcd for C<sub>22</sub>H<sub>22</sub>N<sub>3</sub>O<sub>5</sub> [M + H]<sup>+</sup>, 408.1559; found, 408.1560. Purity: 100.0% by HPLC (<i>R</i><sub>t</sub> = 1.90 min).</div></div><div id="sec5_11_21" class="NLM_sec NLM_sec_level_3"><div id="ac_i52" class="anchor-spacer"></div><h4 class="article-section__title" id="_i52"> (2-(5-Hydroxy-1<i>H</i>-indol-3-yl)-1<i>H</i>-imidazol-4-yl)(3,4,5-trimethoxyphenyl)methanone (<b>10au</b>)</h4><div class="NLM_p last"><b>10au</b> was obtained as a yellowish solid (7.2 mg, 36.5% from <b>10ak</b>). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 12.88 (d, <i>J</i> = 58.5 Hz, 1H), 11.48–10.98 (m, 1H), 8.84 (d, <i>J</i> = 12.5 Hz, 1H), 8.25 (d, <i>J</i> = 2.8 Hz, 1H), 7.89 (d, <i>J</i> = 3.5 Hz, 1H), 7.83 (q, <i>J</i> = 2.0, 1.3 Hz, 1H), 7.24 (dd, <i>J</i> = 8.6, 2.3 Hz, 1H), 7.18 (s, 1H), 6.69 (ddd, <i>J</i> = 11.2, 8.7, 2.5 Hz, 1H), 3.84 (dd, <i>J</i> = 47.9, 6.9 Hz, 9H). HRMS: calcd for C<sub>21</sub>H<sub>20</sub>N<sub>3</sub>O<sub>5</sub> [M + H]<sup>+</sup>, 394.1403; found, 394.1390. Purity: 99.7% by HPLC (<i>R</i><sub>t</sub> = 1.53 min).</div></div><div id="sec5_11_22" class="NLM_sec NLM_sec_level_3"><div id="ac_i53" class="anchor-spacer"></div><h4 class="article-section__title" id="_i53"> (2-(6-Hydroxy-1<i>H</i>-indol-3-yl)-1<i>H</i>-imidazol-4-yl)(3,4,5-trimethoxyphenyl)methanone (<b>10av</b>)</h4><div class="NLM_p last"><b>10av</b> was obtained as a yellowish solid (8.5 mg, 43.1% from <b>10ao</b>). <sup>1</sup>H NMR (400 MHz, methylene chloride-<i>d</i><sub>2</sub>/methanol-<i>d</i><sub>4</sub> = 10:1): δ 7.89 (s, 1H), 7.79 (s, 1H), 7.71 (dd, <i>J</i> = 8.0, 0.9 Hz, 1H), 7.27 (s, 2H), 7.09 (t, <i>J</i> = 7.9 Hz, 1H), 6.70 (dd, <i>J</i> = 7.7, 0.8 Hz, 1H), 3.92 (s, 6H), 3.88 (s, 3H). HRMS: calcd for C<sub>21</sub>H<sub>20</sub>N<sub>3</sub>O<sub>5</sub> [M + H]<sup>+</sup>, 394.1403; found, 394.1418. Purity: 98.4% by HPLC (<i>R</i><sub>t</sub> = 1.59 min).</div></div><div id="sec5_11_23" class="NLM_sec NLM_sec_level_3"><div id="ac_i54" class="anchor-spacer"></div><h4 class="article-section__title" id="_i54"> (2-(1<i>H</i>-Indol-4-yl)-1<i>H</i>-imidazol-4-yl)(3,4,5-trimethoxyphenyl)methanone (<b>10bb</b>)</h4><div class="NLM_p last"><b>10bb</b> was obtained as a yellowish solid (18.8 mg, 49.7% from <b>9bb</b>). <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>): δ 11.06 (s, 1H), 8.80 (s, 1H), 7.94 (s, 1H), 7.69 (d, <i>J</i> = 7.4 Hz, 1H), 7.47 (dt, <i>J</i> = 8.2, 0.9 Hz, 1H), 7.33 (t, <i>J</i> = 2.9 Hz, 2H), 7.26 (d, <i>J</i> = 1.7 Hz, 1H), 7.20 (t, <i>J</i> = 7.8 Hz, 1H), 3.96 (s, 3H), 3.91 (s, 6H). <sup>13</sup>C NMR (101 MHz, chloroform-<i>d</i>): δ 183.67, 153.30, 142.36, 136.84, 133.00, 126.16, 125.49, 121.97, 120.82, 119.18, 113.41, 106.78, 102.88, 61.15, 56.45. HRMS: calcd for C<sub>21</sub>H<sub>20</sub>N<sub>3</sub>O<sub>4</sub> [M + H]<sup>+</sup>, 378.1454; found, 378.1457. Purity: 95.5% by HPLC (<i>R</i><sub>t</sub> = 1.78 min).</div></div><div id="sec5_11_24" class="NLM_sec NLM_sec_level_3"><div id="ac_i55" class="anchor-spacer"></div><h4 class="article-section__title" id="_i55"> (2-(1<i>H</i>-Indol-5-yl)-1<i>H</i>-imidazol-4-yl)(3,4,5-trimethoxyphenyl)methanone (<b>10bc</b>)</h4><div class="NLM_p last"><b>10bc</b> was obtained as a yellowish solid (17.2 mg, 45.5% from <b>9bc</b>). <sup>1</sup>H NMR (400 MHz, methylene chloride-<i>d</i><sub>2</sub>): δ 9.34 (s, 1H), 8.28 (d, <i>J</i> = 1.6 Hz, 1H), 7.83 (dd, <i>J</i> = 8.6, 1.7 Hz, 1H), 7.80 (s, 1H), 7.51 (d, <i>J</i> = 8.6 Hz, 1H), 7.31 (dt, <i>J</i> = 2.7, 1.2 Hz, 1H), 7.26 (s, 2H), 6.61 (dt, <i>J</i> = 3.0, 1.3 Hz, 1H), 3.91 (s, 6H), 3.88 (s, 3H). <sup>13</sup>C NMR (101 MHz, chloroform-<i>d</i>): δ 183.52, 153.35, 142.35, 137.06, 133.13, 128.33, 125.77, 120.90, 120.78, 119.55, 111.83, 106.70, 103.64, 61.15, 56.43. HRMS: calcd for C<sub>21</sub>H<sub>20</sub>N<sub>3</sub>O<sub>4</sub> [M + H]<sup>+</sup>, 378.1454; found, 378.1451. Purity: 95.7% by HPLC (<i>R</i><sub>t</sub> = 1.77 min).</div></div><div id="sec5_11_25" class="NLM_sec NLM_sec_level_3"><div id="ac_i56" class="anchor-spacer"></div><h4 class="article-section__title" id="_i56"> (2-(1<i>H</i>-Indol-6-yl)-1<i>H</i>-imidazol-4-yl)(3,4,5-trimethoxyphenyl)methanone (<b>10bd</b>)</h4><div class="NLM_p last"><b>10bd</b> was obtained as a yellowish solid (16.8 mg, 44.4% from <b>9bd</b>). <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>): δ 11.02 (s, 1H), 8.77 (s, 1H), 7.95 (s, 1H), 7.79–7.65 (m, 1H), 7.49 (d, <i>J</i> = 8.1 Hz, 1H), 7.36 (t, <i>J</i> = 2.8 Hz, 1H), 7.32–7.16 (m, 4H), 3.97 (s, 3H), 3.92 (s, 6H). <sup>13</sup>C NMR (101 MHz, chloroform-<i>d</i>): δ 183.29, 153.36, 151.90, 142.38, 138.95, 136.83, 132.97, 131.17, 126.23, 125.52, 122.01, 120.72, 119.32, 113.51, 106.55, 102.84, 61.16, 56.45. HRMS: calcd for C<sub>21</sub>H<sub>20</sub>N<sub>3</sub>O<sub>4</sub> [M + H]<sup>+</sup>, 378.1454; found, 378.1437. Purity: 100.0% by HPLC (<i>R</i><sub>t</sub> = 1.78 min).</div></div><div id="sec5_11_26" class="NLM_sec NLM_sec_level_3"><div id="ac_i57" class="anchor-spacer"></div><h4 class="article-section__title" id="_i57"> (2-(1<i>H</i>-Indol-7-yl)-1<i>H</i>-imidazol-4-yl)(3,4,5-trimethoxyphenyl)methanone (<b>10be</b>)</h4><div class="NLM_p last"><b>10be</b> was obtained as a yellowish solid (18.8 mg, 49.7% from <b>9be</b>). <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>): δ 8.58 (s, 1H), 8.24 (d, <i>J</i> = 7.5 Hz, 1H), 7.93 (d, <i>J</i> = 3.6 Hz, 1H), 7.87 (dd, <i>J</i> = 7.8, 0.8 Hz, 1H), 7.72 (s, 2H), 7.60 (t, <i>J</i> = 7.7 Hz, 1H), 7.02 (d, <i>J</i> = 3.7 Hz, 1H), 3.97 (d, <i>J</i> = 0.9 Hz, 9H). <sup>13</sup>C NMR (101 MHz, chloroform-<i>d</i>): δ 186.04, 153.10, 143.96, 143.25, 142.87, 142.05, 132.31, 132.01, 128.20, 125.87, 124.94, 123.97, 121.35, 120.31, 112.94, 110.91, 108.31, 61.14, 56.49. HRMS: calcd for C<sub>21</sub>H<sub>20</sub>N<sub>3</sub>O<sub>4</sub> [M + H]<sup>+</sup>, 378.1454; found, 378.1469. Purity: 96.5% by HPLC (<i>R</i><sub>t</sub> = 2.43 min).</div></div></div><div id="sec5_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i58" class="anchor-spacer"></div><h3 class="article-section__title" id="_i58"> Cell Culture and Reagents</h3><div class="NLM_p last">Human melanoma carcinoma cell lines A375, M14, and WM164 (American Type Culture Collection or ATCC, Manassas, VA, USA) were cultured in Dulbecco’s modified Eagle’s medium (DMEM) (Corning, Manassas, VA) supplemented with 10% (v/v) fetal bovine serum (FBS) (Atlanta Biologicals, Lawrenceville, GA) and 1% antibiotic/antimycotic mixture (Sigma-Aldrich, St. Louis MO). Murine melanoma B16F10 cells (ATCC, Manassas, VA, USA) were cultured in a minimum essential medium (Invitrogen, Carlsbad, CA), supplemented with 5% heat-inactivated Hyclone FBS (Thermo Scientific, Rockford, IL), 1% antibiotic–antimycotic mixture (Sigma-Aldrich, St. Louis MO), 1% Mem-sodium pyruvate (Invitrogen, Carlsbad, CA), 1% Mem-vitamin (Invitrogen, Carlsbad, CA), <span class="smallcaps smallerCapital">l</span>-glutamine (2mM final concentration) (Invitrogen, Carlsbad, CA), and 1% Mem NEAA (Invitrogen, Carlsbad, CA). All cell lines were authenticated by ATCC by short tandem repeat profiling. Cultures were maintained to 80–90% confluency at 37 °C in a humidified atmosphere containing 5% CO2. Compounds were dissolved in dimethyl sulfoxide (DMSO) (Sigma-Aldrich, St. Louis, MO) to make a stock solution of 20 mM. Compound solutions were freshly prepared by diluting stocks with cell culture medium before use.</div></div><div id="sec5_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i59" class="anchor-spacer"></div><h3 class="article-section__title" id="_i59"> Cytotoxicity Assay</h3><div class="NLM_p last">A375, M14, and WM-164 were seeded in 96-well plates at a concentration of 1000–5000 cells per well, depending on the growth rate of the cell line. After overnight incubation, the media was replaced, and cells were treated with the test compounds at 10 concentrations ranging from 0.03 nM to 1 μM plus a vehicle control for 72 h in four replicates. Following the treatment, the MTS reagent (Promega, Madison, WI) was added to the cells and incubated in dark at 37 °C for at least 1 h. Absorbance at 490 nm was measured using a plate reader (DYNEX Technologies, Chantilly VA). Percentages of cell survival versus drug concentrations were plotted, and the IC<sub>50</sub> (concentration that inhibited cell growth by 50% of untreated control) values were obtained by the nonlinear regression analysis using GraphPad Prism (GraphPad Software, San Diego, CA).</div></div><div id="sec5_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i60" class="anchor-spacer"></div><h3 class="article-section__title" id="_i60"> Protein Expression and Purification</h3><div class="NLM_p last">The stathmin-like domain of RB3(RB3-SLD) was transformed into and over-expressed in <i>Escherichia coli</i>. The cells were harvested and resuspended in the lysis buffer containing 20 mM Tris-HCl pH 8.0, 1 mM EGTA, 2 mM DTT with the antiprotease cocktail, and the protein was purified by anion-exchange chromatography and gel-filtration chromatography. The peak fractions from gel-filtration column were concentrated to 10 mg/mL and stored at −80 °C.<a onclick="showRef(event, 'ref40 ref41 ref42'); return false;" href="javascript:void(0);" class="ref ref40 ref41 ref42">(40−42)</a> TTL protein was expressed and purified from the <i>E. coli</i> expression system as described in the previous reference.<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> Briefly, the cells were induced overnight by adding IPTG at 25 °C in the LB medium. In addition, the cells were harvested and sonicated in the lysis buffer. The soluble fraction of the lysate was loaded onto Ni-NTA affinity chromatography and then gel-filtration chromatography. The final pure sample was concentrated to 20 mg/mL and saved at −80 °C. The purity of RB3 and TTL was examined by SDS-PAGE. Porcine brain tubulin was supplied at 10 mg/mL in G-PEM (general tubulin buffer: 80 mM PIPES pH 6.9, 2 mM MgCl<sub>2</sub>, 0.5 mM EGTA and 1 mM GTP) as a frozen liquid and saved at −80 °C until use.</div></div><div id="sec5_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i61" class="anchor-spacer"></div><h3 class="article-section__title" id="_i61"> Crystallization and Crystal Soaking</h3><div class="NLM_p last">A detailed process to making crystals of T2R-TTL was according to refs.<a onclick="showRef(event, 'ref43 ref44'); return false;" href="javascript:void(0);" class="ref ref43 ref44">(43,44)</a> In brief, the protein complex containing tubulin (10 mg/mL), TTL (20 mg/mL), and RB3 (6 mg/mL) at the molar ratio of 2:1.3:1.2 (tubulin/RB3/TTL) were incubated on ice supplemented with 1 mM AMPPCP, 5 mM tyrosinol, and 10 mM DTT and then concentrated to 20 mg/mL at 4 °C. Crystals of T2R-TTL were grown at 20 °C using the sitting-drop vapor diffusion method by mixing 1.0 μL of protein complex and 1.0 μL of crystallization buffer containing 6% PEG, 5% glycerol, 0.1M MES, 30 mM CaCl<sub>2</sub>, 30 mM MgCl<sub>2</sub>, and pH 6.7. Initial crystals were observed after 2 days and then the crystal could reach to the final size around a length of 200–300 μm within 3–5 days. For the compound soaking to the crystals, the compounds of ABI-231, <b>10ab</b>, and <b>10bb</b>, were dissolved in DMSO at 10 mM concentration. The crystals were soaked with ABI-231, <b>10ab</b>, and <b>10bb</b> (0.1 μL) at 20 °C for 2–24 h, respectively. The crystals were quickly dumped into the cryoprotectant (30 mM MgCl<sub>2</sub>, 30 mM CaCl<sub>2</sub>, 0.1 M MES, pH 6.7, contained 20% glycerol) and flash-frozen in a 100 K liquid nitrogen for data collection.</div></div><div id="sec5_16" class="NLM_sec NLM_sec_level_2"><div id="ac_i62" class="anchor-spacer"></div><h3 class="article-section__title" id="_i62"> X-ray Data Collection and Structure Determination</h3><div class="NLM_p last">The crystals of the T2R-TTL-ligand complexes were mounted in nylon loops and flash-cooled in a cold nitrogen stream at 100 K. The diffraction data were collected on beamlines BL19U1 at Shanghai Synchrotron Radiation Facility (SSRF) in Shanghai, China. Data were initially processed by the HKL2000 program package.<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> The previously published T2R-TTL structure (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4I55">4I55</a>) as a searching model in the molecular replacement was used to determine the initial phase. The final model was manually built with Coot, and all refinements were performed with a phenix refine module of Phenix program.<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> The model quality was checked with the PROCHECK program, which shows a good stereochemistry according to the Ramachandran plot.</div></div><div id="sec5_17" class="NLM_sec NLM_sec_level_2"><div id="ac_i63" class="anchor-spacer"></div><h3 class="article-section__title" id="_i63"> In Vitro Tubulin Polymerization Assay</h3><div class="NLM_p last">Bovine brain tubulin (0.4 mg, >97% pure) (Cytoskeleton, Denver, CO) was mixed with 10 μM of the test compounds and incubated in 100 μL of general tubulin buffer (80 mM PIPES, 2.0 mM MgCl<sub>2</sub>, 0.5 mM EGTA, and 1 mM GTP) at pH 6.9. The absorbance of wavelength at 340 nm was monitored every 1 min for 20 min by the SYNERGY 4 Microplate Reader (Bio-Tek Instruments, Winooski, VT). The spectrophotometer was set at 37 °C for tubulin polymerization.</div></div><div id="sec5_18" class="NLM_sec NLM_sec_level_2"><div id="ac_i64" class="anchor-spacer"></div><h3 class="article-section__title" id="_i64"> Fluorescence Microscopy</h3><div class="NLM_p last">WM164 cells were seeded and allowed to adhere to glass coverslips in 6-well plates (500 000 cells/well) overnight. Cells were incubated for 18 h with 50 nM of <b>10ab</b> or docetaxel. DMSO was added to the cells in equivalent volume as a negative control. Microtubules were visualized with anti-α-tubulin antibody (Thermo Scientific, Rockford, IL) and Alexa Fluor 647 goat anti-mouse IgG (Molecular Probes, Eugene, OR). The coverslips were mounted with Prolong Diamond Antifade mounting media with DAPI (Invitrogen, Eugene, OR) and images were acquired with a Zeiss 710 Confocal microscope and Zen imaging software (Zeiss, Thornwood, NY).</div></div><div id="sec5_19" class="NLM_sec NLM_sec_level_2"><div id="ac_i65" class="anchor-spacer"></div><h3 class="article-section__title" id="_i65"> Colony Forming Assay</h3><div class="NLM_p last">A375 cells were plated in replicates of 4 in 6 well plates at a concentration of 500 cells/well in DMEM containing full cell culture media. Seeded cells were then incubated at 37 °C overnight to allow cell attachment to the plate bottom. Media was changed and cells were treated with the compound or equivalent vehicle (DMSO) control and incubated for another week. At the end of this period, cells were fixed with chilled methanol (5 min), stained with 0.5% crystal violet solution (4 h), rinsed with sterile water, and air-dried overnight. Images were taken, and colony area was quantified with ImageJ software (NIH, Bethesda, MD).</div></div><div id="sec5_20" class="NLM_sec NLM_sec_level_2"><div id="ac_i66" class="anchor-spacer"></div><h3 class="article-section__title" id="_i66"> Scratch Migration Assay</h3><div class="NLM_p last">A375 and RPMI7951 cells were seeded in 24-well plates in four replicates at a concentration of 200 000 cells/well and incubated overnight. This concentration allowed a confluent monolayer to form in the wells. Using a 200 μL pipette tip, a straight line was scratched through the cell monolayer to remove an area of cells. The plates were then washed several times with media to remove any debris and uprooted cells. Cells were treated with 25 nM of <b>10ab</b>, <b>10bb</b>, or vehicle control. Images were obtained after 0, 12, and 24 h with the Evos Fl Imaging System (Life Technologies, Carlsbad, CA). The analysis was performed with ImageJ software (NIH, Bethesda, MD).</div></div><div id="sec5_21" class="NLM_sec NLM_sec_level_2"><div id="ac_i67" class="anchor-spacer"></div><h3 class="article-section__title" id="_i67"> Liver Microsomes Stability Assay</h3><div class="NLM_p last">The NADPH regenerating agent solutions A (catalog#: 451220) and B (catalog#: 451200) and mouse liver microsomes (CD-1, a mixture of male, catalog#: 452701, and female, catalog#: 452702) were obtained from BD Gentest (Woburn, MA). Liver microsome stability assay was conducted following literature reports.<a onclick="showRef(event, 'ref47 ref48'); return false;" href="javascript:void(0);" class="ref ref47 ref48">(47,48)</a> For each test compound, the mouse liver microsomal solution was prepared by adding 0.058 mL of concentrated mouse liver microsomes (20 mg/mL protein concentration) to 1.756 mL of 0.1 M potassium phosphate buffer (pH 7.4) containing 5 μL of 0.5 M EDTA to make a 0.6381 mg/mL (protein) microsomal solution. Each test compound (2.2 μL of 10 mM DMSO solution) was added directly to 1.79 mL of mouse liver microsomal solution, and 90 μL was transferred to wells in 96-well plates (0, 0.25, 0.5, 1, 2, and 4 h time points each in triplicate). The NADPH regenerating agent was prepared by mixing 0.113 mL of NADPH regenerating agent Solutions A, 0.023 mL of solution B, and 0.315 mL of 0.1 M potassium phosphate buffer (pH 7.4) for each tested compound. To each well of the 96-well plate, 22.5 μL of the NADPH regenerating agent was added to initiate the reaction, and the plate was incubated at 37 °C for each time point (0, 0.25, 0.5, 1, 2, and 4 h time points each in triplicate). The reaction was quenched by adding 225 μL of cold acetonitrile containing warfarin (4 mg/mL) as an internal control to each well. All of the plates were centrifuged at 4000 rpm for 20 min, and the supernatants (100 μL) were transferred to another 96-well plate for the analysis on UPLC–MS (Waters Acquity UPLC linked to Waters Acquity Photodiode Array Detector and Waters Acquity Single Quadrupole Mass Detector) on Acquity UPLC BEH C18 1.7 mm (2.1 × 50 mm) column by running 90–5% gradient for water (+0.1% formic acid) and acetonitrile (+0.1% formic acid) in 2 min. The area under the single ion recording (SIR) channel for the test compound divided by the area under the SIR for internal control at 0-time concentration was considered as 100% to calculate remaining concentration at each time point. The terminal phase rate constant (<i>k</i><sub>e</sub>) was estimated by linear regression of logarithmically transformed concentration versus the data, where <i>k</i><sub>e</sub> = slope × (−ln 10). The half-life <i>t</i><sub>1/2</sub> was calculated as ln 2/<i>k</i><sub>e</sub>. The intrinsic clearance (CL<sub>int,app</sub>) = (0.693/in vitro <i>t</i><sub>1/2</sub>) × (1 mL incubation volume/0.5 mg of microsomal protein) × (45 mg microsomal protein/gram of liver) × (55 g of liver/kg body weight).<a onclick="showRef(event, 'ref48 ref49'); return false;" href="javascript:void(0);" class="ref ref48 ref49">(48,49)</a></div></div><div id="sec5_22" class="NLM_sec NLM_sec_level_2"><div id="ac_i68" class="anchor-spacer"></div><h3 class="article-section__title" id="_i68"> In Vivo Antitumor Efficacy of <b>10bb</b> in the A375 Melanoma Xenograft Model</h3><div class="NLM_p last">All animal experiments were performed in accordance with the NIH animal use guidelines and protocol approved by the Institutional Animal Care and Use Committee (IACUC) at the University of Tennessee Health Science Center (UTHSC, Memphis, TN). We first estimated the acute maximum tolerable dose (MTD) for <b>10bb</b> formulated in PEG300. By progressively increasing injection doses via i.p. route to 6–8 week old female ICR mice (<i>n</i> = 2 per group) (Harlan Laboratories, now Evigo Corporation, Denver, CO, USA), the MTD was estimated to be at least 65 mg/kg. To ensure a safety margin during the repeated treatment, we scaled down the dose to 30 and 15 mg/kg in the animal experiments. Nude mice, 6–8 weeks old, were purchased from Harlan/Evigo. Groups were composed of 6–8 mice per group, with an even number of male and female mice. Logarithmic growth phase A375 (5 × 10<sup>7</sup> cells per mL) cells were prepared in phenyl red-free, FBS-free DMEM media and mixed at a 1:1 ratio with Matrigel. Tumors were established by injecting 100 μL of this mixture subcutaneously in the dorsal flank of each mouse (2.5 × 10<sup>6</sup> cells). After 2 weeks, mice were randomly divided into control or treatment groups. <b>10bb</b> was dissolved in a 1:1 ratio of PEG300: PBS solution to produce desired concentrations. <b>10bb</b> solution (100 μL) corresponding to 15 or 30 mg/kg doses were administered via i.p. injection once daily for 14 days. The control group was given only a vehicle solution of the same preparation and injected at the same frequency. Tumor volume was measured three times a week with a caliper and calculated by using the formula <i>a</i> × <i>b</i><sup>2</sup> × 0.5, where <i>a</i> and <i>b</i> represented the larger and smaller diameters, respectively. TGI at the conclusion of the experiments was calculated as 100 – 100 × ((<i>T</i> – <i>T</i><sub>0</sub>)/(<i>C</i> – <i>C</i><sub>0</sub>)), where <i>T</i>, <i>T</i><sub>0</sub>, <i>C</i>, and <i>C</i><sub>0</sub> are the mean tumor volume for the specific group on the last day of treatment, mean tumor volume of the same group on the first day of treatment, mean tumor volume for the vehicle control group on the last day of treatment, and mean tumor volume for the vehicle control group on the first day of treatment, respectively.<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> Animal activity and body weight were monitored during the entire experiment period to assess potential acute toxicity. At the end of the experiment, mice were sacrificed and the tumors and tissues were dissected out and fixed in 10% buffered formalin phosphate solution for more than 1 week before pathology staining analysis.</div></div><div id="sec5_23" class="NLM_sec NLM_sec_level_2"><div id="ac_i69" class="anchor-spacer"></div><h3 class="article-section__title" id="_i69"> In Vivo Antitumor Efficacy of <b>10bb</b> in the B16F10 Experimental Lung Metastasis Model</h3><div class="NLM_p last">C57BL/6 mice from Charles River Laboratories International, Inc., age 7–8 weeks old, were used to study the inhibition effect of <b>10bb</b> on lung metastasis of melanoma cells. 9–10 mice per group were used for the study, with an even number of males and females divided between the two groups. B16F10 melanoma cells growing in a logarithmic growth phase were suspended in the conditioned media at a density of 1 × 10<sup>6</sup> per mL. Each mouse was injected with 100 μL (1 × 10<sup>5</sup> cells) via the lateral tail vein. The treatment started on the third day after the inoculation to ensure the initiation of metastasis before beginning treatment. <b>10bb</b> (30 mg/kg) was formulated as described above. All of the treatment solutions were kept in the same volume (100 μL) and administered via i.p. injection for 2 weeks, 5 days a week. The vehicle control group was treated by i.p. injection with 100 μL of PEG300 and PBS in a 1:1 ratio. Mice were sacrificed after 15 days after the initiation of the experiment, and the lungs were separated, expanded, and preserved in 10% neutral buffered formalin. The number of lung metastasis nodules was recorded. Major organs were also preserved in 10% neutral formalin buffer for subsequent examination of potential toxicities. The animal activity and body weight were monitored during the entire experiment period to assess acute toxicity.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i70"><a href="/doi/suppl/10.1021/acs.jmedchem.9b00706" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_40327" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_40327" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.9b00706" class="ext-link">10.1021/acs.jmedchem.9b00706</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Spectral data for synthetic intermediates and ABI-231 analogues (<a href="/doi/suppl/10.1021/acs.jmedchem.9b00706/suppl_file/jm9b00706_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular formula strings and biological data (<a href="/doi/suppl/10.1021/acs.jmedchem.9b00706/suppl_file/jm9b00706_si_002.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b00706/suppl_file/jm9b00706_si_001.pdf">jm9b00706_si_001.pdf (4.44 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b00706/suppl_file/jm9b00706_si_002.csv">jm9b00706_si_002.csv (2.55 kb)</a></li></ul></div></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">PDB ID codes:<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6O61">6O61</a> (ABI-231), <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6O5N">6O5N</a> (<b>10ab</b>), and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6O5M">6O5M</a> (<b>10bb</b>): Authors will release the atomic coordinates upon article publication.</p><div class="testing" data-doi="10.1021/acs.jmedchem.9b00706" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_24101" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_24101" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Weimin Li</span> - <span class="hlFld-Affiliation affiliation">Department
of Respiratory and Critical Care Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#4b3c2e2226227b7b780b38283e652e2f3e652825"><span class="__cf_email__" data-cfemail="e790828e8a8ed7d7d4a7948492c9828392c98489">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Wei Li</span> - <span class="hlFld-Affiliation affiliation">Department
of Pharmaceutical Sciences, College of Pharmacy, University of Tennessee Health Science Center, Memphis, Tennessee 38163, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-9522-4474" title="Orcid link">http://orcid.org/0000-0002-9522-4474</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#dea9b2b79eabaab6adbdf0bbbaab"><span class="__cf_email__" data-cfemail="a8dfc4c1e8dddcc0dbcb86cdccdd">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Qinghui Wang</span> - <span class="hlFld-Affiliation affiliation">Department
of Pharmaceutical Sciences, College of Pharmacy, University of Tennessee Health Science Center, Memphis, Tennessee 38163, United States</span>; 
    <span>Present Address:
                        Chemical Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kinsie E. Arnst</span> - <span class="hlFld-Affiliation affiliation">Department
of Pharmaceutical Sciences, College of Pharmacy, University of Tennessee Health Science Center, Memphis, Tennessee 38163, United States</span>; 
    <span>Present Address:
                        UT Southwestern Medical Center, Dallas, TX, 75390, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yuxi Wang</span> - <span class="hlFld-Affiliation affiliation">Department
of Respiratory and Critical Care Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Gyanendra Kumar</span> - <span class="hlFld-Affiliation affiliation">Department
of Structural Biology, St. Jude Children’s
Research Hospital, Memphis, Tennessee 38105, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Dejian Ma</span> - <span class="hlFld-Affiliation affiliation">Department
of Pharmaceutical Sciences, College of Pharmacy, University of Tennessee Health Science Center, Memphis, Tennessee 38163, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Stephen W. White</span> - <span class="hlFld-Affiliation affiliation">Department
of Structural Biology, St. Jude Children’s
Research Hospital, Memphis, Tennessee 38105, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Duane D. Miller</span> - <span class="hlFld-Affiliation affiliation">Department
of Pharmaceutical Sciences, College of Pharmacy, University of Tennessee Health Science Center, Memphis, Tennessee 38163, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-6093-0985" title="Orcid link">http://orcid.org/0000-0002-6093-0985</a></span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>Q.W., K.E.A., and Y.W. contributed equally.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare the following competing financial interest(s): Dr. Wei Li is currently serving as a consultant to Veru Inc., who licensed the patents covering all compounds reported in this manuscript for commercial development. Veru Inc. did not provide any financial support or have any influence on research design, data collections, data analyses, or the writing of this manuscript.<br /></br></div></li></ul></div><div class="ack" id="ack1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i75">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_44700" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_44700" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">This work is supported by NIH/NCI grant R01CA148706 to W.L. and D.D.M.; NIH grants 1S10OD010678-01 and 1S10RR026377-01 to W.L. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIH. The additional support was received from the University of Tennessee College of Pharmacy Drug Discovery Center. We thank Dr. Lei Yang at St. Jude Children’s Research Hospital for the metabolic stability evaluation for new ABI-231 analogues. We also thank Dr. Benoît Gigant (Institute for Integrative Biology of the Cell (I2BC), CEA, CNRS, Univ. Paris-Sud, Université Paris-Saclay, France) and Dr. Michel O. Steinmetz (Paul Scherrer Institute, Switzerland) for kindly providing the plasmids of RB3-SLD and TTL. G.K. and S.W.W. acknowledge the support of American Lebanese Syrian Associated Charities (ALSAC). Y.W. and WML acknowledge the support of National Major Scientific and Technological Special Project (Significant New Drugs Development, 2018ZX09201018-021) for raw data collection in X-ray crystallography studies. No NIH fund was used to support the contributions from Y.W. and WML, and all intellectual properties related to this paper are owned by the University of Tennessee Research Foundation.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations</td></tr><tr><td class="NLM_term">CBSIs</td><td class="NLM_def"><p class="first last">colchicine binding site inhibitors</p></td></tr><tr><td class="NLM_term">MTAs</td><td class="NLM_def"><p class="first last">microtubule-targeting agents</p></td></tr><tr><td class="NLM_term">ABC</td><td class="NLM_def"><p class="first last">ATP-binding cassette</p></td></tr><tr><td class="NLM_term">TGI</td><td class="NLM_def"><p class="first last">tumor growth inhibition</p></td></tr><tr><td class="NLM_term">CA-4</td><td class="NLM_def"><p class="first last">combretastatin A4</p></td></tr><tr><td class="NLM_term">RABI</td><td class="NLM_def"><p class="first last">reverse ABI</p></td></tr><tr><td class="NLM_term">TMP</td><td class="NLM_def"><p class="first last">trimethoxyphenyl</p></td></tr><tr><td class="NLM_term">SAR</td><td class="NLM_def"><p class="first last">structure–activity relationship</p></td></tr><tr><td class="NLM_term">P-gp</td><td class="NLM_def"><p class="first last">P-glycoprotein</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i77">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_40822" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_40822" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 50 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mukhtar, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adhami, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mukhtar, H.</span></span> <span> </span><span class="NLM_article-title">Targeting microtubules by natural agents for cancer therapy</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">275</span>– <span class="NLM_lpage">284</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.mct-13-0791</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=10.1158%2F1535-7163.mct-13-0791" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=24435445" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitFWmsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=275-284&author=E.+Mukhtarauthor=V.+M.+Adhamiauthor=H.+Mukhtar&title=Targeting+microtubules+by+natural+agents+for+cancer+therapy&doi=10.1158%2F1535-7163.mct-13-0791"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting Microtubules by Natural Agents for Cancer Therapy</span></div><div class="casAuthors">Mukhtar, Eiman; Adhami, Vaqar Mustafa; Mukhtar, Hasan</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">275-284</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Natural compds. that target microtubules and disrupt the normal function of the mitotic spindle have proven to be one of the best classes of cancer chemotherapeutic drugs available in clinics to date.  There is increasing evidence showing that even minor alteration of microtubule dynamics can engage the spindle checkpoint, arresting cell-cycle progression at mitosis and subsequently leading to cell death.  Our improved understanding of tumor biol. and our continued appreciation for what the microtubule targeting agents (MTAs) can do have helped pave the way for a new era in the treatment of cancer.  The effectiveness of these agents for cancer therapy has been impaired, however, by various side effects and drug resistance.  Several new MTAs have shown potent activity against the proliferation of various cancer cells, including resistance to the existing MTAs.  Sustained investigation of the mechanisms of action of MTAs, development and discovery of new drugs, and exploring new treatment strategies that reduce side effects and circumvent drug resistance could provide more effective therapeutic options for patients with cancer.  This review focuses on the successful cancer chemotherapy from natural compds. in clin. settings and the challenges that may abort their usefulness.  Mol Cancer Ther; 13(2); 275-84. ©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoSZOcnk6gaB7Vg90H21EOLACvtfcHk0liScAw3ByJ1iw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitFWmsLg%253D&md5=0a14655cff81c9d3a73c0b4514e45112</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.mct-13-0791&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.mct-13-0791%26sid%3Dliteratum%253Aachs%26aulast%3DMukhtar%26aufirst%3DE.%26aulast%3DAdhami%26aufirst%3DV.%2BM.%26aulast%3DMukhtar%26aufirst%3DH.%26atitle%3DTargeting%2520microtubules%2520by%2520natural%2520agents%2520for%2520cancer%2520therapy%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2014%26volume%3D13%26spage%3D275%26epage%3D284%26doi%3D10.1158%2F1535-7163.mct-13-0791" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jordan, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, L.</span></span> <span> </span><span class="NLM_article-title">Microtubules as a target for anticancer drugs</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">253</span>– <span class="NLM_lpage">265</span>, <span class="refDoi"> DOI: 10.1038/nrc1317</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=10.1038%2Fnrc1317" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=15057285" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=1%3ACAS%3A528%3ADC%252BD2cXis1Gmt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2004&pages=253-265&author=M.+A.+Jordanauthor=L.+Wilson&title=Microtubules+as+a+target+for+anticancer+drugs&doi=10.1038%2Fnrc1317"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Microtubules as a target for anticancer drugs</span></div><div class="casAuthors">Jordan, Mary Ann; Wilson, Leslie</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">253-265</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Highly dynamic mitotic-spindle microtubules are among the most successful targets for anticancer therapy.  Microtubule-targeted drugs, including paclitaxel and Vinca alkaloids, were previously considered to work primarily by increasing or decreasing the cellular microtubule mass.  Although these effects might have a role in their chemotherapeutic actions, we now know that at lower concns., microtubule-targeted drugs can suppress microtubule dynamics without changing microtubule mass; this action leads to mitotic block and apoptosis.  In addn. to the expanding array of chem. diverse antimitotic agents, some microtubule-targeted drugs can act as vascular-targeting agents, rapidly depolymg. microtubules of newly formed vasculature to shut down the blood supply to tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqRJbrFnzwqjbVg90H21EOLACvtfcHk0liScAw3ByJ1iw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXis1Gmt74%253D&md5=bbbf212e03ffe6763098fc41f21a8158</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2Fnrc1317&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc1317%26sid%3Dliteratum%253Aachs%26aulast%3DJordan%26aufirst%3DM.%2BA.%26aulast%3DWilson%26aufirst%3DL.%26atitle%3DMicrotubules%2520as%2520a%2520target%2520for%2520anticancer%2520drugs%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2004%26volume%3D4%26spage%3D253%26epage%3D265%26doi%3D10.1038%2Fnrc1317" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Heald, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nogales, E.</span></span> <span> </span><span class="NLM_article-title">Microtubule dynamics</span>. <i>J. Cell Sci.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>115</i></span>,  <span class="NLM_fpage">3</span>– <span class="NLM_lpage">4</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=11801717" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=1%3ACAS%3A528%3ADC%252BD38XovVejsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=2002&pages=3-4&author=R.+Healdauthor=E.+Nogales&title=Microtubule+dynamics"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Microtubule dynamics</span></div><div class="casAuthors">Heald, Rebecca; Nogales, Eva</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cell Science</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">115</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">3-4</span>CODEN:
                <span class="NLM_cas:coden">JNCSAI</span>;
        ISSN:<span class="NLM_cas:issn">0021-9533</span>.
    
            (<span class="NLM_cas:orgname">Company of Biologists Ltd.</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDLiwcMnFurbVg90H21EOLACvtfcHk0lglHVpolrnJlw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XovVejsg%253D%253D&md5=6a9501a826ccf37961fda924297e75b7</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHeald%26aufirst%3DR.%26aulast%3DNogales%26aufirst%3DE.%26atitle%3DMicrotubule%2520dynamics%26jtitle%3DJ.%2520Cell%2520Sci.%26date%3D2002%26volume%3D115%26spage%3D3%26epage%3D4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kuppens, I.</span></span> <span> </span><span class="NLM_article-title">Current state of the art of new tubulin inhibitors in the clinic</span>. <i>Curr. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">57</span>– <span class="NLM_lpage">70</span>, <span class="refDoi"> DOI: 10.2174/157488406775268200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=10.2174%2F157488406775268200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=18666378" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=1%3ACAS%3A528%3ADC%252BD28XitFOgu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2006&pages=57-70&author=I.+Kuppens&title=Current+state+of+the+art+of+new+tubulin+inhibitors+in+the+clinic&doi=10.2174%2F157488406775268200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Current state of the art of new tubulin inhibitors in the clinic</span></div><div class="casAuthors">Kuppens, Isa E. L. M.</div><div class="citationInfo"><span class="NLM_cas:title">Current Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">57-70</span>CODEN:
                <span class="NLM_cas:coden">CCPUC5</span>;
        ISSN:<span class="NLM_cas:issn">1574-8847</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  For years the microtubule stabilizing agents docetaxel and paclitaxel belong to the most successful clin. chemotherapeutic agents.  Several attempts have been made over the years to equal and better these drugs.  Both taxanes are assocd. with the notorious side effect neurotoxicity and are often accompanied with increased drug resistance and cross resistance with other chemotherapeutic agents.  In addn. their high lipophilicity demands use of co-solvents, which are assocd. with less favorable side effects such as hypersensitivity.  To prevent these disadvantages and improve the clin. application of the taxanes several new agents have entered clin. testing.  The agents that are discussed are the drug class of the discodermolides; XAA296A and the epothilones; BMS-247550, BMS-310705, epo906, kos-862 and the agents ABT-751 and D-24851.  Here we present an overview of recently performed clin. studies to det. the current state of the art of the tubulin inhibitors which are intended to enlarge and improve the clin. use of the taxanes docetaxel and paclitaxel.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpiAXF3Hrb0ubVg90H21EOLACvtfcHk0lglHVpolrnJlw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XitFOgu7c%253D&md5=e0ab529443ebf69c924de9d76ccc685d</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.2174%2F157488406775268200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F157488406775268200%26sid%3Dliteratum%253Aachs%26aulast%3DKuppens%26aufirst%3DI.%26atitle%3DCurrent%2520state%2520of%2520the%2520art%2520of%2520new%2520tubulin%2520inhibitors%2520in%2520the%2520clinic%26jtitle%3DCurr.%2520Clin.%2520Pharmacol.%26date%3D2006%26volume%3D1%26spage%3D57%26epage%3D70%26doi%3D10.2174%2F157488406775268200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yeo, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loong, H. H.</span></span> <span> </span><span class="NLM_article-title">Microtubule-targeting agents in oncology and therapeutic potential in hepatocellular carcinoma</span>. <i>OncoTargets Ther.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">575</span>– <span class="NLM_lpage">585</span>, <span class="refDoi"> DOI: 10.2147/OTT.S46019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=10.2147%2FOTT.S46019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=24790457" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1ynurbI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2014&pages=575-585&author=W.+Yeoauthor=H.+H.+Loong&title=Microtubule-targeting+agents+in+oncology+and+therapeutic+potential+in+hepatocellular+carcinoma&doi=10.2147%2FOTT.S46019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Microtubule-targeting agents in oncology and therapeutic potential in hepatocellular carcinoma</span></div><div class="casAuthors">Loong, Herbert H.; Yeo, Winnie</div><div class="citationInfo"><span class="NLM_cas:title">OncoTargets and Therapy</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">575-585, 11 pp.</span>CODEN:
                <span class="NLM_cas:coden">OTNHAZ</span>;
        ISSN:<span class="NLM_cas:issn">1178-6930</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">A review.  In mammalian cells, microtubules are present both in interphase and dividing cells.  In the latter, microtubules forming the mitotic spindle are highly dynamic and exquisitely sensitive to therapeutic inhibitors.  Developed to alter microtubule function, microtubule-binding agents have been proven to be highly active as an anticancer treatment.  Significant development of microtubule-binding agents has taken place in recent years, with newer anti-tubulin agents now showing novel properties of enhanced tumor specificity, reduced neurotoxicity, and insensitivity to chemoresistance mechanisms.  Hepatocellular carcinoma remains one of the most difficult cancers to treat, with chemotherapies being relatively ineffective.  There is now evidence to suggest that microtubule-binding agents may be effective in the treatment of hepatocellular carcinoma, esp. when used in combination with mammalian target of rapamycin inhibitors.  Preclin. models have suggested that the latter may be able to overcome resistance to microtubule binding agents.  In this review article, recent developments of novel microtubule binding agents and their relevance to the treatment of hepatocellular carcinoma will be discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpUy8BJ1xF1ibVg90H21EOLACvtfcHk0lglHVpolrnJlw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1ynurbI&md5=4a5bed4720f2ba46a7f08f9cd22d5130</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.2147%2FOTT.S46019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FOTT.S46019%26sid%3Dliteratum%253Aachs%26aulast%3DYeo%26aufirst%3DW.%26aulast%3DLoong%26aufirst%3DH.%2BH.%26atitle%3DMicrotubule-targeting%2520agents%2520in%2520oncology%2520and%2520therapeutic%2520potential%2520in%2520hepatocellular%2520carcinoma%26jtitle%3DOncoTargets%2520Ther.%26date%3D2014%26volume%3D7%26spage%3D575%26epage%3D585%26doi%3D10.2147%2FOTT.S46019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McGuire, S.</span></span> <span> </span><span class="NLM_article-title">World Cancer Report 2014. Geneva, Switzerland: World Health Organization, International Agency for Research on Cancer, WHO Press, 2015</span>. <i>Adv. Nutr.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">418</span>– <span class="NLM_lpage">419</span>, <span class="refDoi"> DOI: 10.3945/an.116.012211</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=10.3945%2Fan.116.012211" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=26980827" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=1%3ACAS%3A280%3ADC%252BC28fgslGhug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=418-419&author=S.+McGuire&title=World+Cancer+Report+2014.+Geneva%2C+Switzerland%3A+World+Health+Organization%2C+International+Agency+for+Research+on+Cancer%2C+WHO+Press%2C+2015&doi=10.3945%2Fan.116.012211"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">World Cancer Report 2014. Geneva, Switzerland: World Health Organization, International Agency for Research on Cancer, WHO Press, 2015</span></div><div class="casAuthors">McGuire Shelley</div><div class="citationInfo"><span class="NLM_cas:title">Advances in nutrition (Bethesda, Md.)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">418-9</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTrQN7I_r2GkZ0d-O_J5C0AfW6udTcc2eZSVH79LdiMt7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28fgslGhug%253D%253D&md5=fb111acc7e8cd67cdb11adaef7a981cd</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.3945%2Fan.116.012211&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3945%252Fan.116.012211%26sid%3Dliteratum%253Aachs%26aulast%3DMcGuire%26aufirst%3DS.%26atitle%3DWorld%2520Cancer%2520Report%25202014.%2520Geneva%252C%2520Switzerland%253A%2520World%2520Health%2520Organization%252C%2520International%2520Agency%2520for%2520Research%2520on%2520Cancer%252C%2520WHO%2520Press%252C%25202015%26jtitle%3DAdv.%2520Nutr.%26date%3D2016%26volume%3D7%26spage%3D418%26epage%3D419%26doi%3D10.3945%2Fan.116.012211" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Orr, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verdier-Pinard, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDaid, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horwitz, S. B.</span></span> <span> </span><span class="NLM_article-title">Mechanisms of Taxol resistance related to microtubules</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">7280</span>– <span class="NLM_lpage">7295</span>, <span class="refDoi"> DOI: 10.1038/sj.onc.1206934</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=10.1038%2Fsj.onc.1206934" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=14576838" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=1%3ACAS%3A528%3ADC%252BD3sXotlajtbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2003&pages=7280-7295&author=G.+A.+Orrauthor=P.+Verdier-Pinardauthor=H.+McDaidauthor=S.+B.+Horwitz&title=Mechanisms+of+Taxol+resistance+related+to+microtubules&doi=10.1038%2Fsj.onc.1206934"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of Taxol resistance related to microtubules</span></div><div class="casAuthors">Orr, George A.; Verdier-Pinard, Pascal; McDaid, Hayley; Horwitz, Susan Band</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">47</span>),
    <span class="NLM_cas:pages">7280-7295</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Since its approval by the FDA in 1992 for the treatment of ovarian cancer, the use of Taxol has dramatically increased.  Although treatment with Taxol has led to improvement in the duration and quality of life for some cancer patients, the majority eventually develop progressive disease after initially responding to Taxol treatment.  Drug resistance represents a major obstacle to improving the overall response and survival of cancer patients.  This review focuses on mechanisms of Taxol resistance that occur directly at the microtubule, such as mutations, tubulin isotype selection and post-translational modifications, and also at the level of regulatory proteins.  A review of tubulin structure, microtubule dynamics, the mechanism of action of Taxol and its binding site on the microtubule are included, so that the reader can evaluate Taxol resistance in context.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrdPHARrQvHZbVg90H21EOLACvtfcHk0lj5iOZ6Z_65kQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXotlajtbc%253D&md5=97f06b552ed6ed3df45f5c3a051d8671</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1206934&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1206934%26sid%3Dliteratum%253Aachs%26aulast%3DOrr%26aufirst%3DG.%2BA.%26aulast%3DVerdier-Pinard%26aufirst%3DP.%26aulast%3DMcDaid%26aufirst%3DH.%26aulast%3DHorwitz%26aufirst%3DS.%2BB.%26atitle%3DMechanisms%2520of%2520Taxol%2520resistance%2520related%2520to%2520microtubules%26jtitle%3DOncogene%26date%3D2003%26volume%3D22%26spage%3D7280%26epage%3D7295%26doi%3D10.1038%2Fsj.onc.1206934" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kavallaris, M.</span></span> <span> </span><span class="NLM_article-title">Microtubules and resistance to tubulin-binding agents</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">194</span>– <span class="NLM_lpage">204</span>, <span class="refDoi"> DOI: 10.1038/nrc2803</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=10.1038%2Fnrc2803" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=20147901" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhvVKrtbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2010&pages=194-204&author=M.+Kavallaris&title=Microtubules+and+resistance+to+tubulin-binding+agents&doi=10.1038%2Fnrc2803"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Microtubules and resistance to tubulin-binding agents</span></div><div class="casAuthors">Kavallaris, Maria</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">194-204</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Microtubules are dynamic structures composed of α-β-tubulin heterodimers that are essential in cell division and are important targets for cancer drugs.  Mutations in β-tubulin that affect microtubule polymer mass and/or drug binding are assocd. with resistance to tubulin-binding agents such as paclitaxel.  The aberrant expression of specific β-tubulin isotypes, in particular βIII-tubulin, or of microtubule-regulating proteins is important clin. in tumor aggressiveness and resistance to chemotherapy.  In addn., changes in actin regulation can also mediate resistance to tubulin-binding agents.  Understanding the mol. mechanisms that mediate resistance to tubulin-binding agents will be vital to improve the efficacy of these agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNkoVu03ikmrVg90H21EOLACvtfcHk0lj5iOZ6Z_65kQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhvVKrtbg%253D&md5=1ce71cc537091459d7ee6866c0950b33</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1038%2Fnrc2803&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2803%26sid%3Dliteratum%253Aachs%26aulast%3DKavallaris%26aufirst%3DM.%26atitle%3DMicrotubules%2520and%2520resistance%2520to%2520tubulin-binding%2520agents%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2010%26volume%3D10%26spage%3D194%26epage%3D204%26doi%3D10.1038%2Fnrc2803" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kavallaris, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tait, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walsh, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, L. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horwitz, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norris, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haber, M.</span></span> <span> </span><span class="NLM_article-title">Multiple microtubule alterations are associated with Vinca alkaloid resistance in human leukemia cells</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">5803</span>– <span class="NLM_lpage">5809</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=11479219" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=1%3ACAS%3A528%3ADC%252BD3MXlvVCgtbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2001&pages=5803-5809&author=M.+Kavallarisauthor=A.+S.+Taitauthor=B.+J.+Walshauthor=L.+F.+Heauthor=S.+B.+Horwitzauthor=M.+D.+Norrisauthor=M.+Haber&title=Multiple+microtubule+alterations+are+associated+with+Vinca+alkaloid+resistance+in+human+leukemia+cells"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Multiple microtubule alterations are associated with Vinca alkaloid resistance in human leukemia cells</span></div><div class="casAuthors">Kavallaris, Maria; Tait, A. Sasha; Walsh, Bradley J.; He, Lifeng; Horwitz, Susan B.; Norris, Murray D.; Haber, Michelle</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">5803-5809</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Vinca alkaloids are used extensively in the treatment of childhood acute lymphoblastic leukemia (ALL) and despite their usefulness, drug resistance remains a serious clin. problem.  Vinca alkaloids bind to the β-tubulin subunit of the α/β-tubulin heterodimer and inhibit polymn. of microtubules.  Recent studies have implicated altered β-tubulin isotype expression and mutations in resistance to microtubule-stabilizing agents.  Microtubule-assocd. protein (MAP) MAP4 binds to and stabilizes microtubules, and increased expression is assocd. with decreased sensitivity to microtubule-depolymg. agents.  To address the significance of β-tubulin and MAP4 alterations in childhood ALL, two CCRF-CEM-derived Vinca alkaloid resistant cell lines, VCR R (vincristine) and VLB100 (vinblastine), were examd.  Decreased expression of class III β-tubulin was detected in both VCR R and VLB100 cells.  VCR R cells and to a lesser extent VLB100 cells expressed increased levels of MAP4 protein.  Increased microtubule stability was obsd. in these VCR R cells as identified by the high levels of polymd. tubulin (45.6±2.6%; P < 0.005) compared with CEM and VLB100 cells (24.7±3.3% and 24.7±2.5%, resp.).  Expression was assocd. with a single MAP4 isoform in the polymd. microtubule fraction in CEM and VCR cells.  In contrast, VLB100 cells expressed a lower mol. wt. isoform in the polymd. fraction.  Two-dimensional-PAGE and immunoblotting revealed marked posttranslational changes in class I β-tubulin in VCR R cells not evident in CEM cells.  Sequencing of the β-tubulin (HM40) gene identified a point mutation in VCR R cells in nucleotide 843 (CTC→ATC; Leu240→Ile) that was not present in CEM or VLB100 cells.  This mutation resides in a region of β-tubulin that lies in close proximity to the α/β tubulin interface.  Multiple alterations related to normal microtubule function were identified in ALL cells selected for resistance to Vinca alkaloids, and these alterations may provide important insight into mechanisms mediating resistance to Vinca alkaloids.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGry3hyzM6Okt7Vg90H21EOLACvtfcHk0lj5iOZ6Z_65kQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXlvVCgtbY%253D&md5=e1002656ad0a75785f3fb81ed05c8e27</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKavallaris%26aufirst%3DM.%26aulast%3DTait%26aufirst%3DA.%2BS.%26aulast%3DWalsh%26aufirst%3DB.%2BJ.%26aulast%3DHe%26aufirst%3DL.%2BF.%26aulast%3DHorwitz%26aufirst%3DS.%2BB.%26aulast%3DNorris%26aufirst%3DM.%2BD.%26aulast%3DHaber%26aufirst%3DM.%26atitle%3DMultiple%2520microtubule%2520alterations%2520are%2520associated%2520with%2520Vinca%2520alkaloid%2520resistance%2520in%2520human%2520leukemia%2520cells%26jtitle%3DCancer%2520Res.%26date%3D2001%26volume%3D61%26spage%3D5803%26epage%3D5809" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zagouri, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sergentanis, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chrysikos, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bamias, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dimopoulos, A.-M.</span></span> <span> </span><span class="NLM_article-title">Epothilones in epithelial ovarian, fallopian tube, or primary peritoneal cancer: a systematic review</span>. <i>OncoTargets Ther.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">2187</span>– <span class="NLM_lpage">2198</span>, <span class="refDoi"> DOI: 10.2147/ott.s77342</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=10.2147%2Fott.s77342" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=26316786" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsFegt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2015&pages=2187-2198&author=F.+Zagouriauthor=T.+Sergentanisauthor=D.+Chrysikosauthor=A.+Bamiasauthor=A.-M.+Dimopoulos&title=Epothilones+in+epithelial+ovarian%2C+fallopian+tube%2C+or+primary+peritoneal+cancer%3A+a+systematic+review&doi=10.2147%2Fott.s77342"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Epothilones in epithelial ovarian, fallopian tube, or primary peritoneal cancer: a systematic review</span></div><div class="casAuthors">Zagouri, Flora; Sergentanis, Theodoros N.; Chrysikos, Dimosthenis; Dimopoulos, Meletios-Athanasios; Bamias, Aristotle</div><div class="citationInfo"><span class="NLM_cas:title">OncoTargets and Therapy</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">2187-2198</span>CODEN:
                <span class="NLM_cas:coden">OTNHAZ</span>;
        ISSN:<span class="NLM_cas:issn">1178-6930</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">Ovarian cancer is the most lethal gynecol. malignancy; consequently, there is a need for effective therapies.  Epothilones are microtubule-stabilizing agents that inhibit cell growth.  Currently, patupilone and its four synthetic derivs. ixabepilone, BMS-310705, sagopilone, 20-desmethyl-20-methylsulfanyl epothilone B and epothilone D, as well as its deriv. KOS-1584, are under clin. evaluation.  This is the first systematic review conducted in accordance with the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines that synthesizes all available data emerging from trials and evaluates the efficacy and safety of epothilones in epithelial ovarian, primary fallopian tube, and primary peritoneal cancer.  Despite the fact that epothilones have proven active in taxane-resistant settings in preclin. models, it is not yet clear from Phase II/III studies reviewed here that their clin. activity is superior to that of taxanes.  Nevertheless, responses to epothilones have been obsd. in platinum-refractory/resistant ovarian cancer patients.  Moreover, despite the shared mechanism of action of epothilones, their clin. profile seems clearly different, with diarrhea being the most common dose-limiting toxicity encountered with patupilone, whereas neutropenia and sensory neuropathy are the most common toxic effects obsd. with the other epothilones.  In any case, randomized trials comparing epothilones with std. treatments seem warranted to define further the role of these agents, whereas biomarker anal. might further optimize patient selection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJ8yVQvMB3RrVg90H21EOLACvtfcHk0liiovOs3BplZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsFegt7s%253D&md5=2e298515baae3a522280b6adcdedbbbb</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.2147%2Fott.s77342&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252Fott.s77342%26sid%3Dliteratum%253Aachs%26aulast%3DZagouri%26aufirst%3DF.%26aulast%3DSergentanis%26aufirst%3DT.%26aulast%3DChrysikos%26aufirst%3DD.%26aulast%3DBamias%26aufirst%3DA.%26aulast%3DDimopoulos%26aufirst%3DA.-M.%26atitle%3DEpothilones%2520in%2520epithelial%2520ovarian%252C%2520fallopian%2520tube%252C%2520or%2520primary%2520peritoneal%2520cancer%253A%2520a%2520systematic%2520review%26jtitle%3DOncoTargets%2520Ther.%26date%3D2015%26volume%3D8%26spage%3D2187%26epage%3D2198%26doi%3D10.2147%2Fott.s77342" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Trendowski, M.</span></span> <span> </span><span class="NLM_article-title">Recent advances in the development of antineoplastic agents derived from natural products</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>75</i></span>,  <span class="NLM_fpage">1993</span>– <span class="NLM_lpage">2016</span>, <span class="refDoi"> DOI: 10.1007/s40265-015-0489-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=10.1007%2Fs40265-015-0489-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=26501980" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslyksr%252FE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2015&pages=1993-2016&author=M.+Trendowski&title=Recent+advances+in+the+development+of+antineoplastic+agents+derived+from+natural+products&doi=10.1007%2Fs40265-015-0489-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Recent Advances in the Development of Antineoplastic Agents Derived from Natural Products</span></div><div class="casAuthors">Trendowski, Matthew</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">75</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">1993-2016</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Through years of evolutionary selection pressures, organisms have developed potent toxins that coincidentally have marked antineoplastic activity.  These natural products have been vital for the development of multiagent treatment regimens currently employed in cancer chemotherapy, and are used in the treatment of a variety of malignancies.  Therefore, this review catalogs recent advances in natural product-based drug discovery via the examn. of mechanisms of action and available clin. data to highlight the utility of these novel compds. in the burgeoning age of precision medicine.  The review also highlights the recent development of antibody-drug conjugates and other immunotoxins, which are capable of delivering highly cytotoxic agents previously deemed too toxic to elicit therapeutic benefit preferentially to neoplastic cells.  Finally, the review examines natural products not currently used in the clinic that have novel mechanisms of action, and may serve to supplement current chemotherapeutic protocols.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHU2L2IX0DgbVg90H21EOLACvtfcHk0liiovOs3BplZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslyksr%252FE&md5=3c40bf11412ed0e627c966246fd54ee1</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1007%2Fs40265-015-0489-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-015-0489-4%26sid%3Dliteratum%253Aachs%26aulast%3DTrendowski%26aufirst%3DM.%26atitle%3DRecent%2520advances%2520in%2520the%2520development%2520of%2520antineoplastic%2520agents%2520derived%2520from%2520natural%2520products%26jtitle%3DDrugs%26date%3D2015%26volume%3D75%26spage%3D1993%26epage%3D2016%26doi%3D10.1007%2Fs40265-015-0489-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Aseyev, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ribeiro, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cardoso, F.</span></span> <span> </span><span class="NLM_article-title">Review on the clinical use of eribulin mesylate for the treatment of breast cancer</span>. <i>Expert Opin. Pharmacother.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">589</span>– <span class="NLM_lpage">600</span>, <span class="refDoi"> DOI: 10.1517/14656566.2016.1146683</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=10.1517%2F14656566.2016.1146683" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=26809667" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=1%3ACAS%3A528%3ADC%252BC28Xjt1OgtLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2016&pages=589-600&author=O.+Aseyevauthor=J.+M.+Ribeiroauthor=F.+Cardoso&title=Review+on+the+clinical+use+of+eribulin+mesylate+for+the+treatment+of+breast+cancer&doi=10.1517%2F14656566.2016.1146683"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Review on the clinical use of eribulin mesylate for the treatment of breast cancer</span></div><div class="casAuthors">Aseyev, Olexiy; Ribeiro, Joana M.; Cardoso, Fatima</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Pharmacotherapy</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">589-600</span>CODEN:
                <span class="NLM_cas:coden">EOPHF7</span>;
        ISSN:<span class="NLM_cas:issn">1465-6566</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Breast cancer is the second leading cause of cancer death among women and the median survival of metastatic breast cancer (MBC) has remained, for many decades, at two to three years after diagnosis.  Eribulin mesylate is a nontaxane inhibitor of microtubule dynamics and the only cytotoxic agent in the last decade to improve overall survival in heavily pretreated patients with MBC.  Eribulin was approved for the treatment of MBC in 2010 by the FDA in patients that received at least two prior chemotherapy regimens and as second-line treatment in 2011 by EMA.  In both cases prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting.  This manuscript reviews the current available data on the use of this important cytotoxic agent including its pharmacol., pharmacokinetics, clin. efficacy, safety, and potential economic factors as well as ongoing clin. trials and main areas of research.  Eribulin mesylate is a novel microtubule dynamics inhibitor compd. important for the management of MBC and can be used for the treatment of patients who have previously received one/two chemotherapeutic regimens for metastatic disease and whose prior therapy included an anthracycline and a taxane.  It's toxicity profile is acceptable and presents several favorable features namely a low probability of drug-drug interactions in the clin. setting, easy administration as bolus, low hypersensitivity chances and full tolerability in renal dysfunction patients.  Eribulin is currently being evaluated as first-line treatment for MBC, in the adjuvant/neoadjuvant setting alone and in combination with a variety of agents, particularly biol. treatments.  Future research is needed to optimize the role of eribulin in the treatment of MBC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp4L7JToNF0VbVg90H21EOLACvtfcHk0liiovOs3BplZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xjt1OgtLo%253D&md5=2c0f8be3792e858e091d2088b404fae3</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1517%2F14656566.2016.1146683&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14656566.2016.1146683%26sid%3Dliteratum%253Aachs%26aulast%3DAseyev%26aufirst%3DO.%26aulast%3DRibeiro%26aufirst%3DJ.%2BM.%26aulast%3DCardoso%26aufirst%3DF.%26atitle%3DReview%2520on%2520the%2520clinical%2520use%2520of%2520eribulin%2520mesylate%2520for%2520the%2520treatment%2520of%2520breast%2520cancer%26jtitle%3DExpert%2520Opin.%2520Pharmacother.%26date%3D2016%26volume%3D17%26spage%3D589%26epage%3D600%26doi%3D10.1517%2F14656566.2016.1146683" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ravelli, R. B. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gigant, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curmi, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jourdain, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lachkar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sobel, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knossow, M.</span></span> <span> </span><span class="NLM_article-title">Insight into tubulin regulation from a complex with colchicine and a stathmin-like domain</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>428</i></span>,  <span class="NLM_fpage">198</span>– <span class="NLM_lpage">202</span>, <span class="refDoi"> DOI: 10.1038/nature02393</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=10.1038%2Fnature02393" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=15014504" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhvFCls7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=428&publication_year=2004&pages=198-202&author=R.+B.+G.+Ravelliauthor=B.+Gigantauthor=P.+A.+Curmiauthor=I.+Jourdainauthor=S.+Lachkarauthor=A.+Sobelauthor=M.+Knossow&title=Insight+into+tubulin+regulation+from+a+complex+with+colchicine+and+a+stathmin-like+domain&doi=10.1038%2Fnature02393"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Insight into tubulin regulation from a complex with colchicine and a stathmin-like domain</span></div><div class="casAuthors">Ravelli, Raimond B. G.; Gigant, Benoit; Curmi, Patrick A.; Jourdain, Isabelle; Lachkar, Sylvie; Sobel, Andre; Knossow, Marcel</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">428</span>
        (<span class="NLM_cas:issue">6979</span>),
    <span class="NLM_cas:pages">198-202</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Microtubules are cytoskeletal polymers of tubulin involved in many cellular functions.  Their dynamic instability is controlled by numerous compds. and proteins, including colchicine and stathmin family proteins.  The way in which microtubule instability is regulated at the mol. level has remained elusive, mainly because of the lack of appropriate structural data.  Here, the authors present the structure, at 3.5 Å resoln., of tubulin in complex with colchicine (I) and with the stathmin-like domain (SLD) of RB3.  It showed the interaction of RB3-SLD with 2 tubulin heterodimers in a curved complex capped by the SLD N-terminal domain, which prevented the incorporation of the complexed tubulin into microtubules.  A comparison with the structure of tubulin in protofilaments showed changes in the subunits of tubulin as it switched from its straight conformation to a curved one.  These changes correlated with the loss of lateral contacts and provided a rationale for the rapid microtubule depolymn. characteristic of dynamic instability.  Moreover, the tubulin-I complex shed light on the mechanism of I activity; it was shown that I binds at a location where it prevents curved tubulin from adopting a straight structure, which inhibits assembly.  Thus, the results establish a relation between the onset and speed of microtubule disassembly and the changes in tubulin subunits when tubulin switches from its straight to its curved conformation.  The results further provide a mol. description of the interaction of RB3-SLD and I with tubulin, and may be useful for the development of novel therapeutic I analogs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqx2vePjtf347Vg90H21EOLACvtfcHk0liiovOs3BplZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhvFCls7g%253D&md5=9fbb1edfc64239638a3c2eac879bffe9</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1038%2Fnature02393&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature02393%26sid%3Dliteratum%253Aachs%26aulast%3DRavelli%26aufirst%3DR.%2BB.%2BG.%26aulast%3DGigant%26aufirst%3DB.%26aulast%3DCurmi%26aufirst%3DP.%2BA.%26aulast%3DJourdain%26aufirst%3DI.%26aulast%3DLachkar%26aufirst%3DS.%26aulast%3DSobel%26aufirst%3DA.%26aulast%3DKnossow%26aufirst%3DM.%26atitle%3DInsight%2520into%2520tubulin%2520regulation%2520from%2520a%2520complex%2520with%2520colchicine%2520and%2520a%2520stathmin-like%2520domain%26jtitle%3DNature%26date%3D2004%26volume%3D428%26spage%3D198%26epage%3D202%26doi%3D10.1038%2Fnature02393" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Finkelstein, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aks, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hutson, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Juurlink, D. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubnov-Raz, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollak, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koren, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bentur, Y.</span></span> <span> </span><span class="NLM_article-title">Colchicine poisoning: the dark side of an ancient drug</span>. <i>Clin. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">407</span>– <span class="NLM_lpage">414</span>, <span class="refDoi"> DOI: 10.3109/15563650.2010.495348</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=10.3109%2F15563650.2010.495348" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=1%3ACAS%3A528%3ADC%252BC3cXot1anurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2010&pages=407-414&author=Y.+Finkelsteinauthor=S.+E.+Aksauthor=J.+R.+Hutsonauthor=D.+N.+Juurlinkauthor=P.+Nguyenauthor=G.+Dubnov-Razauthor=U.+Pollakauthor=G.+Korenauthor=Y.+Bentur&title=Colchicine+poisoning%3A+the+dark+side+of+an+ancient+drug&doi=10.3109%2F15563650.2010.495348"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Colchicine poisoning: The dark side of an ancient drug</span></div><div class="casAuthors">Finkelstein, Yaron; Aks, Steven E.; Hutson, Janine R.; Juurlink, David N.; Nguyen, Patricia; Dubnov-Raz, Gal; Pollak, Uri; Koren, Gideon; Bentur, Yedidia</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Toxicology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">407-414</span>CODEN:
                <span class="NLM_cas:coden">CTPPA5</span>;
        ISSN:<span class="NLM_cas:issn">1556-3650</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: Colchicine is used mainly for the treatment and prevention of gout and for familial Mediterranean fever (FMF).  It has a narrow therapeutic index, with no clear-cut distinction between nontoxic, toxic, and LDs, causing substantial confusion among clinicians.  Although colchicine poisoning is sometimes intentional, unintentional toxicity is common and often assocd. with a poor outcome.  Methods: We performed a systematic review by searching OVID MEDLINE between 1966 and Jan. 2010.  The search strategy included "colchicine" and "poisoning" or "overdose" or "toxicity" or "intoxication." Toxicokinetics: Colchicine is readily absorbed after oral administration, but undergoes extensive first-pass metab.  It is widely distributed and binds to intracellular elements.  Colchicine is primarily metabolized by the liver, undergoes significant enterohepatic re-circulation, and is also excreted by the kidneys.  Therapeutic and toxic doses: The usual adult oral doses for FMF is 1.2-2.4 mg/day; in acute gout 1.2 mg/day and for gout prophylaxis 0.5-0.6 mg/day three to four times a week.  High fatality rate was reported after acute ingestions exceeding 0.5 mg/kg.  The lowest reported LDs of oral colchicine are 7-26 mg.  Drug interactions: CYP 3A4 and P-glycoprotein inhibitors, such as clarithromycin, erythromycin, ketoconazole, ciclosporin, and natural grapefruit juice can increase colchicine concns.  Co-administration with statins may increase the risk of myopathy.  Mechanisms of toxicity: Colchicine's toxicity is an extension of its mechanism of action - binding to tubulin and disrupting the microtubular network.  As a result, affected cells experience impaired protein assembly, decreased endocytosis and exocytosis, altered cell morphol., decreased cellular motility, arrest of mitosis, and interrupted cardiac myocyte conduction and contractility.  The culmination of these mechanisms leads to multi-organ dysfunction and failure.  Reproductive toxicol. and lactation: Colchicine was not shown to adversely affect reproductive potential in males or females.  It crosses the placenta but there is no evidence of fetal toxicity.  Colchicine is excreted into breast milk and considered compatible with lactation.  Clin. features: Colchicine poisoning presents in three sequential and usually overlapping phases, 1; 10-24 h after ingestion - gastrointestinal phase mimicking gastroenteritis may be absent after i.v. administration, 2; 24 h to 7 days after ingestion - multi-organ dysfunction.  Death results from rapidly progressive multi-organ failure and sepsis.  Delayed presentation, pre-existing renal or liver impairment are assocd. with poor prognosis, 3; Recovery typically occurs within a few weeks of ingestion, and is generally a complete recovery barring complications of the acute illness.  Diagnosis: History of ingestion of tablets, parenteral administration, or consumption of colchicine-contg. plants suggest the diagnosis.  Colchicine poisoning should be suspected in patients with access to the drug and the typical toxidrome (gastroenteritis, hypotension, lactic acidosis, and prerenal azotemia).  Management: Timely gastrointestinal decontamination should be considered with activated charcoal, and very large, recent (<60 min) ingestions may warrant gastric lavage.  Supportive treatments including administration of granulocyte colony-stimulating factor are the mainstay of treatment.  Although a specific exptl. treatment (Fab fragment antibodies) for colchicine poisoning has been used, it is not com. available.  Conclusion: Although colchicine poisoning is relatively uncommon, it is imperative to recognize its features as it is assocd. with a high mortality rate when missed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqtFb69vkDP27Vg90H21EOLACvtfcHk0ljO-mC0o3gbsQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXot1anurk%253D&md5=14f982b390cf79e506369eb7b97e6342</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.3109%2F15563650.2010.495348&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F15563650.2010.495348%26sid%3Dliteratum%253Aachs%26aulast%3DFinkelstein%26aufirst%3DY.%26aulast%3DAks%26aufirst%3DS.%2BE.%26aulast%3DHutson%26aufirst%3DJ.%2BR.%26aulast%3DJuurlink%26aufirst%3DD.%2BN.%26aulast%3DNguyen%26aufirst%3DP.%26aulast%3DDubnov-Raz%26aufirst%3DG.%26aulast%3DPollak%26aufirst%3DU.%26aulast%3DKoren%26aufirst%3DG.%26aulast%3DBentur%26aufirst%3DY.%26atitle%3DColchicine%2520poisoning%253A%2520the%2520dark%2520side%2520of%2520an%2520ancient%2520drug%26jtitle%3DClin.%2520Toxicol.%26date%3D2010%26volume%3D48%26spage%3D407%26epage%3D414%26doi%3D10.3109%2F15563650.2010.495348" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Borisy, G. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, E. W.</span></span> <span> </span><span class="NLM_article-title">The mechanism of action of colchicine. Binding of colchincine-3H to cellular protein</span>. <i>J. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">1967</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">525</span>– <span class="NLM_lpage">533</span>, <span class="refDoi"> DOI: 10.1083/jcb.34.2.525</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=10.1083%2Fjcb.34.2.525" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=6068183" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=1%3ACAS%3A528%3ADyaF2sXks1aksr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=1967&pages=525-533&author=G.+G.+Borisyauthor=E.+W.+Taylor&title=The+mechanism+of+action+of+colchicine.+Binding+of+colchincine-3H+to+cellular+protein&doi=10.1083%2Fjcb.34.2.525"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">The mechanism of action of colchicine.  Binding of colchicine-3H to cellular protein</span></div><div class="casAuthors">Borisy, G. G.; Taylor, Edwin William</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cell Biology</span>
        (<span class="NLM_cas:date">1967</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">525-33</span>CODEN:
                <span class="NLM_cas:coden">JCLBA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9525</span>.
    </div><div class="casAbstract">The majority of the colchicine-3H bound by tissue culture cells (KB or HeLa) was present as a noncovalent complex with a macromol. which appears in the sol. fraction after homogenization.  Similar binding was demonstrated in vitro and was confined to a component of the sol. fraction.  The binding-equil. const. and the kinetic consts. were essentially the same in vivo and in vitro.  Bound radioactivity was reisolated and shown to be present in a mol. with the same chromatographic behavior and specific antimitotic activity as colchicine.  In vitro assay of binding activity of a variety of cells and tissues showed a correlation with the presence of microtubules.  High binding activity was given by dividing cells, mitotic app., cilia, sperm tails, and brain tissue.  Binding to exts. of slime mold or to purified muscle proteins was very low or undetectable.  The binding site had a sedimentation const. of 6S and it is suggested that the protein is a subunit of microtubules.  34 references.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdLQFA3pJhKbVg90H21EOLACvtfcHk0ljO-mC0o3gbsQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaF2sXks1aksr0%253D&md5=ca115da1d843e43ed8fa3108fba389ab</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1083%2Fjcb.34.2.525&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1083%252Fjcb.34.2.525%26sid%3Dliteratum%253Aachs%26aulast%3DBorisy%26aufirst%3DG.%2BG.%26aulast%3DTaylor%26aufirst%3DE.%2BW.%26atitle%3DThe%2520mechanism%2520of%2520action%2520of%2520colchicine.%2520Binding%2520of%2520colchincine-3H%2520to%2520cellular%2520protein%26jtitle%3DJ.%2520Cell%2520Biol.%26date%3D1967%26volume%3D34%26spage%3D525%26epage%3D533%26doi%3D10.1083%2Fjcb.34.2.525" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kanthou, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tozer, G. M.</span></span> <span> </span><span class="NLM_article-title">Microtubule depolymerizing vascular disrupting agents: novel therapeutic agents for oncology and other pathologies</span>. <i>Int. J. Exp. Pathol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>90</i></span>,  <span class="NLM_fpage">284</span>– <span class="NLM_lpage">294</span>, <span class="refDoi"> DOI: 10.1111/j.1365-2613.2009.00651.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=10.1111%2Fj.1365-2613.2009.00651.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=19563611" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=1%3ACAS%3A528%3ADC%252BD1MXotV2isr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=90&publication_year=2009&pages=284-294&author=C.+Kanthouauthor=G.+M.+Tozer&title=Microtubule+depolymerizing+vascular+disrupting+agents%3A+novel+therapeutic+agents+for+oncology+and+other+pathologies&doi=10.1111%2Fj.1365-2613.2009.00651.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Microtubule depolymerizing vascular disrupting agents: novel therapeutic agents for oncology and other pathologies</span></div><div class="casAuthors">Kanthou, Chryso; Tozer, Gillian M.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Experimental Pathology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">90</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">284-294</span>CODEN:
                <span class="NLM_cas:coden">IJEPEI</span>;
        ISSN:<span class="NLM_cas:issn">0959-9673</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Vascular disrupting agents (VDAs) are a relatively new group of "vascular targeting" agents that exhibit selective activity against established tumor vascular networks, causing severe interruption of tumor blood flow and necrosis to the tumor mass.  Microtubule depolymg. agents form by far the largest group of small mol. wt. VDAs many of which, including lead compd. disodium combretastatin A-4 3-O-phosphate (CA-4-P), are under clin. development for cancer.  Although distinct from the angiogenesis inhibitors, VDAs can also interfere with angiogenesis and therefore constitute a potential group of novel drugs for the treatment of pathol. conditions characterized by excessive angiogenesis, in addn. to cancer.  The endothelial cytoskeleton is the primary cellular target of this family of drugs, and some progress in understanding the mol. and signalling mechanisms assocd. with their endothelial disrupting activity has been made in the last few years.  Susceptibility of tumor vessels to VDA damage is ascribed to their immature pericyte-defective nature, although the exact mol. mechanisms involved have not been clearly defined.  Despite causing profound damage to tumors, VDAs fail to halt tumor growth unless used together with conventional treatments.  This failure is attributed to resistance mechanisms, primarily assocd. with cells that remain viable within the tumor rim, and enhanced angiogenesis.  The focus is now to understand mechanisms of susceptibility and resistance to identify novel mol. targets and develop strategies that are more effective.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmpN7il32X0rVg90H21EOLACvtfcHk0ljO-mC0o3gbsQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXotV2isr4%253D&md5=42b728813bf9c53bbc6d32d262639d15</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2613.2009.00651.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2613.2009.00651.x%26sid%3Dliteratum%253Aachs%26aulast%3DKanthou%26aufirst%3DC.%26aulast%3DTozer%26aufirst%3DG.%2BM.%26atitle%3DMicrotubule%2520depolymerizing%2520vascular%2520disrupting%2520agents%253A%2520novel%2520therapeutic%2520agents%2520for%2520oncology%2520and%2520other%2520pathologies%26jtitle%3DInt.%2520J.%2520Exp.%2520Pathol.%26date%3D2009%26volume%3D90%26spage%3D284%26epage%3D294%26doi%3D10.1111%2Fj.1365-2613.2009.00651.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stengel, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leese, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Potter, B. V. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reed, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Purohit, A.</span></span> <span> </span><span class="NLM_article-title">Class III β-tubulin expression and in vitro resistance to microtubule targeting agents</span>. <i>Brit. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>102</i></span>,  <span class="NLM_fpage">316</span>– <span class="NLM_lpage">324</span>, <span class="refDoi"> DOI: 10.1038/sj.bjc.6605489</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=10.1038%2Fsj.bjc.6605489" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=20029418" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=1%3ACAS%3A528%3ADC%252BC3cXntlKisQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2010&pages=316-324&author=C.+Stengelauthor=S.+P.+Newmanauthor=M.+P.+Leeseauthor=B.+V.+L.+Potterauthor=M.+J.+Reedauthor=A.+Purohit&title=Class+III+%CE%B2-tubulin+expression+and+in+vitro+resistance+to+microtubule+targeting+agents&doi=10.1038%2Fsj.bjc.6605489"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Class III β-tubulin expression and in vitro resistance to microtubule targeting agents</span></div><div class="casAuthors">Stengel, C.; Newman, S. P.; Leese, M. P.; Potter, B. V. L.; Reed, M. J.; Purohit, A.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">102</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">316-324</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Background: Class III β-tubulin overexpression is a marker of resistance to microtubule disruptors in vitro, in vivo and in the clinic for many cancers, including breast cancer.  The aims of this study were to develop a new model of class III β-tubulin expression, avoiding the toxicity assocd. with chronic overexpression of class III β-tubulin, and study the efficacy of a panel of clin. and pre-clin. drugs in this model.  Methods: MCF-7 (ER+ve) and MDA-MB-231 (ER-ve) were either transfected with pALTER-TUBB3 or siRNA-tubb3 and 24 h later exposed to test compds. for a further 96 h for proliferation studies.  RT-PCR and immunoblotting were used to monitor the changes in class III β-tubulin mRNA and protein expression.  Results: The model allowed for subtle changes in class III β-tubulin expression to be achieved, which had no direct effect on the viability of the cells.  Class III β-tubulin overexpression conferred resistance to paclitaxel and vinorelbine, whereas downregulation of class III β-tubulin rendered cells more sensitive to these two drugs.  The efficacy of the colchicine-site binding agents, 2-MeOE2, colchicine, STX140, ENMD1198 and STX243 was unaffected by the changes in class III β-tubulin expression.  Conclusion: These data indicate that the effect of class III β-tubulin overexpression may depend on where the drug's binding site is located on the tubulin.  Therefore, this study highlights for the first time the potential key role of targeting the colchicine-binding site, to develop new treatment modalities for taxane-refractory breast cancer.  British Journal of Cancer (2010) 102, 316-324; doi:10.1038/sj.bjc.6605489 www.bjcancer.com Published online 22 Dec. 2009.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2hulEpiTJA7Vg90H21EOLACvtfcHk0liL6TtZMdIVLA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXntlKisQ%253D%253D&md5=02d84566d0f23c1781ba74a1add4fed2</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjc.6605489&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjc.6605489%26sid%3Dliteratum%253Aachs%26aulast%3DStengel%26aufirst%3DC.%26aulast%3DNewman%26aufirst%3DS.%2BP.%26aulast%3DLeese%26aufirst%3DM.%2BP.%26aulast%3DPotter%26aufirst%3DB.%2BV.%2BL.%26aulast%3DReed%26aufirst%3DM.%2BJ.%26aulast%3DPurohit%26aufirst%3DA.%26atitle%3DClass%2520III%2520%25CE%25B2-tubulin%2520expression%2520and%2520in%2520vitro%2520resistance%2520to%2520microtubule%2520targeting%2520agents%26jtitle%3DBrit.%2520J.%2520Cancer%26date%3D2010%26volume%3D102%26spage%3D316%26epage%3D324%26doi%3D10.1038%2Fsj.bjc.6605489" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span> <span> </span><span class="NLM_article-title">Recent advances in heterocyclic tubulin inhibitors targeting the colchicine binding site</span>. <i>Anti-Cancer Agents Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">1325</span>– <span class="NLM_lpage">1338</span>, <span class="refDoi"> DOI: 10.2174/1871520616666160219161921</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=10.2174%2F1871520616666160219161921" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=26899186" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVOhsrfE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2016&pages=1325-1338&author=X.+Wuauthor=Q.+Wangauthor=W.+Li&title=Recent+advances+in+heterocyclic+tubulin+inhibitors+targeting+the+colchicine+binding+site&doi=10.2174%2F1871520616666160219161921"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Recent Advances in Heterocyclic Tubulin Inhibitors Targeting the Colchicine Binding Site</span></div><div class="casAuthors">Wu, Xiaoxin; Wang, Qinghui; Li, Wei</div><div class="citationInfo"><span class="NLM_cas:title">Anti-Cancer Agents in Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1325-1338</span>CODEN:
                <span class="NLM_cas:coden">AAMCE4</span>;
        ISSN:<span class="NLM_cas:issn">1871-5206</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">Microtubules are involved in many crit. cellular processes including cell division, cell shape maintenance, vesicle transportation and motility regulation.  Disruption of tubulin dynamics is a well-validated cancer drug target with several FDA approved, highly efficacious tubulin inhibitors targeting the taxane or the vinca binding sites.  Despite the tremendous successes for these clin. tubulin inhibitors, their limitations are also apparent, particularly in the development of transporter mediated drug resistance.  While currently there are no FDA approved inhibitors targeting the colchicine binding site in tubulin, extensive preclin. studies have suggested that colchicine binding site inhibitors (CBSIs) have significantly less susceptibility to transporter medicated drug resistance.  The presence of one or more heterocyclic moieties is often crit. for the antiproliferative activities for most of these CBSIs.  This article aims to review the structures and antiproliferative activities of most recently developed heterocyclic CBSIs from 2013 to present.  We focus this review on compds. that are designed based on the CA-4, chalcone and PTOX scaffolds which are well established to interact with the colchicine binding site in tubulin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpsh10kAoyRzLVg90H21EOLACvtfcHk0liL6TtZMdIVLA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVOhsrfE&md5=7959990391bd432fa2a417cf1309aec4</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.2174%2F1871520616666160219161921&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1871520616666160219161921%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DLi%26aufirst%3DW.%26atitle%3DRecent%2520advances%2520in%2520heterocyclic%2520tubulin%2520inhibitors%2520targeting%2520the%2520colchicine%2520binding%2520site%26jtitle%3DAnti-Cancer%2520Agents%2520Med.%2520Chem.%26date%3D2016%26volume%3D16%26spage%3D1325%26epage%3D1338%26doi%3D10.2174%2F1871520616666160219161921" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalton, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, D. D.</span></span> <span> </span><span class="NLM_article-title">Discovery of 4-Substituted Methoxybenzoyl-aryl-thiazole as Novel Anticancer Agents: Synthesis, Biological Evaluation, and Structure–Activity Relationships</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">1701</span>– <span class="NLM_lpage">1711</span>, <span class="refDoi"> DOI: 10.1021/jm801449a</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm801449a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=1%3ACAS%3A528%3ADC%252BD1MXisVCis7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=1701-1711&author=Y.+Luauthor=C.-M.+Liauthor=Z.+Wangauthor=C.+R.+Rossauthor=J.+Chenauthor=J.+T.+Daltonauthor=W.+Liauthor=D.+D.+Miller&title=Discovery+of+4-Substituted+Methoxybenzoyl-aryl-thiazole+as+Novel+Anticancer+Agents%3A+Synthesis%2C+Biological+Evaluation%2C+and+Structure%E2%80%93Activity+Relationships&doi=10.1021%2Fjm801449a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 4-Substituted Methoxybenzoyl-aryl-thiazole as Novel Anticancer Agents: Synthesis, Biological Evaluation, and Structure-Activity Relationships</span></div><div class="casAuthors">Lu, Yan; Li, Chien-Ming; Wang, Zhao; Ross, Charles R., II; Chen, Jianjun; Dalton, James T.; Li, Wei; Miller, Duane D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1701-1711</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of 4-substituted methoxybenzoyl-aryl-thiazoles (SMART) have been discovered and synthesized as a result of structural modifications of the lead compd. 2-arylthiazolidine-4-carboxylic acid amides (ATCAA).  The antiproliferative activity of the SMART agents against melanoma and prostate cancer cells was improved from μM to low nM range compared with the ATCAA series.  The structure-activity relationship was discussed from modifications of "A", "B", and "C" rings and the linker.  Preliminary mechanism of action studies indicated that these compds. exert their anticancer activity through inhibition of tubulin polymn.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQnsk5EK9mVLVg90H21EOLACvtfcHk0liL6TtZMdIVLA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXisVCis7g%253D&md5=68261f1589c55ffca6f44c4410c91c9c</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1021%2Fjm801449a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm801449a%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DC.-M.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DRoss%26aufirst%3DC.%2BR.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DDalton%26aufirst%3DJ.%2BT.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DMiller%26aufirst%3DD.%2BD.%26atitle%3DDiscovery%2520of%25204-Substituted%2520Methoxybenzoyl-aryl-thiazole%2520as%2520Novel%2520Anticancer%2520Agents%253A%2520Synthesis%252C%2520Biological%2520Evaluation%252C%2520and%2520Structure%25E2%2580%2593Activity%2520Relationships%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D1701%26epage%3D1711%26doi%3D10.1021%2Fjm801449a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaddady, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meibohm, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalton, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span> <span> </span><span class="NLM_article-title">Discovery of novel 2-aryl-4-benzoyl-imidazoles targeting the colchicines binding site in tubulin as potential anticancer agents</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">7414</span>– <span class="NLM_lpage">7427</span>, <span class="refDoi"> DOI: 10.1021/jm100884b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm100884b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht1eku73O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=7414-7427&author=J.+Chenauthor=Z.+Wangauthor=C.-M.+Liauthor=Y.+Luauthor=P.+K.+Vaddadyauthor=B.+Meibohmauthor=J.+T.+Daltonauthor=D.+D.+Millerauthor=W.+Li&title=Discovery+of+novel+2-aryl-4-benzoyl-imidazoles+targeting+the+colchicines+binding+site+in+tubulin+as+potential+anticancer+agents&doi=10.1021%2Fjm100884b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of novel 2-aryl-4-benzoyl-imidazoles targeting the colchicines binding site in tubulin as potential anticancer agents</span></div><div class="casAuthors">Chen, Jianjun; Wang, Zhao; Li, Chien-Ming; Lu, Yan; Vaddady, Pavan K.; Meibohm, Bernd; Dalton, James T.; Miller, Duane D.; Li, Wei</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">7414-7427</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of 2-aryl-4-benzoyl-imidazoles (ABI) was synthesized as a result of structural modifications based on the previous set of 2-aryl-imidazole-4-carboxylic amide (AICA) derivs. and 4-substituted methoxylbenzoyl-aryl-thiazoles (SMART).  The av. IC50 of the most active compd. I ( R = Me) was 15.7 nM.  ABI analogs have substantially improved aq. soly. (48.9 μg/mL for I ( R = NMe2) vs 0.909 μg/mL for SMART-1, 0.137 μg/mL for paclitaxel, and 1.04 μg/mL for combretastatin A4).  Mechanism of action studies indicate that the anticancer activity of ABI analogs is through inhibition of tubulin polymn. by interacting with the colchicine binding site.  Unlike paclitaxel and colchicine, the ABI compds. were equally potent against multidrug resistant cancer cells and the sensitive parental melanoma cancer cells.  In vivo results indicated that II was more effective than DTIC in inhibiting melanoma xenograph tumor growth.  Our results suggest that the novel ABI compds. may be developed to effectively treat drug-resistant tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq0en8R0EjqRrVg90H21EOLACvtfcHk0ljfQFFga8gg-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht1eku73O&md5=7eb4d70e1e2bf16dce361a6308ea6f93</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1021%2Fjm100884b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100884b%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DLi%26aufirst%3DC.-M.%26aulast%3DLu%26aufirst%3DY.%26aulast%3DVaddady%26aufirst%3DP.%2BK.%26aulast%3DMeibohm%26aufirst%3DB.%26aulast%3DDalton%26aufirst%3DJ.%2BT.%26aulast%3DMiller%26aufirst%3DD.%2BD.%26aulast%3DLi%26aufirst%3DW.%26atitle%3DDiscovery%2520of%2520novel%25202-aryl-4-benzoyl-imidazoles%2520targeting%2520the%2520colchicines%2520binding%2520site%2520in%2520tubulin%2520as%2520potential%2520anticancer%2520agents%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D7414%26epage%3D7427%26doi%3D10.1021%2Fjm100884b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalton, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span> <span> </span><span class="NLM_article-title">Synthesis and antiproliferative activity of novel 2-aryl-4-benzoyl-imidazole derivatives targeting tubulin polymerization</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">4782</span>– <span class="NLM_lpage">4795</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2011.06.084</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=10.1016%2Fj.bmc.2011.06.084" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=21775150" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=1%3ACAS%3A528%3ADC%252BC3MXpvFWitbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2011&pages=4782-4795&author=J.+Chenauthor=C.-M.+Liauthor=J.+Wangauthor=S.+Ahnauthor=Z.+Wangauthor=Y.+Luauthor=J.+T.+Daltonauthor=D.+D.+Millerauthor=W.+Li&title=Synthesis+and+antiproliferative+activity+of+novel+2-aryl-4-benzoyl-imidazole+derivatives+targeting+tubulin+polymerization&doi=10.1016%2Fj.bmc.2011.06.084"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and antiproliferative activity of novel 2-aryl-4-benzoyl-imidazole derivatives targeting tubulin polymerization</span></div><div class="casAuthors">Chen, Jianjun; Li, Chien-Ming; Wang, Jin; Ahn, Sunjoo; Wang, Zhao; Lu, Yan; Dalton, James T.; Miller, Duane D.; Li, Wei</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">4782-4795</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Previously, the discovery of 2-aryl-4-benzoyl-imidazoles (ABI-I) as potent antiproliferative agents for melanoma was reported.  To further understand the structural requirements for the potency of ABI analogs, gain insight in the structure-activity relationships (SAR), and investigate metabolic stability for these compds., extensive SAR studies on the ABI-I scaffold are reported.  Compared with the previous set of ABI-I analogs, the newly synthesized ABI-II analogs have lower potency in general, but some of the new analogs have comparable potency to the most active compds. in the previous set when tested in two melanoma and four prostate cancer cell lines.  These SAR studies indicated that the antiproliferative activity was very sensitive to subtle changes in the ligand.  Tested compds. I and II are equally active against highly paclitaxel resistant cancer cell lines and their parental cell lines, indicating that drugs developed based on ABI-I analogs may have therapeutic advantages over paclitaxel in treating resistant tumors.  Metabolic stability studies of compd. I revealed that the N-Me imidazole failed to exhibit stability as the literature reported because de-methylation was found as the major metabolic pathway in rat and mouse liver microsomes.  However, this sheds light on the possibility of many modifications on the imidazole ring for further lead optimization, since the modification on imidazole, such as compd. I, did not impact the potency.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqU3-PVr9QmTrVg90H21EOLACvtfcHk0ljfQFFga8gg-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXpvFWitbg%253D&md5=39fc9a69658cb461327cc5bd60f1fcb3</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2011.06.084&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2011.06.084%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DC.-M.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DAhn%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DLu%26aufirst%3DY.%26aulast%3DDalton%26aufirst%3DJ.%2BT.%26aulast%3DMiller%26aufirst%3DD.%2BD.%26aulast%3DLi%26aufirst%3DW.%26atitle%3DSynthesis%2520and%2520antiproliferative%2520activity%2520of%2520novel%25202-aryl-4-benzoyl-imidazole%2520derivatives%2520targeting%2520tubulin%2520polymerization%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2011%26volume%3D19%26spage%3D4782%26epage%3D4795%26doi%3D10.1016%2Fj.bmc.2011.06.084" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalton, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span> <span> </span><span class="NLM_article-title">Discovery of novel 2-aryl-4-benzoyl-imidazole (ABI-III) analogues targeting tubulin polymerization as antiproliferative agents</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">7285</span>– <span class="NLM_lpage">7289</span>, <span class="refDoi"> DOI: 10.1021/jm300564b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300564b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVWhtL7I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=7285-7289&author=J.+Chenauthor=S.+Ahnauthor=J.+Wangauthor=Y.+Luauthor=J.+T.+Daltonauthor=D.+D.+Millerauthor=W.+Li&title=Discovery+of+novel+2-aryl-4-benzoyl-imidazole+%28ABI-III%29+analogues+targeting+tubulin+polymerization+as+antiproliferative+agents&doi=10.1021%2Fjm300564b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Novel 2-Aryl-4-benzoyl-imidazole (ABI-III) Analogues Targeting Tubulin Polymerization As Antiproliferative Agents</span></div><div class="casAuthors">Chen, Jianjun; Ahn, Sunjoo; Wang, Jin; Lu, Yan; Dalton, James T.; Miller, Duane D.; Li, Wei</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">7285-7289</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Novel ABI-III compds. were designed and synthesized based on our previously reported ABI-I and ABI-II analogs.  ABI-III compds. are highly potent against a panel of melanoma and prostate cancer cell lines, with the best compd. having an av. IC50 value of 3.8 nM.  They are not substrate of Pgp and thus may effectively overcome Pgp-mediated multidrug resistance.  ABI-III analogs maintain their mechanisms of action by inhibition of tubulin polymn.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpd3i19x2xBrVg90H21EOLACvtfcHk0lidZQH-WwT_4Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVWhtL7I&md5=b7eee50b4916f704e49c9e30b1a803d5</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Fjm300564b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300564b%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DAhn%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DLu%26aufirst%3DY.%26aulast%3DDalton%26aufirst%3DJ.%2BT.%26aulast%3DMiller%26aufirst%3DD.%2BD.%26aulast%3DLi%26aufirst%3DW.%26atitle%3DDiscovery%2520of%2520novel%25202-aryl-4-benzoyl-imidazole%2520%2528ABI-III%2529%2520analogues%2520targeting%2520tubulin%2520polymerization%2520as%2520antiproliferative%2520agents%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D7285%26epage%3D7289%26doi%3D10.1021%2Fjm300564b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalton, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span> <span> </span><span class="NLM_article-title">Discovery of 4-aryl-2-benzoyl-imidazoles as tubulin polymerization inhibitor with potent antiproliferative properties</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">3318</span>– <span class="NLM_lpage">3329</span>, <span class="refDoi"> DOI: 10.1021/jm4001117</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm4001117" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=1%3ACAS%3A528%3ADC%252BC3sXltV2msrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=3318-3329&author=M.+Xiaoauthor=S.+Ahnauthor=J.+Wangauthor=J.+Chenauthor=D.+D.+Millerauthor=J.+T.+Daltonauthor=W.+Li&title=Discovery+of+4-aryl-2-benzoyl-imidazoles+as+tubulin+polymerization+inhibitor+with+potent+antiproliferative+properties&doi=10.1021%2Fjm4001117"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 4-Aryl-2-benzoyl-imidazoles as Tubulin Polymerization Inhibitor with Potent Antiproliferative Properties</span></div><div class="casAuthors">Xiao, Min; Ahn, Sunjoo; Wang, Jin; Chen, Jianjun; Miller, Duane. D.; Dalton, James T.; Li, Wei</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3318-3329</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of 4-aryl-2-benzoyl-imidazoles were designed and synthesized based on our previously reported 2-aryl-4-benzoyl-imidazole (ABI) derivs.  The new structures reversed the aryl group and the benzoyl group of previous ABI structures and were named as reverse ABI (RABI) analogs.  RABIs were evaluated for biol. activity against eight cancer cell lines including multidrug-resistant cancer cell lines.  In vitro assays indicated that several RABI compds. had excellent antiproliferative properties, with IC50 values in the low nanomolar range.  The av. IC50 of the most active compd. I is 14 nM.  In addn., the mechanism of action of these new analogs was investigated by cell cycle anal., tubulin polymn. assay, competitive mass spectrometry binding assay, and mol. docking studies.  These studies confirmed that these new RABI analogs maintain their mechanisms of action by disrupting tubulin polymn., similar to their parental ABI analogs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKd5PthijXy7Vg90H21EOLACvtfcHk0lidZQH-WwT_4Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXltV2msrw%253D&md5=9f91ab1eb19f9c3308a968f46e483a56</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Fjm4001117&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm4001117%26sid%3Dliteratum%253Aachs%26aulast%3DXiao%26aufirst%3DM.%26aulast%3DAhn%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DMiller%26aufirst%3DD.%2BD.%26aulast%3DDalton%26aufirst%3DJ.%2BT.%26aulast%3DLi%26aufirst%3DW.%26atitle%3DDiscovery%2520of%25204-aryl-2-benzoyl-imidazoles%2520as%2520tubulin%2520polymerization%2520inhibitor%2520with%2520potent%2520antiproliferative%2520properties%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D3318%26epage%3D3329%26doi%3D10.1021%2Fjm4001117" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hwang, D.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, D. D.</span></span> <span> </span><span class="NLM_article-title">Structural optimization of indole derivatives acting at colchicine binding site as potential anticancer agents</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">993</span>– <span class="NLM_lpage">997</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.5b00208</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.5b00208" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht12gs77N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=993-997&author=D.-J.+Hwangauthor=J.+Wangauthor=W.+Liauthor=D.+D.+Miller&title=Structural+optimization+of+indole+derivatives+acting+at+colchicine+binding+site+as+potential+anticancer+agents&doi=10.1021%2Facsmedchemlett.5b00208"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Structural Optimization of Indole Derivatives Acting at Colchicine Binding Site as Potential Anticancer Agents</span></div><div class="casAuthors">Hwang, Dong-Jin; Wang, Jin; Li, Wei; Miller, Duane D.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">993-997</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Diarylisoquinolines and (trimethoxyphenyl)(indolyl)imidazopyridines I (R = 2-indolyl, 3-indolyl, 4-indolyl, 6-indolyl, 7-indolyl), analogs of a previous trimethoxybenzoylphenylindole and I (R = 5-indolyl), were prepd. as tubulin polymn. inhibitors acting at the colchicine binding site for potential use as antitumor agents with improved metabolic stabilities and cytotoxicities.  I (R = 2-indolyl, 3-indolyl, 4-indolyl, 6-indolyl, 7-indolyl) inhibited tubulin polymn. with IC50 values of 3 to 175 nM against a panel of human melanoma and prostate cancer cell lines.  In particular, I (R = 6-indolyl) showed improved cytotoxic potency (av. IC50 of 9.75 nM vs 55.75 nM) and metabolic stability in human liver microsomes (half-life time was 56.3 min vs. 45.4 min) as compared to previously reported I (R = 5-indolyl).  I (R = 6-indolyl) was effective against P-glycoprotein (P-gp) mediated multiple drug resistance (MDR) and taxol resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8lYd6NtCgfbVg90H21EOLACvtfcHk0lidZQH-WwT_4Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht12gs77N&md5=839b8e906ff050b9f96d167796bb912d</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.5b00208&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.5b00208%26sid%3Dliteratum%253Aachs%26aulast%3DHwang%26aufirst%3DD.-J.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DMiller%26aufirst%3DD.%2BD.%26atitle%3DStructural%2520optimization%2520of%2520indole%2520derivatives%2520acting%2520at%2520colchicine%2520binding%2520site%2520as%2520potential%2520anticancer%2520agents%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D6%26spage%3D993%26epage%3D997%26doi%3D10.1021%2Facsmedchemlett.5b00208" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narayanan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kearbey, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parke, D. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalton, J. T.</span></span> <span> </span><span class="NLM_article-title">Biological Activity of 4-Substituted Methoxybenzoyl- Aryl-Thiazole: An Active Microtubule Inhibitor</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>71</i></span>,  <span class="NLM_fpage">216</span>– <span class="NLM_lpage">224</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.can-10-1725</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=10.1158%2F0008-5472.can-10-1725" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=21084278" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=1%3ACAS%3A528%3ADC%252BC3MXovFOk" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2011&pages=216-224&author=C.-M.+Liauthor=Z.+Wangauthor=Y.+Luauthor=S.+Ahnauthor=R.+Narayananauthor=J.+D.+Kearbeyauthor=D.+N.+Parkeauthor=W.+Liauthor=D.+D.+Millerauthor=J.+T.+Dalton&title=Biological+Activity+of+4-Substituted+Methoxybenzoyl-+Aryl-Thiazole%3A+An+Active+Microtubule+Inhibitor&doi=10.1158%2F0008-5472.can-10-1725"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Biological Activity of 4-Substituted Methoxybenzoyl- Aryl-Thiazole: An Active Microtubule Inhibitor</span></div><div class="casAuthors">Li, Chien-Ming; Wang, Zhao; Lu, Yan; Ahn, Sunjoo; Narayanan, Ramesh; Kearbey, Jeffrey D.; Parke, Deanna N.; Li, Wei; Miller, Duane D.; Dalton, James T.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">216-224</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Formation of microtubules is a dynamic process that involves polymn. and depolymn. of αβ-tubulin heterodimers.  Drugs that enhance or inhibit tubulin polymn. can destroy this dynamic process, arresting cells in the G2/M phase of the cell cycle.  Although drugs that target tubulin generally demonstrate cytotoxic potency in the subnanomolar range, resistance due to drug efflux is a common phenomenon among the antitubulin agents.  We recently reported a class of 4-substituted methoxybenzoyl-aryl-thiazoles (SMART) that exhibited great in vitro potency and broad spectrum cellular cytotoxicity.  Evaluation of the in vitro and in vivo anticancer activities of 3 SMART compds., SMART-H (H), SMART-F (F), and SMART-OH (OH), with varying substituents at the 4-position of aryl ring, demonstrated that they bind potently to the colchicine-binding site in tubulin, inhibit tubulin polymn., arrest cancer cells in G2/M phase of the cell cycle, and induce their apoptosis.  The SMART compds. also equipotently inhibit the growth of parental and MDR-overexpressing cells in vitro, indicating that they can overcome multidrug resistance.  In vivo antitumor efficacy studies in human prostate (PC-3) and melanoma (A375) cancer xenograft models demonstrated that SMART-H and SMART-F treatments resulted in %T/C values ranging from 4% to 30%.  In addn., in vivo SMART-H treatment for 21days at the higher dose (15 mg/kg) failed to produce any apparent neurotoxicity.  These studies provide the first in vivo evidence and proof-of-concept that SMART compds. are similarly efficacious to currently FDA approved antitubulin drugs for cancer treatment, but they can circumvent P-glycoprotein-mediated drug resistance.  Cancer Res; 71(1); 216-24.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq7124GCCHtorVg90H21EOLACvtfcHk0lidZQH-WwT_4Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXovFOk&md5=107be0442abff7e1874f9a45690d1f08</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.can-10-1725&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.can-10-1725%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DC.-M.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DLu%26aufirst%3DY.%26aulast%3DAhn%26aufirst%3DS.%26aulast%3DNarayanan%26aufirst%3DR.%26aulast%3DKearbey%26aufirst%3DJ.%2BD.%26aulast%3DParke%26aufirst%3DD.%2BN.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DMiller%26aufirst%3DD.%2BD.%26aulast%3DDalton%26aufirst%3DJ.%2BT.%26atitle%3DBiological%2520Activity%2520of%25204-Substituted%2520Methoxybenzoyl-%2520Aryl-Thiazole%253A%2520An%2520Active%2520Microtubule%2520Inhibitor%26jtitle%3DCancer%2520Res.%26date%3D2011%26volume%3D71%26spage%3D216%26epage%3D224%26doi%3D10.1158%2F0008-5472.can-10-1725" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohler, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalton, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, D. D.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, and SAR studies of 4-substituted methoxylbenzoyl-aryl-thiazoles analogues as potent and orally bioavailable anticancer agents</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">4678</span>– <span class="NLM_lpage">4693</span>, <span class="refDoi"> DOI: 10.1021/jm2003427</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm2003427" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=1%3ACAS%3A528%3ADC%252BC3MXnt1ahu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=4678-4693&author=Y.+Luauthor=C.-M.+Liauthor=Z.+Wangauthor=J.+Chenauthor=M.+L.+Mohlerauthor=W.+Liauthor=J.+T.+Daltonauthor=D.+D.+Miller&title=Design%2C+synthesis%2C+and+SAR+studies+of+4-substituted+methoxylbenzoyl-aryl-thiazoles+analogues+as+potent+and+orally+bioavailable+anticancer+agents&doi=10.1021%2Fjm2003427"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis, and SAR studies of 4-substituted methoxylbenzoyl-aryl-thiazoles analogues as potent and orally bioavailable anticancer agents</span></div><div class="casAuthors">Lu, Yan; Li, Chien-Ming; Wang, Zhao; Chen, Jianjun; Mohler, Michael L.; Li, Wei; Dalton, James T.; Miller, Duane D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">4678-4693</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In a continued effort to improve upon the previously published 4-substituted methoxybenzoyl-aryl-thiazole (SMART) template, we explored chemodiverse "B" rings and "B" to "C" ring linkage.  Further, to overcome the poor aq. soly. of this series of agents, we introduced polar and ionizable hydrophilic groups to obtain water-sol. compds.  For instance, based on in vivo pharmacokinetic (PK) studies, an orally bioavailable phenyl-amino-thiazole (PAT) template was designed and synthesized in which an amino linkage was inserted between "A" and "B" rings of compd. I.  The PAT template maintained nanomolar (nM) range potency against cancer cell lines via inhibiting tubulin polymn. and was not susceptible to P-glycoprotein mediated multidrug resistance in vitro, and markedly improved soly. and bioavailability compared with the SMART template (II (R = H, Me, F) (PAT) vs I (SMART)).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrU325PJRUuh7Vg90H21EOLACvtfcHk0lgaaNEt5vc-QQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXnt1ahu74%253D&md5=fa3a6233ae97bc202aec36774242fcd6</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Fjm2003427&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm2003427%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DC.-M.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DMohler%26aufirst%3DM.%2BL.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DDalton%26aufirst%3DJ.%2BT.%26aulast%3DMiller%26aufirst%3DD.%2BD.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520SAR%2520studies%2520of%25204-substituted%2520methoxylbenzoyl-aryl-thiazoles%2520analogues%2520as%2520potent%2520and%2520orally%2520bioavailable%2520anticancer%2520agents%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D4678%26epage%3D4693%26doi%3D10.1021%2Fjm2003427" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahato, R. I.</span></span> <span> </span><span class="NLM_article-title">Synthesis, formulation and in vitro evaluation of a novel microtubule destabilizer, SMART-100</span>. <i>J. Control Release</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>143</i></span>,  <span class="NLM_fpage">151</span>– <span class="NLM_lpage">158</span>, <span class="refDoi"> DOI: 10.1016/j.jconrel.2009.12.028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=10.1016%2Fj.jconrel.2009.12.028" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=20060430" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjtFOju7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=143&publication_year=2010&pages=151-158&author=F.+Liauthor=Y.+Luauthor=W.+Liauthor=D.+D.+Millerauthor=R.+I.+Mahato&title=Synthesis%2C+formulation+and+in+vitro+evaluation+of+a+novel+microtubule+destabilizer%2C+SMART-100&doi=10.1016%2Fj.jconrel.2009.12.028"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis, formulation and in vitro evaluation of a novel microtubule destabilizer, SMART-100</span></div><div class="casAuthors">Li, Feng; Lu, Yan; Li, Wei; Miller, Duane D.; Mahato, Ram I.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Controlled Release</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">143</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">151-158</span>CODEN:
                <span class="NLM_cas:coden">JCREEC</span>;
        ISSN:<span class="NLM_cas:issn">0168-3659</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A novel microtubule destabilizer, substituted methoxybenzoyl-ary-thiazole (SMART)-100, was synthesized, which showed good anticancer activity in HepG2 cells.  SMART-100 was able to circumvent multidrug resistance (MDR) and effectively inhibited the growth of cell lines that overexpress P-glycoprotein (P-gp).  SMART-100 inhibited P-gp activity, which may be responsible for its ability to overcome MDR.  Since SMART-100 is poorly sol. in water, it was formulated in polyethylene-b-poly(D,L-lactide) (PEG-PLA) micelles.  The soly. of SMART-100 was increased by more than 1.1 × 105 folds.  SMART-100 loaded PEG-PLA micelles could effectively inhibit HepG2 cell growth and arrest cell cycle progression at G2/M phase, followed by appearance of a sub-G1 phase, which is indicative of cell apoptosis.  Increased Caspase-3 activity was also obsd. when HepG2 cells were treated with SMART-100.  The anticancer activity of SMART-100 loaded PEG-PLA micelles was also evaluated on luciferase expressing C4-2-Luc cell lines by IVIS imaging.  Our results suggest that SMART-100 has the potential to treat resistant cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoAqZoBDbb9xLVg90H21EOLACvtfcHk0lgaaNEt5vc-QQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjtFOju7Y%253D&md5=e06d0eed2a8a9c88367bfd8fa56b2bfe</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1016%2Fj.jconrel.2009.12.028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jconrel.2009.12.028%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DF.%26aulast%3DLu%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DMiller%26aufirst%3DD.%2BD.%26aulast%3DMahato%26aufirst%3DR.%2BI.%26atitle%3DSynthesis%252C%2520formulation%2520and%2520in%2520vitro%2520evaluation%2520of%2520a%2520novel%2520microtubule%2520destabilizer%252C%2520SMART-100%26jtitle%3DJ.%2520Control%2520Release%26date%3D2010%26volume%3D143%26spage%3D151%26epage%3D158%26doi%3D10.1016%2Fj.jconrel.2009.12.028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">de
Sa Alves, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barreiro, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fraga, C. A. M.</span></span> <span> </span><span class="NLM_article-title">From nature to drug discovery: the indole scaffold as a ‘privileged structure’</span>. <i>Mini-Rev. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">782</span>– <span class="NLM_lpage">793</span>, <span class="refDoi"> DOI: 10.2174/138955709788452649</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=10.2174%2F138955709788452649" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=19519503" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=1%3ACAS%3A280%3ADC%252BD1MvhtlymtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2009&pages=782-793&author=F.+de%0ASa+Alvesauthor=E.+Barreiroauthor=C.+A.+M.+Fraga&title=From+nature+to+drug+discovery%3A+the+indole+scaffold+as+a+%E2%80%98privileged+structure%E2%80%99&doi=10.2174%2F138955709788452649"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">From nature to drug discovery: the indole scaffold as a 'privileged structure'</span></div><div class="casAuthors">de Sa Alves Fernando Rodrigues; Barreiro Eliezer J; Fraga Carlos Alberto Manssour</div><div class="citationInfo"><span class="NLM_cas:title">Mini reviews in medicinal chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">782-93</span>
        ISSN:<span class="NLM_cas:issn">1389-5575</span>.
    </div><div class="casAbstract">The indole scaffold probably represents one of the most important structural subunits for the discovery of new drug candidates.  The demonstration that many alkaloids contain the indole nucleus, the recognition of the importance of essential amino acid tryptophan in human nutrition and the discovery of plant hormones served to bring about a massive search on indole chemistry, giving rise to a vast number of biologically active natural and synthetic products, with a wide range of therapeutic targets, such as anti-inflammatories, phosphodiesterase inhibitors, 5-hydroxytryptamine receptor agonists and antagonists, cannabinoid receptors agonists and HMG-CoA reductase inhibitors.  Many of these target-receptors belong to the class of GPCRs (integral membrane G-protein coupled receptors) and possess a conserved binding pocket that is recognized by the indole scaffold in a "common" complementary binding domain, explaining the great number of drugs that contain the indole substructure, such as indomethacin, ergotamine, frovatriptan, ondansetron, tadalafil, among many others.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTBKUu7YDCtEQWRJ3OJdH_qfW6udTcc2eafodSBXBpYyrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1MvhtlymtQ%253D%253D&md5=34fa9e3785856259b4486d57af2e75ee</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.2174%2F138955709788452649&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138955709788452649%26sid%3Dliteratum%253Aachs%26aulast%3Dde%2BSa%2BAlves%26aufirst%3DF.%26aulast%3DBarreiro%26aufirst%3DE.%26aulast%3DFraga%26aufirst%3DC.%2BA.%2BM.%26atitle%3DFrom%2520nature%2520to%2520drug%2520discovery%253A%2520the%2520indole%2520scaffold%2520as%2520a%2520%25E2%2580%2598privileged%2520structure%25E2%2580%2599%26jtitle%3DMini-Rev.%2520Med.%2520Chem.%26date%3D2009%26volume%3D9%26spage%3D782%26epage%3D793%26doi%3D10.2174%2F138955709788452649" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalton, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span> <span> </span><span class="NLM_article-title">Discovery of novel 2-aryl-4-benzoyl-imidazole (ABI-III) analogues targeting tubulin polymerization as antiproliferative agents</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">7285</span>– <span class="NLM_lpage">7289</span>, <span class="refDoi"> DOI: 10.1021/jm300564b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300564b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVWhtL7I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=7285-7289&author=J.+Chenauthor=S.+Ahnauthor=J.+Wangauthor=Y.+Luauthor=J.+T.+Daltonauthor=D.+D.+Millerauthor=W.+Li&title=Discovery+of+novel+2-aryl-4-benzoyl-imidazole+%28ABI-III%29+analogues+targeting+tubulin+polymerization+as+antiproliferative+agents&doi=10.1021%2Fjm300564b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Novel 2-Aryl-4-benzoyl-imidazole (ABI-III) Analogues Targeting Tubulin Polymerization As Antiproliferative Agents</span></div><div class="casAuthors">Chen, Jianjun; Ahn, Sunjoo; Wang, Jin; Lu, Yan; Dalton, James T.; Miller, Duane D.; Li, Wei</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">7285-7289</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Novel ABI-III compds. were designed and synthesized based on our previously reported ABI-I and ABI-II analogs.  ABI-III compds. are highly potent against a panel of melanoma and prostate cancer cell lines, with the best compd. having an av. IC50 value of 3.8 nM.  They are not substrate of Pgp and thus may effectively overcome Pgp-mediated multidrug resistance.  ABI-III analogs maintain their mechanisms of action by inhibition of tubulin polymn.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpd3i19x2xBrVg90H21EOLACvtfcHk0lgOkc9bQM527g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVWhtL7I&md5=b7eee50b4916f704e49c9e30b1a803d5</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1021%2Fjm300564b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300564b%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DAhn%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DLu%26aufirst%3DY.%26aulast%3DDalton%26aufirst%3DJ.%2BT.%26aulast%3DMiller%26aufirst%3DD.%2BD.%26aulast%3DLi%26aufirst%3DW.%26atitle%3DDiscovery%2520of%2520novel%25202-aryl-4-benzoyl-imidazole%2520%2528ABI-III%2529%2520analogues%2520targeting%2520tubulin%2520polymerization%2520as%2520antiproliferative%2520agents%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D7285%26epage%3D7289%26doi%3D10.1021%2Fjm300564b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kashyap, V.
K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Setua, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagesh, P. K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chauhan, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumari, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chowdhury, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yallapu, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaggi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hafeez, B. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chauhan, S. C.</span></span> <span> </span><span class="NLM_article-title">Therapeutic efficacy of a novel betaIII/betaIV-tubulin inhibitor (VERU-111) in pancreatic cancer</span>. <i>J. Exp. Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">29</span>, <span class="refDoi"> DOI: 10.1186/s13046-018-1009-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=10.1186%2Fs13046-018-1009-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=30674344" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=1%3ACAS%3A280%3ADC%252BB3cjksFagug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2019&pages=29&author=V.%0AK.+Kashyapauthor=Q.+Wangauthor=S.+Setuaauthor=P.+K.+B.+Nageshauthor=N.+Chauhanauthor=S.+Kumariauthor=P.+Chowdhuryauthor=D.+D.+Millerauthor=M.+M.+Yallapuauthor=W.+Liauthor=M.+Jaggiauthor=B.+B.+Hafeezauthor=S.+C.+Chauhan&title=Therapeutic+efficacy+of+a+novel+betaIII%2FbetaIV-tubulin+inhibitor+%28VERU-111%29+in+pancreatic+cancer&doi=10.1186%2Fs13046-018-1009-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic efficacy of a novel βIII/βIV-tubulin inhibitor (VERU-111) in pancreatic cancer</span></div><div class="casAuthors">Kashyap Vivek K; Wang Qinghui; Setua Saini; Nagesh Prashanth K B; Chauhan Neeraj; Kumari Sonam; Chowdhury Pallabita; Miller Duane D; Yallapu Murali M; Li Wei; Jaggi Meena; Hafeez Bilal Bin; Chauhan Subhash C</div><div class="citationInfo"><span class="NLM_cas:title">Journal of experimental & clinical cancer research : CR</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">29</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  The management of pancreatic cancer (PanCa) is exceptionally difficult due to poor response to available therapeutic modalities.  Tubulins play a major role in cell dynamics, thus are important molecular targets for cancer therapy.  Among various tubulins, βIII and βIV-tubulin isoforms have been primarily implicated in PanCa progression, metastasis and chemo-resistance.  However, specific inhibitors of these isoforms that have potent anti-cancer activity with low toxicity are not readily available.  METHODS:  We determined anti-cancer molecular mechanisms and therapeutic efficacy of a novel small molecule inhibitor (VERU-111) using in vitro (MTS, wound healing, Boyden chamber and real-time xCELLigence assays) and in vivo (xenograft studies) models of PanCa.  The effects of VERU-111 treatment on the expression of β-tubulin isoforms, apoptosis, cancer markers and microRNAs were determined by Western blot, immunohistochemistry (IHC), confocal microscopy, qRT-PCR and in situ hybridization (ISH) analyses.  RESULTS:  We have identified a novel small molecule inhibitor (VERU-111), which preferentially represses clinically important, βIII and βIV tubulin isoforms via restoring the expression of miR-200c.  As a result, VERU-111 efficiently inhibited tumorigenic and metastatic characteristics of PanCa cells.  VERU-111 arrested the cell cycle in the G2/M phase and induced apoptosis in PanCa cell lines via modulation of cell cycle regulatory (Cdc2, Cdc25c, and Cyclin B1) and apoptosis - associated (Bax, Bad, Bcl-2, and Bcl-xl) proteins.  VERU-111 treatment also inhibited tumor growth (P < 0.01) in a PanCa xenograft mouse model.  CONCLUSIONS:  This study has identified an inhibitor of βIII/βIV tubulins, which appears to have excellent potential as monotherapy or in combination with conventional therapeutic regimens for PanCa treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTXobOg3bD1Rw20zIbnCCI3fW6udTcc2eYIqA59-6IjM7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cjksFagug%253D%253D&md5=6c965874d8dfd995f26ec76bfc37c4ce</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1186%2Fs13046-018-1009-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13046-018-1009-7%26sid%3Dliteratum%253Aachs%26aulast%3DKashyap%26aufirst%3DV.%2BK.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DSetua%26aufirst%3DS.%26aulast%3DNagesh%26aufirst%3DP.%2BK.%2BB.%26aulast%3DChauhan%26aufirst%3DN.%26aulast%3DKumari%26aufirst%3DS.%26aulast%3DChowdhury%26aufirst%3DP.%26aulast%3DMiller%26aufirst%3DD.%2BD.%26aulast%3DYallapu%26aufirst%3DM.%2BM.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DJaggi%26aufirst%3DM.%26aulast%3DHafeez%26aufirst%3DB.%2BB.%26aulast%3DChauhan%26aufirst%3DS.%2BC.%26atitle%3DTherapeutic%2520efficacy%2520of%2520a%2520novel%2520betaIII%252FbetaIV-tubulin%2520inhibitor%2520%2528VERU-111%2529%2520in%2520pancreatic%2520cancer%26jtitle%3DJ.%2520Exp.%2520Clin.%2520Cancer%2520Res.%26date%3D2019%26volume%3D38%26spage%3D29%26doi%3D10.1186%2Fs13046-018-1009-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnst, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span> <span> </span><span class="NLM_article-title">Structural Modification of the 3,4,5-Trimethoxyphenyl Moiety in the Tubulin Inhibitor VERU-111 Leads to Improved Antiproliferative Activities</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">7877</span>– <span class="NLM_lpage">7891</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00827</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00827" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsFerurrP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=7877-7891&author=Q.+Wangauthor=K.+E.+Arnstauthor=Y.+Wangauthor=G.+Kumarauthor=D.+Maauthor=H.+Chenauthor=Z.+Wuauthor=J.+Yangauthor=S.+W.+Whiteauthor=D.+D.+Millerauthor=W.+Li&title=Structural+Modification+of+the+3%2C4%2C5-Trimethoxyphenyl+Moiety+in+the+Tubulin+Inhibitor+VERU-111+Leads+to+Improved+Antiproliferative+Activities&doi=10.1021%2Facs.jmedchem.8b00827"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Structural Modification of the 3,4,5-Trimethoxyphenyl Moiety in the Tubulin Inhibitor VERU-111 Leads to Improved Antiproliferative Activities</span></div><div class="casAuthors">Wang, Qinghui; Arnst, Kinsie E.; Wang, Yuxi; Kumar, Gyanendra; Ma, Dejian; Chen, Hao; Wu, Zhongzhi; Yang, Jinliang; White, Stephen W.; Miller, Duane D.; Li, Wei</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">7877-7891</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Colchicine binding site inhibitors (CBSIs) hold great potential in developing new generations of antimitotic drugs.  Unlike existing tubulin inhibitors such as paclitaxel, they are generally much less susceptible to resistance caused by the overexpression of drug efflux pumps.  The 3,4,5-trimethoxyphenyl (TMP) moiety is a crit. component present in many CBSIs, playing an important role in maintaining suitable mol. conformations of CBSIs and contributing to their high binding affinities to tubulin.  Previously reported modifications to the TMP moiety in a variety of scaffolds of CBSIs have usually resulted in reduced antiproliferative potency.  We previously reported a potent CBSI, VERU-111, that also contains the TMP moiety.  Herein, we report the discovery of a VERU-111 analog I that is significantly more potent than VERU-111.  The X-ray crystal structure of I in complex with tubulin confirms its direct binding to the colchicine site.  In addn., I exhibited a strong inhibitory effect on tumor growth in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcjzgnUpHhEbVg90H21EOLACvtfcHk0lgOkc9bQM527g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsFerurrP&md5=0d175fcf0efc28e5e120b4837dfc72b9</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00827&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00827%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DArnst%26aufirst%3DK.%2BE.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DKumar%26aufirst%3DG.%26aulast%3DMa%26aufirst%3DD.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DWu%26aufirst%3DZ.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DWhite%26aufirst%3DS.%2BW.%26aulast%3DMiller%26aufirst%3DD.%2BD.%26aulast%3DLi%26aufirst%3DW.%26atitle%3DStructural%2520Modification%2520of%2520the%25203%252C4%252C5-Trimethoxyphenyl%2520Moiety%2520in%2520the%2520Tubulin%2520Inhibitor%2520VERU-111%2520Leads%2520to%2520Improved%2520Antiproliferative%2520Activities%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D7877%26epage%3D7891%26doi%3D10.1021%2Facs.jmedchem.8b00827" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fujioka, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murai, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kubo, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohba, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kita, Y.</span></span> <span> </span><span class="NLM_article-title">One-pot synthesis of imidazolines from aldehydes: detailed study about solvents and substrates</span>. <i>Tetrahedron</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">638</span>– <span class="NLM_lpage">643</span>, <span class="refDoi"> DOI: 10.1016/j.tet.2006.11.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=10.1016%2Fj.tet.2006.11.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtlagtrrP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2007&pages=638-643&author=H.+Fujiokaauthor=K.+Muraiauthor=O.+Kuboauthor=Y.+Ohbaauthor=Y.+Kita&title=One-pot+synthesis+of+imidazolines+from+aldehydes%3A+detailed+study+about+solvents+and+substrates&doi=10.1016%2Fj.tet.2006.11.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">One-pot synthesis of imidazolines from aldehydes: detailed study about solvents and substrates</span></div><div class="casAuthors">Fujioka, Hiromichi; Murai, Kenichi; Kubo, Ozora; Ohba, Yusuke; Kita, Yasuyuki</div><div class="citationInfo"><span class="NLM_cas:title">Tetrahedron</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">638-643</span>CODEN:
                <span class="NLM_cas:coden">TETRAB</span>;
        ISSN:<span class="NLM_cas:issn">0040-4020</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Imidazolines were prepd. in 1-pot operation from aldehydes and diamines through oxidn. of aminal intermediates by NBS.  This method could be applied to various arom. and aliph. aldehydes and N-nonsubstituted and N-monosubstituted 1,2-diamines.  Also, CH2Cl2 could be altered to TBME, a more environmentally friendly solvent, in the reaction using N-nonsubstituted 1,2-diamines.  The reaction conditions were very mild and chemoselective.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWoQm3g9xTBbVg90H21EOLACvtfcHk0lh_ovVzei4WCA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtlagtrrP&md5=37face1338e5d2fe65a2e43cff1f40e8</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1016%2Fj.tet.2006.11.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tet.2006.11.007%26sid%3Dliteratum%253Aachs%26aulast%3DFujioka%26aufirst%3DH.%26aulast%3DMurai%26aufirst%3DK.%26aulast%3DKubo%26aufirst%3DO.%26aulast%3DOhba%26aufirst%3DY.%26aulast%3DKita%26aufirst%3DY.%26atitle%3DOne-pot%2520synthesis%2520of%2520imidazolines%2520from%2520aldehydes%253A%2520detailed%2520study%2520about%2520solvents%2520and%2520substrates%26jtitle%3DTetrahedron%26date%3D2007%26volume%3D63%26spage%3D638%26epage%3D643%26doi%3D10.1016%2Fj.tet.2006.11.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Briot, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baehr, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brouillard, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mioskowski, C.</span></span> <span> </span><span class="NLM_article-title">Concise synthesis of dihydrochalcones via palladium-catalyzed coupling of aryl halides and 1-aryl-2-propen-1-ols</span>. <i>J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>69</i></span>,  <span class="NLM_fpage">1374</span>– <span class="NLM_lpage">1377</span>, <span class="refDoi"> DOI: 10.1021/jo034936c</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo034936c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=1%3ACAS%3A528%3ADC%252BD2cXkt1Gmuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2004&pages=1374-1377&author=A.+Briotauthor=C.+Baehrauthor=R.+Brouillardauthor=A.+Wagnerauthor=C.+Mioskowski&title=Concise+synthesis+of+dihydrochalcones+via+palladium-catalyzed+coupling+of+aryl+halides+and+1-aryl-2-propen-1-ols&doi=10.1021%2Fjo034936c"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Concise Synthesis of Dihydrochalcones via Palladium-Catalyzed Coupling of Aryl Halides and 1-Aryl-2-propen-1-ols</span></div><div class="casAuthors">Briot, Anne; Baehr, Corinne; Brouillard, Raymond; Wagner, Alain; Mioskowski, Charles</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1374-1377</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">An expedient route to substituted dihydrochalcones, e.g., I, is reported.  The key step is a palladium-assisted arylation of 1-aryl-2-propen-1-ols, e.g., II.  This two-step/one-purifn. process allows the synthesis of a wide range of compds. with original substitution patterns, including polyphenolic derivs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq94e1-31j877Vg90H21EOLACvtfcHk0lh_ovVzei4WCA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXkt1Gmuw%253D%253D&md5=637a7745197145b35d63a24cef454c34</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1021%2Fjo034936c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo034936c%26sid%3Dliteratum%253Aachs%26aulast%3DBriot%26aufirst%3DA.%26aulast%3DBaehr%26aufirst%3DC.%26aulast%3DBrouillard%26aufirst%3DR.%26aulast%3DWagner%26aufirst%3DA.%26aulast%3DMioskowski%26aufirst%3DC.%26atitle%3DConcise%2520synthesis%2520of%2520dihydrochalcones%2520via%2520palladium-catalyzed%2520coupling%2520of%2520aryl%2520halides%2520and%25201-aryl-2-propen-1-ols%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2004%26volume%3D69%26spage%3D1374%26epage%3D1377%26doi%3D10.1021%2Fjo034936c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohn, H.</span></span> <span> </span><span class="NLM_article-title">Cyclic disulfide C(8) iminoporfiromycin: nucleophilic activation of a porfiromycin</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>126</i></span>,  <span class="NLM_fpage">4281</span>– <span class="NLM_lpage">4292</span>, <span class="refDoi"> DOI: 10.1021/ja030577r</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja030577r" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhvF2itbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=126&publication_year=2004&pages=4281-4292&author=S.+H.+Leeauthor=H.+Kohn&title=Cyclic+disulfide+C%288%29+iminoporfiromycin%3A+nucleophilic+activation+of+a+porfiromycin&doi=10.1021%2Fja030577r"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclic Disulfide C(8) Iminoporfiromycin: Nucleophilic Activation of a Porfiromycin</span></div><div class="casAuthors">Lee, Sang Hyup; Kohn, Harold</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">126</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">4281-4292</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The clin. success of mitomycin C (I) and its assocd. toxicities and resistance have led to efforts to prep. semisynthetic analogs (i.e., KW-2149 (II), BMS-181174) that have improved pharmacol. profiles.  In this study, we report the prepn. and evaluation of the novel 7-N-(1'-amino-4',5'-dithian-2'-yl)porfiromycin C(8) cyclized imine III (X = S) (IV) and its ref. compd., 7-N-(1'-aminocyclohex-2'-yl)porfiromycin C(8) cyclized imine III (X = CH2) (V).  (4R,5R)-4,5-Diamino-1,2-dithiane, prepd. starting from (2R,3R)-1,4-dibenzyloxy-2,3-butanediol, reacted with mitomycin F to give IV in 72% yield.  Porfiromycin IV contains a disulfide unit that, upon cleavage, may provide thiol(s) that affect drug reactivity.  We demonstrated that phosphines dramatically accelerated IV activation and solvolysis in methanolic solns. ("pH 7.4") compared with V.  Porfiromycins IV and V efficiently cross-linked EcoRI-linearized pBR322 DNA upon addn. of Et3P.  We found enhanced levels of interstrand cross-link (ISC) adducts for IV and V compared with porfiromycin (VI) and that IV was more efficient than V.  The large Et3P-mediated rate enhancements for the solvolysis of IV compared with V and a N(7)-substituted analog of I, and the increased levels of ISC adducts for IV compared with V and VI are attributed to a nucleophile-assisted disulfide cleavage process that permits porfiromycin activation and nucleophile (MeOH, DNA) adduction.  The in vitro antiproliferative activities of IV and V using the A549 tumor cell line (lung adenocarcinoma) were detd. under aerobic and hypoxic conditions and then compared with VI.  Both IV and V were more cytotoxic than VI, with V being more potent than IV.  The C(8) iminoporfiromycins IV and V displayed anticancer profiles similar to II.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRnpvLemcVSrVg90H21EOLACvtfcHk0lh_ovVzei4WCA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhvF2itbc%253D&md5=b4bea1cc62522c5f98dc60be686292c5</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1021%2Fja030577r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja030577r%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DS.%2BH.%26aulast%3DKohn%26aufirst%3DH.%26atitle%3DCyclic%2520disulfide%2520C%25288%2529%2520iminoporfiromycin%253A%2520nucleophilic%2520activation%2520of%2520a%2520porfiromycin%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2004%26volume%3D126%26spage%3D4281%26epage%3D4292%26doi%3D10.1021%2Fja030577r" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guinchard, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vallée, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denis, J.-N.</span></span> <span> </span><span class="NLM_article-title">Total synthesis of marine sponge bis(indole) alkaloids of the topsentin class</span>. <i>J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>72</i></span>,  <span class="NLM_fpage">3972</span>– <span class="NLM_lpage">3975</span>, <span class="refDoi"> DOI: 10.1021/jo070286r</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo070286r" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=1%3ACAS%3A528%3ADC%252BD2sXktlyjtLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2007&pages=3972-3975&author=X.+Guinchardauthor=Y.+Vall%C3%A9eauthor=J.-N.+Denis&title=Total+synthesis+of+marine+sponge+bis%28indole%29+alkaloids+of+the+topsentin+class&doi=10.1021%2Fjo070286r"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Total Synthesis of Marine Sponge Bis(indole) Alkaloids of the Topsentin Class</span></div><div class="casAuthors">Guinchard, Xavier; Vallee, Yannick; Denis, Jean-Noeel</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">3972-3975</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The synthesis of four natural bis(indole) alkaloids of the topsentin class is described.  Their bis(indole) α-carbonylimidazoline and subsequently bis(indole) α-carbonylimidazole moieties have been built via the condensation between indolic α-ketothioimidate salts and 1-(indol-3'-yl)-1,2-diaminoethane.  This is the first total synthesis of compds. isobromodeoxytopsentin I (double bond, R = Br), (±)-topsentin D I (single bond, R = H), and (±)-spongotine B I (single bond, R = Br).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGprrlRZqsUJrbVg90H21EOLACvtfcHk0lh_ovVzei4WCA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXktlyjtLY%253D&md5=a1b33bb71c7206f4246f428ed127872e</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1021%2Fjo070286r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo070286r%26sid%3Dliteratum%253Aachs%26aulast%3DGuinchard%26aufirst%3DX.%26aulast%3DVall%25C3%25A9e%26aufirst%3DY.%26aulast%3DDenis%26aufirst%3DJ.-N.%26atitle%3DTotal%2520synthesis%2520of%2520marine%2520sponge%2520bis%2528indole%2529%2520alkaloids%2520of%2520the%2520topsentin%2520class%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2007%26volume%3D72%26spage%3D3972%26epage%3D3975%26doi%3D10.1021%2Fjo070286r" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hwang, D.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, D. D.</span></span> <span> </span><span class="NLM_article-title">Structural Optimization of Indole Derivatives Acting at Colchicine Binding Site as Potential Anticancer Agents</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">993</span>– <span class="NLM_lpage">997</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.5b00208</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.5b00208" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht12gs77N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=993-997&author=D.-J.+Hwangauthor=J.+Wangauthor=W.+Liauthor=D.+D.+Miller&title=Structural+Optimization+of+Indole+Derivatives+Acting+at+Colchicine+Binding+Site+as+Potential+Anticancer+Agents&doi=10.1021%2Facsmedchemlett.5b00208"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Structural Optimization of Indole Derivatives Acting at Colchicine Binding Site as Potential Anticancer Agents</span></div><div class="casAuthors">Hwang, Dong-Jin; Wang, Jin; Li, Wei; Miller, Duane D.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">993-997</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Diarylisoquinolines and (trimethoxyphenyl)(indolyl)imidazopyridines I (R = 2-indolyl, 3-indolyl, 4-indolyl, 6-indolyl, 7-indolyl), analogs of a previous trimethoxybenzoylphenylindole and I (R = 5-indolyl), were prepd. as tubulin polymn. inhibitors acting at the colchicine binding site for potential use as antitumor agents with improved metabolic stabilities and cytotoxicities.  I (R = 2-indolyl, 3-indolyl, 4-indolyl, 6-indolyl, 7-indolyl) inhibited tubulin polymn. with IC50 values of 3 to 175 nM against a panel of human melanoma and prostate cancer cell lines.  In particular, I (R = 6-indolyl) showed improved cytotoxic potency (av. IC50 of 9.75 nM vs 55.75 nM) and metabolic stability in human liver microsomes (half-life time was 56.3 min vs. 45.4 min) as compared to previously reported I (R = 5-indolyl).  I (R = 6-indolyl) was effective against P-glycoprotein (P-gp) mediated multiple drug resistance (MDR) and taxol resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8lYd6NtCgfbVg90H21EOLACvtfcHk0ljylpvv7PyPCA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht12gs77N&md5=839b8e906ff050b9f96d167796bb912d</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.5b00208&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.5b00208%26sid%3Dliteratum%253Aachs%26aulast%3DHwang%26aufirst%3DD.-J.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DMiller%26aufirst%3DD.%2BD.%26atitle%3DStructural%2520Optimization%2520of%2520Indole%2520Derivatives%2520Acting%2520at%2520Colchicine%2520Binding%2520Site%2520as%2520Potential%2520Anticancer%2520Agents%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D6%26spage%3D993%26epage%3D997%26doi%3D10.1021%2Facsmedchemlett.5b00208" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Banerjee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnst, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, G.-b.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, D. D.</span></span> <span> </span><span class="NLM_article-title">Heterocyclic-fused pyrimidines as novel tubulin polymerization inhibitors targeting the colchicine binding site: structural basis and antitumor efficacy</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">1704</span>– <span class="NLM_lpage">1718</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01858</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01858" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=1%3ACAS%3A528%3ADC%252BC1cXit1Wjt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=1704-1718&author=S.+Banerjeeauthor=K.+E.+Arnstauthor=Y.+Wangauthor=G.+Kumarauthor=S.+Dengauthor=L.+Yangauthor=G.-b.+Liauthor=J.+Yangauthor=S.+W.+Whiteauthor=W.+Liauthor=D.+D.+Miller&title=Heterocyclic-fused+pyrimidines+as+novel+tubulin+polymerization+inhibitors+targeting+the+colchicine+binding+site%3A+structural+basis+and+antitumor+efficacy&doi=10.1021%2Facs.jmedchem.7b01858"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Heterocyclic-Fused Pyrimidines as Novel Tubulin Polymerization Inhibitors Targeting the Colchicine Binding Site: Structural Basis and Antitumor Efficacy</span></div><div class="casAuthors">Banerjee, Souvik; Arnst, Kinsie E.; Wang, Yuxi; Kumar, Gyanendra; Deng, Shanshan; Yang, Lei; Li, Guo-bo; Yang, Jinliang; White, Stephen W.; Li, Wei; Miller, Duane D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1704-1718</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We report the design, synthesis, and biol. evaluation of heterocyclic-fused pyrimidines as tubulin polymn. inhibitors targeting the colchicine binding site with significantly improved therapeutic index.  Addnl., for the first time, we report high-resoln. X-ray crystal structures for the best compds. in this scaffold.  These structures not only confirm their direct binding to the colchicine site in tubulin and reveal their detailed mol. interactions but also contrast the previously published proposed binding mode.  Compds. I and II significantly inhibited tumor growth in an A375 melanoma xenograft model and were accompanied by elevated levels of apoptosis and disruption of tumor vasculature.  Finally, we demonstrated that compd. I significantly overcame clin. relevant multidrug resistance in a paclitaxel resistant PC-3/TxR prostate cancer xenograft model.  Collectively, these studies provide preclin. and structural proof of concept to support the continued development of this scaffold as a new generation of tubulin inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoW5JWRge37JbVg90H21EOLACvtfcHk0ljylpvv7PyPCA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXit1Wjt7g%253D&md5=622af5cc1bf424daa681a22c33dfe288</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01858&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01858%26sid%3Dliteratum%253Aachs%26aulast%3DBanerjee%26aufirst%3DS.%26aulast%3DArnst%26aufirst%3DK.%2BE.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DKumar%26aufirst%3DG.%26aulast%3DDeng%26aufirst%3DS.%26aulast%3DYang%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DG.-b.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DWhite%26aufirst%3DS.%2BW.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DMiller%26aufirst%3DD.%2BD.%26atitle%3DHeterocyclic-fused%2520pyrimidines%2520as%2520novel%2520tubulin%2520polymerization%2520inhibitors%2520targeting%2520the%2520colchicine%2520binding%2520site%253A%2520structural%2520basis%2520and%2520antitumor%2520efficacy%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D1704%26epage%3D1718%26doi%3D10.1021%2Facs.jmedchem.7b01858" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dorleans, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gigant, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ravelli, R. B. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mailliet, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mikol, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knossow, M.</span></span> <span> </span><span class="NLM_article-title">Variations in the colchicine-binding domain provide insight into the structural switch of tubulin</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>106</i></span>,  <span class="NLM_fpage">13775</span>– <span class="NLM_lpage">13779</span>, <span class="refDoi"> DOI: 10.1073/pnas.0904223106</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=10.1073%2Fpnas.0904223106" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=19666559" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtFWksLrO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2009&pages=13775-13779&author=A.+Dorleansauthor=B.+Gigantauthor=R.+B.+G.+Ravelliauthor=P.+Maillietauthor=V.+Mikolauthor=M.+Knossow&title=Variations+in+the+colchicine-binding+domain+provide+insight+into+the+structural+switch+of+tubulin&doi=10.1073%2Fpnas.0904223106"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Variations in the colchicine-binding domain provide insight into the structural switch of tubulin</span></div><div class="casAuthors">Dorleans, Audrey; Gigant, Benoit; Ravelli, Raimond B. G.; Mailliet, Patrick; Mikol, Vincent; Knossow, Marcel</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">106</span>
        (<span class="NLM_cas:issue">33</span>),
    <span class="NLM_cas:pages">13775-13779, S13775/1-S13775/8</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Structural changes occur in the αβ-tubulin heterodimer during the microtubule assembly/disassembly cycle.  Their most prominent feature is a transition from a straight, microtubular structure to a curved structure.  There is a broad range of small mol. compds. that disturbs the microtubule cycle, a class of which targets the colchicine-binding site and prevents microtubule assembly.  This class includes compds. with very different chem. structures, and it is presently unknown whether they prevent tubulin polymn. by the same mechanism.  To address this issue, we have detd. the structures of tubulin complexed with a set of such ligands and show that they interfere with several of the movements of tubulin subunit structural elements upon its transition from curved to straight.  We also detd. the structure of tubulin unliganded at the colchicine site; this reveals that a β-tubulin loop (termed T7) flips into this site.  As with colchicine site ligands, this prevents a helix which is at the interface with α-tubulin from stacking onto a β-tubulin P sheet as in straight protofilaments.  Whereas in the presence of these ligands the interference with microtubule assembly gets frozen, by flipping in and out, the β-subunit T7 loop participates in a reversible way in the resistance to straightening that opposes microtubule assembly.  Our results suggest that it thereby contributes to microtubule dynamic instability.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDDUQBAmYNvbVg90H21EOLACvtfcHk0ljylpvv7PyPCA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtFWksLrO&md5=6d18732f78ac484b9db09ad1ec52aa5c</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0904223106&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0904223106%26sid%3Dliteratum%253Aachs%26aulast%3DDorleans%26aufirst%3DA.%26aulast%3DGigant%26aufirst%3DB.%26aulast%3DRavelli%26aufirst%3DR.%2BB.%2BG.%26aulast%3DMailliet%26aufirst%3DP.%26aulast%3DMikol%26aufirst%3DV.%26aulast%3DKnossow%26aufirst%3DM.%26atitle%3DVariations%2520in%2520the%2520colchicine-binding%2520domain%2520provide%2520insight%2520into%2520the%2520structural%2520switch%2520of%2520tubulin%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2009%26volume%3D106%26spage%3D13775%26epage%3D13779%26doi%3D10.1073%2Fpnas.0904223106" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Takeda, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mizokami, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mamiya, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keller, E. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Namiki, M.</span></span> <span> </span><span class="NLM_article-title">The establishment of two paclitaxel-resistant prostate cancer cell lines and the mechanisms of paclitaxel resistance with two cell lines</span>. <i>Prostate</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>67</i></span>,  <span class="NLM_fpage">955</span>– <span class="NLM_lpage">967</span>, <span class="refDoi"> DOI: 10.1002/pros.20581</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=10.1002%2Fpros.20581" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=17440963" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=1%3ACAS%3A528%3ADC%252BD2sXmvVKqt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2007&pages=955-967&author=M.+Takedaauthor=A.+Mizokamiauthor=K.+Mamiyaauthor=Y.+Q.+Liauthor=J.+Zhangauthor=E.+T.+Kellerauthor=M.+Namiki&title=The+establishment+of+two+paclitaxel-resistant+prostate+cancer+cell+lines+and+the+mechanisms+of+paclitaxel+resistance+with+two+cell+lines&doi=10.1002%2Fpros.20581"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">The establishment of two paclitaxel-resistant prostate cancer cell lines and the mechanisms of paclitaxel resistance with two cell lines</span></div><div class="casAuthors">Takeda, Masashi; Mizokami, Atsushi; Mamiya, Kiminori; Li, You Qiang; Zhang, Jian; Keller, Evan T.; Namiki, Mikio</div><div class="citationInfo"><span class="NLM_cas:title">Prostate (Hoboken, NJ, United States)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">955-967</span>CODEN:
                <span class="NLM_cas:coden">PRSTDS</span>;
        ISSN:<span class="NLM_cas:issn">0270-4137</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">BACKGROUND: Although paclitaxel is used for hormone-resistant prostate cancer, relapse definitely occurs later.  Details of the mol. mechanism responsible for paclitaxel-resistance remain unclear.  METHODS: We established paclitaxel-resistant cells, DU145-TxR and PC-3-TxR from parent DU145 and PC-3.  To characterize these cells, we examd. cross-resistance to other anticancer drugs.  Expression of several potential genes that had been related to drug-resistance was compared with parent cells by RT-PCR and Western blotting.  Methylation anal. of multiple drug resistance (MDR1) promoter was carried out using bisulfite-modified DNA from cell lines.  Knockdown expts. using small interfering RNA (siRNA) were also performed to confirm responsibility of drug-resistance.  Finally, cDNA microarray was performed to quantify gene expression in PC-3 and PC-3-TxR cells.  RESULTS: The IC50 for paclitaxel in DU145-TxR and PC-3-TxR was 34.0- and 43.4-fold higher than that in both parent cells, resp.  Both cells showed cross-resistance to some drugs, but not to VP-16 and cisplatin.  Methylation anal. revealed that methylated CpG sites of MDR1 promoter in DU145 and PC-3 cells were demethylated in DU145-TxR cells, but not in PC-3-TxR cells.  Knockdown of P-glycoprotein (P-gp), which was up-regulated in resistant cells, by MDR-1 siRNA restored paclitaxel sensitivity in DU145-TxR but not in PC-3-TxR, indicating that up-regulation of P-gp was not always main cause of paclitaxel-resistance.  Microarray anal. identified 201 (1.34%) up-regulated genes and 218 (1.45%) out of screened genes in PC-3-TxR.  CONCLUSIONS: Our data will provide mol. mechanisms of paclitaxel-resistance and be useful for screening target genes to diagnose paclitaxel sensitivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCs6firNNZ87Vg90H21EOLACvtfcHk0ljcuG0LKy5Amg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXmvVKqt7c%253D&md5=1b0e44bab963a7b82abc3eb6c979ca24</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1002%2Fpros.20581&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpros.20581%26sid%3Dliteratum%253Aachs%26aulast%3DTakeda%26aufirst%3DM.%26aulast%3DMizokami%26aufirst%3DA.%26aulast%3DMamiya%26aufirst%3DK.%26aulast%3DLi%26aufirst%3DY.%2BQ.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DKeller%26aufirst%3DE.%2BT.%26aulast%3DNamiki%26aufirst%3DM.%26atitle%3DThe%2520establishment%2520of%2520two%2520paclitaxel-resistant%2520prostate%2520cancer%2520cell%2520lines%2520and%2520the%2520mechanisms%2520of%2520paclitaxel%2520resistance%2520with%2520two%2520cell%2520lines%26jtitle%3DProstate%26date%3D2007%26volume%3D67%26spage%3D955%26epage%3D967%26doi%3D10.1002%2Fpros.20581" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Charbaut, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curmi, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ozon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lachkar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Redeker, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sobel, A.</span></span> <span> </span><span class="NLM_article-title">Stathmin family proteins display specific molecular and tubulin binding properties</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>276</i></span>,  <span class="NLM_fpage">16146</span>– <span class="NLM_lpage">16154</span>, <span class="refDoi"> DOI: 10.1074/jbc.m010637200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=10.1074%2Fjbc.m010637200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=11278715" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=1%3ACAS%3A528%3ADC%252BD3MXjvFaktL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=276&publication_year=2001&pages=16146-16154&author=E.+Charbautauthor=P.+A.+Curmiauthor=S.+Ozonauthor=S.+Lachkarauthor=V.+Redekerauthor=A.+Sobel&title=Stathmin+family+proteins+display+specific+molecular+and+tubulin+binding+properties&doi=10.1074%2Fjbc.m010637200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Stathmin family proteins display specific molecular and tubulin binding properties</span></div><div class="casAuthors">Charbaut, Elodie; Curmi, Patrick A.; Ozon, Sylvie; Lachkar, Sylvie; Redeker, Virginie; Sobel, Andre</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">276</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">16146-16154</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Stathmin family phosphoproteins (stathmin, SCG10, SCLIP, and RB3/RB3'/RB3") are involved in signal transduction and regulation of microtubule dynamics.  With the exception of stathmin, they are expressed exclusively in the nervous system, where they display different spatio-temporal and functional regulations and hence play at least partially distinct and possibly complementary roles in relation to the control of development, plasticity, and neuronal activities.  At the mol. level, each possesses a specific "stathmin-like domain" and, with the exception of stathmin, various combinations of N-terminal extensions involved in their assocn. with intracellular membrane compartments.  We show here that each stathmin-like domain also displays specific biochem. and tubulin interaction properties.  They are all able to sequester two α/β tubulin heterodimers as revealed by their inhibitory action on tubulin polymn. and by gel filtration.  However, they differ in the stabilities of the complexes formed as well as in their interaction kinetics with tubulin followed by surface plasmon resonance as follows: strong stability and slow kinetics for RB3; medium for SCG10, SCLIP, and stathmin; and weak stability and rapid kinetics for RB3'.  These results suggest that the fine-tuning of their stathmin-like domains contributes to the specific functional roles of stathmin family proteins in the regulation of microtubule dynamics within the various cell types and subcellular compartments of the developing or mature nervous system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoujSttSW0RxrVg90H21EOLACvtfcHk0ljcuG0LKy5Amg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXjvFaktL4%253D&md5=32e2b5ff9a7a14eaffcfd4a6b1b178ce</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1074%2Fjbc.m010637200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.m010637200%26sid%3Dliteratum%253Aachs%26aulast%3DCharbaut%26aufirst%3DE.%26aulast%3DCurmi%26aufirst%3DP.%2BA.%26aulast%3DOzon%26aufirst%3DS.%26aulast%3DLachkar%26aufirst%3DS.%26aulast%3DRedeker%26aufirst%3DV.%26aulast%3DSobel%26aufirst%3DA.%26atitle%3DStathmin%2520family%2520proteins%2520display%2520specific%2520molecular%2520and%2520tubulin%2520binding%2520properties%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2001%26volume%3D276%26spage%3D16146%26epage%3D16154%26doi%3D10.1074%2Fjbc.m010637200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dorleans, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gigant, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ravelli, R. B. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mailliet, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mikol, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knossow, M.</span></span> <span> </span><span class="NLM_article-title">Variations in the colchicine-binding domain provide insight into the structural switch of tubulin</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>106</i></span>,  <span class="NLM_fpage">13775</span>– <span class="NLM_lpage">13779</span>, <span class="refDoi"> DOI: 10.1073/pnas.0904223106</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=10.1073%2Fpnas.0904223106" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=19666559" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtFWksLrO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2009&pages=13775-13779&author=A.+Dorleansauthor=B.+Gigantauthor=R.+B.+G.+Ravelliauthor=P.+Maillietauthor=V.+Mikolauthor=M.+Knossow&title=Variations+in+the+colchicine-binding+domain+provide+insight+into+the+structural+switch+of+tubulin&doi=10.1073%2Fpnas.0904223106"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Variations in the colchicine-binding domain provide insight into the structural switch of tubulin</span></div><div class="casAuthors">Dorleans, Audrey; Gigant, Benoit; Ravelli, Raimond B. G.; Mailliet, Patrick; Mikol, Vincent; Knossow, Marcel</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">106</span>
        (<span class="NLM_cas:issue">33</span>),
    <span class="NLM_cas:pages">13775-13779, S13775/1-S13775/8</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Structural changes occur in the αβ-tubulin heterodimer during the microtubule assembly/disassembly cycle.  Their most prominent feature is a transition from a straight, microtubular structure to a curved structure.  There is a broad range of small mol. compds. that disturbs the microtubule cycle, a class of which targets the colchicine-binding site and prevents microtubule assembly.  This class includes compds. with very different chem. structures, and it is presently unknown whether they prevent tubulin polymn. by the same mechanism.  To address this issue, we have detd. the structures of tubulin complexed with a set of such ligands and show that they interfere with several of the movements of tubulin subunit structural elements upon its transition from curved to straight.  We also detd. the structure of tubulin unliganded at the colchicine site; this reveals that a β-tubulin loop (termed T7) flips into this site.  As with colchicine site ligands, this prevents a helix which is at the interface with α-tubulin from stacking onto a β-tubulin P sheet as in straight protofilaments.  Whereas in the presence of these ligands the interference with microtubule assembly gets frozen, by flipping in and out, the β-subunit T7 loop participates in a reversible way in the resistance to straightening that opposes microtubule assembly.  Our results suggest that it thereby contributes to microtubule dynamic instability.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDDUQBAmYNvbVg90H21EOLACvtfcHk0ljcuG0LKy5Amg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtFWksLrO&md5=6d18732f78ac484b9db09ad1ec52aa5c</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0904223106&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0904223106%26sid%3Dliteratum%253Aachs%26aulast%3DDorleans%26aufirst%3DA.%26aulast%3DGigant%26aufirst%3DB.%26aulast%3DRavelli%26aufirst%3DR.%2BB.%2BG.%26aulast%3DMailliet%26aufirst%3DP.%26aulast%3DMikol%26aufirst%3DV.%26aulast%3DKnossow%26aufirst%3DM.%26atitle%3DVariations%2520in%2520the%2520colchicine-binding%2520domain%2520provide%2520insight%2520into%2520the%2520structural%2520switch%2520of%2520tubulin%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2009%26volume%3D106%26spage%3D13775%26epage%3D13779%26doi%3D10.1073%2Fpnas.0904223106" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gigant, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span> <span> </span><span class="NLM_article-title">Structures of a diverse set of colchicine binding site inhibitors in complex with tubulin provide a rationale for drug discovery</span>. <i>FEBS J.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>283</i></span>,  <span class="NLM_fpage">102</span>– <span class="NLM_lpage">111</span>, <span class="refDoi"> DOI: 10.1111/febs.13555</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=10.1111%2Ffebs.13555" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=26462166" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslKktrzP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=283&publication_year=2016&pages=102-111&author=Y.+Wangauthor=H.+Zhangauthor=B.+Gigantauthor=Y.+Yuauthor=Y.+Wuauthor=X.+Chenauthor=Q.+Laiauthor=Z.+Yangauthor=Q.+Chenauthor=J.+Yang&title=Structures+of+a+diverse+set+of+colchicine+binding+site+inhibitors+in+complex+with+tubulin+provide+a+rationale+for+drug+discovery&doi=10.1111%2Ffebs.13555"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Structures of a diverse set of colchicine binding site inhibitors in complex with tubulin provide a rationale for drug discovery</span></div><div class="casAuthors">Wang, Yuxi; Zhang, Hang; Gigant, Benoit; Yu, Yamei; Wu, Yangping; Chen, Xiangzheng; Lai, Qinhuai; Yang, Zhaoya; Chen, Qiang; Yang, Jinliang</div><div class="citationInfo"><span class="NLM_cas:title">FEBS Journal</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">283</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">102-111</span>CODEN:
                <span class="NLM_cas:coden">FJEOAC</span>;
        ISSN:<span class="NLM_cas:issn">1742-464X</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Microtubules are dynamic assemblies of αβ-tubulin heterodimers and have been recognized as highly attractive targets for cancer chemotherapy.  A broad range of agents bind to tubulin and interfere with microtubule assembly.  Despite having a long history of characterization, colchicine binding site inhibitors (CBSIs) have not yet reached the com. phase as anti-cancer drugs to date.  We detd. the structures of tubulin complexed with a set of structurally diverse CBSIs (lexibulin, nocodazole, plinabulin and tivantinib), among which nocodazole and tivantinib are both binary-function inhibitors targeting cancer-related kinases and microtubules simultaneously.  High resoln. structures revealed the detailed interactions between these ligands and tubulin.  Our results showed that the binding modes of the CBSIs were different from previous docking models, highlighting the importance of crystal structure information in structure-based drug design.  A real structure-based pharmacophore was proposed to rationalize key common interactions of the CBSIs at the colchicine domain.  Our studies provide a solid structural basis for developing new anti-cancer agents for the colchicine binding site.  Database : The at. coordinates and structure factors for tubulin complexed with lexibulin, nocodazole, plinabulin and tivantinib have been deposited in the Protein Data Bank under accession codes , , and , resp.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpSIAVSS_EsIbVg90H21EOLACvtfcHk0ljBM1eksqEm0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslKktrzP&md5=d5a17d9a3ac54d8eda44d0543ffa5fbd</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1111%2Ffebs.13555&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Ffebs.13555%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DGigant%26aufirst%3DB.%26aulast%3DYu%26aufirst%3DY.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DLai%26aufirst%3DQ.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DChen%26aufirst%3DQ.%26aulast%3DYang%26aufirst%3DJ.%26atitle%3DStructures%2520of%2520a%2520diverse%2520set%2520of%2520colchicine%2520binding%2520site%2520inhibitors%2520in%2520complex%2520with%2520tubulin%2520provide%2520a%2520rationale%2520for%2520drug%2520discovery%26jtitle%3DFEBS%2520J.%26date%3D2016%26volume%3D283%26spage%3D102%26epage%3D111%26doi%3D10.1111%2Ffebs.13555" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Prota, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bargsten, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zurwerra, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Field, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Díaz, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altmann, K.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinmetz, M. O.</span></span> <span> </span><span class="NLM_article-title">Molecular mechanism of action of microtubule-stabilizing anticancer agents</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>339</i></span>,  <span class="NLM_fpage">587</span>– <span class="NLM_lpage">590</span>, <span class="refDoi"> DOI: 10.1126/science.1230582</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=10.1126%2Fscience.1230582" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=23287720" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsFGrsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=339&publication_year=2013&pages=587-590&author=A.+E.+Protaauthor=K.+Bargstenauthor=D.+Zurwerraauthor=J.+J.+Fieldauthor=J.+F.+D%C3%ADazauthor=K.-H.+Altmannauthor=M.+O.+Steinmetz&title=Molecular+mechanism+of+action+of+microtubule-stabilizing+anticancer+agents&doi=10.1126%2Fscience.1230582"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular Mechanism of Action of Microtubule-Stabilizing Anticancer Agents</span></div><div class="casAuthors">Prota, Andrea E.; Bargsten, Katja; Zurwerra, Didier; Field, Jessica J.; Diaz, Jose Fernando; Altmann, Karl-Heinz; Steinmetz, Michel O.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">339</span>
        (<span class="NLM_cas:issue">6119</span>),
    <span class="NLM_cas:pages">587-590</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Microtubule-stabilizing agents (MSAs) are efficacious chemotherapeutic drugs widely used for the treatment of cancer.  Despite the importance of MSAs for medical applications and basic research, their mol. mechanisms of action on tubulin and microtubules remain elusive.  We detd. high-resoln. crystal structures of αβ-tubulin in complex with two unrelated MSAs, zampanolide and epothilone A.  Both compds. were bound to the taxane pocket of β-tubulin and used their resp. side chains to induce structuring of the M-loop into a short helix.  Because the M-loop establishes lateral tubulin contacts in microtubules, these findings explain how taxane-site MSAs promote microtubule assembly and stability.  Further, our results offer fundamental structural insights into the control mechanisms of microtubule dynamics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_p8NfCWTU-rVg90H21EOLACvtfcHk0ljBM1eksqEm0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsFGrsrw%253D&md5=b253c015f75f5eac4857d01e34d65f54</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1126%2Fscience.1230582&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1230582%26sid%3Dliteratum%253Aachs%26aulast%3DProta%26aufirst%3DA.%2BE.%26aulast%3DBargsten%26aufirst%3DK.%26aulast%3DZurwerra%26aufirst%3DD.%26aulast%3DField%26aufirst%3DJ.%2BJ.%26aulast%3DD%25C3%25ADaz%26aufirst%3DJ.%2BF.%26aulast%3DAltmann%26aufirst%3DK.-H.%26aulast%3DSteinmetz%26aufirst%3DM.%2BO.%26atitle%3DMolecular%2520mechanism%2520of%2520action%2520of%2520microtubule-stabilizing%2520anticancer%2520agents%26jtitle%3DScience%26date%3D2013%26volume%3D339%26spage%3D587%26epage%3D590%26doi%3D10.1126%2Fscience.1230582" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, G. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gigant, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span> <span> </span><span class="NLM_article-title">Mechanism of microtubule stabilization by taccalonolide AJ</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">15787</span>, <span class="refDoi"> DOI: 10.1038/ncomms15787</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=10.1038%2Fncomms15787" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=28585532" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=1%3ACAS%3A528%3ADC%252BC2sXpsVCju7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=15787&author=Y.+Wangauthor=Y.+Yuauthor=G.+B.+Liauthor=S.+A.+Liauthor=C.+Wuauthor=B.+Gigantauthor=W.+Qinauthor=H.+Chenauthor=Y.+Wuauthor=Q.+Chenauthor=J.+Yang&title=Mechanism+of+microtubule+stabilization+by+taccalonolide+AJ&doi=10.1038%2Fncomms15787"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanism of microtubule stabilization by taccalonolide AJ</span></div><div class="casAuthors">Wang, Yuxi; Yu, Yamei; Li, Guo-Bo; Li, Shu-Ang; Wu, Chengyong; Gigant, Benoit; Qin, Wenming; Chen, Hao; Wu, Yangping; Chen, Qiang; Yang, Jinliang</div><div class="citationInfo"><span class="NLM_cas:title">Nature Communications</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">15787</span>CODEN:
                <span class="NLM_cas:coden">NCAOBW</span>;
        ISSN:<span class="NLM_cas:issn">2041-1723</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">As a major component of the cytoskeleton, microtubules consist of αβ-tubulin heterodimers and have been recognized as attractive targets for cancer chemotherapy.  Microtubule-stabilizing agents (MSAs) promote polymn. of tubulin and stabilize the polymer, preventing depolymn.  The mol. mechanisms by which MSAs stabilize microtubules remain elusive.  Here we report a 2.05 Å crystal structure of tubulin complexed with taccalonolide AJ, a newly identified taxane-site MSA.  Taccalonolide AJ covalently binds to β-tubulin D226.  On AJ binding, the M-loop undergoes a conformational shift to facilitate tubulin polymn.  In this tubulin-AJ complex, the E-site of tubulin is occupied by GTP rather than GDP.  Biochem. analyses confirm that AJ inhibits the hydrolysis of the E-site GTP.  Thus, we propose that the β-tubulin E-site is locked into a GTP-preferred status by AJ binding.  Our results provide exptl. evidence for the connection between MSA binding and tubulin nucleotide state, and will help design new MSAs to overcome taxane resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqSK9tvLSmUDbVg90H21EOLACvtfcHk0ljBM1eksqEm0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXpsVCju7o%253D&md5=7179fffb3aeade3b4bfd76ead6565363</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1038%2Fncomms15787&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncomms15787%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DY.%26aulast%3DYu%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DG.%2BB.%26aulast%3DLi%26aufirst%3DS.%2BA.%26aulast%3DWu%26aufirst%3DC.%26aulast%3DGigant%26aufirst%3DB.%26aulast%3DQin%26aufirst%3DW.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DQ.%26aulast%3DYang%26aufirst%3DJ.%26atitle%3DMechanism%2520of%2520microtubule%2520stabilization%2520by%2520taccalonolide%2520AJ%26jtitle%3DNat.%2520Commun.%26date%3D2017%26volume%3D8%26spage%3D15787%26doi%3D10.1038%2Fncomms15787" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Otwinowski, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minor, W.</span></span> <span> </span><span class="NLM_article-title">[20] Processing of X-ray diffraction data collected in oscillation mode</span>. <i>Methods Enzymol.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>276</i></span>,  <span class="NLM_fpage">307</span>– <span class="NLM_lpage">326</span>, <span class="refDoi"> DOI: 10.1016/s0076-6879(97)76066-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=10.1016%2FS0076-6879%2897%2976066-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=27754618" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=1%3ACAS%3A528%3ADyaK2sXivFehsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=276&publication_year=1997&pages=307-326&author=Z.+Otwinowskiauthor=W.+Minor&title=%5B20%5D+Processing+of+X-ray+diffraction+data+collected+in+oscillation+mode&doi=10.1016%2Fs0076-6879%2897%2976066-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Processing of x-ray diffraction data collected in oscillation mode</span></div><div class="casAuthors">Otwinowski, Zbyszek; Minor, Wladek</div><div class="citationInfo"><span class="NLM_cas:title">Methods in Enzymology</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">276</span>
        (<span class="NLM_cas:issue">Macromolecular Crystallography, Part A</span>),
    <span class="NLM_cas:pages">307-326</span>CODEN:
                <span class="NLM_cas:coden">MENZAU</span>;
        ISSN:<span class="NLM_cas:issn">0076-6879</span>.
    
            (<span class="NLM_cas:orgname">Academic</span>)
        </div><div class="casAbstract">Macromol. crystallog. is an iterative process.  Rarely do the first crystals provide all the necessary data to solve the biol. problem being studied.  Each step benefits from experience learned in previous steps.  To monitor the progress, the HKL package provides 2 tools: (1) statistics, both weighted (χ2) and unweighted (R-merge), are provided, and the Bayesian reasoning and multicomponent error model facilitates obtaining the proper error ests. and (2) visualization of the process plays a double role by helping the operator to confirm that the process of data redn., including the resulting statistics, is correct, and allowing one to evaluate problems for which there are no good statistical criteria.  Visualization also provides confidence that the point of diminishing returns in data collection and redn. has been reached.  At that point, the effort should be directed to solving the structure.  The methods presented here have been applied to solve a large variety of problems, from inorg. mols. with 5 Å unit cell to rotavirus of 700 Å diam. crystd. in 700 × 1000 × 1400 Å cell.  Overall quality of the method was tested by many researchers by successful application of the programs to MAD structure detns.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrA3fvBOHqhhrVg90H21EOLACvtfcHk0lij6abx1n4CHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXivFehsbw%253D&md5=c9536971d4e32cc35352c40fb9368131</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1016%2FS0076-6879%2897%2976066-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0076-6879%252897%252976066-X%26sid%3Dliteratum%253Aachs%26aulast%3DOtwinowski%26aufirst%3DZ.%26aulast%3DMinor%26aufirst%3DW.%26atitle%3D%255B20%255D%2520Processing%2520of%2520X-ray%2520diffraction%2520data%2520collected%2520in%2520oscillation%2520mode%26jtitle%3DMethods%2520Enzymol.%26date%3D1997%26volume%3D276%26spage%3D307%26epage%3D326%26doi%3D10.1016%2Fs0076-6879%2897%2976066-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Adams, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grosse-Kunstleve, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hung, L.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ioerger, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCoy, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moriarty, N. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Read, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sacchettini, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sauter, N. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terwilliger, T. C.</span></span> <span> </span><span class="NLM_article-title">PHENIX: building new software for automated crystallographic structure determination</span>. <i>Acta Crystallogr. D</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">1948</span>– <span class="NLM_lpage">1954</span>, <span class="refDoi"> DOI: 10.1107/s0907444902016657</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=10.1107%2Fs0907444902016657" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=12393927" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=1%3ACAS%3A528%3ADC%252BD38XotVCksbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2002&pages=1948-1954&author=P.+D.+Adamsauthor=R.+W.+Grosse-Kunstleveauthor=L.-W.+Hungauthor=T.+R.+Ioergerauthor=A.+J.+McCoyauthor=N.+W.+Moriartyauthor=R.+J.+Readauthor=J.+C.+Sacchettiniauthor=N.+K.+Sauterauthor=T.+C.+Terwilliger&title=PHENIX%3A+building+new+software+for+automated+crystallographic+structure+determination&doi=10.1107%2Fs0907444902016657"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">PHENIX: building new software for automated crystallographic structure determination</span></div><div class="casAuthors">Adams, Paul D.; Grosse-Kunstleve, Ralf W.; Hung, Li Wei; Ioerger, Thomas R.; McCoy, Airlie J.; Moriarty, Nigel W.; Read, Randy J.; Sacchettini, James C.; Sauter, Nicholas K.; Terwilliger, Thomas C.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">D58</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1948-1954</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Munksgaard</span>)
        </div><div class="casAbstract">Structural genomics seeks to rapidly expand the no. of protein structures to ext. the max. amt. of information from genomic sequence databases.  The advent of several large-scale projects worldwide leads to many new challenges in the field of crystallog. macromol. structure detn.  A novel software package, called PHENIX (Python-based Hierarchical Environment for Integrated Xtallog.), is therefore being developed.  This new software will provide the necessary algorithms to proceed from reduced intensity data to a refined mol. model and to facilitate structure soln. for both the novice and expert crystallographer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrOtuUfHXPmCbVg90H21EOLACvtfcHk0lij6abx1n4CHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XotVCksbc%253D&md5=9a3b66e1f7d064183f7a9ce108cb4e5e</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1107%2Fs0907444902016657&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252Fs0907444902016657%26sid%3Dliteratum%253Aachs%26aulast%3DAdams%26aufirst%3DP.%2BD.%26aulast%3DGrosse-Kunstleve%26aufirst%3DR.%2BW.%26aulast%3DHung%26aufirst%3DL.-W.%26aulast%3DIoerger%26aufirst%3DT.%2BR.%26aulast%3DMcCoy%26aufirst%3DA.%2BJ.%26aulast%3DMoriarty%26aufirst%3DN.%2BW.%26aulast%3DRead%26aufirst%3DR.%2BJ.%26aulast%3DSacchettini%26aufirst%3DJ.%2BC.%26aulast%3DSauter%26aufirst%3DN.%2BK.%26aulast%3DTerwilliger%26aufirst%3DT.%2BC.%26atitle%3DPHENIX%253A%2520building%2520new%2520software%2520for%2520automated%2520crystallographic%2520structure%2520determination%26jtitle%3DActa%2520Crystallogr.%2520D%26date%3D2002%26volume%3D58%26spage%3D1948%26epage%3D1954%26doi%3D10.1107%2Fs0907444902016657" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mahindroo, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Connelly, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Punchihewa, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujii, N.</span></span> <span> </span><span class="NLM_article-title">Amide conjugates of ketoprofen and indole as inhibitors of Gli1-mediated transcription in the Hedgehog pathway</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">4801</span>– <span class="NLM_lpage">4811</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2010.05.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=10.1016%2Fj.bmc.2010.05.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=20605720" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=1%3ACAS%3A528%3ADC%252BC3cXnsValsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2010&pages=4801-4811&author=N.+Mahindrooauthor=M.+C.+Connellyauthor=C.+Punchihewaauthor=L.+Yangauthor=B.+Yanauthor=N.+Fujii&title=Amide+conjugates+of+ketoprofen+and+indole+as+inhibitors+of+Gli1-mediated+transcription+in+the+Hedgehog+pathway&doi=10.1016%2Fj.bmc.2010.05.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Amide conjugates of ketoprofen and indole as inhibitors of Gli1-mediated transcription in the Hedgehog pathway</span></div><div class="casAuthors">Mahindroo, Neeraj; Connelly, Michele C.; Punchihewa, Chandanamali; Yang, Lei; Yan, Bing; Fujii, Naoaki</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">4801-4811</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">We have previously reported small-mol. inhibitors of Gli1-mediated transcription, an essential down-stream element of the Hh pathway.  We created new derivs. of the previous compds. aiming to improve the druggable properties.  The new compds., amide conjugates of ketoprofen and indole, showed inhibitory activity and membrane permeability, while also improving the microsome stability.  Among them, 33 and 42 inhibited Gli-luciferase reporter in C3H10T1/2 cells that were exogenously transfected with Gli1 with 2.6 μM and 1.6 μM of IC50, resp., and in Rh30 cells that endogenously overexpress Gli1, and were selective to Gli1 over Gli2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoobxouC8aCzrVg90H21EOLACvtfcHk0lij6abx1n4CHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXnsValsbs%253D&md5=5a9380d12788fb1d058f3850b465e24a</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2010.05.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2010.05.001%26sid%3Dliteratum%253Aachs%26aulast%3DMahindroo%26aufirst%3DN.%26aulast%3DConnelly%26aufirst%3DM.%2BC.%26aulast%3DPunchihewa%26aufirst%3DC.%26aulast%3DYang%26aufirst%3DL.%26aulast%3DYan%26aufirst%3DB.%26aulast%3DFujii%26aufirst%3DN.%26atitle%3DAmide%2520conjugates%2520of%2520ketoprofen%2520and%2520indole%2520as%2520inhibitors%2520of%2520Gli1-mediated%2520transcription%2520in%2520the%2520Hedgehog%2520pathway%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2010%26volume%3D18%26spage%3D4801%26epage%3D4811%26doi%3D10.1016%2Fj.bmc.2010.05.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Di, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kerns, E. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petusky, S. L.</span></span> <span> </span><span class="NLM_article-title">High throughput microsomal stability assay for insoluble compounds</span>. <i>Int. J. Pharm.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>317</i></span>,  <span class="NLM_fpage">54</span>– <span class="NLM_lpage">60</span>, <span class="refDoi"> DOI: 10.1016/j.ijpharm.2006.03.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=10.1016%2Fj.ijpharm.2006.03.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=16621364" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=1%3ACAS%3A528%3ADC%252BD28XlsFClt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=317&publication_year=2006&pages=54-60&author=L.+Diauthor=E.+H.+Kernsauthor=S.+Q.+Liauthor=S.+L.+Petusky&title=High+throughput+microsomal+stability+assay+for+insoluble+compounds&doi=10.1016%2Fj.ijpharm.2006.03.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">High throughput microsomal stability assay for insoluble compounds</span></div><div class="casAuthors">Di, Li; Kerns, Edward H.; Li, Susan Q.; Petusky, Susan L.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Pharmaceutics</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">317</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">54-60</span>CODEN:
                <span class="NLM_cas:coden">IJPHDE</span>;
        ISSN:<span class="NLM_cas:issn">0378-5173</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">High throughput metabolic stability assays are widely implemented in drug discovery to guide structural modification, predict in vivo performance, develop structure-metabolic stability relationships, and triage compds. for in vivo animal studies.  However, these methods are often developed and validated using com. drugs.  Many drug discovery compds. differ from com. drugs, with many having high lipophilicity, high mol. wt. and low soly.  The impact of very low soly. on metabolic stability assay results was explored.  Two metabolic stability assays, the aq. diln. method' and the cosolvent method, were compared.  For com. drugs and most discovery compds. having reasonable drug-like properties, the two methods gave comparable results.  For highly lipophilic, insol. drug discovery compds., the aq. diln. method' gave artificially higher stability results.  The cosolvent method performs compd. dilns. in solns. with higher org. solvent content and adds solns. directly to microsomes to assist with solubilization, minimize pptn. and reduce non-specific binding to plastics.  This method is more applicable in drug discovery where compds. of a wide range of soly. are studied.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGi5RwiHs137Vg90H21EOLACvtfcHk0lgNXt6ViJ3zzw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XlsFClt70%253D&md5=8c84b1043c094df280ac095290d0f9aa</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1016%2Fj.ijpharm.2006.03.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ijpharm.2006.03.007%26sid%3Dliteratum%253Aachs%26aulast%3DDi%26aufirst%3DL.%26aulast%3DKerns%26aufirst%3DE.%2BH.%26aulast%3DLi%26aufirst%3DS.%2BQ.%26aulast%3DPetusky%26aufirst%3DS.%2BL.%26atitle%3DHigh%2520throughput%2520microsomal%2520stability%2520assay%2520for%2520insoluble%2520compounds%26jtitle%3DInt.%2520J.%2520Pharm.%26date%3D2006%26volume%3D317%26spage%3D54%26epage%3D60%26doi%3D10.1016%2Fj.ijpharm.2006.03.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Davies, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morris, T.</span></span> <span> </span><span class="NLM_article-title">Physiological-parameters in laboratory-animals and humans</span>. <i>Pharm. Res.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">1093</span>– <span class="NLM_lpage">1095</span>, <span class="refDoi"> DOI: 10.1023/a:1018943613122</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=10.1023%2Fa%3A1018943613122" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=8378254" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=1%3ACAS%3A280%3ADyaK3szptFaqsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=1993&pages=1093-1095&author=B.+Daviesauthor=T.+Morris&title=Physiological-parameters+in+laboratory-animals+and+humans&doi=10.1023%2Fa%3A1018943613122"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Physiological parameters in laboratory animals and humans</span></div><div class="casAuthors">Davies B; Morris T</div><div class="citationInfo"><span class="NLM_cas:title">Pharmaceutical research</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1093-5</span>
        ISSN:<span class="NLM_cas:issn">0724-8741</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRDDwka3A6hEYYPsCkJIw00fW6udTcc2ebN3XUcWadfvrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK3szptFaqsg%253D%253D&md5=094cdd17306b58cc17c8cf4fd5db9927</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1023%2Fa%3A1018943613122&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1023%252Fa%253A1018943613122%26sid%3Dliteratum%253Aachs%26aulast%3DDavies%26aufirst%3DB.%26aulast%3DMorris%26aufirst%3DT.%26atitle%3DPhysiological-parameters%2520in%2520laboratory-animals%2520and%2520humans%26jtitle%3DPharm.%2520Res.%26date%3D1993%26volume%3D10%26spage%3D1093%26epage%3D1095%26doi%3D10.1023%2Fa%3A1018943613122" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span> <span> </span><span class="NLM_article-title">Synergistic Combination of Novel Tubulin Inhibitor ABI-274 and Vemurafenib Overcomes Vemurafenib Acquired Resistance in BRAFV600E Melanoma</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">16</span>– <span class="NLM_lpage">26</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.mct-13-0212</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=10.1158%2F1535-7163.mct-13-0212" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=24249714" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=1%3ACAS%3A528%3ADC%252BC2cXnsFSgug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=16-26&author=J.+Wangauthor=J.+Chenauthor=D.+D.+Millerauthor=W.+Li&title=Synergistic+Combination+of+Novel+Tubulin+Inhibitor+ABI-274+and+Vemurafenib+Overcomes+Vemurafenib+Acquired+Resistance+in+BRAFV600E+Melanoma&doi=10.1158%2F1535-7163.mct-13-0212"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Synergistic Combination of Novel Tubulin Inhibitor ABI-274 and Vemurafenib Overcome Vemurafenib Acquired Resistance in BRAFV600E Melanoma</span></div><div class="casAuthors">Wang, Jin; Chen, Jianjun; Miller, Duane D.; Li, Wei</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">16-26</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Acquired clin. resistance to vemurafenib, a selective BRAFV600E inhibitor, arises frequently after short-term chemotherapy.  Because inhibitions of targets in the RAF-MEK-ERK pathway result in G0-G1 cell-cycle arrest, vemurafenib-resistant cancer cells are expected to escape this cell-cycle arrest and progress to the subsequent G2-M phase.  We hypothesized that a combined therapy using vemurafenib with a G2-M phase blocking agent will trap resistant cells and overcome vemurafenib resistance.  To test this hypothesis, we first detd. the combination index (CI) values of our novel tubulin inhibitor ABI-274 and vemurafenib on parental human A375 and MDA-MB-435 melanoma cell lines to be 0.32 and 0.1, resp., suggesting strong synergy for the combination.  We then developed an A375RF21 subline with significant acquired resistance to vemurafenib and confirmed the strong synergistic effect.  Next, we studied the potential mechanisms of overcoming vemurafenib resistance.  Flow cytometry confirmed that the combination of ABI-274 and vemurafenib synergistically arrested cells in the G1-G2-M phase, and significantly increased apoptosis in both parental A375 and the vemurafenib-resistant A375RF21 cells.  Western blot anal. revealed that the combination treatment effectively reduced the level of phosphorylated and total AKT, activated the apoptosis cascade, and increased cleaved caspase-3 and cleaved PARP, but had no significant influence on the level of extracellular signal-regulated kinase (ERK) phosphorylation.  Finally, in vivo coadministration of vemurafenib with ABI-274 showed strong synergistic efficacy in the vemurafenib-resistant xenograft model in nude mice.  Overall, these results offer a rational combination strategy to significantly enhance the therapeutic benefit in patients with melanoma who inevitably become resistant to current vemurafenib therapy.  Mol Cancer Ther; 13(1); 16-26. ©2013 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoRH17pt08sjrVg90H21EOLACvtfcHk0lgNXt6ViJ3zzw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXnsFSgug%253D%253D&md5=06102f006f2cd3b41a56d0ef3e72e6e9</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.mct-13-0212&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.mct-13-0212%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DMiller%26aufirst%3DD.%2BD.%26aulast%3DLi%26aufirst%3DW.%26atitle%3DSynergistic%2520Combination%2520of%2520Novel%2520Tubulin%2520Inhibitor%2520ABI-274%2520and%2520Vemurafenib%2520Overcomes%2520Vemurafenib%2520Acquired%2520Resistance%2520in%2520BRAFV600E%2520Melanoma%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2014%26volume%3D13%26spage%3D16%26epage%3D26%26doi%3D10.1158%2F1535-7163.mct-13-0212" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 20 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Xiaopeng Peng, Jingxuan Chen, Ling Li, Zhiqiang Sun, Jin Liu, Yichang Ren, Junli Huang, <span class="NLM_string-name hlFld-ContribAuthor">Jianjun Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Efficient Synthesis and Bioevaluation of Novel Dual Tubulin/Histone Deacetylase 3 Inhibitors as Potential Anticancer Agents. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (12)
                                     , 8447-8473. <a href="https://doi.org/10.1021/acs.jmedchem.1c00413" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.1c00413</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.1c00413&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.1c00413%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DEfficient%252BSynthesis%252Band%252BBioevaluation%252Bof%252BNovel%252BDual%252BTubulin%25252FHistone%252BDeacetylase%252B3%252BInhibitors%252Bas%252BPotential%252BAnticancer%252BAgents%26aulast%3DPeng%26aufirst%3DXiaopeng%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D08032021%26date%3D07062021%26volume%3D64%26issue%3D12%26spage%3D8447%26epage%3D8473" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Yichang Ren, Yuxi Wang, Gang Li, Zherong Zhang, Lingling Ma, Binbin Cheng, <span class="NLM_string-name hlFld-ContribAuthor">Jianjun Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of Novel Benzimidazole and Indazole Analogues as Tubulin Polymerization Inhibitors with Potent Anticancer Activities. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (8)
                                     , 4498-4515. <a href="https://doi.org/10.1021/acs.jmedchem.0c01837" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01837</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01837&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01837%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BNovel%252BBenzimidazole%252Band%252BIndazole%252BAnalogues%252Bas%252BTubulin%252BPolymerization%252BInhibitors%252Bwith%252BPotent%252BAnticancer%252BActivities%26aulast%3DRen%26aufirst%3DYichang%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D21102020%26date%3D31032021%26volume%3D64%26issue%3D8%26spage%3D4498%26epage%3D4515" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Yi He, Liangliang Song, Chao Liu, Danjun Wu, Zhenghua Li, Luc Van Meervelt, <span class="NLM_string-name hlFld-ContribAuthor">Erik V. Van der Eycken</span>. </span><span class="cited-content_cbyCitation_article-title">Access to Polycyclic Azepino[5,4,3-cd]indoles via a Gold-Catalyzed Post-Ugi Dearomatization Cascade. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Organic Chemistry</span><span> <strong>2020,</strong> <em>85 </em>
                                    (23)
                                     , 15092-15103. <a href="https://doi.org/10.1021/acs.joc.0c01972" title="DOI URL">https://doi.org/10.1021/acs.joc.0c01972</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.joc.0c01972&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.joc.0c01972%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DAccess%252Bto%252BPolycyclic%252BAzepino%25255B5%25252C4%25252C3-cd%25255Dindoles%252Bvia%252Ba%252BGold-Catalyzed%252BPost-Ugi%252BDearomatization%252BCascade%26aulast%3DHe%26aufirst%3DYi%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D15082020%26date%3D17112020%26volume%3D85%26issue%3D23%26spage%3D15092%26epage%3D15103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Pan Huang, Xiangyang Le, Fei Huang, Jie Yang, Haofeng Yang, Junlong Ma, Gaoyun Hu, Qianbin Li, <span class="NLM_string-name hlFld-ContribAuthor">Zhuo Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of a Dual Tubulin Polymerization and Cell Division Cycle 20 Homologue Inhibitor via Structural Modification on Apcin. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (9)
                                     , 4685-4700. <a href="https://doi.org/10.1021/acs.jmedchem.9b02097" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b02097</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b02097&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b02097%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Ba%252BDual%252BTubulin%252BPolymerization%252Band%252BCell%252BDivision%252BCycle%252B20%252BHomologue%252BInhibitor%252Bvia%252BStructural%252BModification%252Bon%252BApcin%26aulast%3DHuang%26aufirst%3DPan%26date%3D2020%26date%3D2020%26date%3D2019%26date%3D17122019%26date%3D27042020%26date%3D15042020%26volume%3D63%26issue%3D9%26spage%3D4685%26epage%3D4700" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Hao Chen, Shanshan Deng, Yuxi Wang, Najah Albadari, Gyanendra Kumar, Dejian Ma, Weimin Li, Stephen W. White, Duane D. Miller, <span class="NLM_string-name hlFld-ContribAuthor">Wei Li</span>. </span><span class="cited-content_cbyCitation_article-title">Structure–Activity Relationship Study of Novel 6-Aryl-2-benzoyl-pyridines as Tubulin Polymerization Inhibitors with Potent Antiproliferative Properties. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (2)
                                     , 827-846. <a href="https://doi.org/10.1021/acs.jmedchem.9b01815" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b01815</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b01815&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b01815%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DStructure%2525E2%252580%252593Activity%252BRelationship%252BStudy%252Bof%252BNovel%252B6-Aryl-2-benzoyl-pyridines%252Bas%252BTubulin%252BPolymerization%252BInhibitors%252Bwith%252BPotent%252BAntiproliferative%252BProperties%26aulast%3DChen%26aufirst%3DHao%26date%3D2020%26date%3D2019%26date%3D2019%26date%3D01112019%26date%3D07012020%26date%3D20122019%26volume%3D63%26issue%3D2%26spage%3D827%26epage%3D846" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hairong  Tang</span>, <span class="hlFld-ContribAuthor ">Yuru  Liang</span>, <span class="hlFld-ContribAuthor ">Jiayi  Cheng</span>, <span class="hlFld-ContribAuthor ">Kuiling  Ding</span>, <span class="hlFld-ContribAuthor ">Yang  Wang</span>. </span><span class="cited-content_cbyCitation_article-title">Bifunctional chiral selenium-containing 1,4-diarylazetidin-2-ones with potent antitumor activities by disrupting tubulin polymerization and inducing reactive oxygen species production. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>221 </em>, 113531. <a href="https://doi.org/10.1016/j.ejmech.2021.113531" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113531</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113531&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113531%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DBifunctional%252Bchiral%252Bselenium-containing%252B1%25252C4-diarylazetidin-2-ones%252Bwith%252Bpotent%252Bantitumor%252Bactivities%252Bby%252Bdisrupting%252Btubulin%252Bpolymerization%252Band%252Binducing%252Breactive%252Boxygen%252Bspecies%252Bproduction%26aulast%3DTang%26aufirst%3DHairong%26date%3D2021%26volume%3D221%26spage%3D113531" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shuai  Lian</span>, <span class="hlFld-ContribAuthor ">Xun  Gao</span>, <span class="hlFld-ContribAuthor ">Chao  Song</span>, <span class="hlFld-ContribAuthor ">Hui  Li</span>, <span class="hlFld-ContribAuthor ">Jingquan  Lin</span>. </span><span class="cited-content_cbyCitation_article-title">The characteristics of Raman spectroscopy of fenbendazole-gold nanoparticles based on the chemical adsorption effect. </span><span class="cited-content_cbyCitation_journal-name">Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy</span><span> <strong>2021,</strong> <em>257 </em>, 119799. <a href="https://doi.org/10.1016/j.saa.2021.119799" title="DOI URL">https://doi.org/10.1016/j.saa.2021.119799</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.saa.2021.119799&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.saa.2021.119799%26sid%3Dliteratum%253Aachs%26jtitle%3DSpectrochimica%2520Acta%2520Part%2520A%253A%2520Molecular%2520and%2520Biomolecular%2520Spectroscopy%26atitle%3DThe%252Bcharacteristics%252Bof%252BRaman%252Bspectroscopy%252Bof%252Bfenbendazole-gold%252Bnanoparticles%252Bbased%252Bon%252Bthe%252Bchemical%252Badsorption%252Beffect%26aulast%3DLian%26aufirst%3DShuai%26date%3D2021%26volume%3D257%26spage%3D119799" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Pankaj  Sharma</span>, <span class="hlFld-ContribAuthor ">Chris  LaRosa</span>, <span class="hlFld-ContribAuthor ">Janet  Antwi</span>, <span class="hlFld-ContribAuthor ">Rajgopal  Govindarajan</span>, <span class="hlFld-ContribAuthor ">Karl A.  Werbovetz</span>. </span><span class="cited-content_cbyCitation_article-title">Imidazoles as Potential Anticancer Agents: An Update on Recent Studies. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2021,</strong> <em>26 </em>
                                    (14)
                                     , 4213. <a href="https://doi.org/10.3390/molecules26144213" title="DOI URL">https://doi.org/10.3390/molecules26144213</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules26144213&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules26144213%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DImidazoles%252Bas%252BPotential%252BAnticancer%252BAgents%25253A%252BAn%252BUpdate%252Bon%252BRecent%252BStudies%26aulast%3DSharma%26aufirst%3DPankaj%26date%3D2021%26date%3D2021%26volume%3D26%26issue%3D14%26spage%3D4213" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Da-Yun  Luo</span>, <span class="hlFld-ContribAuthor ">Xing-Mei  Hu</span>, <span class="hlFld-ContribAuthor ">Rong  Huang</span>, <span class="hlFld-ContribAuthor ">Shi-Sheng  Cui</span>, <span class="hlFld-ContribAuthor ">Sheng-Jiao  Yan</span>. </span><span class="cited-content_cbyCitation_article-title">Base-promoted relay reaction of heterocyclic ketene aminals with o-difluorobenzene derivatives for the highly site-selective synthesis of functionalized indoles. </span><span class="cited-content_cbyCitation_journal-name">Tetrahedron</span><span> <strong>2021,</strong> <em>92 </em>, 132275. <a href="https://doi.org/10.1016/j.tet.2021.132275" title="DOI URL">https://doi.org/10.1016/j.tet.2021.132275</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.tet.2021.132275&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.tet.2021.132275%26sid%3Dliteratum%253Aachs%26jtitle%3DTetrahedron%26atitle%3DBase-promoted%252Brelay%252Breaction%252Bof%252Bheterocyclic%252Bketene%252Baminals%252Bwith%252Bo-difluorobenzene%252Bderivatives%252Bfor%252Bthe%252Bhighly%252Bsite-selective%252Bsynthesis%252Bof%252Bfunctionalized%252Bindoles%26aulast%3DLuo%26aufirst%3DDa-Yun%26date%3D2021%26volume%3D92%26spage%3D132275" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ghanshyam  Teli</span>, <span class="hlFld-ContribAuthor ">Pooja A.  Chawla</span>. </span><span class="cited-content_cbyCitation_article-title">Hybridization of Imidazole with Various Heterocycles in Targeting Cancer: A Decade's Work. </span><span class="cited-content_cbyCitation_journal-name">ChemistrySelect</span><span> <strong>2021,</strong> <em>6 </em>
                                    (19)
                                     , 4803-4836. <a href="https://doi.org/10.1002/slct.202101038" title="DOI URL">https://doi.org/10.1002/slct.202101038</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/slct.202101038&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fslct.202101038%26sid%3Dliteratum%253Aachs%26jtitle%3DChemistrySelect%26atitle%3DHybridization%252Bof%252BImidazole%252Bwith%252BVarious%252BHeterocycles%252Bin%252BTargeting%252BCancer%25253A%252BA%252BDecade%252527s%252BWork%26aulast%3DTeli%26aufirst%3DGhanshyam%26date%3D2021%26date%3D2021%26volume%3D6%26issue%3D19%26spage%3D4803%26epage%3D4836" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lan-Shan  Liao</span>, <span class="hlFld-ContribAuthor ">Yin  Chen</span>, <span class="hlFld-ContribAuthor ">Zu-Yu  Mo</span>, <span class="hlFld-ContribAuthor ">Cheng  Hou</span>, <span class="hlFld-ContribAuthor ">Gui-Fa  Su</span>, <span class="hlFld-ContribAuthor ">Hong  Liang</span>, <span class="hlFld-ContribAuthor ">Zhen-Feng  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Ni(
              ii
              ), Cu(
              ii
              ) and Zn(
              ii
              ) complexes with the 1-trifluoroethoxyl-2,9,10-trimethoxy-7-oxoaporphine ligand simultaneously target microtubules and mitochondria for cancer therapy. </span><span class="cited-content_cbyCitation_journal-name">Inorganic Chemistry Frontiers</span><span> <strong>2021,</strong> <em>8 </em>
                                    (9)
                                     , 2225-2247. <a href="https://doi.org/10.1039/D0QI01463J" title="DOI URL">https://doi.org/10.1039/D0QI01463J</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D0QI01463J&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD0QI01463J%26sid%3Dliteratum%253Aachs%26jtitle%3DInorganic%2520Chemistry%2520Frontiers%26atitle%3DNi%252528%252Bii%252B%252529%25252C%252BCu%252528%252Bii%252B%252529%252Band%252BZn%252528%252Bii%252B%252529%252Bcomplexes%252Bwith%252Bthe%252B1-trifluoroethoxyl-2%25252C9%25252C10-trimethoxy-7-oxoaporphine%252Bligand%252Bsimultaneously%252Btarget%252Bmicrotubules%252Band%252Bmitochondria%252Bfor%252Bcancer%252Btherapy%26aulast%3DLiao%26aufirst%3DLan-Shan%26date%3D2021%26date%3D2021%26volume%3D8%26issue%3D9%26spage%3D2225%26epage%3D2247" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kewei  Sun</span>, <span class="hlFld-ContribAuthor ">Zhonghao  Sun</span>, <span class="hlFld-ContribAuthor ">Fenglan  Zhao</span>, <span class="hlFld-ContribAuthor ">Guangzhi  Shan</span>, <span class="hlFld-ContribAuthor ">Qingguo  Meng</span>. </span><span class="cited-content_cbyCitation_article-title">Recent advances in research of colchicine binding site inhibitors and their interaction modes with tubulin. </span><span class="cited-content_cbyCitation_journal-name">Future Medicinal Chemistry</span><span> <strong>2021,</strong> <em>13 </em>
                                    (9)
                                     , 839-858. <a href="https://doi.org/10.4155/fmc-2020-0376" title="DOI URL">https://doi.org/10.4155/fmc-2020-0376</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.4155/fmc-2020-0376&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.4155%2Ffmc-2020-0376%26sid%3Dliteratum%253Aachs%26jtitle%3DFuture%2520Medicinal%2520Chemistry%26atitle%3DRecent%252Badvances%252Bin%252Bresearch%252Bof%252Bcolchicine%252Bbinding%252Bsite%252Binhibitors%252Band%252Btheir%252Binteraction%252Bmodes%252Bwith%252Btubulin%26aulast%3DSun%26aufirst%3DKewei%26date%3D2021%26volume%3D13%26issue%3D9%26spage%3D839%26epage%3D858" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hanbing  Ning</span>, <span class="hlFld-ContribAuthor ">Wenquan  Lu</span>, <span class="hlFld-ContribAuthor ">Qiaoyu  Jia</span>, <span class="hlFld-ContribAuthor ">Jingyun  Wang</span>, <span class="hlFld-ContribAuthor ">Tingting  Yao</span>, <span class="hlFld-ContribAuthor ">Shuai  Lv</span>, <span class="hlFld-ContribAuthor ">Yingxia  Li</span>, <span class="hlFld-ContribAuthor ">Hongtao  Wen</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of oxyepiberberine as a novel tubulin polymerization inhibitor and an anti-colon cancer agent against LS-1034 cells. </span><span class="cited-content_cbyCitation_journal-name">Investigational New Drugs</span><span> <strong>2021,</strong> <em>39 </em>
                                    (2)
                                     , 386-393. <a href="https://doi.org/10.1007/s10637-020-01006-0" title="DOI URL">https://doi.org/10.1007/s10637-020-01006-0</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s10637-020-01006-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs10637-020-01006-0%26sid%3Dliteratum%253Aachs%26jtitle%3DInvestigational%2520New%2520Drugs%26atitle%3DDiscovery%252Bof%252Boxyepiberberine%252Bas%252Ba%252Bnovel%252Btubulin%252Bpolymerization%252Binhibitor%252Band%252Ban%252Banti-colon%252Bcancer%252Bagent%252Bagainst%252BLS-1034%252Bcells%26aulast%3DNing%26aufirst%3DHanbing%26date%3D2021%26date%3D2020%26volume%3D39%26issue%3D2%26spage%3D386%26epage%3D393" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hongmei  Cui</span>, <span class="hlFld-ContribAuthor ">Qinghui  Wang</span>, <span class="hlFld-ContribAuthor ">Duane D.  Miller</span>, <span class="hlFld-ContribAuthor ">Wei  Li</span>. </span><span class="cited-content_cbyCitation_article-title">The Tubulin Inhibitor VERU-111 in Combination With Vemurafenib Provides an Effective Treatment of Vemurafenib-Resistant A375 Melanoma. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Pharmacology</span><span> <strong>2021,</strong> <em>12 </em><a href="https://doi.org/10.3389/fphar.2021.637098" title="DOI URL">https://doi.org/10.3389/fphar.2021.637098</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fphar.2021.637098&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffphar.2021.637098%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Pharmacology%26atitle%3DThe%252BTubulin%252BInhibitor%252BVERU-111%252Bin%252BCombination%252BWith%252BVemurafenib%252BProvides%252Ban%252BEffective%252BTreatment%252Bof%252BVemurafenib-Resistant%252BA375%252BMelanoma%26aulast%3DCui%26aufirst%3DHongmei%26date%3D2021%26date%3D2021%26volume%3D12" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Gloria  Ana</span>, <span class="hlFld-ContribAuthor ">Patrick M.  Kelly</span>, <span class="hlFld-ContribAuthor ">Azizah M.  Malebari</span>, <span class="hlFld-ContribAuthor ">Sara  Noorani</span>, <span class="hlFld-ContribAuthor ">Seema M.  Nathwani</span>, <span class="hlFld-ContribAuthor ">Brendan  Twamley</span>, <span class="hlFld-ContribAuthor ">Darren  Fayne</span>, <span class="hlFld-ContribAuthor ">Niamh M.  O’Boyle</span>, <span class="hlFld-ContribAuthor ">Daniela M.  Zisterer</span>, <span class="hlFld-ContribAuthor ">Elisangela Flavia  Pimentel</span>, <span class="hlFld-ContribAuthor ">Denise Coutinho  Endringer</span>, <span class="hlFld-ContribAuthor ">Mary J.  Meegan</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and Biological Evaluation of 1-(Diarylmethyl)-1H-1,2,4-triazoles and 1-(Diarylmethyl)-1H-imidazoles as a Novel Class of Anti-Mitotic Agent for Activity in Breast Cancer. </span><span class="cited-content_cbyCitation_journal-name">Pharmaceuticals</span><span> <strong>2021,</strong> <em>14 </em>
                                    (2)
                                     , 169. <a href="https://doi.org/10.3390/ph14020169" title="DOI URL">https://doi.org/10.3390/ph14020169</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/ph14020169&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fph14020169%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmaceuticals%26atitle%3DSynthesis%252Band%252BBiological%252BEvaluation%252Bof%252B1-%252528Diarylmethyl%252529-1H-1%25252C2%25252C4-triazoles%252Band%252B1-%252528Diarylmethyl%252529-1H-imidazoles%252Bas%252Ba%252BNovel%252BClass%252Bof%252BAnti-Mitotic%252BAgent%252Bfor%252BActivity%252Bin%252BBreast%252BCancer%26aulast%3DAna%26aufirst%3DGloria%26date%3D2021%26date%3D2021%26volume%3D14%26issue%3D2%26spage%3D169" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Chao  Wang</span>, <span class="hlFld-ContribAuthor ">Yuelin  Li</span>, <span class="hlFld-ContribAuthor ">Zi  Liu</span>, <span class="hlFld-ContribAuthor ">Zeyu  Wang</span>, <span class="hlFld-ContribAuthor ">Zihan  Liu</span>, <span class="hlFld-ContribAuthor ">Shuai  Man</span>, <span class="hlFld-ContribAuthor ">Yujing  Zhang</span>, <span class="hlFld-ContribAuthor ">Kai  Bao</span>, <span class="hlFld-ContribAuthor ">Yingliang  Wu</span>, <span class="hlFld-ContribAuthor ">Qi  Guan</span>, <span class="hlFld-ContribAuthor ">Daiying  Zuo</span>, <span class="hlFld-ContribAuthor ">Weige  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and biological evaluation of 1-Aryl-5-(4-arylpiperazine-1-carbonyl)-1
              H
              -tetrazols as novel microtubule destabilizers. </span><span class="cited-content_cbyCitation_journal-name">Journal of Enzyme Inhibition and Medicinal Chemistry</span><span> <strong>2021,</strong> <em>36 </em>
                                    (1)
                                     , 549-560. <a href="https://doi.org/10.1080/14756366.2020.1759582" title="DOI URL">https://doi.org/10.1080/14756366.2020.1759582</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/14756366.2020.1759582&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F14756366.2020.1759582%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Enzyme%2520Inhibition%2520and%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252B1-Aryl-5-%2525284-arylpiperazine-1-carbonyl%252529-1%252BH%252B-tetrazols%252Bas%252Bnovel%252Bmicrotubule%252Bdestabilizers%26aulast%3DWang%26aufirst%3DChao%26date%3D2021%26date%3D2021%26volume%3D36%26issue%3D1%26spage%3D549%26epage%3D560" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Gang  Li</span>, <span class="hlFld-ContribAuthor ">Yuxi  Wang</span>, <span class="hlFld-ContribAuthor ">Ling  Li</span>, <span class="hlFld-ContribAuthor ">Yichang  Ren</span>, <span class="hlFld-ContribAuthor ">Xin  Deng</span>, <span class="hlFld-ContribAuthor ">Jin  Liu</span>, <span class="hlFld-ContribAuthor ">Wei  Wang</span>, <span class="hlFld-ContribAuthor ">Meihua  Luo</span>, <span class="hlFld-ContribAuthor ">Shuwen  Liu</span>, <span class="hlFld-ContribAuthor ">Jianjun  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis, and bioevaluation of pyrazolo[1,5-a]pyrimidine derivatives as tubulin polymerization inhibitors targeting the colchicine binding site with potent anticancer activities. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>202 </em>, 112519. <a href="https://doi.org/10.1016/j.ejmech.2020.112519" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112519</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112519&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112519%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%25252C%252Band%252Bbioevaluation%252Bof%252Bpyrazolo%25255B1%25252C5-a%25255Dpyrimidine%252Bderivatives%252Bas%252Btubulin%252Bpolymerization%252Binhibitors%252Btargeting%252Bthe%252Bcolchicine%252Bbinding%252Bsite%252Bwith%252Bpotent%252Banticancer%252Bactivities%26aulast%3DLi%26aufirst%3DGang%26date%3D2020%26volume%3D202%26spage%3D112519" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yanshu  Jia</span>, <span class="hlFld-ContribAuthor ">Xiaoyue  Wen</span>, <span class="hlFld-ContribAuthor ">Yufeng  Gong</span>, <span class="hlFld-ContribAuthor ">Xuefeng  Wang</span>. </span><span class="cited-content_cbyCitation_article-title">Current scenario of indole derivatives with potential anti-drug-resistant cancer activity. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>200 </em>, 112359. <a href="https://doi.org/10.1016/j.ejmech.2020.112359" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112359</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112359&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112359%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DCurrent%252Bscenario%252Bof%252Bindole%252Bderivatives%252Bwith%252Bpotential%252Banti-drug-resistant%252Bcancer%252Bactivity%26aulast%3DJia%26aufirst%3DYanshu%26date%3D2020%26volume%3D200%26spage%3D112359" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yuanyuan  Li</span>, <span class="hlFld-ContribAuthor ">Jiazhen  Yang</span>, <span class="hlFld-ContribAuthor ">Lu  Niu</span>, <span class="hlFld-ContribAuthor ">Daojun  Hu</span>, <span class="hlFld-ContribAuthor ">Huijuan  Li</span>, <span class="hlFld-ContribAuthor ">Lijuan  Chen</span>, <span class="hlFld-ContribAuthor ">Yamei  Yu</span>, <span class="hlFld-ContribAuthor ">Qiang  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Structural insights into the design of indole derivatives as tubulin polymerization inhibitors. </span><span class="cited-content_cbyCitation_journal-name">FEBS Letters</span><span> <strong>2020,</strong> <em>594 </em>
                                    (1)
                                     , 199-204. <a href="https://doi.org/10.1002/1873-3468.13566" title="DOI URL">https://doi.org/10.1002/1873-3468.13566</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/1873-3468.13566&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F1873-3468.13566%26sid%3Dliteratum%253Aachs%26jtitle%3DFEBS%2520Letters%26atitle%3DStructural%252Binsights%252Binto%252Bthe%252Bdesign%252Bof%252Bindole%252Bderivatives%252Bas%252Btubulin%252Bpolymerization%252Binhibitors%26aulast%3DLi%26aufirst%3DYuanyuan%26date%3D2020%26date%3D2019%26volume%3D594%26issue%3D1%26spage%3D199%26epage%3D204" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Eavan C.  McLoughlin</span>, <span class="hlFld-ContribAuthor ">Niamh M.  O’Boyle</span>. </span><span class="cited-content_cbyCitation_article-title">Colchicine-Binding Site Inhibitors from Chemistry to Clinic: A Review. </span><span class="cited-content_cbyCitation_journal-name">Pharmaceuticals</span><span> <strong>2020,</strong> <em>13 </em>
                                    (1)
                                     , 8. <a href="https://doi.org/10.3390/ph13010008" title="DOI URL">https://doi.org/10.3390/ph13010008</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/ph13010008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fph13010008%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmaceuticals%26atitle%3DColchicine-Binding%252BSite%252BInhibitors%252Bfrom%252BChemistry%252Bto%252BClinic%25253A%252BA%252BReview%26aulast%3DMcLoughlin%26aufirst%3DEavan%2BC.%26date%3D2020%26date%3D2020%26volume%3D13%26issue%3D1%26spage%3D8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00706/20190719/images/medium/jm-2019-00706x_0011.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00706/20190719/images/large/jm-2019-00706x_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00706&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00706/20190719/images/medium/jm-2019-00706x_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00706/20190719/images/large/jm-2019-00706x_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Examples of microtubule inhibitors that target colchicine binding sites in tubulin.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00706/20190719/images/large/jm-2019-00706x_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00706&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00706/20190719/images/medium/jm-2019-00706x_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00706/20190719/images/large/jm-2019-00706x_0008.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Diamine Intermediate <b>6</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00706/20190719/images/large/jm-2019-00706x_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00706&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00706/20190719/images/medium/jm-2019-00706x_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00706/20190719/images/large/jm-2019-00706x_0009.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of ABI-231 Analogues Modifying the Indole Moiety</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00706/20190719/images/large/jm-2019-00706x_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00706&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00706/20190719/images/medium/jm-2019-00706x_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00706/20190719/images/large/jm-2019-00706x_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Complex structures of ABI-231 (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6O61">6O61</a>) and the new analogues <b>10ab</b> (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6O5N">6O5N</a>) and <b>10bb</b> (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6O5M">6O5M</a>) with tubulin protein. (A,D,G) Overall crystal structure of the three compounds in complex with tubulin proteins. (B,E,H) Detailed interactions between ABI-231, <b>10ab</b>, and <b>10bb</b> and tubulin (ABI-231 is in yellow stick representation, <b>10ab</b> is in green stick representation, and <b>10bb</b> is in orange stick representation). (C,F,I) 90° counterclockwise rotation view of the corresponding structures along the <i>x</i> axis.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00706/20190719/images/large/jm-2019-00706x_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00706&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00706/20190719/images/medium/jm-2019-00706x_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00706/20190719/images/large/jm-2019-00706x_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. New ABI-231 analogues inhibit tubulin polymerization. (A) Polymerization of purified tubulin in a cell-free assay. Tubulin (3.33 mg/mL) was exposed to vehicle control or 10 μM of the compounds (<i>n</i> = 2). Absorbance at 340 nm was monitored at 37 °C every minute for 30 min. (B) Effect on microtubules of WM164 cells following 18 h exposure to 100 nM of <b>10ab</b>, <b>10bb</b>, docetaxel, or vehicle control. Confocal microscopy was utilized to visualize the microtubules following immunofluorescent staining. Microtubules are shown in red and DNA is shown in blue. Scale bar = 20 μm.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00706/20190719/images/large/jm-2019-00706x_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00706&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00706/20190719/images/medium/jm-2019-00706x_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00706/20190719/images/large/jm-2019-00706x_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. <b>10ab</b> and <b>10bb</b> inhibit colony growth and cancer cell migration. (A) Representative images of A375 colony formation for control or treated cells. (B) Quantification of colony numbers (<i>n</i> = 3). Statistical analysis was performed by ANOVA (<i>P</i> < 0.0001) followed by Dunnett’s multiple comparison test. (C) Representative images of wound area in a scratch assay. Images were obtained after 18–22 h for A375 (top) or RPMI7951 (bottom) cells after treatment with 5 or 25 nM concentrations of <b>10ab</b>, <b>10bb</b>, colchicine, or untreated control. (D) Percentage of the wound closed for A375 cells (top) or RPMI7951 cells (bottom) (<i>n</i> = 3). Area of the wound channel was calculated using ImageJ software. Statistical analysis was performed by ANOVA (<i>P</i> < 0.0001 for A375, <i>P</i> = 0.0004 for RPMI7951) followed by the Dunnett’s multiple comparison test.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00706/20190719/images/large/jm-2019-00706x_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00706&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00706/20190719/images/medium/jm-2019-00706x_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00706/20190719/images/large/jm-2019-00706x_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. <b>10bb</b> inhibits melanoma tumor growth and metastasis in vivo. (A) Tumor volumes in an A375 xenograft model in nude mice (<i>n</i> = 10). Statistical significance for final tumor volume was determined by ANOVA (<i>P</i> = 0.0014) followed by Dunnett’s multiple comparison test. (B) Individual tumor weights. Error bars represent 95% CIs. Statistical significance was determined by ANOVA (<i>P</i> = 0.0024) analysis followed by Dunnett’s multiple comparison test. (C) B16F10 lung metastasis in C57BL/6 mice. The graph represents the tumor index for mice (<i>n</i> = 10) and error bars represent 95% CIs. An unpaired Student’s <i>t</i>-test was performed to show statistical significance between the groups (<i>P</i> = 0.0013). Mouse body weights in the xenograft model (D) and lung metastasis model (E). Graph represents percent change in body weight compared to the starting weight.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00706/20190719/images/large/jm-2019-00706x_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00706&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00706/20190719/images/medium/jm-2019-00706x_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00706/20190719/images/large/jm-2019-00706x_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. <b>10bb</b> does not cause apparent toxicities to major organs. Pathological sections of major tissues (heart, kidney, liver, lung, and spleen) were obtained from the (A) A375 xenograft and (B) B16F10 lung metastasis studies. Organs were stained with hematoxylin and eosin (H&E) and representative images were captured. (C) In vitro pharmacological profiling of <b>10bb</b> to assess potential off-target effects to major targets at 1 μM concentrations using the Safety47 Panel (<i>n</i> = 2). Graph represents mean percent response ± range. Values in between −70 and +70% (indicated with dashed lines) are considered insignificant.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00706/20190719/images/large/jm-2019-00706x_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00706&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00706/20190719/images/medium/jm-2019-00706x_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00706/20190719/images/large/jm-2019-00706x_0007.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. <b>10bb</b> is effective in vivo at inhibiting Taxol resistant tumor growth. Two models were investigated in nude mice, one with parental PC-3 xenograft tumors and another with Taxol resistant PC-3/TxR tumors. (A) Tumor volumes for the PC-3 xenograft model (<i>n</i> = 7). Statistical analysis was performed by an unpaired <i>t</i>-test, showing a significant difference for the final volumes of the paclitaxel-treated group compared to the control group (<i>P</i> = 0.003). (B) Final tumor weights for the PC-3 xenograft model. Error bars represent 95% CIs. An unpaired <i>t</i>-test showed a significant difference between the paclitaxel- and vehicle-treated groups (<i>P</i> = 0.0003). (C) Mouse body weights expressed as percent change compared to the starting weight in the PC-3 model. (D) Tumor volumes for the PC-3/TxR xenograft model (<i>n</i> = 8). Statistical analysis was performed by ANOVA (<i>P</i> < 0.0001) followed by Dunnett’s multiple comparisons test for the final tumor volumes. (E) Final tumor weights for PC-3/TxR mice. Error bars represent 95% CIs. Statistical analysis was performed by ANOVA (<i>P</i> = 0.0001) followed by Dunnet’s multiple comparisons test (F) Body weights for PC-3/TxR mouse model. Graph represents mean body weight change as a percentage compared to initial weight.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00706/20190719/images/large/jm-2019-00706x_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00706&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i77">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_60223" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_60223" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 50 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mukhtar, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adhami, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mukhtar, H.</span></span> <span> </span><span class="NLM_article-title">Targeting microtubules by natural agents for cancer therapy</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">275</span>– <span class="NLM_lpage">284</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.mct-13-0791</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=10.1158%2F1535-7163.mct-13-0791" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=24435445" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitFWmsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=275-284&author=E.+Mukhtarauthor=V.+M.+Adhamiauthor=H.+Mukhtar&title=Targeting+microtubules+by+natural+agents+for+cancer+therapy&doi=10.1158%2F1535-7163.mct-13-0791"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting Microtubules by Natural Agents for Cancer Therapy</span></div><div class="casAuthors">Mukhtar, Eiman; Adhami, Vaqar Mustafa; Mukhtar, Hasan</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">275-284</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Natural compds. that target microtubules and disrupt the normal function of the mitotic spindle have proven to be one of the best classes of cancer chemotherapeutic drugs available in clinics to date.  There is increasing evidence showing that even minor alteration of microtubule dynamics can engage the spindle checkpoint, arresting cell-cycle progression at mitosis and subsequently leading to cell death.  Our improved understanding of tumor biol. and our continued appreciation for what the microtubule targeting agents (MTAs) can do have helped pave the way for a new era in the treatment of cancer.  The effectiveness of these agents for cancer therapy has been impaired, however, by various side effects and drug resistance.  Several new MTAs have shown potent activity against the proliferation of various cancer cells, including resistance to the existing MTAs.  Sustained investigation of the mechanisms of action of MTAs, development and discovery of new drugs, and exploring new treatment strategies that reduce side effects and circumvent drug resistance could provide more effective therapeutic options for patients with cancer.  This review focuses on the successful cancer chemotherapy from natural compds. in clin. settings and the challenges that may abort their usefulness.  Mol Cancer Ther; 13(2); 275-84. ©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoSZOcnk6gaB7Vg90H21EOLACvtfcHk0lh5T9ZXg0TnAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitFWmsLg%253D&md5=0a14655cff81c9d3a73c0b4514e45112</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.mct-13-0791&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.mct-13-0791%26sid%3Dliteratum%253Aachs%26aulast%3DMukhtar%26aufirst%3DE.%26aulast%3DAdhami%26aufirst%3DV.%2BM.%26aulast%3DMukhtar%26aufirst%3DH.%26atitle%3DTargeting%2520microtubules%2520by%2520natural%2520agents%2520for%2520cancer%2520therapy%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2014%26volume%3D13%26spage%3D275%26epage%3D284%26doi%3D10.1158%2F1535-7163.mct-13-0791" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jordan, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, L.</span></span> <span> </span><span class="NLM_article-title">Microtubules as a target for anticancer drugs</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">253</span>– <span class="NLM_lpage">265</span>, <span class="refDoi"> DOI: 10.1038/nrc1317</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=10.1038%2Fnrc1317" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=15057285" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=1%3ACAS%3A528%3ADC%252BD2cXis1Gmt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2004&pages=253-265&author=M.+A.+Jordanauthor=L.+Wilson&title=Microtubules+as+a+target+for+anticancer+drugs&doi=10.1038%2Fnrc1317"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Microtubules as a target for anticancer drugs</span></div><div class="casAuthors">Jordan, Mary Ann; Wilson, Leslie</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">253-265</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Highly dynamic mitotic-spindle microtubules are among the most successful targets for anticancer therapy.  Microtubule-targeted drugs, including paclitaxel and Vinca alkaloids, were previously considered to work primarily by increasing or decreasing the cellular microtubule mass.  Although these effects might have a role in their chemotherapeutic actions, we now know that at lower concns., microtubule-targeted drugs can suppress microtubule dynamics without changing microtubule mass; this action leads to mitotic block and apoptosis.  In addn. to the expanding array of chem. diverse antimitotic agents, some microtubule-targeted drugs can act as vascular-targeting agents, rapidly depolymg. microtubules of newly formed vasculature to shut down the blood supply to tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqRJbrFnzwqjbVg90H21EOLACvtfcHk0lh5T9ZXg0TnAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXis1Gmt74%253D&md5=bbbf212e03ffe6763098fc41f21a8158</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2Fnrc1317&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc1317%26sid%3Dliteratum%253Aachs%26aulast%3DJordan%26aufirst%3DM.%2BA.%26aulast%3DWilson%26aufirst%3DL.%26atitle%3DMicrotubules%2520as%2520a%2520target%2520for%2520anticancer%2520drugs%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2004%26volume%3D4%26spage%3D253%26epage%3D265%26doi%3D10.1038%2Fnrc1317" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Heald, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nogales, E.</span></span> <span> </span><span class="NLM_article-title">Microtubule dynamics</span>. <i>J. Cell Sci.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>115</i></span>,  <span class="NLM_fpage">3</span>– <span class="NLM_lpage">4</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=11801717" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=1%3ACAS%3A528%3ADC%252BD38XovVejsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=2002&pages=3-4&author=R.+Healdauthor=E.+Nogales&title=Microtubule+dynamics"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Microtubule dynamics</span></div><div class="casAuthors">Heald, Rebecca; Nogales, Eva</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cell Science</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">115</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">3-4</span>CODEN:
                <span class="NLM_cas:coden">JNCSAI</span>;
        ISSN:<span class="NLM_cas:issn">0021-9533</span>.
    
            (<span class="NLM_cas:orgname">Company of Biologists Ltd.</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDLiwcMnFurbVg90H21EOLACvtfcHk0lh5T9ZXg0TnAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XovVejsg%253D%253D&md5=6a9501a826ccf37961fda924297e75b7</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHeald%26aufirst%3DR.%26aulast%3DNogales%26aufirst%3DE.%26atitle%3DMicrotubule%2520dynamics%26jtitle%3DJ.%2520Cell%2520Sci.%26date%3D2002%26volume%3D115%26spage%3D3%26epage%3D4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kuppens, I.</span></span> <span> </span><span class="NLM_article-title">Current state of the art of new tubulin inhibitors in the clinic</span>. <i>Curr. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">57</span>– <span class="NLM_lpage">70</span>, <span class="refDoi"> DOI: 10.2174/157488406775268200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=10.2174%2F157488406775268200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=18666378" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=1%3ACAS%3A528%3ADC%252BD28XitFOgu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2006&pages=57-70&author=I.+Kuppens&title=Current+state+of+the+art+of+new+tubulin+inhibitors+in+the+clinic&doi=10.2174%2F157488406775268200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Current state of the art of new tubulin inhibitors in the clinic</span></div><div class="casAuthors">Kuppens, Isa E. L. M.</div><div class="citationInfo"><span class="NLM_cas:title">Current Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">57-70</span>CODEN:
                <span class="NLM_cas:coden">CCPUC5</span>;
        ISSN:<span class="NLM_cas:issn">1574-8847</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  For years the microtubule stabilizing agents docetaxel and paclitaxel belong to the most successful clin. chemotherapeutic agents.  Several attempts have been made over the years to equal and better these drugs.  Both taxanes are assocd. with the notorious side effect neurotoxicity and are often accompanied with increased drug resistance and cross resistance with other chemotherapeutic agents.  In addn. their high lipophilicity demands use of co-solvents, which are assocd. with less favorable side effects such as hypersensitivity.  To prevent these disadvantages and improve the clin. application of the taxanes several new agents have entered clin. testing.  The agents that are discussed are the drug class of the discodermolides; XAA296A and the epothilones; BMS-247550, BMS-310705, epo906, kos-862 and the agents ABT-751 and D-24851.  Here we present an overview of recently performed clin. studies to det. the current state of the art of the tubulin inhibitors which are intended to enlarge and improve the clin. use of the taxanes docetaxel and paclitaxel.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpiAXF3Hrb0ubVg90H21EOLACvtfcHk0lh5T9ZXg0TnAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XitFOgu7c%253D&md5=e0ab529443ebf69c924de9d76ccc685d</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.2174%2F157488406775268200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F157488406775268200%26sid%3Dliteratum%253Aachs%26aulast%3DKuppens%26aufirst%3DI.%26atitle%3DCurrent%2520state%2520of%2520the%2520art%2520of%2520new%2520tubulin%2520inhibitors%2520in%2520the%2520clinic%26jtitle%3DCurr.%2520Clin.%2520Pharmacol.%26date%3D2006%26volume%3D1%26spage%3D57%26epage%3D70%26doi%3D10.2174%2F157488406775268200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yeo, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loong, H. H.</span></span> <span> </span><span class="NLM_article-title">Microtubule-targeting agents in oncology and therapeutic potential in hepatocellular carcinoma</span>. <i>OncoTargets Ther.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">575</span>– <span class="NLM_lpage">585</span>, <span class="refDoi"> DOI: 10.2147/OTT.S46019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=10.2147%2FOTT.S46019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=24790457" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1ynurbI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2014&pages=575-585&author=W.+Yeoauthor=H.+H.+Loong&title=Microtubule-targeting+agents+in+oncology+and+therapeutic+potential+in+hepatocellular+carcinoma&doi=10.2147%2FOTT.S46019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Microtubule-targeting agents in oncology and therapeutic potential in hepatocellular carcinoma</span></div><div class="casAuthors">Loong, Herbert H.; Yeo, Winnie</div><div class="citationInfo"><span class="NLM_cas:title">OncoTargets and Therapy</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">575-585, 11 pp.</span>CODEN:
                <span class="NLM_cas:coden">OTNHAZ</span>;
        ISSN:<span class="NLM_cas:issn">1178-6930</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">A review.  In mammalian cells, microtubules are present both in interphase and dividing cells.  In the latter, microtubules forming the mitotic spindle are highly dynamic and exquisitely sensitive to therapeutic inhibitors.  Developed to alter microtubule function, microtubule-binding agents have been proven to be highly active as an anticancer treatment.  Significant development of microtubule-binding agents has taken place in recent years, with newer anti-tubulin agents now showing novel properties of enhanced tumor specificity, reduced neurotoxicity, and insensitivity to chemoresistance mechanisms.  Hepatocellular carcinoma remains one of the most difficult cancers to treat, with chemotherapies being relatively ineffective.  There is now evidence to suggest that microtubule-binding agents may be effective in the treatment of hepatocellular carcinoma, esp. when used in combination with mammalian target of rapamycin inhibitors.  Preclin. models have suggested that the latter may be able to overcome resistance to microtubule binding agents.  In this review article, recent developments of novel microtubule binding agents and their relevance to the treatment of hepatocellular carcinoma will be discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpUy8BJ1xF1ibVg90H21EOLACvtfcHk0liTkkrHofufng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1ynurbI&md5=4a5bed4720f2ba46a7f08f9cd22d5130</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.2147%2FOTT.S46019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FOTT.S46019%26sid%3Dliteratum%253Aachs%26aulast%3DYeo%26aufirst%3DW.%26aulast%3DLoong%26aufirst%3DH.%2BH.%26atitle%3DMicrotubule-targeting%2520agents%2520in%2520oncology%2520and%2520therapeutic%2520potential%2520in%2520hepatocellular%2520carcinoma%26jtitle%3DOncoTargets%2520Ther.%26date%3D2014%26volume%3D7%26spage%3D575%26epage%3D585%26doi%3D10.2147%2FOTT.S46019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McGuire, S.</span></span> <span> </span><span class="NLM_article-title">World Cancer Report 2014. Geneva, Switzerland: World Health Organization, International Agency for Research on Cancer, WHO Press, 2015</span>. <i>Adv. Nutr.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">418</span>– <span class="NLM_lpage">419</span>, <span class="refDoi"> DOI: 10.3945/an.116.012211</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=10.3945%2Fan.116.012211" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=26980827" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=1%3ACAS%3A280%3ADC%252BC28fgslGhug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=418-419&author=S.+McGuire&title=World+Cancer+Report+2014.+Geneva%2C+Switzerland%3A+World+Health+Organization%2C+International+Agency+for+Research+on+Cancer%2C+WHO+Press%2C+2015&doi=10.3945%2Fan.116.012211"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">World Cancer Report 2014. Geneva, Switzerland: World Health Organization, International Agency for Research on Cancer, WHO Press, 2015</span></div><div class="casAuthors">McGuire Shelley</div><div class="citationInfo"><span class="NLM_cas:title">Advances in nutrition (Bethesda, Md.)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">418-9</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTrQN7I_r2GkZ0d-O_J5C0AfW6udTcc2eYXNDinbO-Zz7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28fgslGhug%253D%253D&md5=fb111acc7e8cd67cdb11adaef7a981cd</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.3945%2Fan.116.012211&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3945%252Fan.116.012211%26sid%3Dliteratum%253Aachs%26aulast%3DMcGuire%26aufirst%3DS.%26atitle%3DWorld%2520Cancer%2520Report%25202014.%2520Geneva%252C%2520Switzerland%253A%2520World%2520Health%2520Organization%252C%2520International%2520Agency%2520for%2520Research%2520on%2520Cancer%252C%2520WHO%2520Press%252C%25202015%26jtitle%3DAdv.%2520Nutr.%26date%3D2016%26volume%3D7%26spage%3D418%26epage%3D419%26doi%3D10.3945%2Fan.116.012211" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Orr, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verdier-Pinard, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDaid, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horwitz, S. B.</span></span> <span> </span><span class="NLM_article-title">Mechanisms of Taxol resistance related to microtubules</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">7280</span>– <span class="NLM_lpage">7295</span>, <span class="refDoi"> DOI: 10.1038/sj.onc.1206934</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=10.1038%2Fsj.onc.1206934" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=14576838" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=1%3ACAS%3A528%3ADC%252BD3sXotlajtbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2003&pages=7280-7295&author=G.+A.+Orrauthor=P.+Verdier-Pinardauthor=H.+McDaidauthor=S.+B.+Horwitz&title=Mechanisms+of+Taxol+resistance+related+to+microtubules&doi=10.1038%2Fsj.onc.1206934"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of Taxol resistance related to microtubules</span></div><div class="casAuthors">Orr, George A.; Verdier-Pinard, Pascal; McDaid, Hayley; Horwitz, Susan Band</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">47</span>),
    <span class="NLM_cas:pages">7280-7295</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Since its approval by the FDA in 1992 for the treatment of ovarian cancer, the use of Taxol has dramatically increased.  Although treatment with Taxol has led to improvement in the duration and quality of life for some cancer patients, the majority eventually develop progressive disease after initially responding to Taxol treatment.  Drug resistance represents a major obstacle to improving the overall response and survival of cancer patients.  This review focuses on mechanisms of Taxol resistance that occur directly at the microtubule, such as mutations, tubulin isotype selection and post-translational modifications, and also at the level of regulatory proteins.  A review of tubulin structure, microtubule dynamics, the mechanism of action of Taxol and its binding site on the microtubule are included, so that the reader can evaluate Taxol resistance in context.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrdPHARrQvHZbVg90H21EOLACvtfcHk0liTkkrHofufng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXotlajtbc%253D&md5=97f06b552ed6ed3df45f5c3a051d8671</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1206934&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1206934%26sid%3Dliteratum%253Aachs%26aulast%3DOrr%26aufirst%3DG.%2BA.%26aulast%3DVerdier-Pinard%26aufirst%3DP.%26aulast%3DMcDaid%26aufirst%3DH.%26aulast%3DHorwitz%26aufirst%3DS.%2BB.%26atitle%3DMechanisms%2520of%2520Taxol%2520resistance%2520related%2520to%2520microtubules%26jtitle%3DOncogene%26date%3D2003%26volume%3D22%26spage%3D7280%26epage%3D7295%26doi%3D10.1038%2Fsj.onc.1206934" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kavallaris, M.</span></span> <span> </span><span class="NLM_article-title">Microtubules and resistance to tubulin-binding agents</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">194</span>– <span class="NLM_lpage">204</span>, <span class="refDoi"> DOI: 10.1038/nrc2803</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=10.1038%2Fnrc2803" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=20147901" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhvVKrtbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2010&pages=194-204&author=M.+Kavallaris&title=Microtubules+and+resistance+to+tubulin-binding+agents&doi=10.1038%2Fnrc2803"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Microtubules and resistance to tubulin-binding agents</span></div><div class="casAuthors">Kavallaris, Maria</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">194-204</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Microtubules are dynamic structures composed of α-β-tubulin heterodimers that are essential in cell division and are important targets for cancer drugs.  Mutations in β-tubulin that affect microtubule polymer mass and/or drug binding are assocd. with resistance to tubulin-binding agents such as paclitaxel.  The aberrant expression of specific β-tubulin isotypes, in particular βIII-tubulin, or of microtubule-regulating proteins is important clin. in tumor aggressiveness and resistance to chemotherapy.  In addn., changes in actin regulation can also mediate resistance to tubulin-binding agents.  Understanding the mol. mechanisms that mediate resistance to tubulin-binding agents will be vital to improve the efficacy of these agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNkoVu03ikmrVg90H21EOLACvtfcHk0liqRUy96oVUBQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhvVKrtbg%253D&md5=1ce71cc537091459d7ee6866c0950b33</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1038%2Fnrc2803&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2803%26sid%3Dliteratum%253Aachs%26aulast%3DKavallaris%26aufirst%3DM.%26atitle%3DMicrotubules%2520and%2520resistance%2520to%2520tubulin-binding%2520agents%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2010%26volume%3D10%26spage%3D194%26epage%3D204%26doi%3D10.1038%2Fnrc2803" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kavallaris, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tait, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walsh, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, L. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horwitz, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norris, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haber, M.</span></span> <span> </span><span class="NLM_article-title">Multiple microtubule alterations are associated with Vinca alkaloid resistance in human leukemia cells</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">5803</span>– <span class="NLM_lpage">5809</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=11479219" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=1%3ACAS%3A528%3ADC%252BD3MXlvVCgtbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2001&pages=5803-5809&author=M.+Kavallarisauthor=A.+S.+Taitauthor=B.+J.+Walshauthor=L.+F.+Heauthor=S.+B.+Horwitzauthor=M.+D.+Norrisauthor=M.+Haber&title=Multiple+microtubule+alterations+are+associated+with+Vinca+alkaloid+resistance+in+human+leukemia+cells"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Multiple microtubule alterations are associated with Vinca alkaloid resistance in human leukemia cells</span></div><div class="casAuthors">Kavallaris, Maria; Tait, A. Sasha; Walsh, Bradley J.; He, Lifeng; Horwitz, Susan B.; Norris, Murray D.; Haber, Michelle</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">5803-5809</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Vinca alkaloids are used extensively in the treatment of childhood acute lymphoblastic leukemia (ALL) and despite their usefulness, drug resistance remains a serious clin. problem.  Vinca alkaloids bind to the β-tubulin subunit of the α/β-tubulin heterodimer and inhibit polymn. of microtubules.  Recent studies have implicated altered β-tubulin isotype expression and mutations in resistance to microtubule-stabilizing agents.  Microtubule-assocd. protein (MAP) MAP4 binds to and stabilizes microtubules, and increased expression is assocd. with decreased sensitivity to microtubule-depolymg. agents.  To address the significance of β-tubulin and MAP4 alterations in childhood ALL, two CCRF-CEM-derived Vinca alkaloid resistant cell lines, VCR R (vincristine) and VLB100 (vinblastine), were examd.  Decreased expression of class III β-tubulin was detected in both VCR R and VLB100 cells.  VCR R cells and to a lesser extent VLB100 cells expressed increased levels of MAP4 protein.  Increased microtubule stability was obsd. in these VCR R cells as identified by the high levels of polymd. tubulin (45.6±2.6%; P < 0.005) compared with CEM and VLB100 cells (24.7±3.3% and 24.7±2.5%, resp.).  Expression was assocd. with a single MAP4 isoform in the polymd. microtubule fraction in CEM and VCR cells.  In contrast, VLB100 cells expressed a lower mol. wt. isoform in the polymd. fraction.  Two-dimensional-PAGE and immunoblotting revealed marked posttranslational changes in class I β-tubulin in VCR R cells not evident in CEM cells.  Sequencing of the β-tubulin (HM40) gene identified a point mutation in VCR R cells in nucleotide 843 (CTC→ATC; Leu240→Ile) that was not present in CEM or VLB100 cells.  This mutation resides in a region of β-tubulin that lies in close proximity to the α/β tubulin interface.  Multiple alterations related to normal microtubule function were identified in ALL cells selected for resistance to Vinca alkaloids, and these alterations may provide important insight into mechanisms mediating resistance to Vinca alkaloids.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGry3hyzM6Okt7Vg90H21EOLACvtfcHk0liqRUy96oVUBQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXlvVCgtbY%253D&md5=e1002656ad0a75785f3fb81ed05c8e27</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKavallaris%26aufirst%3DM.%26aulast%3DTait%26aufirst%3DA.%2BS.%26aulast%3DWalsh%26aufirst%3DB.%2BJ.%26aulast%3DHe%26aufirst%3DL.%2BF.%26aulast%3DHorwitz%26aufirst%3DS.%2BB.%26aulast%3DNorris%26aufirst%3DM.%2BD.%26aulast%3DHaber%26aufirst%3DM.%26atitle%3DMultiple%2520microtubule%2520alterations%2520are%2520associated%2520with%2520Vinca%2520alkaloid%2520resistance%2520in%2520human%2520leukemia%2520cells%26jtitle%3DCancer%2520Res.%26date%3D2001%26volume%3D61%26spage%3D5803%26epage%3D5809" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zagouri, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sergentanis, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chrysikos, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bamias, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dimopoulos, A.-M.</span></span> <span> </span><span class="NLM_article-title">Epothilones in epithelial ovarian, fallopian tube, or primary peritoneal cancer: a systematic review</span>. <i>OncoTargets Ther.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">2187</span>– <span class="NLM_lpage">2198</span>, <span class="refDoi"> DOI: 10.2147/ott.s77342</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=10.2147%2Fott.s77342" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=26316786" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsFegt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2015&pages=2187-2198&author=F.+Zagouriauthor=T.+Sergentanisauthor=D.+Chrysikosauthor=A.+Bamiasauthor=A.-M.+Dimopoulos&title=Epothilones+in+epithelial+ovarian%2C+fallopian+tube%2C+or+primary+peritoneal+cancer%3A+a+systematic+review&doi=10.2147%2Fott.s77342"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Epothilones in epithelial ovarian, fallopian tube, or primary peritoneal cancer: a systematic review</span></div><div class="casAuthors">Zagouri, Flora; Sergentanis, Theodoros N.; Chrysikos, Dimosthenis; Dimopoulos, Meletios-Athanasios; Bamias, Aristotle</div><div class="citationInfo"><span class="NLM_cas:title">OncoTargets and Therapy</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">2187-2198</span>CODEN:
                <span class="NLM_cas:coden">OTNHAZ</span>;
        ISSN:<span class="NLM_cas:issn">1178-6930</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">Ovarian cancer is the most lethal gynecol. malignancy; consequently, there is a need for effective therapies.  Epothilones are microtubule-stabilizing agents that inhibit cell growth.  Currently, patupilone and its four synthetic derivs. ixabepilone, BMS-310705, sagopilone, 20-desmethyl-20-methylsulfanyl epothilone B and epothilone D, as well as its deriv. KOS-1584, are under clin. evaluation.  This is the first systematic review conducted in accordance with the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines that synthesizes all available data emerging from trials and evaluates the efficacy and safety of epothilones in epithelial ovarian, primary fallopian tube, and primary peritoneal cancer.  Despite the fact that epothilones have proven active in taxane-resistant settings in preclin. models, it is not yet clear from Phase II/III studies reviewed here that their clin. activity is superior to that of taxanes.  Nevertheless, responses to epothilones have been obsd. in platinum-refractory/resistant ovarian cancer patients.  Moreover, despite the shared mechanism of action of epothilones, their clin. profile seems clearly different, with diarrhea being the most common dose-limiting toxicity encountered with patupilone, whereas neutropenia and sensory neuropathy are the most common toxic effects obsd. with the other epothilones.  In any case, randomized trials comparing epothilones with std. treatments seem warranted to define further the role of these agents, whereas biomarker anal. might further optimize patient selection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJ8yVQvMB3RrVg90H21EOLACvtfcHk0liqRUy96oVUBQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsFegt7s%253D&md5=2e298515baae3a522280b6adcdedbbbb</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.2147%2Fott.s77342&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252Fott.s77342%26sid%3Dliteratum%253Aachs%26aulast%3DZagouri%26aufirst%3DF.%26aulast%3DSergentanis%26aufirst%3DT.%26aulast%3DChrysikos%26aufirst%3DD.%26aulast%3DBamias%26aufirst%3DA.%26aulast%3DDimopoulos%26aufirst%3DA.-M.%26atitle%3DEpothilones%2520in%2520epithelial%2520ovarian%252C%2520fallopian%2520tube%252C%2520or%2520primary%2520peritoneal%2520cancer%253A%2520a%2520systematic%2520review%26jtitle%3DOncoTargets%2520Ther.%26date%3D2015%26volume%3D8%26spage%3D2187%26epage%3D2198%26doi%3D10.2147%2Fott.s77342" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Trendowski, M.</span></span> <span> </span><span class="NLM_article-title">Recent advances in the development of antineoplastic agents derived from natural products</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>75</i></span>,  <span class="NLM_fpage">1993</span>– <span class="NLM_lpage">2016</span>, <span class="refDoi"> DOI: 10.1007/s40265-015-0489-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=10.1007%2Fs40265-015-0489-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=26501980" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslyksr%252FE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2015&pages=1993-2016&author=M.+Trendowski&title=Recent+advances+in+the+development+of+antineoplastic+agents+derived+from+natural+products&doi=10.1007%2Fs40265-015-0489-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Recent Advances in the Development of Antineoplastic Agents Derived from Natural Products</span></div><div class="casAuthors">Trendowski, Matthew</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">75</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">1993-2016</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Through years of evolutionary selection pressures, organisms have developed potent toxins that coincidentally have marked antineoplastic activity.  These natural products have been vital for the development of multiagent treatment regimens currently employed in cancer chemotherapy, and are used in the treatment of a variety of malignancies.  Therefore, this review catalogs recent advances in natural product-based drug discovery via the examn. of mechanisms of action and available clin. data to highlight the utility of these novel compds. in the burgeoning age of precision medicine.  The review also highlights the recent development of antibody-drug conjugates and other immunotoxins, which are capable of delivering highly cytotoxic agents previously deemed too toxic to elicit therapeutic benefit preferentially to neoplastic cells.  Finally, the review examines natural products not currently used in the clinic that have novel mechanisms of action, and may serve to supplement current chemotherapeutic protocols.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHU2L2IX0DgbVg90H21EOLACvtfcHk0liqRUy96oVUBQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslyksr%252FE&md5=3c40bf11412ed0e627c966246fd54ee1</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1007%2Fs40265-015-0489-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-015-0489-4%26sid%3Dliteratum%253Aachs%26aulast%3DTrendowski%26aufirst%3DM.%26atitle%3DRecent%2520advances%2520in%2520the%2520development%2520of%2520antineoplastic%2520agents%2520derived%2520from%2520natural%2520products%26jtitle%3DDrugs%26date%3D2015%26volume%3D75%26spage%3D1993%26epage%3D2016%26doi%3D10.1007%2Fs40265-015-0489-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Aseyev, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ribeiro, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cardoso, F.</span></span> <span> </span><span class="NLM_article-title">Review on the clinical use of eribulin mesylate for the treatment of breast cancer</span>. <i>Expert Opin. Pharmacother.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">589</span>– <span class="NLM_lpage">600</span>, <span class="refDoi"> DOI: 10.1517/14656566.2016.1146683</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=10.1517%2F14656566.2016.1146683" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=26809667" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=1%3ACAS%3A528%3ADC%252BC28Xjt1OgtLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2016&pages=589-600&author=O.+Aseyevauthor=J.+M.+Ribeiroauthor=F.+Cardoso&title=Review+on+the+clinical+use+of+eribulin+mesylate+for+the+treatment+of+breast+cancer&doi=10.1517%2F14656566.2016.1146683"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Review on the clinical use of eribulin mesylate for the treatment of breast cancer</span></div><div class="casAuthors">Aseyev, Olexiy; Ribeiro, Joana M.; Cardoso, Fatima</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Pharmacotherapy</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">589-600</span>CODEN:
                <span class="NLM_cas:coden">EOPHF7</span>;
        ISSN:<span class="NLM_cas:issn">1465-6566</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Breast cancer is the second leading cause of cancer death among women and the median survival of metastatic breast cancer (MBC) has remained, for many decades, at two to three years after diagnosis.  Eribulin mesylate is a nontaxane inhibitor of microtubule dynamics and the only cytotoxic agent in the last decade to improve overall survival in heavily pretreated patients with MBC.  Eribulin was approved for the treatment of MBC in 2010 by the FDA in patients that received at least two prior chemotherapy regimens and as second-line treatment in 2011 by EMA.  In both cases prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting.  This manuscript reviews the current available data on the use of this important cytotoxic agent including its pharmacol., pharmacokinetics, clin. efficacy, safety, and potential economic factors as well as ongoing clin. trials and main areas of research.  Eribulin mesylate is a novel microtubule dynamics inhibitor compd. important for the management of MBC and can be used for the treatment of patients who have previously received one/two chemotherapeutic regimens for metastatic disease and whose prior therapy included an anthracycline and a taxane.  It's toxicity profile is acceptable and presents several favorable features namely a low probability of drug-drug interactions in the clin. setting, easy administration as bolus, low hypersensitivity chances and full tolerability in renal dysfunction patients.  Eribulin is currently being evaluated as first-line treatment for MBC, in the adjuvant/neoadjuvant setting alone and in combination with a variety of agents, particularly biol. treatments.  Future research is needed to optimize the role of eribulin in the treatment of MBC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp4L7JToNF0VbVg90H21EOLACvtfcHk0lgt4vr9d_PsrQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xjt1OgtLo%253D&md5=2c0f8be3792e858e091d2088b404fae3</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1517%2F14656566.2016.1146683&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14656566.2016.1146683%26sid%3Dliteratum%253Aachs%26aulast%3DAseyev%26aufirst%3DO.%26aulast%3DRibeiro%26aufirst%3DJ.%2BM.%26aulast%3DCardoso%26aufirst%3DF.%26atitle%3DReview%2520on%2520the%2520clinical%2520use%2520of%2520eribulin%2520mesylate%2520for%2520the%2520treatment%2520of%2520breast%2520cancer%26jtitle%3DExpert%2520Opin.%2520Pharmacother.%26date%3D2016%26volume%3D17%26spage%3D589%26epage%3D600%26doi%3D10.1517%2F14656566.2016.1146683" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ravelli, R. B. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gigant, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curmi, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jourdain, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lachkar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sobel, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knossow, M.</span></span> <span> </span><span class="NLM_article-title">Insight into tubulin regulation from a complex with colchicine and a stathmin-like domain</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>428</i></span>,  <span class="NLM_fpage">198</span>– <span class="NLM_lpage">202</span>, <span class="refDoi"> DOI: 10.1038/nature02393</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=10.1038%2Fnature02393" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=15014504" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhvFCls7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=428&publication_year=2004&pages=198-202&author=R.+B.+G.+Ravelliauthor=B.+Gigantauthor=P.+A.+Curmiauthor=I.+Jourdainauthor=S.+Lachkarauthor=A.+Sobelauthor=M.+Knossow&title=Insight+into+tubulin+regulation+from+a+complex+with+colchicine+and+a+stathmin-like+domain&doi=10.1038%2Fnature02393"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Insight into tubulin regulation from a complex with colchicine and a stathmin-like domain</span></div><div class="casAuthors">Ravelli, Raimond B. G.; Gigant, Benoit; Curmi, Patrick A.; Jourdain, Isabelle; Lachkar, Sylvie; Sobel, Andre; Knossow, Marcel</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">428</span>
        (<span class="NLM_cas:issue">6979</span>),
    <span class="NLM_cas:pages">198-202</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Microtubules are cytoskeletal polymers of tubulin involved in many cellular functions.  Their dynamic instability is controlled by numerous compds. and proteins, including colchicine and stathmin family proteins.  The way in which microtubule instability is regulated at the mol. level has remained elusive, mainly because of the lack of appropriate structural data.  Here, the authors present the structure, at 3.5 Å resoln., of tubulin in complex with colchicine (I) and with the stathmin-like domain (SLD) of RB3.  It showed the interaction of RB3-SLD with 2 tubulin heterodimers in a curved complex capped by the SLD N-terminal domain, which prevented the incorporation of the complexed tubulin into microtubules.  A comparison with the structure of tubulin in protofilaments showed changes in the subunits of tubulin as it switched from its straight conformation to a curved one.  These changes correlated with the loss of lateral contacts and provided a rationale for the rapid microtubule depolymn. characteristic of dynamic instability.  Moreover, the tubulin-I complex shed light on the mechanism of I activity; it was shown that I binds at a location where it prevents curved tubulin from adopting a straight structure, which inhibits assembly.  Thus, the results establish a relation between the onset and speed of microtubule disassembly and the changes in tubulin subunits when tubulin switches from its straight to its curved conformation.  The results further provide a mol. description of the interaction of RB3-SLD and I with tubulin, and may be useful for the development of novel therapeutic I analogs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqx2vePjtf347Vg90H21EOLACvtfcHk0ljEmF6ZJ9gONA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhvFCls7g%253D&md5=9fbb1edfc64239638a3c2eac879bffe9</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1038%2Fnature02393&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature02393%26sid%3Dliteratum%253Aachs%26aulast%3DRavelli%26aufirst%3DR.%2BB.%2BG.%26aulast%3DGigant%26aufirst%3DB.%26aulast%3DCurmi%26aufirst%3DP.%2BA.%26aulast%3DJourdain%26aufirst%3DI.%26aulast%3DLachkar%26aufirst%3DS.%26aulast%3DSobel%26aufirst%3DA.%26aulast%3DKnossow%26aufirst%3DM.%26atitle%3DInsight%2520into%2520tubulin%2520regulation%2520from%2520a%2520complex%2520with%2520colchicine%2520and%2520a%2520stathmin-like%2520domain%26jtitle%3DNature%26date%3D2004%26volume%3D428%26spage%3D198%26epage%3D202%26doi%3D10.1038%2Fnature02393" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Finkelstein, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aks, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hutson, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Juurlink, D. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubnov-Raz, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollak, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koren, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bentur, Y.</span></span> <span> </span><span class="NLM_article-title">Colchicine poisoning: the dark side of an ancient drug</span>. <i>Clin. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">407</span>– <span class="NLM_lpage">414</span>, <span class="refDoi"> DOI: 10.3109/15563650.2010.495348</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=10.3109%2F15563650.2010.495348" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=1%3ACAS%3A528%3ADC%252BC3cXot1anurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2010&pages=407-414&author=Y.+Finkelsteinauthor=S.+E.+Aksauthor=J.+R.+Hutsonauthor=D.+N.+Juurlinkauthor=P.+Nguyenauthor=G.+Dubnov-Razauthor=U.+Pollakauthor=G.+Korenauthor=Y.+Bentur&title=Colchicine+poisoning%3A+the+dark+side+of+an+ancient+drug&doi=10.3109%2F15563650.2010.495348"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Colchicine poisoning: The dark side of an ancient drug</span></div><div class="casAuthors">Finkelstein, Yaron; Aks, Steven E.; Hutson, Janine R.; Juurlink, David N.; Nguyen, Patricia; Dubnov-Raz, Gal; Pollak, Uri; Koren, Gideon; Bentur, Yedidia</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Toxicology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">407-414</span>CODEN:
                <span class="NLM_cas:coden">CTPPA5</span>;
        ISSN:<span class="NLM_cas:issn">1556-3650</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: Colchicine is used mainly for the treatment and prevention of gout and for familial Mediterranean fever (FMF).  It has a narrow therapeutic index, with no clear-cut distinction between nontoxic, toxic, and LDs, causing substantial confusion among clinicians.  Although colchicine poisoning is sometimes intentional, unintentional toxicity is common and often assocd. with a poor outcome.  Methods: We performed a systematic review by searching OVID MEDLINE between 1966 and Jan. 2010.  The search strategy included "colchicine" and "poisoning" or "overdose" or "toxicity" or "intoxication." Toxicokinetics: Colchicine is readily absorbed after oral administration, but undergoes extensive first-pass metab.  It is widely distributed and binds to intracellular elements.  Colchicine is primarily metabolized by the liver, undergoes significant enterohepatic re-circulation, and is also excreted by the kidneys.  Therapeutic and toxic doses: The usual adult oral doses for FMF is 1.2-2.4 mg/day; in acute gout 1.2 mg/day and for gout prophylaxis 0.5-0.6 mg/day three to four times a week.  High fatality rate was reported after acute ingestions exceeding 0.5 mg/kg.  The lowest reported LDs of oral colchicine are 7-26 mg.  Drug interactions: CYP 3A4 and P-glycoprotein inhibitors, such as clarithromycin, erythromycin, ketoconazole, ciclosporin, and natural grapefruit juice can increase colchicine concns.  Co-administration with statins may increase the risk of myopathy.  Mechanisms of toxicity: Colchicine's toxicity is an extension of its mechanism of action - binding to tubulin and disrupting the microtubular network.  As a result, affected cells experience impaired protein assembly, decreased endocytosis and exocytosis, altered cell morphol., decreased cellular motility, arrest of mitosis, and interrupted cardiac myocyte conduction and contractility.  The culmination of these mechanisms leads to multi-organ dysfunction and failure.  Reproductive toxicol. and lactation: Colchicine was not shown to adversely affect reproductive potential in males or females.  It crosses the placenta but there is no evidence of fetal toxicity.  Colchicine is excreted into breast milk and considered compatible with lactation.  Clin. features: Colchicine poisoning presents in three sequential and usually overlapping phases, 1; 10-24 h after ingestion - gastrointestinal phase mimicking gastroenteritis may be absent after i.v. administration, 2; 24 h to 7 days after ingestion - multi-organ dysfunction.  Death results from rapidly progressive multi-organ failure and sepsis.  Delayed presentation, pre-existing renal or liver impairment are assocd. with poor prognosis, 3; Recovery typically occurs within a few weeks of ingestion, and is generally a complete recovery barring complications of the acute illness.  Diagnosis: History of ingestion of tablets, parenteral administration, or consumption of colchicine-contg. plants suggest the diagnosis.  Colchicine poisoning should be suspected in patients with access to the drug and the typical toxidrome (gastroenteritis, hypotension, lactic acidosis, and prerenal azotemia).  Management: Timely gastrointestinal decontamination should be considered with activated charcoal, and very large, recent (<60 min) ingestions may warrant gastric lavage.  Supportive treatments including administration of granulocyte colony-stimulating factor are the mainstay of treatment.  Although a specific exptl. treatment (Fab fragment antibodies) for colchicine poisoning has been used, it is not com. available.  Conclusion: Although colchicine poisoning is relatively uncommon, it is imperative to recognize its features as it is assocd. with a high mortality rate when missed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqtFb69vkDP27Vg90H21EOLACvtfcHk0ljEmF6ZJ9gONA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXot1anurk%253D&md5=14f982b390cf79e506369eb7b97e6342</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.3109%2F15563650.2010.495348&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F15563650.2010.495348%26sid%3Dliteratum%253Aachs%26aulast%3DFinkelstein%26aufirst%3DY.%26aulast%3DAks%26aufirst%3DS.%2BE.%26aulast%3DHutson%26aufirst%3DJ.%2BR.%26aulast%3DJuurlink%26aufirst%3DD.%2BN.%26aulast%3DNguyen%26aufirst%3DP.%26aulast%3DDubnov-Raz%26aufirst%3DG.%26aulast%3DPollak%26aufirst%3DU.%26aulast%3DKoren%26aufirst%3DG.%26aulast%3DBentur%26aufirst%3DY.%26atitle%3DColchicine%2520poisoning%253A%2520the%2520dark%2520side%2520of%2520an%2520ancient%2520drug%26jtitle%3DClin.%2520Toxicol.%26date%3D2010%26volume%3D48%26spage%3D407%26epage%3D414%26doi%3D10.3109%2F15563650.2010.495348" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Borisy, G. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, E. W.</span></span> <span> </span><span class="NLM_article-title">The mechanism of action of colchicine. Binding of colchincine-3H to cellular protein</span>. <i>J. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">1967</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">525</span>– <span class="NLM_lpage">533</span>, <span class="refDoi"> DOI: 10.1083/jcb.34.2.525</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=10.1083%2Fjcb.34.2.525" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=6068183" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=1%3ACAS%3A528%3ADyaF2sXks1aksr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=1967&pages=525-533&author=G.+G.+Borisyauthor=E.+W.+Taylor&title=The+mechanism+of+action+of+colchicine.+Binding+of+colchincine-3H+to+cellular+protein&doi=10.1083%2Fjcb.34.2.525"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">The mechanism of action of colchicine.  Binding of colchicine-3H to cellular protein</span></div><div class="casAuthors">Borisy, G. G.; Taylor, Edwin William</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cell Biology</span>
        (<span class="NLM_cas:date">1967</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">525-33</span>CODEN:
                <span class="NLM_cas:coden">JCLBA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9525</span>.
    </div><div class="casAbstract">The majority of the colchicine-3H bound by tissue culture cells (KB or HeLa) was present as a noncovalent complex with a macromol. which appears in the sol. fraction after homogenization.  Similar binding was demonstrated in vitro and was confined to a component of the sol. fraction.  The binding-equil. const. and the kinetic consts. were essentially the same in vivo and in vitro.  Bound radioactivity was reisolated and shown to be present in a mol. with the same chromatographic behavior and specific antimitotic activity as colchicine.  In vitro assay of binding activity of a variety of cells and tissues showed a correlation with the presence of microtubules.  High binding activity was given by dividing cells, mitotic app., cilia, sperm tails, and brain tissue.  Binding to exts. of slime mold or to purified muscle proteins was very low or undetectable.  The binding site had a sedimentation const. of 6S and it is suggested that the protein is a subunit of microtubules.  34 references.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdLQFA3pJhKbVg90H21EOLACvtfcHk0ljEmF6ZJ9gONA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaF2sXks1aksr0%253D&md5=ca115da1d843e43ed8fa3108fba389ab</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1083%2Fjcb.34.2.525&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1083%252Fjcb.34.2.525%26sid%3Dliteratum%253Aachs%26aulast%3DBorisy%26aufirst%3DG.%2BG.%26aulast%3DTaylor%26aufirst%3DE.%2BW.%26atitle%3DThe%2520mechanism%2520of%2520action%2520of%2520colchicine.%2520Binding%2520of%2520colchincine-3H%2520to%2520cellular%2520protein%26jtitle%3DJ.%2520Cell%2520Biol.%26date%3D1967%26volume%3D34%26spage%3D525%26epage%3D533%26doi%3D10.1083%2Fjcb.34.2.525" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kanthou, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tozer, G. M.</span></span> <span> </span><span class="NLM_article-title">Microtubule depolymerizing vascular disrupting agents: novel therapeutic agents for oncology and other pathologies</span>. <i>Int. J. Exp. Pathol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>90</i></span>,  <span class="NLM_fpage">284</span>– <span class="NLM_lpage">294</span>, <span class="refDoi"> DOI: 10.1111/j.1365-2613.2009.00651.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=10.1111%2Fj.1365-2613.2009.00651.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=19563611" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=1%3ACAS%3A528%3ADC%252BD1MXotV2isr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=90&publication_year=2009&pages=284-294&author=C.+Kanthouauthor=G.+M.+Tozer&title=Microtubule+depolymerizing+vascular+disrupting+agents%3A+novel+therapeutic+agents+for+oncology+and+other+pathologies&doi=10.1111%2Fj.1365-2613.2009.00651.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Microtubule depolymerizing vascular disrupting agents: novel therapeutic agents for oncology and other pathologies</span></div><div class="casAuthors">Kanthou, Chryso; Tozer, Gillian M.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Experimental Pathology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">90</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">284-294</span>CODEN:
                <span class="NLM_cas:coden">IJEPEI</span>;
        ISSN:<span class="NLM_cas:issn">0959-9673</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Vascular disrupting agents (VDAs) are a relatively new group of "vascular targeting" agents that exhibit selective activity against established tumor vascular networks, causing severe interruption of tumor blood flow and necrosis to the tumor mass.  Microtubule depolymg. agents form by far the largest group of small mol. wt. VDAs many of which, including lead compd. disodium combretastatin A-4 3-O-phosphate (CA-4-P), are under clin. development for cancer.  Although distinct from the angiogenesis inhibitors, VDAs can also interfere with angiogenesis and therefore constitute a potential group of novel drugs for the treatment of pathol. conditions characterized by excessive angiogenesis, in addn. to cancer.  The endothelial cytoskeleton is the primary cellular target of this family of drugs, and some progress in understanding the mol. and signalling mechanisms assocd. with their endothelial disrupting activity has been made in the last few years.  Susceptibility of tumor vessels to VDA damage is ascribed to their immature pericyte-defective nature, although the exact mol. mechanisms involved have not been clearly defined.  Despite causing profound damage to tumors, VDAs fail to halt tumor growth unless used together with conventional treatments.  This failure is attributed to resistance mechanisms, primarily assocd. with cells that remain viable within the tumor rim, and enhanced angiogenesis.  The focus is now to understand mechanisms of susceptibility and resistance to identify novel mol. targets and develop strategies that are more effective.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmpN7il32X0rVg90H21EOLACvtfcHk0ljEmF6ZJ9gONA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXotV2isr4%253D&md5=42b728813bf9c53bbc6d32d262639d15</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2613.2009.00651.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2613.2009.00651.x%26sid%3Dliteratum%253Aachs%26aulast%3DKanthou%26aufirst%3DC.%26aulast%3DTozer%26aufirst%3DG.%2BM.%26atitle%3DMicrotubule%2520depolymerizing%2520vascular%2520disrupting%2520agents%253A%2520novel%2520therapeutic%2520agents%2520for%2520oncology%2520and%2520other%2520pathologies%26jtitle%3DInt.%2520J.%2520Exp.%2520Pathol.%26date%3D2009%26volume%3D90%26spage%3D284%26epage%3D294%26doi%3D10.1111%2Fj.1365-2613.2009.00651.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stengel, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leese, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Potter, B. V. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reed, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Purohit, A.</span></span> <span> </span><span class="NLM_article-title">Class III β-tubulin expression and in vitro resistance to microtubule targeting agents</span>. <i>Brit. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>102</i></span>,  <span class="NLM_fpage">316</span>– <span class="NLM_lpage">324</span>, <span class="refDoi"> DOI: 10.1038/sj.bjc.6605489</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=10.1038%2Fsj.bjc.6605489" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=20029418" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=1%3ACAS%3A528%3ADC%252BC3cXntlKisQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2010&pages=316-324&author=C.+Stengelauthor=S.+P.+Newmanauthor=M.+P.+Leeseauthor=B.+V.+L.+Potterauthor=M.+J.+Reedauthor=A.+Purohit&title=Class+III+%CE%B2-tubulin+expression+and+in+vitro+resistance+to+microtubule+targeting+agents&doi=10.1038%2Fsj.bjc.6605489"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Class III β-tubulin expression and in vitro resistance to microtubule targeting agents</span></div><div class="casAuthors">Stengel, C.; Newman, S. P.; Leese, M. P.; Potter, B. V. L.; Reed, M. J.; Purohit, A.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">102</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">316-324</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Background: Class III β-tubulin overexpression is a marker of resistance to microtubule disruptors in vitro, in vivo and in the clinic for many cancers, including breast cancer.  The aims of this study were to develop a new model of class III β-tubulin expression, avoiding the toxicity assocd. with chronic overexpression of class III β-tubulin, and study the efficacy of a panel of clin. and pre-clin. drugs in this model.  Methods: MCF-7 (ER+ve) and MDA-MB-231 (ER-ve) were either transfected with pALTER-TUBB3 or siRNA-tubb3 and 24 h later exposed to test compds. for a further 96 h for proliferation studies.  RT-PCR and immunoblotting were used to monitor the changes in class III β-tubulin mRNA and protein expression.  Results: The model allowed for subtle changes in class III β-tubulin expression to be achieved, which had no direct effect on the viability of the cells.  Class III β-tubulin overexpression conferred resistance to paclitaxel and vinorelbine, whereas downregulation of class III β-tubulin rendered cells more sensitive to these two drugs.  The efficacy of the colchicine-site binding agents, 2-MeOE2, colchicine, STX140, ENMD1198 and STX243 was unaffected by the changes in class III β-tubulin expression.  Conclusion: These data indicate that the effect of class III β-tubulin overexpression may depend on where the drug's binding site is located on the tubulin.  Therefore, this study highlights for the first time the potential key role of targeting the colchicine-binding site, to develop new treatment modalities for taxane-refractory breast cancer.  British Journal of Cancer (2010) 102, 316-324; doi:10.1038/sj.bjc.6605489 www.bjcancer.com Published online 22 Dec. 2009.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2hulEpiTJA7Vg90H21EOLACvtfcHk0litChs1rphB_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXntlKisQ%253D%253D&md5=02d84566d0f23c1781ba74a1add4fed2</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjc.6605489&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjc.6605489%26sid%3Dliteratum%253Aachs%26aulast%3DStengel%26aufirst%3DC.%26aulast%3DNewman%26aufirst%3DS.%2BP.%26aulast%3DLeese%26aufirst%3DM.%2BP.%26aulast%3DPotter%26aufirst%3DB.%2BV.%2BL.%26aulast%3DReed%26aufirst%3DM.%2BJ.%26aulast%3DPurohit%26aufirst%3DA.%26atitle%3DClass%2520III%2520%25CE%25B2-tubulin%2520expression%2520and%2520in%2520vitro%2520resistance%2520to%2520microtubule%2520targeting%2520agents%26jtitle%3DBrit.%2520J.%2520Cancer%26date%3D2010%26volume%3D102%26spage%3D316%26epage%3D324%26doi%3D10.1038%2Fsj.bjc.6605489" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span> <span> </span><span class="NLM_article-title">Recent advances in heterocyclic tubulin inhibitors targeting the colchicine binding site</span>. <i>Anti-Cancer Agents Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">1325</span>– <span class="NLM_lpage">1338</span>, <span class="refDoi"> DOI: 10.2174/1871520616666160219161921</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=10.2174%2F1871520616666160219161921" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=26899186" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVOhsrfE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2016&pages=1325-1338&author=X.+Wuauthor=Q.+Wangauthor=W.+Li&title=Recent+advances+in+heterocyclic+tubulin+inhibitors+targeting+the+colchicine+binding+site&doi=10.2174%2F1871520616666160219161921"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Recent Advances in Heterocyclic Tubulin Inhibitors Targeting the Colchicine Binding Site</span></div><div class="casAuthors">Wu, Xiaoxin; Wang, Qinghui; Li, Wei</div><div class="citationInfo"><span class="NLM_cas:title">Anti-Cancer Agents in Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1325-1338</span>CODEN:
                <span class="NLM_cas:coden">AAMCE4</span>;
        ISSN:<span class="NLM_cas:issn">1871-5206</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">Microtubules are involved in many crit. cellular processes including cell division, cell shape maintenance, vesicle transportation and motility regulation.  Disruption of tubulin dynamics is a well-validated cancer drug target with several FDA approved, highly efficacious tubulin inhibitors targeting the taxane or the vinca binding sites.  Despite the tremendous successes for these clin. tubulin inhibitors, their limitations are also apparent, particularly in the development of transporter mediated drug resistance.  While currently there are no FDA approved inhibitors targeting the colchicine binding site in tubulin, extensive preclin. studies have suggested that colchicine binding site inhibitors (CBSIs) have significantly less susceptibility to transporter medicated drug resistance.  The presence of one or more heterocyclic moieties is often crit. for the antiproliferative activities for most of these CBSIs.  This article aims to review the structures and antiproliferative activities of most recently developed heterocyclic CBSIs from 2013 to present.  We focus this review on compds. that are designed based on the CA-4, chalcone and PTOX scaffolds which are well established to interact with the colchicine binding site in tubulin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpsh10kAoyRzLVg90H21EOLACvtfcHk0litChs1rphB_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVOhsrfE&md5=7959990391bd432fa2a417cf1309aec4</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.2174%2F1871520616666160219161921&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1871520616666160219161921%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DLi%26aufirst%3DW.%26atitle%3DRecent%2520advances%2520in%2520heterocyclic%2520tubulin%2520inhibitors%2520targeting%2520the%2520colchicine%2520binding%2520site%26jtitle%3DAnti-Cancer%2520Agents%2520Med.%2520Chem.%26date%3D2016%26volume%3D16%26spage%3D1325%26epage%3D1338%26doi%3D10.2174%2F1871520616666160219161921" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalton, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, D. D.</span></span> <span> </span><span class="NLM_article-title">Discovery of 4-Substituted Methoxybenzoyl-aryl-thiazole as Novel Anticancer Agents: Synthesis, Biological Evaluation, and Structure–Activity Relationships</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">1701</span>– <span class="NLM_lpage">1711</span>, <span class="refDoi"> DOI: 10.1021/jm801449a</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm801449a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=1%3ACAS%3A528%3ADC%252BD1MXisVCis7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=1701-1711&author=Y.+Luauthor=C.-M.+Liauthor=Z.+Wangauthor=C.+R.+Rossauthor=J.+Chenauthor=J.+T.+Daltonauthor=W.+Liauthor=D.+D.+Miller&title=Discovery+of+4-Substituted+Methoxybenzoyl-aryl-thiazole+as+Novel+Anticancer+Agents%3A+Synthesis%2C+Biological+Evaluation%2C+and+Structure%E2%80%93Activity+Relationships&doi=10.1021%2Fjm801449a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 4-Substituted Methoxybenzoyl-aryl-thiazole as Novel Anticancer Agents: Synthesis, Biological Evaluation, and Structure-Activity Relationships</span></div><div class="casAuthors">Lu, Yan; Li, Chien-Ming; Wang, Zhao; Ross, Charles R., II; Chen, Jianjun; Dalton, James T.; Li, Wei; Miller, Duane D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1701-1711</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of 4-substituted methoxybenzoyl-aryl-thiazoles (SMART) have been discovered and synthesized as a result of structural modifications of the lead compd. 2-arylthiazolidine-4-carboxylic acid amides (ATCAA).  The antiproliferative activity of the SMART agents against melanoma and prostate cancer cells was improved from μM to low nM range compared with the ATCAA series.  The structure-activity relationship was discussed from modifications of "A", "B", and "C" rings and the linker.  Preliminary mechanism of action studies indicated that these compds. exert their anticancer activity through inhibition of tubulin polymn.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQnsk5EK9mVLVg90H21EOLACvtfcHk0litChs1rphB_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXisVCis7g%253D&md5=68261f1589c55ffca6f44c4410c91c9c</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1021%2Fjm801449a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm801449a%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DC.-M.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DRoss%26aufirst%3DC.%2BR.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DDalton%26aufirst%3DJ.%2BT.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DMiller%26aufirst%3DD.%2BD.%26atitle%3DDiscovery%2520of%25204-Substituted%2520Methoxybenzoyl-aryl-thiazole%2520as%2520Novel%2520Anticancer%2520Agents%253A%2520Synthesis%252C%2520Biological%2520Evaluation%252C%2520and%2520Structure%25E2%2580%2593Activity%2520Relationships%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D1701%26epage%3D1711%26doi%3D10.1021%2Fjm801449a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaddady, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meibohm, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalton, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span> <span> </span><span class="NLM_article-title">Discovery of novel 2-aryl-4-benzoyl-imidazoles targeting the colchicines binding site in tubulin as potential anticancer agents</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">7414</span>– <span class="NLM_lpage">7427</span>, <span class="refDoi"> DOI: 10.1021/jm100884b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm100884b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht1eku73O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=7414-7427&author=J.+Chenauthor=Z.+Wangauthor=C.-M.+Liauthor=Y.+Luauthor=P.+K.+Vaddadyauthor=B.+Meibohmauthor=J.+T.+Daltonauthor=D.+D.+Millerauthor=W.+Li&title=Discovery+of+novel+2-aryl-4-benzoyl-imidazoles+targeting+the+colchicines+binding+site+in+tubulin+as+potential+anticancer+agents&doi=10.1021%2Fjm100884b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of novel 2-aryl-4-benzoyl-imidazoles targeting the colchicines binding site in tubulin as potential anticancer agents</span></div><div class="casAuthors">Chen, Jianjun; Wang, Zhao; Li, Chien-Ming; Lu, Yan; Vaddady, Pavan K.; Meibohm, Bernd; Dalton, James T.; Miller, Duane D.; Li, Wei</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">7414-7427</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of 2-aryl-4-benzoyl-imidazoles (ABI) was synthesized as a result of structural modifications based on the previous set of 2-aryl-imidazole-4-carboxylic amide (AICA) derivs. and 4-substituted methoxylbenzoyl-aryl-thiazoles (SMART).  The av. IC50 of the most active compd. I ( R = Me) was 15.7 nM.  ABI analogs have substantially improved aq. soly. (48.9 μg/mL for I ( R = NMe2) vs 0.909 μg/mL for SMART-1, 0.137 μg/mL for paclitaxel, and 1.04 μg/mL for combretastatin A4).  Mechanism of action studies indicate that the anticancer activity of ABI analogs is through inhibition of tubulin polymn. by interacting with the colchicine binding site.  Unlike paclitaxel and colchicine, the ABI compds. were equally potent against multidrug resistant cancer cells and the sensitive parental melanoma cancer cells.  In vivo results indicated that II was more effective than DTIC in inhibiting melanoma xenograph tumor growth.  Our results suggest that the novel ABI compds. may be developed to effectively treat drug-resistant tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq0en8R0EjqRrVg90H21EOLACvtfcHk0ljRz--AX_bWbA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht1eku73O&md5=7eb4d70e1e2bf16dce361a6308ea6f93</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1021%2Fjm100884b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100884b%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DLi%26aufirst%3DC.-M.%26aulast%3DLu%26aufirst%3DY.%26aulast%3DVaddady%26aufirst%3DP.%2BK.%26aulast%3DMeibohm%26aufirst%3DB.%26aulast%3DDalton%26aufirst%3DJ.%2BT.%26aulast%3DMiller%26aufirst%3DD.%2BD.%26aulast%3DLi%26aufirst%3DW.%26atitle%3DDiscovery%2520of%2520novel%25202-aryl-4-benzoyl-imidazoles%2520targeting%2520the%2520colchicines%2520binding%2520site%2520in%2520tubulin%2520as%2520potential%2520anticancer%2520agents%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D7414%26epage%3D7427%26doi%3D10.1021%2Fjm100884b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalton, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span> <span> </span><span class="NLM_article-title">Synthesis and antiproliferative activity of novel 2-aryl-4-benzoyl-imidazole derivatives targeting tubulin polymerization</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">4782</span>– <span class="NLM_lpage">4795</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2011.06.084</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=10.1016%2Fj.bmc.2011.06.084" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=21775150" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=1%3ACAS%3A528%3ADC%252BC3MXpvFWitbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2011&pages=4782-4795&author=J.+Chenauthor=C.-M.+Liauthor=J.+Wangauthor=S.+Ahnauthor=Z.+Wangauthor=Y.+Luauthor=J.+T.+Daltonauthor=D.+D.+Millerauthor=W.+Li&title=Synthesis+and+antiproliferative+activity+of+novel+2-aryl-4-benzoyl-imidazole+derivatives+targeting+tubulin+polymerization&doi=10.1016%2Fj.bmc.2011.06.084"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and antiproliferative activity of novel 2-aryl-4-benzoyl-imidazole derivatives targeting tubulin polymerization</span></div><div class="casAuthors">Chen, Jianjun; Li, Chien-Ming; Wang, Jin; Ahn, Sunjoo; Wang, Zhao; Lu, Yan; Dalton, James T.; Miller, Duane D.; Li, Wei</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">4782-4795</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Previously, the discovery of 2-aryl-4-benzoyl-imidazoles (ABI-I) as potent antiproliferative agents for melanoma was reported.  To further understand the structural requirements for the potency of ABI analogs, gain insight in the structure-activity relationships (SAR), and investigate metabolic stability for these compds., extensive SAR studies on the ABI-I scaffold are reported.  Compared with the previous set of ABI-I analogs, the newly synthesized ABI-II analogs have lower potency in general, but some of the new analogs have comparable potency to the most active compds. in the previous set when tested in two melanoma and four prostate cancer cell lines.  These SAR studies indicated that the antiproliferative activity was very sensitive to subtle changes in the ligand.  Tested compds. I and II are equally active against highly paclitaxel resistant cancer cell lines and their parental cell lines, indicating that drugs developed based on ABI-I analogs may have therapeutic advantages over paclitaxel in treating resistant tumors.  Metabolic stability studies of compd. I revealed that the N-Me imidazole failed to exhibit stability as the literature reported because de-methylation was found as the major metabolic pathway in rat and mouse liver microsomes.  However, this sheds light on the possibility of many modifications on the imidazole ring for further lead optimization, since the modification on imidazole, such as compd. I, did not impact the potency.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqU3-PVr9QmTrVg90H21EOLACvtfcHk0ljRz--AX_bWbA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXpvFWitbg%253D&md5=39fc9a69658cb461327cc5bd60f1fcb3</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2011.06.084&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2011.06.084%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DC.-M.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DAhn%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DLu%26aufirst%3DY.%26aulast%3DDalton%26aufirst%3DJ.%2BT.%26aulast%3DMiller%26aufirst%3DD.%2BD.%26aulast%3DLi%26aufirst%3DW.%26atitle%3DSynthesis%2520and%2520antiproliferative%2520activity%2520of%2520novel%25202-aryl-4-benzoyl-imidazole%2520derivatives%2520targeting%2520tubulin%2520polymerization%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2011%26volume%3D19%26spage%3D4782%26epage%3D4795%26doi%3D10.1016%2Fj.bmc.2011.06.084" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalton, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span> <span> </span><span class="NLM_article-title">Discovery of novel 2-aryl-4-benzoyl-imidazole (ABI-III) analogues targeting tubulin polymerization as antiproliferative agents</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">7285</span>– <span class="NLM_lpage">7289</span>, <span class="refDoi"> DOI: 10.1021/jm300564b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300564b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVWhtL7I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=7285-7289&author=J.+Chenauthor=S.+Ahnauthor=J.+Wangauthor=Y.+Luauthor=J.+T.+Daltonauthor=D.+D.+Millerauthor=W.+Li&title=Discovery+of+novel+2-aryl-4-benzoyl-imidazole+%28ABI-III%29+analogues+targeting+tubulin+polymerization+as+antiproliferative+agents&doi=10.1021%2Fjm300564b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Novel 2-Aryl-4-benzoyl-imidazole (ABI-III) Analogues Targeting Tubulin Polymerization As Antiproliferative Agents</span></div><div class="casAuthors">Chen, Jianjun; Ahn, Sunjoo; Wang, Jin; Lu, Yan; Dalton, James T.; Miller, Duane D.; Li, Wei</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">7285-7289</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Novel ABI-III compds. were designed and synthesized based on our previously reported ABI-I and ABI-II analogs.  ABI-III compds. are highly potent against a panel of melanoma and prostate cancer cell lines, with the best compd. having an av. IC50 value of 3.8 nM.  They are not substrate of Pgp and thus may effectively overcome Pgp-mediated multidrug resistance.  ABI-III analogs maintain their mechanisms of action by inhibition of tubulin polymn.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpd3i19x2xBrVg90H21EOLACvtfcHk0ljRz--AX_bWbA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVWhtL7I&md5=b7eee50b4916f704e49c9e30b1a803d5</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Fjm300564b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300564b%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DAhn%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DLu%26aufirst%3DY.%26aulast%3DDalton%26aufirst%3DJ.%2BT.%26aulast%3DMiller%26aufirst%3DD.%2BD.%26aulast%3DLi%26aufirst%3DW.%26atitle%3DDiscovery%2520of%2520novel%25202-aryl-4-benzoyl-imidazole%2520%2528ABI-III%2529%2520analogues%2520targeting%2520tubulin%2520polymerization%2520as%2520antiproliferative%2520agents%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D7285%26epage%3D7289%26doi%3D10.1021%2Fjm300564b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalton, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span> <span> </span><span class="NLM_article-title">Discovery of 4-aryl-2-benzoyl-imidazoles as tubulin polymerization inhibitor with potent antiproliferative properties</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">3318</span>– <span class="NLM_lpage">3329</span>, <span class="refDoi"> DOI: 10.1021/jm4001117</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm4001117" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=1%3ACAS%3A528%3ADC%252BC3sXltV2msrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=3318-3329&author=M.+Xiaoauthor=S.+Ahnauthor=J.+Wangauthor=J.+Chenauthor=D.+D.+Millerauthor=J.+T.+Daltonauthor=W.+Li&title=Discovery+of+4-aryl-2-benzoyl-imidazoles+as+tubulin+polymerization+inhibitor+with+potent+antiproliferative+properties&doi=10.1021%2Fjm4001117"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 4-Aryl-2-benzoyl-imidazoles as Tubulin Polymerization Inhibitor with Potent Antiproliferative Properties</span></div><div class="casAuthors">Xiao, Min; Ahn, Sunjoo; Wang, Jin; Chen, Jianjun; Miller, Duane. D.; Dalton, James T.; Li, Wei</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3318-3329</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of 4-aryl-2-benzoyl-imidazoles were designed and synthesized based on our previously reported 2-aryl-4-benzoyl-imidazole (ABI) derivs.  The new structures reversed the aryl group and the benzoyl group of previous ABI structures and were named as reverse ABI (RABI) analogs.  RABIs were evaluated for biol. activity against eight cancer cell lines including multidrug-resistant cancer cell lines.  In vitro assays indicated that several RABI compds. had excellent antiproliferative properties, with IC50 values in the low nanomolar range.  The av. IC50 of the most active compd. I is 14 nM.  In addn., the mechanism of action of these new analogs was investigated by cell cycle anal., tubulin polymn. assay, competitive mass spectrometry binding assay, and mol. docking studies.  These studies confirmed that these new RABI analogs maintain their mechanisms of action by disrupting tubulin polymn., similar to their parental ABI analogs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKd5PthijXy7Vg90H21EOLACvtfcHk0lgWSTAo6bs8nw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXltV2msrw%253D&md5=9f91ab1eb19f9c3308a968f46e483a56</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Fjm4001117&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm4001117%26sid%3Dliteratum%253Aachs%26aulast%3DXiao%26aufirst%3DM.%26aulast%3DAhn%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DMiller%26aufirst%3DD.%2BD.%26aulast%3DDalton%26aufirst%3DJ.%2BT.%26aulast%3DLi%26aufirst%3DW.%26atitle%3DDiscovery%2520of%25204-aryl-2-benzoyl-imidazoles%2520as%2520tubulin%2520polymerization%2520inhibitor%2520with%2520potent%2520antiproliferative%2520properties%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D3318%26epage%3D3329%26doi%3D10.1021%2Fjm4001117" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hwang, D.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, D. D.</span></span> <span> </span><span class="NLM_article-title">Structural optimization of indole derivatives acting at colchicine binding site as potential anticancer agents</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">993</span>– <span class="NLM_lpage">997</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.5b00208</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.5b00208" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht12gs77N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=993-997&author=D.-J.+Hwangauthor=J.+Wangauthor=W.+Liauthor=D.+D.+Miller&title=Structural+optimization+of+indole+derivatives+acting+at+colchicine+binding+site+as+potential+anticancer+agents&doi=10.1021%2Facsmedchemlett.5b00208"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Structural Optimization of Indole Derivatives Acting at Colchicine Binding Site as Potential Anticancer Agents</span></div><div class="casAuthors">Hwang, Dong-Jin; Wang, Jin; Li, Wei; Miller, Duane D.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">993-997</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Diarylisoquinolines and (trimethoxyphenyl)(indolyl)imidazopyridines I (R = 2-indolyl, 3-indolyl, 4-indolyl, 6-indolyl, 7-indolyl), analogs of a previous trimethoxybenzoylphenylindole and I (R = 5-indolyl), were prepd. as tubulin polymn. inhibitors acting at the colchicine binding site for potential use as antitumor agents with improved metabolic stabilities and cytotoxicities.  I (R = 2-indolyl, 3-indolyl, 4-indolyl, 6-indolyl, 7-indolyl) inhibited tubulin polymn. with IC50 values of 3 to 175 nM against a panel of human melanoma and prostate cancer cell lines.  In particular, I (R = 6-indolyl) showed improved cytotoxic potency (av. IC50 of 9.75 nM vs 55.75 nM) and metabolic stability in human liver microsomes (half-life time was 56.3 min vs. 45.4 min) as compared to previously reported I (R = 5-indolyl).  I (R = 6-indolyl) was effective against P-glycoprotein (P-gp) mediated multiple drug resistance (MDR) and taxol resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8lYd6NtCgfbVg90H21EOLACvtfcHk0lgWSTAo6bs8nw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht12gs77N&md5=839b8e906ff050b9f96d167796bb912d</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.5b00208&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.5b00208%26sid%3Dliteratum%253Aachs%26aulast%3DHwang%26aufirst%3DD.-J.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DMiller%26aufirst%3DD.%2BD.%26atitle%3DStructural%2520optimization%2520of%2520indole%2520derivatives%2520acting%2520at%2520colchicine%2520binding%2520site%2520as%2520potential%2520anticancer%2520agents%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D6%26spage%3D993%26epage%3D997%26doi%3D10.1021%2Facsmedchemlett.5b00208" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narayanan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kearbey, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parke, D. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalton, J. T.</span></span> <span> </span><span class="NLM_article-title">Biological Activity of 4-Substituted Methoxybenzoyl- Aryl-Thiazole: An Active Microtubule Inhibitor</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>71</i></span>,  <span class="NLM_fpage">216</span>– <span class="NLM_lpage">224</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.can-10-1725</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=10.1158%2F0008-5472.can-10-1725" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=21084278" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=1%3ACAS%3A528%3ADC%252BC3MXovFOk" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2011&pages=216-224&author=C.-M.+Liauthor=Z.+Wangauthor=Y.+Luauthor=S.+Ahnauthor=R.+Narayananauthor=J.+D.+Kearbeyauthor=D.+N.+Parkeauthor=W.+Liauthor=D.+D.+Millerauthor=J.+T.+Dalton&title=Biological+Activity+of+4-Substituted+Methoxybenzoyl-+Aryl-Thiazole%3A+An+Active+Microtubule+Inhibitor&doi=10.1158%2F0008-5472.can-10-1725"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Biological Activity of 4-Substituted Methoxybenzoyl- Aryl-Thiazole: An Active Microtubule Inhibitor</span></div><div class="casAuthors">Li, Chien-Ming; Wang, Zhao; Lu, Yan; Ahn, Sunjoo; Narayanan, Ramesh; Kearbey, Jeffrey D.; Parke, Deanna N.; Li, Wei; Miller, Duane D.; Dalton, James T.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">216-224</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Formation of microtubules is a dynamic process that involves polymn. and depolymn. of αβ-tubulin heterodimers.  Drugs that enhance or inhibit tubulin polymn. can destroy this dynamic process, arresting cells in the G2/M phase of the cell cycle.  Although drugs that target tubulin generally demonstrate cytotoxic potency in the subnanomolar range, resistance due to drug efflux is a common phenomenon among the antitubulin agents.  We recently reported a class of 4-substituted methoxybenzoyl-aryl-thiazoles (SMART) that exhibited great in vitro potency and broad spectrum cellular cytotoxicity.  Evaluation of the in vitro and in vivo anticancer activities of 3 SMART compds., SMART-H (H), SMART-F (F), and SMART-OH (OH), with varying substituents at the 4-position of aryl ring, demonstrated that they bind potently to the colchicine-binding site in tubulin, inhibit tubulin polymn., arrest cancer cells in G2/M phase of the cell cycle, and induce their apoptosis.  The SMART compds. also equipotently inhibit the growth of parental and MDR-overexpressing cells in vitro, indicating that they can overcome multidrug resistance.  In vivo antitumor efficacy studies in human prostate (PC-3) and melanoma (A375) cancer xenograft models demonstrated that SMART-H and SMART-F treatments resulted in %T/C values ranging from 4% to 30%.  In addn., in vivo SMART-H treatment for 21days at the higher dose (15 mg/kg) failed to produce any apparent neurotoxicity.  These studies provide the first in vivo evidence and proof-of-concept that SMART compds. are similarly efficacious to currently FDA approved antitubulin drugs for cancer treatment, but they can circumvent P-glycoprotein-mediated drug resistance.  Cancer Res; 71(1); 216-24.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq7124GCCHtorVg90H21EOLACvtfcHk0lgWSTAo6bs8nw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXovFOk&md5=107be0442abff7e1874f9a45690d1f08</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.can-10-1725&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.can-10-1725%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DC.-M.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DLu%26aufirst%3DY.%26aulast%3DAhn%26aufirst%3DS.%26aulast%3DNarayanan%26aufirst%3DR.%26aulast%3DKearbey%26aufirst%3DJ.%2BD.%26aulast%3DParke%26aufirst%3DD.%2BN.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DMiller%26aufirst%3DD.%2BD.%26aulast%3DDalton%26aufirst%3DJ.%2BT.%26atitle%3DBiological%2520Activity%2520of%25204-Substituted%2520Methoxybenzoyl-%2520Aryl-Thiazole%253A%2520An%2520Active%2520Microtubule%2520Inhibitor%26jtitle%3DCancer%2520Res.%26date%3D2011%26volume%3D71%26spage%3D216%26epage%3D224%26doi%3D10.1158%2F0008-5472.can-10-1725" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohler, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalton, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, D. D.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, and SAR studies of 4-substituted methoxylbenzoyl-aryl-thiazoles analogues as potent and orally bioavailable anticancer agents</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">4678</span>– <span class="NLM_lpage">4693</span>, <span class="refDoi"> DOI: 10.1021/jm2003427</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm2003427" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=1%3ACAS%3A528%3ADC%252BC3MXnt1ahu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=4678-4693&author=Y.+Luauthor=C.-M.+Liauthor=Z.+Wangauthor=J.+Chenauthor=M.+L.+Mohlerauthor=W.+Liauthor=J.+T.+Daltonauthor=D.+D.+Miller&title=Design%2C+synthesis%2C+and+SAR+studies+of+4-substituted+methoxylbenzoyl-aryl-thiazoles+analogues+as+potent+and+orally+bioavailable+anticancer+agents&doi=10.1021%2Fjm2003427"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis, and SAR studies of 4-substituted methoxylbenzoyl-aryl-thiazoles analogues as potent and orally bioavailable anticancer agents</span></div><div class="casAuthors">Lu, Yan; Li, Chien-Ming; Wang, Zhao; Chen, Jianjun; Mohler, Michael L.; Li, Wei; Dalton, James T.; Miller, Duane D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">4678-4693</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In a continued effort to improve upon the previously published 4-substituted methoxybenzoyl-aryl-thiazole (SMART) template, we explored chemodiverse "B" rings and "B" to "C" ring linkage.  Further, to overcome the poor aq. soly. of this series of agents, we introduced polar and ionizable hydrophilic groups to obtain water-sol. compds.  For instance, based on in vivo pharmacokinetic (PK) studies, an orally bioavailable phenyl-amino-thiazole (PAT) template was designed and synthesized in which an amino linkage was inserted between "A" and "B" rings of compd. I.  The PAT template maintained nanomolar (nM) range potency against cancer cell lines via inhibiting tubulin polymn. and was not susceptible to P-glycoprotein mediated multidrug resistance in vitro, and markedly improved soly. and bioavailability compared with the SMART template (II (R = H, Me, F) (PAT) vs I (SMART)).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrU325PJRUuh7Vg90H21EOLACvtfcHk0lhyTrMyt6zCdQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXnt1ahu74%253D&md5=fa3a6233ae97bc202aec36774242fcd6</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Fjm2003427&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm2003427%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DC.-M.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DMohler%26aufirst%3DM.%2BL.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DDalton%26aufirst%3DJ.%2BT.%26aulast%3DMiller%26aufirst%3DD.%2BD.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520SAR%2520studies%2520of%25204-substituted%2520methoxylbenzoyl-aryl-thiazoles%2520analogues%2520as%2520potent%2520and%2520orally%2520bioavailable%2520anticancer%2520agents%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D4678%26epage%3D4693%26doi%3D10.1021%2Fjm2003427" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahato, R. I.</span></span> <span> </span><span class="NLM_article-title">Synthesis, formulation and in vitro evaluation of a novel microtubule destabilizer, SMART-100</span>. <i>J. Control Release</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>143</i></span>,  <span class="NLM_fpage">151</span>– <span class="NLM_lpage">158</span>, <span class="refDoi"> DOI: 10.1016/j.jconrel.2009.12.028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=10.1016%2Fj.jconrel.2009.12.028" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=20060430" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjtFOju7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=143&publication_year=2010&pages=151-158&author=F.+Liauthor=Y.+Luauthor=W.+Liauthor=D.+D.+Millerauthor=R.+I.+Mahato&title=Synthesis%2C+formulation+and+in+vitro+evaluation+of+a+novel+microtubule+destabilizer%2C+SMART-100&doi=10.1016%2Fj.jconrel.2009.12.028"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis, formulation and in vitro evaluation of a novel microtubule destabilizer, SMART-100</span></div><div class="casAuthors">Li, Feng; Lu, Yan; Li, Wei; Miller, Duane D.; Mahato, Ram I.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Controlled Release</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">143</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">151-158</span>CODEN:
                <span class="NLM_cas:coden">JCREEC</span>;
        ISSN:<span class="NLM_cas:issn">0168-3659</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A novel microtubule destabilizer, substituted methoxybenzoyl-ary-thiazole (SMART)-100, was synthesized, which showed good anticancer activity in HepG2 cells.  SMART-100 was able to circumvent multidrug resistance (MDR) and effectively inhibited the growth of cell lines that overexpress P-glycoprotein (P-gp).  SMART-100 inhibited P-gp activity, which may be responsible for its ability to overcome MDR.  Since SMART-100 is poorly sol. in water, it was formulated in polyethylene-b-poly(D,L-lactide) (PEG-PLA) micelles.  The soly. of SMART-100 was increased by more than 1.1 × 105 folds.  SMART-100 loaded PEG-PLA micelles could effectively inhibit HepG2 cell growth and arrest cell cycle progression at G2/M phase, followed by appearance of a sub-G1 phase, which is indicative of cell apoptosis.  Increased Caspase-3 activity was also obsd. when HepG2 cells were treated with SMART-100.  The anticancer activity of SMART-100 loaded PEG-PLA micelles was also evaluated on luciferase expressing C4-2-Luc cell lines by IVIS imaging.  Our results suggest that SMART-100 has the potential to treat resistant cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoAqZoBDbb9xLVg90H21EOLACvtfcHk0lhyTrMyt6zCdQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjtFOju7Y%253D&md5=e06d0eed2a8a9c88367bfd8fa56b2bfe</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1016%2Fj.jconrel.2009.12.028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jconrel.2009.12.028%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DF.%26aulast%3DLu%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DMiller%26aufirst%3DD.%2BD.%26aulast%3DMahato%26aufirst%3DR.%2BI.%26atitle%3DSynthesis%252C%2520formulation%2520and%2520in%2520vitro%2520evaluation%2520of%2520a%2520novel%2520microtubule%2520destabilizer%252C%2520SMART-100%26jtitle%3DJ.%2520Control%2520Release%26date%3D2010%26volume%3D143%26spage%3D151%26epage%3D158%26doi%3D10.1016%2Fj.jconrel.2009.12.028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">de
Sa Alves, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barreiro, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fraga, C. A. M.</span></span> <span> </span><span class="NLM_article-title">From nature to drug discovery: the indole scaffold as a ‘privileged structure’</span>. <i>Mini-Rev. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">782</span>– <span class="NLM_lpage">793</span>, <span class="refDoi"> DOI: 10.2174/138955709788452649</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=10.2174%2F138955709788452649" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=19519503" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=1%3ACAS%3A280%3ADC%252BD1MvhtlymtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2009&pages=782-793&author=F.+de%0ASa+Alvesauthor=E.+Barreiroauthor=C.+A.+M.+Fraga&title=From+nature+to+drug+discovery%3A+the+indole+scaffold+as+a+%E2%80%98privileged+structure%E2%80%99&doi=10.2174%2F138955709788452649"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">From nature to drug discovery: the indole scaffold as a 'privileged structure'</span></div><div class="casAuthors">de Sa Alves Fernando Rodrigues; Barreiro Eliezer J; Fraga Carlos Alberto Manssour</div><div class="citationInfo"><span class="NLM_cas:title">Mini reviews in medicinal chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">782-93</span>
        ISSN:<span class="NLM_cas:issn">1389-5575</span>.
    </div><div class="casAbstract">The indole scaffold probably represents one of the most important structural subunits for the discovery of new drug candidates.  The demonstration that many alkaloids contain the indole nucleus, the recognition of the importance of essential amino acid tryptophan in human nutrition and the discovery of plant hormones served to bring about a massive search on indole chemistry, giving rise to a vast number of biologically active natural and synthetic products, with a wide range of therapeutic targets, such as anti-inflammatories, phosphodiesterase inhibitors, 5-hydroxytryptamine receptor agonists and antagonists, cannabinoid receptors agonists and HMG-CoA reductase inhibitors.  Many of these target-receptors belong to the class of GPCRs (integral membrane G-protein coupled receptors) and possess a conserved binding pocket that is recognized by the indole scaffold in a "common" complementary binding domain, explaining the great number of drugs that contain the indole substructure, such as indomethacin, ergotamine, frovatriptan, ondansetron, tadalafil, among many others.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTBKUu7YDCtEQWRJ3OJdH_qfW6udTcc2ear9Mwtln0S37ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1MvhtlymtQ%253D%253D&md5=34fa9e3785856259b4486d57af2e75ee</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.2174%2F138955709788452649&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138955709788452649%26sid%3Dliteratum%253Aachs%26aulast%3Dde%2BSa%2BAlves%26aufirst%3DF.%26aulast%3DBarreiro%26aufirst%3DE.%26aulast%3DFraga%26aufirst%3DC.%2BA.%2BM.%26atitle%3DFrom%2520nature%2520to%2520drug%2520discovery%253A%2520the%2520indole%2520scaffold%2520as%2520a%2520%25E2%2580%2598privileged%2520structure%25E2%2580%2599%26jtitle%3DMini-Rev.%2520Med.%2520Chem.%26date%3D2009%26volume%3D9%26spage%3D782%26epage%3D793%26doi%3D10.2174%2F138955709788452649" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalton, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span> <span> </span><span class="NLM_article-title">Discovery of novel 2-aryl-4-benzoyl-imidazole (ABI-III) analogues targeting tubulin polymerization as antiproliferative agents</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">7285</span>– <span class="NLM_lpage">7289</span>, <span class="refDoi"> DOI: 10.1021/jm300564b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300564b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVWhtL7I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=7285-7289&author=J.+Chenauthor=S.+Ahnauthor=J.+Wangauthor=Y.+Luauthor=J.+T.+Daltonauthor=D.+D.+Millerauthor=W.+Li&title=Discovery+of+novel+2-aryl-4-benzoyl-imidazole+%28ABI-III%29+analogues+targeting+tubulin+polymerization+as+antiproliferative+agents&doi=10.1021%2Fjm300564b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Novel 2-Aryl-4-benzoyl-imidazole (ABI-III) Analogues Targeting Tubulin Polymerization As Antiproliferative Agents</span></div><div class="casAuthors">Chen, Jianjun; Ahn, Sunjoo; Wang, Jin; Lu, Yan; Dalton, James T.; Miller, Duane D.; Li, Wei</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">7285-7289</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Novel ABI-III compds. were designed and synthesized based on our previously reported ABI-I and ABI-II analogs.  ABI-III compds. are highly potent against a panel of melanoma and prostate cancer cell lines, with the best compd. having an av. IC50 value of 3.8 nM.  They are not substrate of Pgp and thus may effectively overcome Pgp-mediated multidrug resistance.  ABI-III analogs maintain their mechanisms of action by inhibition of tubulin polymn.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpd3i19x2xBrVg90H21EOLACvtfcHk0lhog8RAz25ZHw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVWhtL7I&md5=b7eee50b4916f704e49c9e30b1a803d5</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1021%2Fjm300564b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300564b%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DAhn%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DLu%26aufirst%3DY.%26aulast%3DDalton%26aufirst%3DJ.%2BT.%26aulast%3DMiller%26aufirst%3DD.%2BD.%26aulast%3DLi%26aufirst%3DW.%26atitle%3DDiscovery%2520of%2520novel%25202-aryl-4-benzoyl-imidazole%2520%2528ABI-III%2529%2520analogues%2520targeting%2520tubulin%2520polymerization%2520as%2520antiproliferative%2520agents%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D7285%26epage%3D7289%26doi%3D10.1021%2Fjm300564b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kashyap, V.
K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Setua, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagesh, P. K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chauhan, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumari, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chowdhury, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yallapu, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaggi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hafeez, B. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chauhan, S. C.</span></span> <span> </span><span class="NLM_article-title">Therapeutic efficacy of a novel betaIII/betaIV-tubulin inhibitor (VERU-111) in pancreatic cancer</span>. <i>J. Exp. Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">29</span>, <span class="refDoi"> DOI: 10.1186/s13046-018-1009-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=10.1186%2Fs13046-018-1009-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=30674344" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=1%3ACAS%3A280%3ADC%252BB3cjksFagug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2019&pages=29&author=V.%0AK.+Kashyapauthor=Q.+Wangauthor=S.+Setuaauthor=P.+K.+B.+Nageshauthor=N.+Chauhanauthor=S.+Kumariauthor=P.+Chowdhuryauthor=D.+D.+Millerauthor=M.+M.+Yallapuauthor=W.+Liauthor=M.+Jaggiauthor=B.+B.+Hafeezauthor=S.+C.+Chauhan&title=Therapeutic+efficacy+of+a+novel+betaIII%2FbetaIV-tubulin+inhibitor+%28VERU-111%29+in+pancreatic+cancer&doi=10.1186%2Fs13046-018-1009-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic efficacy of a novel βIII/βIV-tubulin inhibitor (VERU-111) in pancreatic cancer</span></div><div class="casAuthors">Kashyap Vivek K; Wang Qinghui; Setua Saini; Nagesh Prashanth K B; Chauhan Neeraj; Kumari Sonam; Chowdhury Pallabita; Miller Duane D; Yallapu Murali M; Li Wei; Jaggi Meena; Hafeez Bilal Bin; Chauhan Subhash C</div><div class="citationInfo"><span class="NLM_cas:title">Journal of experimental & clinical cancer research : CR</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">29</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  The management of pancreatic cancer (PanCa) is exceptionally difficult due to poor response to available therapeutic modalities.  Tubulins play a major role in cell dynamics, thus are important molecular targets for cancer therapy.  Among various tubulins, βIII and βIV-tubulin isoforms have been primarily implicated in PanCa progression, metastasis and chemo-resistance.  However, specific inhibitors of these isoforms that have potent anti-cancer activity with low toxicity are not readily available.  METHODS:  We determined anti-cancer molecular mechanisms and therapeutic efficacy of a novel small molecule inhibitor (VERU-111) using in vitro (MTS, wound healing, Boyden chamber and real-time xCELLigence assays) and in vivo (xenograft studies) models of PanCa.  The effects of VERU-111 treatment on the expression of β-tubulin isoforms, apoptosis, cancer markers and microRNAs were determined by Western blot, immunohistochemistry (IHC), confocal microscopy, qRT-PCR and in situ hybridization (ISH) analyses.  RESULTS:  We have identified a novel small molecule inhibitor (VERU-111), which preferentially represses clinically important, βIII and βIV tubulin isoforms via restoring the expression of miR-200c.  As a result, VERU-111 efficiently inhibited tumorigenic and metastatic characteristics of PanCa cells.  VERU-111 arrested the cell cycle in the G2/M phase and induced apoptosis in PanCa cell lines via modulation of cell cycle regulatory (Cdc2, Cdc25c, and Cyclin B1) and apoptosis - associated (Bax, Bad, Bcl-2, and Bcl-xl) proteins.  VERU-111 treatment also inhibited tumor growth (P < 0.01) in a PanCa xenograft mouse model.  CONCLUSIONS:  This study has identified an inhibitor of βIII/βIV tubulins, which appears to have excellent potential as monotherapy or in combination with conventional therapeutic regimens for PanCa treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTXobOg3bD1Rw20zIbnCCI3fW6udTcc2eaojBFufnXz67ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cjksFagug%253D%253D&md5=6c965874d8dfd995f26ec76bfc37c4ce</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1186%2Fs13046-018-1009-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13046-018-1009-7%26sid%3Dliteratum%253Aachs%26aulast%3DKashyap%26aufirst%3DV.%2BK.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DSetua%26aufirst%3DS.%26aulast%3DNagesh%26aufirst%3DP.%2BK.%2BB.%26aulast%3DChauhan%26aufirst%3DN.%26aulast%3DKumari%26aufirst%3DS.%26aulast%3DChowdhury%26aufirst%3DP.%26aulast%3DMiller%26aufirst%3DD.%2BD.%26aulast%3DYallapu%26aufirst%3DM.%2BM.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DJaggi%26aufirst%3DM.%26aulast%3DHafeez%26aufirst%3DB.%2BB.%26aulast%3DChauhan%26aufirst%3DS.%2BC.%26atitle%3DTherapeutic%2520efficacy%2520of%2520a%2520novel%2520betaIII%252FbetaIV-tubulin%2520inhibitor%2520%2528VERU-111%2529%2520in%2520pancreatic%2520cancer%26jtitle%3DJ.%2520Exp.%2520Clin.%2520Cancer%2520Res.%26date%3D2019%26volume%3D38%26spage%3D29%26doi%3D10.1186%2Fs13046-018-1009-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnst, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span> <span> </span><span class="NLM_article-title">Structural Modification of the 3,4,5-Trimethoxyphenyl Moiety in the Tubulin Inhibitor VERU-111 Leads to Improved Antiproliferative Activities</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">7877</span>– <span class="NLM_lpage">7891</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00827</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00827" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsFerurrP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=7877-7891&author=Q.+Wangauthor=K.+E.+Arnstauthor=Y.+Wangauthor=G.+Kumarauthor=D.+Maauthor=H.+Chenauthor=Z.+Wuauthor=J.+Yangauthor=S.+W.+Whiteauthor=D.+D.+Millerauthor=W.+Li&title=Structural+Modification+of+the+3%2C4%2C5-Trimethoxyphenyl+Moiety+in+the+Tubulin+Inhibitor+VERU-111+Leads+to+Improved+Antiproliferative+Activities&doi=10.1021%2Facs.jmedchem.8b00827"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Structural Modification of the 3,4,5-Trimethoxyphenyl Moiety in the Tubulin Inhibitor VERU-111 Leads to Improved Antiproliferative Activities</span></div><div class="casAuthors">Wang, Qinghui; Arnst, Kinsie E.; Wang, Yuxi; Kumar, Gyanendra; Ma, Dejian; Chen, Hao; Wu, Zhongzhi; Yang, Jinliang; White, Stephen W.; Miller, Duane D.; Li, Wei</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">7877-7891</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Colchicine binding site inhibitors (CBSIs) hold great potential in developing new generations of antimitotic drugs.  Unlike existing tubulin inhibitors such as paclitaxel, they are generally much less susceptible to resistance caused by the overexpression of drug efflux pumps.  The 3,4,5-trimethoxyphenyl (TMP) moiety is a crit. component present in many CBSIs, playing an important role in maintaining suitable mol. conformations of CBSIs and contributing to their high binding affinities to tubulin.  Previously reported modifications to the TMP moiety in a variety of scaffolds of CBSIs have usually resulted in reduced antiproliferative potency.  We previously reported a potent CBSI, VERU-111, that also contains the TMP moiety.  Herein, we report the discovery of a VERU-111 analog I that is significantly more potent than VERU-111.  The X-ray crystal structure of I in complex with tubulin confirms its direct binding to the colchicine site.  In addn., I exhibited a strong inhibitory effect on tumor growth in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcjzgnUpHhEbVg90H21EOLACvtfcHk0lhog8RAz25ZHw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsFerurrP&md5=0d175fcf0efc28e5e120b4837dfc72b9</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00827&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00827%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DArnst%26aufirst%3DK.%2BE.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DKumar%26aufirst%3DG.%26aulast%3DMa%26aufirst%3DD.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DWu%26aufirst%3DZ.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DWhite%26aufirst%3DS.%2BW.%26aulast%3DMiller%26aufirst%3DD.%2BD.%26aulast%3DLi%26aufirst%3DW.%26atitle%3DStructural%2520Modification%2520of%2520the%25203%252C4%252C5-Trimethoxyphenyl%2520Moiety%2520in%2520the%2520Tubulin%2520Inhibitor%2520VERU-111%2520Leads%2520to%2520Improved%2520Antiproliferative%2520Activities%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D7877%26epage%3D7891%26doi%3D10.1021%2Facs.jmedchem.8b00827" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fujioka, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murai, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kubo, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohba, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kita, Y.</span></span> <span> </span><span class="NLM_article-title">One-pot synthesis of imidazolines from aldehydes: detailed study about solvents and substrates</span>. <i>Tetrahedron</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">638</span>– <span class="NLM_lpage">643</span>, <span class="refDoi"> DOI: 10.1016/j.tet.2006.11.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=10.1016%2Fj.tet.2006.11.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtlagtrrP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2007&pages=638-643&author=H.+Fujiokaauthor=K.+Muraiauthor=O.+Kuboauthor=Y.+Ohbaauthor=Y.+Kita&title=One-pot+synthesis+of+imidazolines+from+aldehydes%3A+detailed+study+about+solvents+and+substrates&doi=10.1016%2Fj.tet.2006.11.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">One-pot synthesis of imidazolines from aldehydes: detailed study about solvents and substrates</span></div><div class="casAuthors">Fujioka, Hiromichi; Murai, Kenichi; Kubo, Ozora; Ohba, Yusuke; Kita, Yasuyuki</div><div class="citationInfo"><span class="NLM_cas:title">Tetrahedron</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">638-643</span>CODEN:
                <span class="NLM_cas:coden">TETRAB</span>;
        ISSN:<span class="NLM_cas:issn">0040-4020</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Imidazolines were prepd. in 1-pot operation from aldehydes and diamines through oxidn. of aminal intermediates by NBS.  This method could be applied to various arom. and aliph. aldehydes and N-nonsubstituted and N-monosubstituted 1,2-diamines.  Also, CH2Cl2 could be altered to TBME, a more environmentally friendly solvent, in the reaction using N-nonsubstituted 1,2-diamines.  The reaction conditions were very mild and chemoselective.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWoQm3g9xTBbVg90H21EOLACvtfcHk0lg1FIKOA3H69w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtlagtrrP&md5=37face1338e5d2fe65a2e43cff1f40e8</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1016%2Fj.tet.2006.11.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tet.2006.11.007%26sid%3Dliteratum%253Aachs%26aulast%3DFujioka%26aufirst%3DH.%26aulast%3DMurai%26aufirst%3DK.%26aulast%3DKubo%26aufirst%3DO.%26aulast%3DOhba%26aufirst%3DY.%26aulast%3DKita%26aufirst%3DY.%26atitle%3DOne-pot%2520synthesis%2520of%2520imidazolines%2520from%2520aldehydes%253A%2520detailed%2520study%2520about%2520solvents%2520and%2520substrates%26jtitle%3DTetrahedron%26date%3D2007%26volume%3D63%26spage%3D638%26epage%3D643%26doi%3D10.1016%2Fj.tet.2006.11.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Briot, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baehr, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brouillard, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mioskowski, C.</span></span> <span> </span><span class="NLM_article-title">Concise synthesis of dihydrochalcones via palladium-catalyzed coupling of aryl halides and 1-aryl-2-propen-1-ols</span>. <i>J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>69</i></span>,  <span class="NLM_fpage">1374</span>– <span class="NLM_lpage">1377</span>, <span class="refDoi"> DOI: 10.1021/jo034936c</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo034936c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=1%3ACAS%3A528%3ADC%252BD2cXkt1Gmuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2004&pages=1374-1377&author=A.+Briotauthor=C.+Baehrauthor=R.+Brouillardauthor=A.+Wagnerauthor=C.+Mioskowski&title=Concise+synthesis+of+dihydrochalcones+via+palladium-catalyzed+coupling+of+aryl+halides+and+1-aryl-2-propen-1-ols&doi=10.1021%2Fjo034936c"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Concise Synthesis of Dihydrochalcones via Palladium-Catalyzed Coupling of Aryl Halides and 1-Aryl-2-propen-1-ols</span></div><div class="casAuthors">Briot, Anne; Baehr, Corinne; Brouillard, Raymond; Wagner, Alain; Mioskowski, Charles</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1374-1377</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">An expedient route to substituted dihydrochalcones, e.g., I, is reported.  The key step is a palladium-assisted arylation of 1-aryl-2-propen-1-ols, e.g., II.  This two-step/one-purifn. process allows the synthesis of a wide range of compds. with original substitution patterns, including polyphenolic derivs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq94e1-31j877Vg90H21EOLACvtfcHk0lg1FIKOA3H69w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXkt1Gmuw%253D%253D&md5=637a7745197145b35d63a24cef454c34</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1021%2Fjo034936c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo034936c%26sid%3Dliteratum%253Aachs%26aulast%3DBriot%26aufirst%3DA.%26aulast%3DBaehr%26aufirst%3DC.%26aulast%3DBrouillard%26aufirst%3DR.%26aulast%3DWagner%26aufirst%3DA.%26aulast%3DMioskowski%26aufirst%3DC.%26atitle%3DConcise%2520synthesis%2520of%2520dihydrochalcones%2520via%2520palladium-catalyzed%2520coupling%2520of%2520aryl%2520halides%2520and%25201-aryl-2-propen-1-ols%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2004%26volume%3D69%26spage%3D1374%26epage%3D1377%26doi%3D10.1021%2Fjo034936c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohn, H.</span></span> <span> </span><span class="NLM_article-title">Cyclic disulfide C(8) iminoporfiromycin: nucleophilic activation of a porfiromycin</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>126</i></span>,  <span class="NLM_fpage">4281</span>– <span class="NLM_lpage">4292</span>, <span class="refDoi"> DOI: 10.1021/ja030577r</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja030577r" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhvF2itbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=126&publication_year=2004&pages=4281-4292&author=S.+H.+Leeauthor=H.+Kohn&title=Cyclic+disulfide+C%288%29+iminoporfiromycin%3A+nucleophilic+activation+of+a+porfiromycin&doi=10.1021%2Fja030577r"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclic Disulfide C(8) Iminoporfiromycin: Nucleophilic Activation of a Porfiromycin</span></div><div class="casAuthors">Lee, Sang Hyup; Kohn, Harold</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">126</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">4281-4292</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The clin. success of mitomycin C (I) and its assocd. toxicities and resistance have led to efforts to prep. semisynthetic analogs (i.e., KW-2149 (II), BMS-181174) that have improved pharmacol. profiles.  In this study, we report the prepn. and evaluation of the novel 7-N-(1'-amino-4',5'-dithian-2'-yl)porfiromycin C(8) cyclized imine III (X = S) (IV) and its ref. compd., 7-N-(1'-aminocyclohex-2'-yl)porfiromycin C(8) cyclized imine III (X = CH2) (V).  (4R,5R)-4,5-Diamino-1,2-dithiane, prepd. starting from (2R,3R)-1,4-dibenzyloxy-2,3-butanediol, reacted with mitomycin F to give IV in 72% yield.  Porfiromycin IV contains a disulfide unit that, upon cleavage, may provide thiol(s) that affect drug reactivity.  We demonstrated that phosphines dramatically accelerated IV activation and solvolysis in methanolic solns. ("pH 7.4") compared with V.  Porfiromycins IV and V efficiently cross-linked EcoRI-linearized pBR322 DNA upon addn. of Et3P.  We found enhanced levels of interstrand cross-link (ISC) adducts for IV and V compared with porfiromycin (VI) and that IV was more efficient than V.  The large Et3P-mediated rate enhancements for the solvolysis of IV compared with V and a N(7)-substituted analog of I, and the increased levels of ISC adducts for IV compared with V and VI are attributed to a nucleophile-assisted disulfide cleavage process that permits porfiromycin activation and nucleophile (MeOH, DNA) adduction.  The in vitro antiproliferative activities of IV and V using the A549 tumor cell line (lung adenocarcinoma) were detd. under aerobic and hypoxic conditions and then compared with VI.  Both IV and V were more cytotoxic than VI, with V being more potent than IV.  The C(8) iminoporfiromycins IV and V displayed anticancer profiles similar to II.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRnpvLemcVSrVg90H21EOLACvtfcHk0lg1FIKOA3H69w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhvF2itbc%253D&md5=b4bea1cc62522c5f98dc60be686292c5</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1021%2Fja030577r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja030577r%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DS.%2BH.%26aulast%3DKohn%26aufirst%3DH.%26atitle%3DCyclic%2520disulfide%2520C%25288%2529%2520iminoporfiromycin%253A%2520nucleophilic%2520activation%2520of%2520a%2520porfiromycin%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2004%26volume%3D126%26spage%3D4281%26epage%3D4292%26doi%3D10.1021%2Fja030577r" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guinchard, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vallée, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denis, J.-N.</span></span> <span> </span><span class="NLM_article-title">Total synthesis of marine sponge bis(indole) alkaloids of the topsentin class</span>. <i>J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>72</i></span>,  <span class="NLM_fpage">3972</span>– <span class="NLM_lpage">3975</span>, <span class="refDoi"> DOI: 10.1021/jo070286r</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo070286r" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=1%3ACAS%3A528%3ADC%252BD2sXktlyjtLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2007&pages=3972-3975&author=X.+Guinchardauthor=Y.+Vall%C3%A9eauthor=J.-N.+Denis&title=Total+synthesis+of+marine+sponge+bis%28indole%29+alkaloids+of+the+topsentin+class&doi=10.1021%2Fjo070286r"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Total Synthesis of Marine Sponge Bis(indole) Alkaloids of the Topsentin Class</span></div><div class="casAuthors">Guinchard, Xavier; Vallee, Yannick; Denis, Jean-Noeel</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">3972-3975</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The synthesis of four natural bis(indole) alkaloids of the topsentin class is described.  Their bis(indole) α-carbonylimidazoline and subsequently bis(indole) α-carbonylimidazole moieties have been built via the condensation between indolic α-ketothioimidate salts and 1-(indol-3'-yl)-1,2-diaminoethane.  This is the first total synthesis of compds. isobromodeoxytopsentin I (double bond, R = Br), (±)-topsentin D I (single bond, R = H), and (±)-spongotine B I (single bond, R = Br).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGprrlRZqsUJrbVg90H21EOLACvtfcHk0lg1FIKOA3H69w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXktlyjtLY%253D&md5=a1b33bb71c7206f4246f428ed127872e</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1021%2Fjo070286r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo070286r%26sid%3Dliteratum%253Aachs%26aulast%3DGuinchard%26aufirst%3DX.%26aulast%3DVall%25C3%25A9e%26aufirst%3DY.%26aulast%3DDenis%26aufirst%3DJ.-N.%26atitle%3DTotal%2520synthesis%2520of%2520marine%2520sponge%2520bis%2528indole%2529%2520alkaloids%2520of%2520the%2520topsentin%2520class%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2007%26volume%3D72%26spage%3D3972%26epage%3D3975%26doi%3D10.1021%2Fjo070286r" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hwang, D.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, D. D.</span></span> <span> </span><span class="NLM_article-title">Structural Optimization of Indole Derivatives Acting at Colchicine Binding Site as Potential Anticancer Agents</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">993</span>– <span class="NLM_lpage">997</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.5b00208</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.5b00208" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht12gs77N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=993-997&author=D.-J.+Hwangauthor=J.+Wangauthor=W.+Liauthor=D.+D.+Miller&title=Structural+Optimization+of+Indole+Derivatives+Acting+at+Colchicine+Binding+Site+as+Potential+Anticancer+Agents&doi=10.1021%2Facsmedchemlett.5b00208"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Structural Optimization of Indole Derivatives Acting at Colchicine Binding Site as Potential Anticancer Agents</span></div><div class="casAuthors">Hwang, Dong-Jin; Wang, Jin; Li, Wei; Miller, Duane D.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">993-997</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Diarylisoquinolines and (trimethoxyphenyl)(indolyl)imidazopyridines I (R = 2-indolyl, 3-indolyl, 4-indolyl, 6-indolyl, 7-indolyl), analogs of a previous trimethoxybenzoylphenylindole and I (R = 5-indolyl), were prepd. as tubulin polymn. inhibitors acting at the colchicine binding site for potential use as antitumor agents with improved metabolic stabilities and cytotoxicities.  I (R = 2-indolyl, 3-indolyl, 4-indolyl, 6-indolyl, 7-indolyl) inhibited tubulin polymn. with IC50 values of 3 to 175 nM against a panel of human melanoma and prostate cancer cell lines.  In particular, I (R = 6-indolyl) showed improved cytotoxic potency (av. IC50 of 9.75 nM vs 55.75 nM) and metabolic stability in human liver microsomes (half-life time was 56.3 min vs. 45.4 min) as compared to previously reported I (R = 5-indolyl).  I (R = 6-indolyl) was effective against P-glycoprotein (P-gp) mediated multiple drug resistance (MDR) and taxol resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8lYd6NtCgfbVg90H21EOLACvtfcHk0lgmXulkHdIO5Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht12gs77N&md5=839b8e906ff050b9f96d167796bb912d</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.5b00208&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.5b00208%26sid%3Dliteratum%253Aachs%26aulast%3DHwang%26aufirst%3DD.-J.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DMiller%26aufirst%3DD.%2BD.%26atitle%3DStructural%2520Optimization%2520of%2520Indole%2520Derivatives%2520Acting%2520at%2520Colchicine%2520Binding%2520Site%2520as%2520Potential%2520Anticancer%2520Agents%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D6%26spage%3D993%26epage%3D997%26doi%3D10.1021%2Facsmedchemlett.5b00208" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Banerjee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnst, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, G.-b.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, D. D.</span></span> <span> </span><span class="NLM_article-title">Heterocyclic-fused pyrimidines as novel tubulin polymerization inhibitors targeting the colchicine binding site: structural basis and antitumor efficacy</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">1704</span>– <span class="NLM_lpage">1718</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01858</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01858" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=1%3ACAS%3A528%3ADC%252BC1cXit1Wjt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=1704-1718&author=S.+Banerjeeauthor=K.+E.+Arnstauthor=Y.+Wangauthor=G.+Kumarauthor=S.+Dengauthor=L.+Yangauthor=G.-b.+Liauthor=J.+Yangauthor=S.+W.+Whiteauthor=W.+Liauthor=D.+D.+Miller&title=Heterocyclic-fused+pyrimidines+as+novel+tubulin+polymerization+inhibitors+targeting+the+colchicine+binding+site%3A+structural+basis+and+antitumor+efficacy&doi=10.1021%2Facs.jmedchem.7b01858"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Heterocyclic-Fused Pyrimidines as Novel Tubulin Polymerization Inhibitors Targeting the Colchicine Binding Site: Structural Basis and Antitumor Efficacy</span></div><div class="casAuthors">Banerjee, Souvik; Arnst, Kinsie E.; Wang, Yuxi; Kumar, Gyanendra; Deng, Shanshan; Yang, Lei; Li, Guo-bo; Yang, Jinliang; White, Stephen W.; Li, Wei; Miller, Duane D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1704-1718</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We report the design, synthesis, and biol. evaluation of heterocyclic-fused pyrimidines as tubulin polymn. inhibitors targeting the colchicine binding site with significantly improved therapeutic index.  Addnl., for the first time, we report high-resoln. X-ray crystal structures for the best compds. in this scaffold.  These structures not only confirm their direct binding to the colchicine site in tubulin and reveal their detailed mol. interactions but also contrast the previously published proposed binding mode.  Compds. I and II significantly inhibited tumor growth in an A375 melanoma xenograft model and were accompanied by elevated levels of apoptosis and disruption of tumor vasculature.  Finally, we demonstrated that compd. I significantly overcame clin. relevant multidrug resistance in a paclitaxel resistant PC-3/TxR prostate cancer xenograft model.  Collectively, these studies provide preclin. and structural proof of concept to support the continued development of this scaffold as a new generation of tubulin inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoW5JWRge37JbVg90H21EOLACvtfcHk0lgmXulkHdIO5Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXit1Wjt7g%253D&md5=622af5cc1bf424daa681a22c33dfe288</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01858&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01858%26sid%3Dliteratum%253Aachs%26aulast%3DBanerjee%26aufirst%3DS.%26aulast%3DArnst%26aufirst%3DK.%2BE.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DKumar%26aufirst%3DG.%26aulast%3DDeng%26aufirst%3DS.%26aulast%3DYang%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DG.-b.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DWhite%26aufirst%3DS.%2BW.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DMiller%26aufirst%3DD.%2BD.%26atitle%3DHeterocyclic-fused%2520pyrimidines%2520as%2520novel%2520tubulin%2520polymerization%2520inhibitors%2520targeting%2520the%2520colchicine%2520binding%2520site%253A%2520structural%2520basis%2520and%2520antitumor%2520efficacy%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D1704%26epage%3D1718%26doi%3D10.1021%2Facs.jmedchem.7b01858" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dorleans, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gigant, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ravelli, R. B. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mailliet, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mikol, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knossow, M.</span></span> <span> </span><span class="NLM_article-title">Variations in the colchicine-binding domain provide insight into the structural switch of tubulin</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>106</i></span>,  <span class="NLM_fpage">13775</span>– <span class="NLM_lpage">13779</span>, <span class="refDoi"> DOI: 10.1073/pnas.0904223106</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=10.1073%2Fpnas.0904223106" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=19666559" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtFWksLrO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2009&pages=13775-13779&author=A.+Dorleansauthor=B.+Gigantauthor=R.+B.+G.+Ravelliauthor=P.+Maillietauthor=V.+Mikolauthor=M.+Knossow&title=Variations+in+the+colchicine-binding+domain+provide+insight+into+the+structural+switch+of+tubulin&doi=10.1073%2Fpnas.0904223106"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Variations in the colchicine-binding domain provide insight into the structural switch of tubulin</span></div><div class="casAuthors">Dorleans, Audrey; Gigant, Benoit; Ravelli, Raimond B. G.; Mailliet, Patrick; Mikol, Vincent; Knossow, Marcel</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">106</span>
        (<span class="NLM_cas:issue">33</span>),
    <span class="NLM_cas:pages">13775-13779, S13775/1-S13775/8</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Structural changes occur in the αβ-tubulin heterodimer during the microtubule assembly/disassembly cycle.  Their most prominent feature is a transition from a straight, microtubular structure to a curved structure.  There is a broad range of small mol. compds. that disturbs the microtubule cycle, a class of which targets the colchicine-binding site and prevents microtubule assembly.  This class includes compds. with very different chem. structures, and it is presently unknown whether they prevent tubulin polymn. by the same mechanism.  To address this issue, we have detd. the structures of tubulin complexed with a set of such ligands and show that they interfere with several of the movements of tubulin subunit structural elements upon its transition from curved to straight.  We also detd. the structure of tubulin unliganded at the colchicine site; this reveals that a β-tubulin loop (termed T7) flips into this site.  As with colchicine site ligands, this prevents a helix which is at the interface with α-tubulin from stacking onto a β-tubulin P sheet as in straight protofilaments.  Whereas in the presence of these ligands the interference with microtubule assembly gets frozen, by flipping in and out, the β-subunit T7 loop participates in a reversible way in the resistance to straightening that opposes microtubule assembly.  Our results suggest that it thereby contributes to microtubule dynamic instability.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDDUQBAmYNvbVg90H21EOLACvtfcHk0lgmXulkHdIO5Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtFWksLrO&md5=6d18732f78ac484b9db09ad1ec52aa5c</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0904223106&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0904223106%26sid%3Dliteratum%253Aachs%26aulast%3DDorleans%26aufirst%3DA.%26aulast%3DGigant%26aufirst%3DB.%26aulast%3DRavelli%26aufirst%3DR.%2BB.%2BG.%26aulast%3DMailliet%26aufirst%3DP.%26aulast%3DMikol%26aufirst%3DV.%26aulast%3DKnossow%26aufirst%3DM.%26atitle%3DVariations%2520in%2520the%2520colchicine-binding%2520domain%2520provide%2520insight%2520into%2520the%2520structural%2520switch%2520of%2520tubulin%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2009%26volume%3D106%26spage%3D13775%26epage%3D13779%26doi%3D10.1073%2Fpnas.0904223106" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Takeda, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mizokami, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mamiya, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keller, E. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Namiki, M.</span></span> <span> </span><span class="NLM_article-title">The establishment of two paclitaxel-resistant prostate cancer cell lines and the mechanisms of paclitaxel resistance with two cell lines</span>. <i>Prostate</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>67</i></span>,  <span class="NLM_fpage">955</span>– <span class="NLM_lpage">967</span>, <span class="refDoi"> DOI: 10.1002/pros.20581</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=10.1002%2Fpros.20581" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=17440963" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=1%3ACAS%3A528%3ADC%252BD2sXmvVKqt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2007&pages=955-967&author=M.+Takedaauthor=A.+Mizokamiauthor=K.+Mamiyaauthor=Y.+Q.+Liauthor=J.+Zhangauthor=E.+T.+Kellerauthor=M.+Namiki&title=The+establishment+of+two+paclitaxel-resistant+prostate+cancer+cell+lines+and+the+mechanisms+of+paclitaxel+resistance+with+two+cell+lines&doi=10.1002%2Fpros.20581"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">The establishment of two paclitaxel-resistant prostate cancer cell lines and the mechanisms of paclitaxel resistance with two cell lines</span></div><div class="casAuthors">Takeda, Masashi; Mizokami, Atsushi; Mamiya, Kiminori; Li, You Qiang; Zhang, Jian; Keller, Evan T.; Namiki, Mikio</div><div class="citationInfo"><span class="NLM_cas:title">Prostate (Hoboken, NJ, United States)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">955-967</span>CODEN:
                <span class="NLM_cas:coden">PRSTDS</span>;
        ISSN:<span class="NLM_cas:issn">0270-4137</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">BACKGROUND: Although paclitaxel is used for hormone-resistant prostate cancer, relapse definitely occurs later.  Details of the mol. mechanism responsible for paclitaxel-resistance remain unclear.  METHODS: We established paclitaxel-resistant cells, DU145-TxR and PC-3-TxR from parent DU145 and PC-3.  To characterize these cells, we examd. cross-resistance to other anticancer drugs.  Expression of several potential genes that had been related to drug-resistance was compared with parent cells by RT-PCR and Western blotting.  Methylation anal. of multiple drug resistance (MDR1) promoter was carried out using bisulfite-modified DNA from cell lines.  Knockdown expts. using small interfering RNA (siRNA) were also performed to confirm responsibility of drug-resistance.  Finally, cDNA microarray was performed to quantify gene expression in PC-3 and PC-3-TxR cells.  RESULTS: The IC50 for paclitaxel in DU145-TxR and PC-3-TxR was 34.0- and 43.4-fold higher than that in both parent cells, resp.  Both cells showed cross-resistance to some drugs, but not to VP-16 and cisplatin.  Methylation anal. revealed that methylated CpG sites of MDR1 promoter in DU145 and PC-3 cells were demethylated in DU145-TxR cells, but not in PC-3-TxR cells.  Knockdown of P-glycoprotein (P-gp), which was up-regulated in resistant cells, by MDR-1 siRNA restored paclitaxel sensitivity in DU145-TxR but not in PC-3-TxR, indicating that up-regulation of P-gp was not always main cause of paclitaxel-resistance.  Microarray anal. identified 201 (1.34%) up-regulated genes and 218 (1.45%) out of screened genes in PC-3-TxR.  CONCLUSIONS: Our data will provide mol. mechanisms of paclitaxel-resistance and be useful for screening target genes to diagnose paclitaxel sensitivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCs6firNNZ87Vg90H21EOLACvtfcHk0lhaRKGHsZCwmw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXmvVKqt7c%253D&md5=1b0e44bab963a7b82abc3eb6c979ca24</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1002%2Fpros.20581&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpros.20581%26sid%3Dliteratum%253Aachs%26aulast%3DTakeda%26aufirst%3DM.%26aulast%3DMizokami%26aufirst%3DA.%26aulast%3DMamiya%26aufirst%3DK.%26aulast%3DLi%26aufirst%3DY.%2BQ.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DKeller%26aufirst%3DE.%2BT.%26aulast%3DNamiki%26aufirst%3DM.%26atitle%3DThe%2520establishment%2520of%2520two%2520paclitaxel-resistant%2520prostate%2520cancer%2520cell%2520lines%2520and%2520the%2520mechanisms%2520of%2520paclitaxel%2520resistance%2520with%2520two%2520cell%2520lines%26jtitle%3DProstate%26date%3D2007%26volume%3D67%26spage%3D955%26epage%3D967%26doi%3D10.1002%2Fpros.20581" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Charbaut, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curmi, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ozon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lachkar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Redeker, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sobel, A.</span></span> <span> </span><span class="NLM_article-title">Stathmin family proteins display specific molecular and tubulin binding properties</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>276</i></span>,  <span class="NLM_fpage">16146</span>– <span class="NLM_lpage">16154</span>, <span class="refDoi"> DOI: 10.1074/jbc.m010637200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=10.1074%2Fjbc.m010637200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=11278715" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=1%3ACAS%3A528%3ADC%252BD3MXjvFaktL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=276&publication_year=2001&pages=16146-16154&author=E.+Charbautauthor=P.+A.+Curmiauthor=S.+Ozonauthor=S.+Lachkarauthor=V.+Redekerauthor=A.+Sobel&title=Stathmin+family+proteins+display+specific+molecular+and+tubulin+binding+properties&doi=10.1074%2Fjbc.m010637200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Stathmin family proteins display specific molecular and tubulin binding properties</span></div><div class="casAuthors">Charbaut, Elodie; Curmi, Patrick A.; Ozon, Sylvie; Lachkar, Sylvie; Redeker, Virginie; Sobel, Andre</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">276</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">16146-16154</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Stathmin family phosphoproteins (stathmin, SCG10, SCLIP, and RB3/RB3'/RB3") are involved in signal transduction and regulation of microtubule dynamics.  With the exception of stathmin, they are expressed exclusively in the nervous system, where they display different spatio-temporal and functional regulations and hence play at least partially distinct and possibly complementary roles in relation to the control of development, plasticity, and neuronal activities.  At the mol. level, each possesses a specific "stathmin-like domain" and, with the exception of stathmin, various combinations of N-terminal extensions involved in their assocn. with intracellular membrane compartments.  We show here that each stathmin-like domain also displays specific biochem. and tubulin interaction properties.  They are all able to sequester two α/β tubulin heterodimers as revealed by their inhibitory action on tubulin polymn. and by gel filtration.  However, they differ in the stabilities of the complexes formed as well as in their interaction kinetics with tubulin followed by surface plasmon resonance as follows: strong stability and slow kinetics for RB3; medium for SCG10, SCLIP, and stathmin; and weak stability and rapid kinetics for RB3'.  These results suggest that the fine-tuning of their stathmin-like domains contributes to the specific functional roles of stathmin family proteins in the regulation of microtubule dynamics within the various cell types and subcellular compartments of the developing or mature nervous system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoujSttSW0RxrVg90H21EOLACvtfcHk0lhaRKGHsZCwmw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXjvFaktL4%253D&md5=32e2b5ff9a7a14eaffcfd4a6b1b178ce</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1074%2Fjbc.m010637200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.m010637200%26sid%3Dliteratum%253Aachs%26aulast%3DCharbaut%26aufirst%3DE.%26aulast%3DCurmi%26aufirst%3DP.%2BA.%26aulast%3DOzon%26aufirst%3DS.%26aulast%3DLachkar%26aufirst%3DS.%26aulast%3DRedeker%26aufirst%3DV.%26aulast%3DSobel%26aufirst%3DA.%26atitle%3DStathmin%2520family%2520proteins%2520display%2520specific%2520molecular%2520and%2520tubulin%2520binding%2520properties%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2001%26volume%3D276%26spage%3D16146%26epage%3D16154%26doi%3D10.1074%2Fjbc.m010637200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dorleans, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gigant, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ravelli, R. B. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mailliet, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mikol, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knossow, M.</span></span> <span> </span><span class="NLM_article-title">Variations in the colchicine-binding domain provide insight into the structural switch of tubulin</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>106</i></span>,  <span class="NLM_fpage">13775</span>– <span class="NLM_lpage">13779</span>, <span class="refDoi"> DOI: 10.1073/pnas.0904223106</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=10.1073%2Fpnas.0904223106" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=19666559" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtFWksLrO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2009&pages=13775-13779&author=A.+Dorleansauthor=B.+Gigantauthor=R.+B.+G.+Ravelliauthor=P.+Maillietauthor=V.+Mikolauthor=M.+Knossow&title=Variations+in+the+colchicine-binding+domain+provide+insight+into+the+structural+switch+of+tubulin&doi=10.1073%2Fpnas.0904223106"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Variations in the colchicine-binding domain provide insight into the structural switch of tubulin</span></div><div class="casAuthors">Dorleans, Audrey; Gigant, Benoit; Ravelli, Raimond B. G.; Mailliet, Patrick; Mikol, Vincent; Knossow, Marcel</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">106</span>
        (<span class="NLM_cas:issue">33</span>),
    <span class="NLM_cas:pages">13775-13779, S13775/1-S13775/8</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Structural changes occur in the αβ-tubulin heterodimer during the microtubule assembly/disassembly cycle.  Their most prominent feature is a transition from a straight, microtubular structure to a curved structure.  There is a broad range of small mol. compds. that disturbs the microtubule cycle, a class of which targets the colchicine-binding site and prevents microtubule assembly.  This class includes compds. with very different chem. structures, and it is presently unknown whether they prevent tubulin polymn. by the same mechanism.  To address this issue, we have detd. the structures of tubulin complexed with a set of such ligands and show that they interfere with several of the movements of tubulin subunit structural elements upon its transition from curved to straight.  We also detd. the structure of tubulin unliganded at the colchicine site; this reveals that a β-tubulin loop (termed T7) flips into this site.  As with colchicine site ligands, this prevents a helix which is at the interface with α-tubulin from stacking onto a β-tubulin P sheet as in straight protofilaments.  Whereas in the presence of these ligands the interference with microtubule assembly gets frozen, by flipping in and out, the β-subunit T7 loop participates in a reversible way in the resistance to straightening that opposes microtubule assembly.  Our results suggest that it thereby contributes to microtubule dynamic instability.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDDUQBAmYNvbVg90H21EOLACvtfcHk0lhaRKGHsZCwmw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtFWksLrO&md5=6d18732f78ac484b9db09ad1ec52aa5c</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0904223106&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0904223106%26sid%3Dliteratum%253Aachs%26aulast%3DDorleans%26aufirst%3DA.%26aulast%3DGigant%26aufirst%3DB.%26aulast%3DRavelli%26aufirst%3DR.%2BB.%2BG.%26aulast%3DMailliet%26aufirst%3DP.%26aulast%3DMikol%26aufirst%3DV.%26aulast%3DKnossow%26aufirst%3DM.%26atitle%3DVariations%2520in%2520the%2520colchicine-binding%2520domain%2520provide%2520insight%2520into%2520the%2520structural%2520switch%2520of%2520tubulin%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2009%26volume%3D106%26spage%3D13775%26epage%3D13779%26doi%3D10.1073%2Fpnas.0904223106" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gigant, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span> <span> </span><span class="NLM_article-title">Structures of a diverse set of colchicine binding site inhibitors in complex with tubulin provide a rationale for drug discovery</span>. <i>FEBS J.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>283</i></span>,  <span class="NLM_fpage">102</span>– <span class="NLM_lpage">111</span>, <span class="refDoi"> DOI: 10.1111/febs.13555</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=10.1111%2Ffebs.13555" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=26462166" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslKktrzP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=283&publication_year=2016&pages=102-111&author=Y.+Wangauthor=H.+Zhangauthor=B.+Gigantauthor=Y.+Yuauthor=Y.+Wuauthor=X.+Chenauthor=Q.+Laiauthor=Z.+Yangauthor=Q.+Chenauthor=J.+Yang&title=Structures+of+a+diverse+set+of+colchicine+binding+site+inhibitors+in+complex+with+tubulin+provide+a+rationale+for+drug+discovery&doi=10.1111%2Ffebs.13555"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Structures of a diverse set of colchicine binding site inhibitors in complex with tubulin provide a rationale for drug discovery</span></div><div class="casAuthors">Wang, Yuxi; Zhang, Hang; Gigant, Benoit; Yu, Yamei; Wu, Yangping; Chen, Xiangzheng; Lai, Qinhuai; Yang, Zhaoya; Chen, Qiang; Yang, Jinliang</div><div class="citationInfo"><span class="NLM_cas:title">FEBS Journal</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">283</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">102-111</span>CODEN:
                <span class="NLM_cas:coden">FJEOAC</span>;
        ISSN:<span class="NLM_cas:issn">1742-464X</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Microtubules are dynamic assemblies of αβ-tubulin heterodimers and have been recognized as highly attractive targets for cancer chemotherapy.  A broad range of agents bind to tubulin and interfere with microtubule assembly.  Despite having a long history of characterization, colchicine binding site inhibitors (CBSIs) have not yet reached the com. phase as anti-cancer drugs to date.  We detd. the structures of tubulin complexed with a set of structurally diverse CBSIs (lexibulin, nocodazole, plinabulin and tivantinib), among which nocodazole and tivantinib are both binary-function inhibitors targeting cancer-related kinases and microtubules simultaneously.  High resoln. structures revealed the detailed interactions between these ligands and tubulin.  Our results showed that the binding modes of the CBSIs were different from previous docking models, highlighting the importance of crystal structure information in structure-based drug design.  A real structure-based pharmacophore was proposed to rationalize key common interactions of the CBSIs at the colchicine domain.  Our studies provide a solid structural basis for developing new anti-cancer agents for the colchicine binding site.  Database : The at. coordinates and structure factors for tubulin complexed with lexibulin, nocodazole, plinabulin and tivantinib have been deposited in the Protein Data Bank under accession codes , , and , resp.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpSIAVSS_EsIbVg90H21EOLACvtfcHk0lj4c1urifaQkw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslKktrzP&md5=d5a17d9a3ac54d8eda44d0543ffa5fbd</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1111%2Ffebs.13555&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Ffebs.13555%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DGigant%26aufirst%3DB.%26aulast%3DYu%26aufirst%3DY.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DLai%26aufirst%3DQ.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DChen%26aufirst%3DQ.%26aulast%3DYang%26aufirst%3DJ.%26atitle%3DStructures%2520of%2520a%2520diverse%2520set%2520of%2520colchicine%2520binding%2520site%2520inhibitors%2520in%2520complex%2520with%2520tubulin%2520provide%2520a%2520rationale%2520for%2520drug%2520discovery%26jtitle%3DFEBS%2520J.%26date%3D2016%26volume%3D283%26spage%3D102%26epage%3D111%26doi%3D10.1111%2Ffebs.13555" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Prota, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bargsten, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zurwerra, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Field, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Díaz, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altmann, K.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinmetz, M. O.</span></span> <span> </span><span class="NLM_article-title">Molecular mechanism of action of microtubule-stabilizing anticancer agents</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>339</i></span>,  <span class="NLM_fpage">587</span>– <span class="NLM_lpage">590</span>, <span class="refDoi"> DOI: 10.1126/science.1230582</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=10.1126%2Fscience.1230582" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=23287720" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsFGrsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=339&publication_year=2013&pages=587-590&author=A.+E.+Protaauthor=K.+Bargstenauthor=D.+Zurwerraauthor=J.+J.+Fieldauthor=J.+F.+D%C3%ADazauthor=K.-H.+Altmannauthor=M.+O.+Steinmetz&title=Molecular+mechanism+of+action+of+microtubule-stabilizing+anticancer+agents&doi=10.1126%2Fscience.1230582"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular Mechanism of Action of Microtubule-Stabilizing Anticancer Agents</span></div><div class="casAuthors">Prota, Andrea E.; Bargsten, Katja; Zurwerra, Didier; Field, Jessica J.; Diaz, Jose Fernando; Altmann, Karl-Heinz; Steinmetz, Michel O.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">339</span>
        (<span class="NLM_cas:issue">6119</span>),
    <span class="NLM_cas:pages">587-590</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Microtubule-stabilizing agents (MSAs) are efficacious chemotherapeutic drugs widely used for the treatment of cancer.  Despite the importance of MSAs for medical applications and basic research, their mol. mechanisms of action on tubulin and microtubules remain elusive.  We detd. high-resoln. crystal structures of αβ-tubulin in complex with two unrelated MSAs, zampanolide and epothilone A.  Both compds. were bound to the taxane pocket of β-tubulin and used their resp. side chains to induce structuring of the M-loop into a short helix.  Because the M-loop establishes lateral tubulin contacts in microtubules, these findings explain how taxane-site MSAs promote microtubule assembly and stability.  Further, our results offer fundamental structural insights into the control mechanisms of microtubule dynamics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_p8NfCWTU-rVg90H21EOLACvtfcHk0lj4c1urifaQkw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsFGrsrw%253D&md5=b253c015f75f5eac4857d01e34d65f54</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1126%2Fscience.1230582&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1230582%26sid%3Dliteratum%253Aachs%26aulast%3DProta%26aufirst%3DA.%2BE.%26aulast%3DBargsten%26aufirst%3DK.%26aulast%3DZurwerra%26aufirst%3DD.%26aulast%3DField%26aufirst%3DJ.%2BJ.%26aulast%3DD%25C3%25ADaz%26aufirst%3DJ.%2BF.%26aulast%3DAltmann%26aufirst%3DK.-H.%26aulast%3DSteinmetz%26aufirst%3DM.%2BO.%26atitle%3DMolecular%2520mechanism%2520of%2520action%2520of%2520microtubule-stabilizing%2520anticancer%2520agents%26jtitle%3DScience%26date%3D2013%26volume%3D339%26spage%3D587%26epage%3D590%26doi%3D10.1126%2Fscience.1230582" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, G. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gigant, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span> <span> </span><span class="NLM_article-title">Mechanism of microtubule stabilization by taccalonolide AJ</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">15787</span>, <span class="refDoi"> DOI: 10.1038/ncomms15787</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=10.1038%2Fncomms15787" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=28585532" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=1%3ACAS%3A528%3ADC%252BC2sXpsVCju7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=15787&author=Y.+Wangauthor=Y.+Yuauthor=G.+B.+Liauthor=S.+A.+Liauthor=C.+Wuauthor=B.+Gigantauthor=W.+Qinauthor=H.+Chenauthor=Y.+Wuauthor=Q.+Chenauthor=J.+Yang&title=Mechanism+of+microtubule+stabilization+by+taccalonolide+AJ&doi=10.1038%2Fncomms15787"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanism of microtubule stabilization by taccalonolide AJ</span></div><div class="casAuthors">Wang, Yuxi; Yu, Yamei; Li, Guo-Bo; Li, Shu-Ang; Wu, Chengyong; Gigant, Benoit; Qin, Wenming; Chen, Hao; Wu, Yangping; Chen, Qiang; Yang, Jinliang</div><div class="citationInfo"><span class="NLM_cas:title">Nature Communications</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">15787</span>CODEN:
                <span class="NLM_cas:coden">NCAOBW</span>;
        ISSN:<span class="NLM_cas:issn">2041-1723</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">As a major component of the cytoskeleton, microtubules consist of αβ-tubulin heterodimers and have been recognized as attractive targets for cancer chemotherapy.  Microtubule-stabilizing agents (MSAs) promote polymn. of tubulin and stabilize the polymer, preventing depolymn.  The mol. mechanisms by which MSAs stabilize microtubules remain elusive.  Here we report a 2.05 Å crystal structure of tubulin complexed with taccalonolide AJ, a newly identified taxane-site MSA.  Taccalonolide AJ covalently binds to β-tubulin D226.  On AJ binding, the M-loop undergoes a conformational shift to facilitate tubulin polymn.  In this tubulin-AJ complex, the E-site of tubulin is occupied by GTP rather than GDP.  Biochem. analyses confirm that AJ inhibits the hydrolysis of the E-site GTP.  Thus, we propose that the β-tubulin E-site is locked into a GTP-preferred status by AJ binding.  Our results provide exptl. evidence for the connection between MSA binding and tubulin nucleotide state, and will help design new MSAs to overcome taxane resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqSK9tvLSmUDbVg90H21EOLACvtfcHk0lj4c1urifaQkw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXpsVCju7o%253D&md5=7179fffb3aeade3b4bfd76ead6565363</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1038%2Fncomms15787&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncomms15787%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DY.%26aulast%3DYu%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DG.%2BB.%26aulast%3DLi%26aufirst%3DS.%2BA.%26aulast%3DWu%26aufirst%3DC.%26aulast%3DGigant%26aufirst%3DB.%26aulast%3DQin%26aufirst%3DW.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DQ.%26aulast%3DYang%26aufirst%3DJ.%26atitle%3DMechanism%2520of%2520microtubule%2520stabilization%2520by%2520taccalonolide%2520AJ%26jtitle%3DNat.%2520Commun.%26date%3D2017%26volume%3D8%26spage%3D15787%26doi%3D10.1038%2Fncomms15787" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Otwinowski, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minor, W.</span></span> <span> </span><span class="NLM_article-title">[20] Processing of X-ray diffraction data collected in oscillation mode</span>. <i>Methods Enzymol.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>276</i></span>,  <span class="NLM_fpage">307</span>– <span class="NLM_lpage">326</span>, <span class="refDoi"> DOI: 10.1016/s0076-6879(97)76066-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=10.1016%2FS0076-6879%2897%2976066-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=27754618" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=1%3ACAS%3A528%3ADyaK2sXivFehsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=276&publication_year=1997&pages=307-326&author=Z.+Otwinowskiauthor=W.+Minor&title=%5B20%5D+Processing+of+X-ray+diffraction+data+collected+in+oscillation+mode&doi=10.1016%2Fs0076-6879%2897%2976066-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Processing of x-ray diffraction data collected in oscillation mode</span></div><div class="casAuthors">Otwinowski, Zbyszek; Minor, Wladek</div><div class="citationInfo"><span class="NLM_cas:title">Methods in Enzymology</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">276</span>
        (<span class="NLM_cas:issue">Macromolecular Crystallography, Part A</span>),
    <span class="NLM_cas:pages">307-326</span>CODEN:
                <span class="NLM_cas:coden">MENZAU</span>;
        ISSN:<span class="NLM_cas:issn">0076-6879</span>.
    
            (<span class="NLM_cas:orgname">Academic</span>)
        </div><div class="casAbstract">Macromol. crystallog. is an iterative process.  Rarely do the first crystals provide all the necessary data to solve the biol. problem being studied.  Each step benefits from experience learned in previous steps.  To monitor the progress, the HKL package provides 2 tools: (1) statistics, both weighted (χ2) and unweighted (R-merge), are provided, and the Bayesian reasoning and multicomponent error model facilitates obtaining the proper error ests. and (2) visualization of the process plays a double role by helping the operator to confirm that the process of data redn., including the resulting statistics, is correct, and allowing one to evaluate problems for which there are no good statistical criteria.  Visualization also provides confidence that the point of diminishing returns in data collection and redn. has been reached.  At that point, the effort should be directed to solving the structure.  The methods presented here have been applied to solve a large variety of problems, from inorg. mols. with 5 Å unit cell to rotavirus of 700 Å diam. crystd. in 700 × 1000 × 1400 Å cell.  Overall quality of the method was tested by many researchers by successful application of the programs to MAD structure detns.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrA3fvBOHqhhrVg90H21EOLACvtfcHk0liwDCOH6I4Chw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXivFehsbw%253D&md5=c9536971d4e32cc35352c40fb9368131</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1016%2FS0076-6879%2897%2976066-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0076-6879%252897%252976066-X%26sid%3Dliteratum%253Aachs%26aulast%3DOtwinowski%26aufirst%3DZ.%26aulast%3DMinor%26aufirst%3DW.%26atitle%3D%255B20%255D%2520Processing%2520of%2520X-ray%2520diffraction%2520data%2520collected%2520in%2520oscillation%2520mode%26jtitle%3DMethods%2520Enzymol.%26date%3D1997%26volume%3D276%26spage%3D307%26epage%3D326%26doi%3D10.1016%2Fs0076-6879%2897%2976066-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Adams, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grosse-Kunstleve, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hung, L.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ioerger, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCoy, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moriarty, N. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Read, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sacchettini, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sauter, N. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terwilliger, T. C.</span></span> <span> </span><span class="NLM_article-title">PHENIX: building new software for automated crystallographic structure determination</span>. <i>Acta Crystallogr. D</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">1948</span>– <span class="NLM_lpage">1954</span>, <span class="refDoi"> DOI: 10.1107/s0907444902016657</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=10.1107%2Fs0907444902016657" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=12393927" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=1%3ACAS%3A528%3ADC%252BD38XotVCksbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2002&pages=1948-1954&author=P.+D.+Adamsauthor=R.+W.+Grosse-Kunstleveauthor=L.-W.+Hungauthor=T.+R.+Ioergerauthor=A.+J.+McCoyauthor=N.+W.+Moriartyauthor=R.+J.+Readauthor=J.+C.+Sacchettiniauthor=N.+K.+Sauterauthor=T.+C.+Terwilliger&title=PHENIX%3A+building+new+software+for+automated+crystallographic+structure+determination&doi=10.1107%2Fs0907444902016657"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">PHENIX: building new software for automated crystallographic structure determination</span></div><div class="casAuthors">Adams, Paul D.; Grosse-Kunstleve, Ralf W.; Hung, Li Wei; Ioerger, Thomas R.; McCoy, Airlie J.; Moriarty, Nigel W.; Read, Randy J.; Sacchettini, James C.; Sauter, Nicholas K.; Terwilliger, Thomas C.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">D58</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1948-1954</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Munksgaard</span>)
        </div><div class="casAbstract">Structural genomics seeks to rapidly expand the no. of protein structures to ext. the max. amt. of information from genomic sequence databases.  The advent of several large-scale projects worldwide leads to many new challenges in the field of crystallog. macromol. structure detn.  A novel software package, called PHENIX (Python-based Hierarchical Environment for Integrated Xtallog.), is therefore being developed.  This new software will provide the necessary algorithms to proceed from reduced intensity data to a refined mol. model and to facilitate structure soln. for both the novice and expert crystallographer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrOtuUfHXPmCbVg90H21EOLACvtfcHk0liwDCOH6I4Chw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XotVCksbc%253D&md5=9a3b66e1f7d064183f7a9ce108cb4e5e</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1107%2Fs0907444902016657&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252Fs0907444902016657%26sid%3Dliteratum%253Aachs%26aulast%3DAdams%26aufirst%3DP.%2BD.%26aulast%3DGrosse-Kunstleve%26aufirst%3DR.%2BW.%26aulast%3DHung%26aufirst%3DL.-W.%26aulast%3DIoerger%26aufirst%3DT.%2BR.%26aulast%3DMcCoy%26aufirst%3DA.%2BJ.%26aulast%3DMoriarty%26aufirst%3DN.%2BW.%26aulast%3DRead%26aufirst%3DR.%2BJ.%26aulast%3DSacchettini%26aufirst%3DJ.%2BC.%26aulast%3DSauter%26aufirst%3DN.%2BK.%26aulast%3DTerwilliger%26aufirst%3DT.%2BC.%26atitle%3DPHENIX%253A%2520building%2520new%2520software%2520for%2520automated%2520crystallographic%2520structure%2520determination%26jtitle%3DActa%2520Crystallogr.%2520D%26date%3D2002%26volume%3D58%26spage%3D1948%26epage%3D1954%26doi%3D10.1107%2Fs0907444902016657" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mahindroo, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Connelly, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Punchihewa, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujii, N.</span></span> <span> </span><span class="NLM_article-title">Amide conjugates of ketoprofen and indole as inhibitors of Gli1-mediated transcription in the Hedgehog pathway</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">4801</span>– <span class="NLM_lpage">4811</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2010.05.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=10.1016%2Fj.bmc.2010.05.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=20605720" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=1%3ACAS%3A528%3ADC%252BC3cXnsValsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2010&pages=4801-4811&author=N.+Mahindrooauthor=M.+C.+Connellyauthor=C.+Punchihewaauthor=L.+Yangauthor=B.+Yanauthor=N.+Fujii&title=Amide+conjugates+of+ketoprofen+and+indole+as+inhibitors+of+Gli1-mediated+transcription+in+the+Hedgehog+pathway&doi=10.1016%2Fj.bmc.2010.05.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Amide conjugates of ketoprofen and indole as inhibitors of Gli1-mediated transcription in the Hedgehog pathway</span></div><div class="casAuthors">Mahindroo, Neeraj; Connelly, Michele C.; Punchihewa, Chandanamali; Yang, Lei; Yan, Bing; Fujii, Naoaki</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">4801-4811</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">We have previously reported small-mol. inhibitors of Gli1-mediated transcription, an essential down-stream element of the Hh pathway.  We created new derivs. of the previous compds. aiming to improve the druggable properties.  The new compds., amide conjugates of ketoprofen and indole, showed inhibitory activity and membrane permeability, while also improving the microsome stability.  Among them, 33 and 42 inhibited Gli-luciferase reporter in C3H10T1/2 cells that were exogenously transfected with Gli1 with 2.6 μM and 1.6 μM of IC50, resp., and in Rh30 cells that endogenously overexpress Gli1, and were selective to Gli1 over Gli2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoobxouC8aCzrVg90H21EOLACvtfcHk0liwDCOH6I4Chw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXnsValsbs%253D&md5=5a9380d12788fb1d058f3850b465e24a</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2010.05.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2010.05.001%26sid%3Dliteratum%253Aachs%26aulast%3DMahindroo%26aufirst%3DN.%26aulast%3DConnelly%26aufirst%3DM.%2BC.%26aulast%3DPunchihewa%26aufirst%3DC.%26aulast%3DYang%26aufirst%3DL.%26aulast%3DYan%26aufirst%3DB.%26aulast%3DFujii%26aufirst%3DN.%26atitle%3DAmide%2520conjugates%2520of%2520ketoprofen%2520and%2520indole%2520as%2520inhibitors%2520of%2520Gli1-mediated%2520transcription%2520in%2520the%2520Hedgehog%2520pathway%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2010%26volume%3D18%26spage%3D4801%26epage%3D4811%26doi%3D10.1016%2Fj.bmc.2010.05.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Di, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kerns, E. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petusky, S. L.</span></span> <span> </span><span class="NLM_article-title">High throughput microsomal stability assay for insoluble compounds</span>. <i>Int. J. Pharm.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>317</i></span>,  <span class="NLM_fpage">54</span>– <span class="NLM_lpage">60</span>, <span class="refDoi"> DOI: 10.1016/j.ijpharm.2006.03.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=10.1016%2Fj.ijpharm.2006.03.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=16621364" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=1%3ACAS%3A528%3ADC%252BD28XlsFClt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=317&publication_year=2006&pages=54-60&author=L.+Diauthor=E.+H.+Kernsauthor=S.+Q.+Liauthor=S.+L.+Petusky&title=High+throughput+microsomal+stability+assay+for+insoluble+compounds&doi=10.1016%2Fj.ijpharm.2006.03.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">High throughput microsomal stability assay for insoluble compounds</span></div><div class="casAuthors">Di, Li; Kerns, Edward H.; Li, Susan Q.; Petusky, Susan L.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Pharmaceutics</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">317</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">54-60</span>CODEN:
                <span class="NLM_cas:coden">IJPHDE</span>;
        ISSN:<span class="NLM_cas:issn">0378-5173</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">High throughput metabolic stability assays are widely implemented in drug discovery to guide structural modification, predict in vivo performance, develop structure-metabolic stability relationships, and triage compds. for in vivo animal studies.  However, these methods are often developed and validated using com. drugs.  Many drug discovery compds. differ from com. drugs, with many having high lipophilicity, high mol. wt. and low soly.  The impact of very low soly. on metabolic stability assay results was explored.  Two metabolic stability assays, the aq. diln. method' and the cosolvent method, were compared.  For com. drugs and most discovery compds. having reasonable drug-like properties, the two methods gave comparable results.  For highly lipophilic, insol. drug discovery compds., the aq. diln. method' gave artificially higher stability results.  The cosolvent method performs compd. dilns. in solns. with higher org. solvent content and adds solns. directly to microsomes to assist with solubilization, minimize pptn. and reduce non-specific binding to plastics.  This method is more applicable in drug discovery where compds. of a wide range of soly. are studied.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGi5RwiHs137Vg90H21EOLACvtfcHk0liwDCOH6I4Chw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XlsFClt70%253D&md5=8c84b1043c094df280ac095290d0f9aa</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1016%2Fj.ijpharm.2006.03.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ijpharm.2006.03.007%26sid%3Dliteratum%253Aachs%26aulast%3DDi%26aufirst%3DL.%26aulast%3DKerns%26aufirst%3DE.%2BH.%26aulast%3DLi%26aufirst%3DS.%2BQ.%26aulast%3DPetusky%26aufirst%3DS.%2BL.%26atitle%3DHigh%2520throughput%2520microsomal%2520stability%2520assay%2520for%2520insoluble%2520compounds%26jtitle%3DInt.%2520J.%2520Pharm.%26date%3D2006%26volume%3D317%26spage%3D54%26epage%3D60%26doi%3D10.1016%2Fj.ijpharm.2006.03.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Davies, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morris, T.</span></span> <span> </span><span class="NLM_article-title">Physiological-parameters in laboratory-animals and humans</span>. <i>Pharm. Res.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">1093</span>– <span class="NLM_lpage">1095</span>, <span class="refDoi"> DOI: 10.1023/a:1018943613122</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=10.1023%2Fa%3A1018943613122" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=8378254" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=1%3ACAS%3A280%3ADyaK3szptFaqsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=1993&pages=1093-1095&author=B.+Daviesauthor=T.+Morris&title=Physiological-parameters+in+laboratory-animals+and+humans&doi=10.1023%2Fa%3A1018943613122"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Physiological parameters in laboratory animals and humans</span></div><div class="casAuthors">Davies B; Morris T</div><div class="citationInfo"><span class="NLM_cas:title">Pharmaceutical research</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1093-5</span>
        ISSN:<span class="NLM_cas:issn">0724-8741</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRDDwka3A6hEYYPsCkJIw00fW6udTcc2eZEsOdoymhiIbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK3szptFaqsg%253D%253D&md5=094cdd17306b58cc17c8cf4fd5db9927</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1023%2Fa%3A1018943613122&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1023%252Fa%253A1018943613122%26sid%3Dliteratum%253Aachs%26aulast%3DDavies%26aufirst%3DB.%26aulast%3DMorris%26aufirst%3DT.%26atitle%3DPhysiological-parameters%2520in%2520laboratory-animals%2520and%2520humans%26jtitle%3DPharm.%2520Res.%26date%3D1993%26volume%3D10%26spage%3D1093%26epage%3D1095%26doi%3D10.1023%2Fa%3A1018943613122" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span> <span> </span><span class="NLM_article-title">Synergistic Combination of Novel Tubulin Inhibitor ABI-274 and Vemurafenib Overcomes Vemurafenib Acquired Resistance in BRAFV600E Melanoma</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">16</span>– <span class="NLM_lpage">26</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.mct-13-0212</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=10.1158%2F1535-7163.mct-13-0212" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=24249714" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;key=1%3ACAS%3A528%3ADC%252BC2cXnsFSgug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=16-26&author=J.+Wangauthor=J.+Chenauthor=D.+D.+Millerauthor=W.+Li&title=Synergistic+Combination+of+Novel+Tubulin+Inhibitor+ABI-274+and+Vemurafenib+Overcomes+Vemurafenib+Acquired+Resistance+in+BRAFV600E+Melanoma&doi=10.1158%2F1535-7163.mct-13-0212"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Synergistic Combination of Novel Tubulin Inhibitor ABI-274 and Vemurafenib Overcome Vemurafenib Acquired Resistance in BRAFV600E Melanoma</span></div><div class="casAuthors">Wang, Jin; Chen, Jianjun; Miller, Duane D.; Li, Wei</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">16-26</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Acquired clin. resistance to vemurafenib, a selective BRAFV600E inhibitor, arises frequently after short-term chemotherapy.  Because inhibitions of targets in the RAF-MEK-ERK pathway result in G0-G1 cell-cycle arrest, vemurafenib-resistant cancer cells are expected to escape this cell-cycle arrest and progress to the subsequent G2-M phase.  We hypothesized that a combined therapy using vemurafenib with a G2-M phase blocking agent will trap resistant cells and overcome vemurafenib resistance.  To test this hypothesis, we first detd. the combination index (CI) values of our novel tubulin inhibitor ABI-274 and vemurafenib on parental human A375 and MDA-MB-435 melanoma cell lines to be 0.32 and 0.1, resp., suggesting strong synergy for the combination.  We then developed an A375RF21 subline with significant acquired resistance to vemurafenib and confirmed the strong synergistic effect.  Next, we studied the potential mechanisms of overcoming vemurafenib resistance.  Flow cytometry confirmed that the combination of ABI-274 and vemurafenib synergistically arrested cells in the G1-G2-M phase, and significantly increased apoptosis in both parental A375 and the vemurafenib-resistant A375RF21 cells.  Western blot anal. revealed that the combination treatment effectively reduced the level of phosphorylated and total AKT, activated the apoptosis cascade, and increased cleaved caspase-3 and cleaved PARP, but had no significant influence on the level of extracellular signal-regulated kinase (ERK) phosphorylation.  Finally, in vivo coadministration of vemurafenib with ABI-274 showed strong synergistic efficacy in the vemurafenib-resistant xenograft model in nude mice.  Overall, these results offer a rational combination strategy to significantly enhance the therapeutic benefit in patients with melanoma who inevitably become resistant to current vemurafenib therapy.  Mol Cancer Ther; 13(1); 16-26. ©2013 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoRH17pt08sjrVg90H21EOLACvtfcHk0liUvQrma8XEAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXnsFSgug%253D%253D&md5=06102f006f2cd3b41a56d0ef3e72e6e9</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.mct-13-0212&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.mct-13-0212%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DMiller%26aufirst%3DD.%2BD.%26aulast%3DLi%26aufirst%3DW.%26atitle%3DSynergistic%2520Combination%2520of%2520Novel%2520Tubulin%2520Inhibitor%2520ABI-274%2520and%2520Vemurafenib%2520Overcomes%2520Vemurafenib%2520Acquired%2520Resistance%2520in%2520BRAFV600E%2520Melanoma%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2014%26volume%3D13%26spage%3D16%26epage%3D26%26doi%3D10.1158%2F1535-7163.mct-13-0212" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6O61" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6O61','PDB','6O61'); return false;">PDB: 6O61</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6O5N" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6O5N','PDB','6O5N'); return false;">PDB: 6O5N</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6O5M" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6O5M','PDB','6O5M'); return false;">PDB: 6O5M</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4I55" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4I55','PDB','4I55'); return false;">PDB: 4I55</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i70"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b00706">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_30341"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.9b00706">10.1021/acs.jmedchem.9b00706</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Spectral data for synthetic intermediates and ABI-231 analogues (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b00706/suppl_file/jm9b00706_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular formula strings and biological data (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b00706/suppl_file/jm9b00706_si_002.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b00706/suppl_file/jm9b00706_si_001.pdf">jm9b00706_si_001.pdf (4.44 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b00706/suppl_file/jm9b00706_si_002.csv">jm9b00706_si_002.csv (2.55 kb)</a></li></ul></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">PDB ID codes:<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6O61">6O61</a> (ABI-231), <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6O5N">6O5N</a> (<b>10ab</b>), and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6O5M">6O5M</a> (<b>10bb</b>): Authors will release the atomic coordinates upon article publication.</p><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.9b00706&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2019.62.issue-14%3Bwebsite%3Awebsite%3Aacspubs%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.9b00706%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.9b00706" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                8MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"6799c112a8633c4c","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
